Background  ||| S:24 E:43 ||| NN
Whole-genome  ||| S:43 E:56 ||| JJ
expression  ||| S:56 E:67 ||| NN
profiling  ||| S:67 E:77 ||| NN
exemplified  ||| S:77 E:89 ||| NN
by  ||| S:89 E:92 ||| IN
the  ||| S:92 E:104 ||| DT
development  ||| S:104 E:116 ||| NN
of  ||| S:116 E:119 ||| IN
DNA  ||| S:119 E:123 ||| NNP
microarrays  ||| S:123 E:135 ||| NN
represents  ||| S:135 E:146 ||| VBZ
a  ||| S:146 E:148 ||| DT
major  ||| S:148 E:154 ||| JJ
advance  ||| S:154 E:170 ||| NN
in  ||| S:170 E:173 ||| IN
genome-wide  ||| S:173 E:185 ||| JJ
functional  ||| S:185 E:196 ||| JJ
analysis  ||| S:196 E:205 ||| NN
[  ||| S:205 E:207 ||| -LRB-
1  ||| S:207 E:209 ||| CD
2  ||| S:209 E:211 ||| CD
]  ||| S:211 E:213 ||| -RRB-
.  ||| S:213 E:215 ||| .
In  ||| S:215 E:218 ||| IN
a  ||| S:218 E:220 ||| DT
single  ||| S:220 E:235 ||| JJ
assay ||| S:235 E:240 ||| NN
,  ||| S:240 E:242 ||| ,
the  ||| S:242 E:246 ||| DT
transcriptional  ||| S:246 E:262 ||| JJ
response  ||| S:262 E:271 ||| NN
of  ||| S:271 E:274 ||| IN
each  ||| S:274 E:279 ||| DT
gene  ||| S:279 E:284 ||| NN
to  ||| S:284 E:287 ||| TO
a  ||| S:287 E:297 ||| DT
change  ||| S:297 E:304 ||| NN
in  ||| S:304 E:307 ||| IN
cellular  ||| S:307 E:316 ||| JJ
state  ||| S:316 E:322 ||| NN
can  ||| S:322 E:326 ||| MD
be  ||| S:326 E:329 ||| VB
measured ||| S:329 E:337 ||| VBN
,  ||| S:337 E:339 ||| ,
whether  ||| S:339 E:347 ||| IN
it  ||| S:347 E:350 ||| PRP
is  ||| S:350 E:353 ||| VBZ
a  ||| S:353 E:363 ||| DT
viral  ||| S:363 E:369 ||| JJ
infection ||| S:369 E:378 ||| NN
,  ||| S:378 E:380 ||| ,
host  ||| S:380 E:385 ||| NN
cell  ||| S:385 E:390 ||| NN
cycle  ||| S:390 E:396 ||| NN
changes ||| S:396 E:403 ||| NNS
,  ||| S:403 E:405 ||| ,
chemical  ||| S:405 E:422 ||| JJ
treatment ||| S:422 E:431 ||| NN
,  ||| S:431 E:433 ||| ,
or  ||| S:433 E:436 ||| CC
genetic  ||| S:436 E:444 ||| JJ
perturbation ||| S:444 E:456 ||| NN
.  ||| S:456 E:458 ||| .
Specifically ||| S:458 E:470 ||| RB
,  ||| S:470 E:480 ||| ,
systematic  ||| S:480 E:491 ||| JJ
approaches  ||| S:491 E:502 ||| NNS
for  ||| S:502 E:506 ||| IN
identifying  ||| S:506 E:518 ||| VBG
the  ||| S:518 E:522 ||| DT
biological  ||| S:522 E:541 ||| JJ
functions  ||| S:541 E:551 ||| NNS
of  ||| S:551 E:554 ||| IN
cellular  ||| S:554 E:563 ||| JJ
genes  ||| S:563 E:569 ||| NNS
altered  ||| S:569 E:577 ||| VBN
during  ||| S:577 E:584 ||| IN
these  ||| S:584 E:590 ||| DT
changes ||| S:590 E:597 ||| NNS
,  ||| S:597 E:607 ||| ,
such  ||| S:607 E:612 ||| JJ
as  ||| S:612 E:615 ||| IN
HIV-1  ||| S:615 E:621 ||| NNP
infection ||| S:621 E:630 ||| NN
,  ||| S:630 E:632 ||| ,
are  ||| S:632 E:636 ||| VBP
needed  ||| S:636 E:643 ||| VBN
to  ||| S:643 E:646 ||| TO
ensure  ||| S:646 E:653 ||| VB
rapid  ||| S:653 E:667 ||| JJ
progress  ||| S:667 E:676 ||| NN
in  ||| S:676 E:679 ||| IN
defining  ||| S:679 E:688 ||| JJ
significant  ||| S:688 E:700 ||| JJ
host  ||| S:700 E:705 ||| NN
and  ||| S:705 E:709 ||| CC
viral  ||| S:709 E:715 ||| JJ
genome  ||| S:715 E:730 ||| JJ
sequences  ||| S:730 E:740 ||| NN
in  ||| S:740 E:743 ||| IN
directed  ||| S:743 E:752 ||| JJ
experimentation  ||| S:752 E:768 ||| NN
and  ||| S:768 E:772 ||| CC
applications ||| S:772 E:784 ||| NNS
.  ||| S:784 E:794 ||| .
Therefore ||| S:794 E:803 ||| RB
,  ||| S:803 E:805 ||| ,
host  ||| S:805 E:810 ||| NN
cellular  ||| S:810 E:819 ||| JJ
states  ||| S:819 E:826 ||| NNS
can  ||| S:826 E:830 ||| MD
be  ||| S:830 E:833 ||| VB
inferred  ||| S:833 E:842 ||| VBN
from  ||| S:842 E:847 ||| IN
the  ||| S:847 E:859 ||| DT
expression  ||| S:859 E:870 ||| NN
profiles ||| S:870 E:878 ||| NNS
,  ||| S:878 E:880 ||| ,
and  ||| S:880 E:884 ||| CC
the  ||| S:884 E:888 ||| DT
notion  ||| S:888 E:895 ||| NN
that  ||| S:895 E:900 ||| IN
the  ||| S:900 E:904 ||| DT
global  ||| S:904 E:919 ||| JJ
transcriptional  ||| S:919 E:935 ||| JJ
response  ||| S:935 E:944 ||| NN
constitutes  ||| S:944 E:956 ||| VBZ
a  ||| S:956 E:958 ||| DT
detailed  ||| S:958 E:967 ||| JJ
molecular  ||| S:967 E:985 ||| JJ
phenotype ||| S:985 E:994 ||| NN
,  ||| S:994 E:996 ||| ,
such  ||| S:996 E:1001 ||| JJ
as  ||| S:1001 E:1004 ||| IN
class  ||| S:1004 E:1010 ||| NN
discovery ||| S:1010 E:1019 ||| NN
,  ||| S:1019 E:1021 ||| ,
class  ||| S:1021 E:1027 ||| NN
prediction ||| S:1027 E:1037 ||| NN
,  ||| S:1037 E:1039 ||| ,
drug  ||| S:1039 E:1052 ||| NN
target  ||| S:1052 E:1059 ||| NN
validation ||| S:1059 E:1069 ||| NN
,  ||| S:1069 E:1071 ||| ,
and  ||| S:1071 E:1075 ||| CC
the  ||| S:1075 E:1079 ||| DT
classification  ||| S:1079 E:1094 ||| NN
of  ||| S:1094 E:1097 ||| IN
tumors  ||| S:1097 E:1104 ||| NNS
by  ||| S:1104 E:1115 ||| IN
expression  ||| S:1115 E:1126 ||| NN
profiling  ||| S:1126 E:1136 ||| NN
has  ||| S:1136 E:1140 ||| VBZ
begun  ||| S:1140 E:1146 ||| VBN
to  ||| S:1146 E:1149 ||| TO
receive  ||| S:1149 E:1157 ||| VB
considerable  ||| S:1157 E:1178 ||| JJ
attention  ||| S:1178 E:1188 ||| NN
[  ||| S:1188 E:1190 ||| -LRB-
3  ||| S:1190 E:1192 ||| CD
4  ||| S:1192 E:1194 ||| CD
5  ||| S:1194 E:1196 ||| CD
6  ||| S:1196 E:1198 ||| CD
7  ||| S:1198 E:1200 ||| CD
8  ||| S:1200 E:1202 ||| CD
9  ||| S:1202 E:1204 ||| CD
10  ||| S:1204 E:1207 ||| CD
11  ||| S:1207 E:1210 ||| CD
]  ||| S:1210 E:1212 ||| -RRB-
.  ||| S:1212 E:1222 ||| .
Since  ||| S:1222 E:1228 ||| IN
its  ||| S:1228 E:1232 ||| PRP$
discovery ||| S:1232 E:1241 ||| NN
,  ||| S:1241 E:1243 ||| ,
much  ||| S:1243 E:1248 ||| RB
of  ||| S:1248 E:1251 ||| IN
the  ||| S:1251 E:1255 ||| DT
mainstream  ||| S:1255 E:1266 ||| JJ
human  ||| S:1266 E:1280 ||| JJ
immunodeficiency  ||| S:1280 E:1297 ||| JJ
virus  ||| S:1297 E:1303 ||| NN
type  ||| S:1303 E:1308 ||| NN
1  ||| S:1308 E:1310 ||| CD
( ||| S:1310 E:1311 ||| -LRB-
HIV-1 ||| S:1311 E:1316 ||| NNP
)  ||| S:1316 E:1318 ||| -RRB-
Tat  ||| S:1318 E:1322 ||| NNP
research  ||| S:1322 E:1331 ||| NN
has  ||| S:1331 E:1343 ||| VBZ
focused  ||| S:1343 E:1351 ||| VBN
on  ||| S:1351 E:1354 ||| IN
its  ||| S:1354 E:1358 ||| PRP$
ability  ||| S:1358 E:1366 ||| NN
to  ||| S:1366 E:1369 ||| TO
activate  ||| S:1369 E:1378 ||| VB
the  ||| S:1378 E:1382 ||| DT
HIV-1  ||| S:1382 E:1388 ||| NNP
LTR ||| S:1388 E:1391 ||| NNP
.  ||| S:1391 E:1393 ||| .
However ||| S:1393 E:1400 ||| RB
,  ||| S:1400 E:1410 ||| ,
to  ||| S:1410 E:1413 ||| TO
date ||| S:1413 E:1417 ||| NN
,  ||| S:1417 E:1419 ||| ,
besides  ||| S:1419 E:1427 ||| IN
the  ||| S:1427 E:1431 ||| DT
transactivation  ||| S:1431 E:1447 ||| JJ
activity  ||| S:1447 E:1456 ||| NN
on  ||| S:1456 E:1459 ||| IN
the  ||| S:1459 E:1463 ||| DT
HIV-1  ||| S:1463 E:1477 ||| NNP
promoter ||| S:1477 E:1485 ||| NN
,  ||| S:1485 E:1487 ||| ,
few  ||| S:1487 E:1491 ||| JJ
other  ||| S:1491 E:1497 ||| JJ
effects  ||| S:1497 E:1505 ||| NNS
exerted  ||| S:1505 E:1513 ||| VBN
by  ||| S:1513 E:1516 ||| IN
HIV-1  ||| S:1516 E:1522 ||| NNP
Tat  ||| S:1522 E:1526 ||| NNP
on  ||| S:1526 E:1537 ||| IN
cellular  ||| S:1537 E:1546 ||| JJ
and  ||| S:1546 E:1550 ||| CC
viral  ||| S:1550 E:1556 ||| JJ
genes  ||| S:1556 E:1562 ||| NNS
has  ||| S:1562 E:1566 ||| VBZ
also  ||| S:1566 E:1571 ||| RB
been  ||| S:1571 E:1576 ||| VBN
observed ||| S:1576 E:1584 ||| VBN
.  ||| S:1584 E:1586 ||| .
The  ||| S:1586 E:1590 ||| DT
Tat  ||| S:1590 E:1602 ||| JJ
protein  ||| S:1602 E:1610 ||| NN
has  ||| S:1610 E:1614 ||| VBZ
been  ||| S:1614 E:1619 ||| VBN
shown  ||| S:1619 E:1625 ||| VBN
to  ||| S:1625 E:1628 ||| TO
transcriptionally  ||| S:1628 E:1646 ||| VB
repress  ||| S:1646 E:1654 ||| JJ
host  ||| S:1654 E:1667 ||| NN
cellular  ||| S:1667 E:1676 ||| JJ
genes  ||| S:1676 E:1682 ||| NNS
and  ||| S:1682 E:1686 ||| CC
be  ||| S:1686 E:1689 ||| VB
involved  ||| S:1689 E:1698 ||| VBN
in  ||| S:1698 E:1701 ||| IN
the  ||| S:1701 E:1705 ||| DT
immunosuppression  ||| S:1705 E:1731 ||| NN
associated  ||| S:1731 E:1742 ||| VBN
with  ||| S:1742 E:1747 ||| IN
viral  ||| S:1747 E:1753 ||| JJ
infection ||| S:1753 E:1762 ||| NN
.  ||| S:1762 E:1764 ||| .
For  ||| S:1764 E:1768 ||| IN
instance ||| S:1768 E:1776 ||| NN
,  ||| S:1776 E:1778 ||| ,
HIV-1  ||| S:1778 E:1792 ||| NNP
infection  ||| S:1792 E:1802 ||| NN
is  ||| S:1802 E:1805 ||| VBZ
able  ||| S:1805 E:1810 ||| JJ
to  ||| S:1810 E:1813 ||| TO
down-regulate  ||| S:1813 E:1827 ||| JJ
major  ||| S:1827 E:1833 ||| JJ
histocompatibility  ||| S:1833 E:1860 ||| JJ
complex  ||| S:1860 E:1868 ||| JJ
type  ||| S:1868 E:1873 ||| NN
I  ||| S:1873 E:1875 ||| PRP
( ||| S:1875 E:1876 ||| -LRB-
MHC-I ||| S:1876 E:1881 ||| NNP
)  ||| S:1881 E:1883 ||| -RRB-
by  ||| S:1883 E:1886 ||| IN
various  ||| S:1886 E:1894 ||| JJ
different  ||| S:1894 E:1904 ||| JJ
viral  ||| S:1904 E:1910 ||| JJ
proteins ||| S:1910 E:1918 ||| NNS
,  ||| S:1918 E:1928 ||| ,
including  ||| S:1928 E:1938 ||| VBG
Tat  ||| S:1938 E:1942 ||| NNP
which  ||| S:1942 E:1948 ||| WDT
represses  ||| S:1948 E:1958 ||| VBZ
the  ||| S:1958 E:1962 ||| DT
transcription  ||| S:1962 E:1976 ||| NN
of  ||| S:1976 E:1979 ||| IN
MHC-I ||| S:1979 E:1984 ||| NNP
,  ||| S:1984 E:1994 ||| ,
Vpu  ||| S:1994 E:1998 ||| NNP
which  ||| S:1998 E:2004 ||| WDT
retains  ||| S:2004 E:2012 ||| VBZ
nascent  ||| S:2012 E:2020 ||| JJ
MHC-I  ||| S:2020 E:2026 ||| JJ
chains  ||| S:2026 E:2033 ||| NNS
in  ||| S:2033 E:2036 ||| IN
the  ||| S:2036 E:2040 ||| DT
endoplasmic  ||| S:2040 E:2060 ||| JJ
reticulum ||| S:2060 E:2069 ||| NN
,  ||| S:2069 E:2071 ||| ,
and  ||| S:2071 E:2075 ||| CC
Nef  ||| S:2075 E:2079 ||| NNP
which  ||| S:2079 E:2085 ||| WDT
can  ||| S:2085 E:2089 ||| MD
mediate  ||| S:2089 E:2097 ||| VB
selective  ||| S:2097 E:2115 ||| JJ
internalization  ||| S:2115 E:2131 ||| NN
of  ||| S:2131 E:2134 ||| IN
MHC-I  ||| S:2134 E:2140 ||| JJ
molecules  ||| S:2140 E:2150 ||| NNS
from  ||| S:2150 E:2155 ||| IN
the  ||| S:2155 E:2159 ||| DT
plasma  ||| S:2159 E:2174 ||| JJ
membrane ||| S:2174 E:2182 ||| NN
.  ||| S:2182 E:2184 ||| .
MHC  ||| S:2184 E:2188 ||| NNP
class  ||| S:2188 E:2194 ||| NN
I  ||| S:2194 E:2196 ||| NN
gene  ||| S:2196 E:2201 ||| NN
expression  ||| S:2201 E:2212 ||| NN
has  ||| S:2212 E:2216 ||| VBZ
also  ||| S:2216 E:2221 ||| RB
been  ||| S:2221 E:2226 ||| VBN
shown  ||| S:2226 E:2240 ||| VBN
to  ||| S:2240 E:2243 ||| TO
be  ||| S:2243 E:2246 ||| VB
reduced  ||| S:2246 E:2254 ||| VBN
upon  ||| S:2254 E:2259 ||| IN
infection  ||| S:2259 E:2269 ||| NN
with  ||| S:2269 E:2274 ||| IN
the  ||| S:2274 E:2278 ||| DT
wild-type  ||| S:2278 E:2288 ||| JJ
LAI  ||| S:2288 E:2292 ||| NNP
virus  ||| S:2292 E:2306 ||| NN
or  ||| S:2306 E:2309 ||| CC
a  ||| S:2309 E:2311 ||| DT
Tat  ||| S:2311 E:2315 ||| NNP
exon  ||| S:2315 E:2320 ||| VBD
one  ||| S:2320 E:2324 ||| CD
recombinant  ||| S:2324 E:2336 ||| JJ
virus  ||| S:2336 E:2342 ||| NN
[  ||| S:2342 E:2344 ||| -LRB-
12  ||| S:2344 E:2347 ||| CD
13  ||| S:2347 E:2350 ||| CD
]  ||| S:2350 E:2352 ||| -RRB-
.  ||| S:2352 E:2362 ||| .
Tat  ||| S:2362 E:2366 ||| NNP
has  ||| S:2366 E:2370 ||| VBZ
been  ||| S:2370 E:2375 ||| VBN
shown  ||| S:2375 E:2381 ||| VBN
to  ||| S:2381 E:2384 ||| TO
down-regulate  ||| S:2384 E:2398 ||| JJ
mannose  ||| S:2398 E:2406 ||| JJ
receptor ||| S:2406 E:2414 ||| NN
,  ||| S:2414 E:2424 ||| ,
EDF-1 ||| S:2424 E:2429 ||| NNP
,  ||| S:2429 E:2431 ||| ,
CD3-gamma ||| S:2431 E:2440 ||| NNP
,  ||| S:2440 E:2442 ||| ,
and  ||| S:2442 E:2446 ||| CC
TCR ||| S:2446 E:2449 ||| NNP
/ ||| S:2449 E:2450 ||| NNP
CD3  ||| S:2450 E:2454 ||| NNP
surface  ||| S:2454 E:2462 ||| NN
receptor  ||| S:2462 E:2471 ||| NN
[  ||| S:2471 E:2473 ||| -LRB-
14  ||| S:2473 E:2476 ||| CD
]  ||| S:2476 E:2478 ||| -RRB-
.  ||| S:2478 E:2480 ||| .
Tat  ||| S:2480 E:2492 ||| NNP
reduces  ||| S:2492 E:2500 ||| VBZ
mannose  ||| S:2500 E:2508 ||| JJ
receptor  ||| S:2508 E:2517 ||| NN
levels  ||| S:2517 E:2524 ||| NNS
and  ||| S:2524 E:2528 ||| CC
promoter  ||| S:2528 E:2537 ||| JJ
activity  ||| S:2537 E:2546 ||| NN
in  ||| S:2546 E:2557 ||| IN
mature  ||| S:2557 E:2564 ||| JJ
macrophages  ||| S:2564 E:2576 ||| NN
and  ||| S:2576 E:2580 ||| CC
dendritic  ||| S:2580 E:2590 ||| JJ
cells  ||| S:2590 E:2596 ||| NNS
by  ||| S:2596 E:2599 ||| IN
interfering  ||| S:2599 E:2611 ||| VBG
with  ||| S:2611 E:2624 ||| IN
the  ||| S:2624 E:2628 ||| DT
host  ||| S:2628 E:2633 ||| NN
transcriptional  ||| S:2633 E:2649 ||| NN
machinery ||| S:2649 E:2658 ||| NN
;  ||| S:2658 E:2660 ||| :
resulting  ||| S:2660 E:2670 ||| VBG
in  ||| S:2670 E:2673 ||| IN
decreased  ||| S:2673 E:2691 ||| JJ
levels  ||| S:2691 E:2698 ||| NNS
of  ||| S:2698 E:2701 ||| IN
surface  ||| S:2701 E:2709 ||| NN
mannose  ||| S:2709 E:2717 ||| NNS
receptor  ||| S:2717 E:2726 ||| VBP
needed  ||| S:2726 E:2733 ||| VBN
for  ||| S:2733 E:2737 ||| IN
Ag  ||| S:2737 E:2748 ||| NNP
( ||| S:2748 E:2749 ||| -LRB-
mannosylated  ||| S:2749 E:2762 ||| FW
albumin  ||| S:2762 E:2770 ||| FW
uptake ||| S:2770 E:2776 ||| FW
)  ||| S:2776 E:2778 ||| -RRB-
or  ||| S:2778 E:2781 ||| CC
pathogen  ||| S:2781 E:2790 ||| JJ
capture  ||| S:2790 E:2806 ||| NNS
( ||| S:2806 E:2807 ||| -LRB-
Pneumocystis  ||| S:2807 E:2820 ||| FW
carinii  ||| S:2820 E:2828 ||| FW
phagocytosis ||| S:2828 E:2840 ||| FW
) ||| S:2840 E:2841 ||| -RRB-
,  ||| S:2841 E:2843 ||| ,
and  ||| S:2843 E:2847 ||| CC
eventual  ||| S:2847 E:2856 ||| JJ
delivery  ||| S:2856 E:2873 ||| NN
to  ||| S:2873 E:2876 ||| TO
MHC  ||| S:2876 E:2880 ||| NNP
class  ||| S:2880 E:2886 ||| FW
II-containing  ||| S:2886 E:2900 ||| FW
intracellular  ||| S:2900 E:2914 ||| FW
compartments  ||| S:2914 E:2927 ||| FW
[  ||| S:2927 E:2929 ||| -LRB-
15  ||| S:2929 E:2940 ||| CD
]  ||| S:2940 E:2942 ||| -RRB-
.  ||| S:2942 E:2944 ||| .
EDF-1 ||| S:2944 E:2949 ||| NNP
,  ||| S:2949 E:2951 ||| ,
a  ||| S:2951 E:2953 ||| DT
gene  ||| S:2953 E:2958 ||| NN
down-regulated  ||| S:2958 E:2973 ||| NN
when  ||| S:2973 E:2978 ||| WRB
endothelial  ||| S:2978 E:2990 ||| JJ
cells  ||| S:2990 E:2996 ||| NNS
are  ||| S:2996 E:3008 ||| VBP
induced  ||| S:3008 E:3016 ||| VBN
to  ||| S:3016 E:3019 ||| TO
differentiate  ||| S:3019 E:3042 ||| VB
in  ||| S:3042 E:3045 ||| IN
vitro  ||| S:3045 E:3051 ||| NN
,  ||| S:3051 E:3053 ||| ,
was  ||| S:3053 E:3057 ||| VBD
shown  ||| S:3057 E:3063 ||| VBN
to  ||| S:3063 E:3066 ||| TO
be  ||| S:3066 E:3077 ||| VB
down-regulated  ||| S:3077 E:3092 ||| JJ
by  ||| S:3092 E:3095 ||| IN
Tat  ||| S:3095 E:3099 ||| NNP
at  ||| S:3099 E:3102 ||| IN
the  ||| S:3102 E:3106 ||| DT
transcriptional  ||| S:3106 E:3122 ||| JJ
level ||| S:3122 E:3127 ||| NN
,  ||| S:3127 E:3137 ||| ,
resulting  ||| S:3137 E:3147 ||| VBG
in  ||| S:3147 E:3150 ||| IN
the  ||| S:3150 E:3154 ||| DT
inhibition  ||| S:3154 E:3165 ||| NN
of  ||| S:3165 E:3168 ||| IN
endothelial  ||| S:3168 E:3180 ||| JJ
cell  ||| S:3180 E:3185 ||| NN
growth  ||| S:3185 E:3192 ||| NN
and  ||| S:3192 E:3204 ||| CC
in  ||| S:3204 E:3207 ||| IN
the  ||| S:3207 E:3211 ||| DT
transition  ||| S:3211 E:3222 ||| NN
from  ||| S:3222 E:3227 ||| IN
a  ||| S:3227 E:3229 ||| DT
nonpolar  ||| S:3229 E:3238 ||| JJ
cobblestone  ||| S:3238 E:3250 ||| JJ
phenotype  ||| S:3250 E:3260 ||| NN
to  ||| S:3260 E:3271 ||| TO
a  ||| S:3271 E:3273 ||| DT
polar  ||| S:3273 E:3279 ||| JJ
fibroblast-like  ||| S:3279 E:3295 ||| JJ
phenotype  ||| S:3295 E:3305 ||| NNS
[  ||| S:3305 E:3307 ||| -LRB-
16  ||| S:3307 E:3310 ||| CD
]  ||| S:3310 E:3312 ||| -RRB-
.  ||| S:3312 E:3322 ||| .
When  ||| S:3322 E:3327 ||| WRB
examining  ||| S:3327 E:3337 ||| VBG
the  ||| S:3337 E:3350 ||| DT
in  ||| S:3350 E:3353 ||| IN
vivo  ||| S:3353 E:3358 ||| JJ
effects  ||| S:3358 E:3366 ||| NNS
of  ||| S:3366 E:3369 ||| IN
HIV-1  ||| S:3369 E:3375 ||| NNP
Tat  ||| S:3375 E:3379 ||| NNP
protein  ||| S:3379 E:3395 ||| NN
in  ||| S:3395 E:3398 ||| IN
the  ||| S:3398 E:3411 ||| DT
Xenopus  ||| S:3411 E:3419 ||| JJ
embryo ||| S:3419 E:3425 ||| NN
,  ||| S:3425 E:3427 ||| ,
it  ||| S:3427 E:3430 ||| PRP
was  ||| S:3430 E:3434 ||| VBD
found  ||| S:3434 E:3440 ||| VBN
that  ||| S:3440 E:3453 ||| IN
upon  ||| S:3453 E:3458 ||| IN
injection  ||| S:3458 E:3468 ||| NN
of  ||| S:3468 E:3471 ||| IN
synthetic  ||| S:3471 E:3481 ||| JJ
Tat  ||| S:3481 E:3485 ||| NNP
mRNA  ||| S:3485 E:3490 ||| NNP
into  ||| S:3490 E:3495 ||| IN
zygotes ||| S:3495 E:3502 ||| NN
,  ||| S:3502 E:3504 ||| ,
a  ||| S:3504 E:3506 ||| DT
marked  ||| S:3506 E:3521 ||| JJ
delay  ||| S:3521 E:3527 ||| NN
in  ||| S:3527 E:3530 ||| IN
gastrulation  ||| S:3530 E:3543 ||| NN
occurred ||| S:3543 E:3551 ||| VBD
.  ||| S:3551 E:3553 ||| .
This  ||| S:3553 E:3558 ||| DT
led  ||| S:3558 E:3562 ||| VBN
to  ||| S:3562 E:3565 ||| TO
the  ||| S:3565 E:3569 ||| DT
altered  ||| S:3569 E:3585 ||| JJ
specification  ||| S:3585 E:3599 ||| NN
of  ||| S:3599 E:3602 ||| IN
the  ||| S:3602 E:3606 ||| DT
anterior-posterior  ||| S:3606 E:3625 ||| JJ
axis  ||| S:3625 E:3630 ||| NN
and  ||| S:3630 E:3634 ||| CC
partial  ||| S:3634 E:3650 ||| JJ
loss  ||| S:3650 E:3655 ||| NN
of  ||| S:3655 E:3658 ||| IN
the  ||| S:3658 E:3662 ||| DT
anterior  ||| S:3662 E:3671 ||| JJ
embryo  ||| S:3671 E:3678 ||| NN
structures ||| S:3678 E:3688 ||| NNS
.  ||| S:3688 E:3690 ||| .
Mechanistically ||| S:3690 E:3705 ||| NNP
,  ||| S:3705 E:3715 ||| ,
HIV-1  ||| S:3715 E:3721 ||| NNP
Tat  ||| S:3721 E:3725 ||| NNP
elicited  ||| S:3725 E:3734 ||| VBD
a  ||| S:3734 E:3736 ||| DT
general  ||| S:3736 E:3744 ||| JJ
suppression  ||| S:3744 E:3756 ||| NN
of  ||| S:3756 E:3759 ||| IN
gene  ||| S:3759 E:3772 ||| NN
expression ||| S:3772 E:3782 ||| NN
,  ||| S:3782 E:3784 ||| ,
including  ||| S:3784 E:3794 ||| VBG
that  ||| S:3794 E:3799 ||| IN
of  ||| S:3799 E:3811 ||| IN
Xbra  ||| S:3811 E:3816 ||| NNP
and  ||| S:3816 E:3829 ||| CC
gsc  ||| S:3829 E:3833 ||| NN
,  ||| S:3833 E:3835 ||| ,
two  ||| S:3835 E:3839 ||| CD
early  ||| S:3839 E:3845 ||| JJ
genes  ||| S:3845 E:3851 ||| NNS
whose  ||| S:3851 E:3865 ||| WP$
expression  ||| S:3865 E:3876 ||| NNS
are  ||| S:3876 E:3880 ||| VBP
required  ||| S:3880 E:3889 ||| VBN
for  ||| S:3889 E:3893 ||| IN
proper  ||| S:3893 E:3900 ||| JJ
gastrulation  ||| S:3900 E:3913 ||| NNS
[  ||| S:3913 E:3915 ||| -LRB-
17  ||| S:3915 E:3918 ||| CD
]  ||| S:3918 E:3928 ||| -RRB-
.  ||| S:3928 E:3938 ||| .
In  ||| S:3938 E:3941 ||| IN
relation  ||| S:3941 E:3950 ||| NN
to  ||| S:3950 E:3953 ||| TO
the  ||| S:3953 E:3957 ||| DT
cell  ||| S:3957 E:3962 ||| NN
cycle ||| S:3962 E:3967 ||| NN
,  ||| S:3967 E:3969 ||| ,
Tat  ||| S:3969 E:3973 ||| NNP
has  ||| S:3973 E:3977 ||| VBZ
also  ||| S:3977 E:3982 ||| RB
been  ||| S:3982 E:3987 ||| VBN
shown  ||| S:3987 E:4001 ||| VBN
to  ||| S:4001 E:4004 ||| TO
bind  ||| S:4004 E:4009 ||| VB
to  ||| S:4009 E:4012 ||| TO
p53  ||| S:4012 E:4016 ||| NN
and  ||| S:4016 E:4020 ||| CC
inhibit  ||| S:4020 E:4028 ||| VB
the  ||| S:4028 E:4032 ||| DT
transcription  ||| S:4032 E:4046 ||| NN
of  ||| S:4046 E:4049 ||| IN
p53  ||| S:4049 E:4061 ||| NN
responsive  ||| S:4061 E:4072 ||| JJ
elements ||| S:4072 E:4080 ||| NNS
,  ||| S:4080 E:4082 ||| ,
such  ||| S:4082 E:4087 ||| JJ
as  ||| S:4087 E:4090 ||| IN
the  ||| S:4090 E:4094 ||| DT
p21 ||| S:4094 E:4097 ||| CD
/ ||| S:4097 E:4098 ||| CD
Waf1  ||| S:4098 E:4103 ||| CD
gene  ||| S:4103 E:4108 ||| NN
promoter ||| S:4108 E:4116 ||| NN
.  ||| S:4116 E:4126 ||| .
Consequently ||| S:4126 E:4138 ||| RB
,  ||| S:4138 E:4140 ||| ,
upon  ||| S:4140 E:4145 ||| IN
introduction  ||| S:4145 E:4158 ||| NN
of  ||| S:4158 E:4161 ||| IN
stress  ||| S:4161 E:4168 ||| NN
signals  ||| S:4168 E:4176 ||| NNS
( ||| S:4176 E:4177 ||| -LRB-
e.g. ||| S:4177 E:4181 ||| NNP
,  ||| S:4181 E:4191 ||| ,
gamma  ||| S:4191 E:4197 ||| JJ
irradiation ||| S:4197 E:4208 ||| NN
) ||| S:4208 E:4209 ||| -RRB-
,  ||| S:4209 E:4211 ||| ,
HIV-1-infected  ||| S:4211 E:4226 ||| CD
cells  ||| S:4226 E:4232 ||| NNS
lose  ||| S:4232 E:4237 ||| VBP
their  ||| S:4237 E:4243 ||| PRP$
G1 ||| S:4243 E:4245 ||| NNP
/ ||| S:4245 E:4246 ||| NNP
S  ||| S:4246 E:4256 ||| NNP
checkpoint ||| S:4256 E:4266 ||| NN
,  ||| S:4266 E:4268 ||| ,
enter  ||| S:4268 E:4274 ||| VB
the  ||| S:4274 E:4278 ||| DT
S-phase  ||| S:4278 E:4286 ||| JJ
inappropriately ||| S:4286 E:4301 ||| NN
,  ||| S:4301 E:4303 ||| ,
and  ||| S:4303 E:4307 ||| CC
apoptose  ||| S:4307 E:4324 ||| NNS
[  ||| S:4324 E:4326 ||| -LRB-
18  ||| S:4326 E:4329 ||| CD
19  ||| S:4329 E:4332 ||| CD
20  ||| S:4332 E:4335 ||| CD
]  ||| S:4335 E:4337 ||| -RRB-
.  ||| S:4337 E:4339 ||| .
Finally ||| S:4339 E:4346 ||| RB
,  ||| S:4346 E:4348 ||| ,
the  ||| S:4348 E:4352 ||| DT
inhibition  ||| S:4352 E:4363 ||| NN
of  ||| S:4363 E:4366 ||| IN
Tat  ||| S:4366 E:4370 ||| NNP
on  ||| S:4370 E:4381 ||| IN
translational  ||| S:4381 E:4395 ||| JJ
machinery  ||| S:4395 E:4405 ||| NN
has  ||| S:4405 E:4409 ||| VBZ
also  ||| S:4409 E:4414 ||| RB
been  ||| S:4414 E:4419 ||| VBN
noted ||| S:4419 E:4424 ||| VBN
.  ||| S:4424 E:4426 ||| .
The  ||| S:4426 E:4430 ||| DT
potential  ||| S:4430 E:4448 ||| JJ
translational  ||| S:4448 E:4462 ||| JJ
inhibitory  ||| S:4462 E:4473 ||| JJ
effects  ||| S:4473 E:4481 ||| NNS
of  ||| S:4481 E:4484 ||| IN
the  ||| S:4484 E:4488 ||| DT
TAR  ||| S:4488 E:4492 ||| NNP
RNA  ||| S:4492 E:4496 ||| NNP
region  ||| S:4496 E:4503 ||| NN
is  ||| S:4503 E:4514 ||| VBZ
mediated  ||| S:4514 E:4523 ||| VBN
by  ||| S:4523 E:4526 ||| IN
the  ||| S:4526 E:4530 ||| DT
activation  ||| S:4530 E:4541 ||| NN
of  ||| S:4541 E:4544 ||| IN
p68  ||| S:4544 E:4548 ||| NNP
( ||| S:4548 E:4549 ||| -LRB-
the  ||| S:4549 E:4553 ||| DT
interferon-induced  ||| S:4553 E:4580 ||| JJ
68-kilodalton  ||| S:4580 E:4594 ||| CD
protein  ||| S:4594 E:4602 ||| NN
kinase ||| S:4602 E:4608 ||| NN
)  ||| S:4608 E:4610 ||| -RRB-
kinase ||| S:4610 E:4616 ||| NN
,  ||| S:4616 E:4618 ||| ,
which  ||| S:4618 E:4624 ||| WDT
was  ||| S:4624 E:4636 ||| VBD
down-regulated  ||| S:4636 E:4651 ||| JJ
by  ||| S:4651 E:4654 ||| IN
Tat  ||| S:4654 E:4658 ||| NNP
during  ||| S:4658 E:4665 ||| IN
productive  ||| S:4665 E:4676 ||| JJ
HIV-1  ||| S:4676 E:4682 ||| NNP
infection  ||| S:4682 E:4692 ||| NN
[  ||| S:4692 E:4702 ||| -LRB-
22  ||| S:4702 E:4705 ||| CD
]  ||| S:4705 E:4707 ||| -RRB-
.  ||| S:4707 E:4717 ||| .
Although  ||| S:4717 E:4726 ||| IN
the  ||| S:4726 E:4730 ||| DT
mechanism  ||| S:4730 E:4740 ||| NN
of  ||| S:4740 E:4743 ||| IN
the  ||| S:4743 E:4747 ||| DT
host  ||| S:4747 E:4752 ||| NN
cellular  ||| S:4752 E:4769 ||| JJ
down-regulation  ||| S:4769 E:4785 ||| NN
remains  ||| S:4785 E:4793 ||| VBZ
largely  ||| S:4793 E:4801 ||| RB
unknown ||| S:4801 E:4808 ||| JJ
,  ||| S:4808 E:4810 ||| ,
few  ||| S:4810 E:4814 ||| JJ
reports  ||| S:4814 E:4822 ||| NNS
have  ||| S:4822 E:4835 ||| VBP
attempted  ||| S:4835 E:4845 ||| VBN
to  ||| S:4845 E:4848 ||| TO
decipher  ||| S:4848 E:4857 ||| VB
the  ||| S:4857 E:4861 ||| DT
mechanism  ||| S:4861 E:4871 ||| NN
of  ||| S:4871 E:4874 ||| IN
the  ||| S:4874 E:4878 ||| DT
observed  ||| S:4878 E:4895 ||| JJ
inhibition ||| S:4895 E:4905 ||| NN
.  ||| S:4905 E:4907 ||| .
For  ||| S:4907 E:4911 ||| IN
instance ||| S:4911 E:4919 ||| NN
,  ||| S:4919 E:4921 ||| ,
the  ||| S:4921 E:4925 ||| DT
addition  ||| S:4925 E:4934 ||| NN
of  ||| S:4934 E:4937 ||| IN
Tat  ||| S:4937 E:4941 ||| NNP
to  ||| S:4941 E:4944 ||| TO
PC12  ||| S:4944 E:4949 ||| CD
cells  ||| S:4949 E:4963 ||| NNS
up-regulated  ||| S:4963 E:4976 ||| JJ
the  ||| S:4976 E:4980 ||| DT
expression  ||| S:4980 E:4991 ||| NN
of  ||| S:4991 E:4994 ||| IN
the  ||| S:4994 E:4998 ||| DT
inducible  ||| S:4998 E:5008 ||| JJ
cAMP  ||| S:5008 E:5013 ||| JJ
early  ||| S:5013 E:5027 ||| JJ
repressor  ||| S:5027 E:5037 ||| NNS
( ||| S:5037 E:5038 ||| -LRB-
ICER ||| S:5038 E:5042 ||| NNP
) ||| S:5042 E:5043 ||| -RRB-
,  ||| S:5043 E:5045 ||| ,
a  ||| S:5045 E:5047 ||| DT
specific  ||| S:5047 E:5056 ||| JJ
member  ||| S:5056 E:5063 ||| NN
of  ||| S:5063 E:5066 ||| IN
the  ||| S:5066 E:5070 ||| DT
cAMP-responsive  ||| S:5070 E:5094 ||| JJ
element  ||| S:5094 E:5102 ||| NN
modulator  ||| S:5102 E:5112 ||| VBZ
transcription  ||| S:5112 E:5126 ||| JJ
factor  ||| S:5126 E:5133 ||| NN
family ||| S:5133 E:5139 ||| NN
,  ||| S:5139 E:5141 ||| ,
in  ||| S:5141 E:5144 ||| IN
a  ||| S:5144 E:5154 ||| DT
cAMP-dependent  ||| S:5154 E:5169 ||| JJ
manner ||| S:5169 E:5175 ||| NN
.  ||| S:5175 E:5177 ||| .
In  ||| S:5177 E:5180 ||| IN
turn ||| S:5180 E:5184 ||| NN
,  ||| S:5184 E:5186 ||| ,
ICER  ||| S:5186 E:5191 ||| NNP
overexpression  ||| S:5191 E:5214 ||| VBZ
abrogated  ||| S:5214 E:5224 ||| VBG
the  ||| S:5224 E:5228 ||| DT
transcriptional  ||| S:5228 E:5244 ||| JJ
activity  ||| S:5244 E:5253 ||| NN
of  ||| S:5253 E:5256 ||| IN
the  ||| S:5256 E:5260 ||| DT
TH  ||| S:5260 E:5263 ||| NNP
promoter ||| S:5263 E:5271 ||| NN
,  ||| S:5271 E:5281 ||| ,
strongly  ||| S:5281 E:5290 ||| RB
suggesting  ||| S:5290 E:5301 ||| VBG
ICER ||| S:5301 E:5305 ||| NNP
's  ||| S:5305 E:5308 ||| POS
involvement  ||| S:5308 E:5320 ||| NN
in  ||| S:5320 E:5323 ||| IN
Tat-mediated  ||| S:5323 E:5344 ||| JJ
inhibition  ||| S:5344 E:5355 ||| NN
of  ||| S:5355 E:5358 ||| IN
gene  ||| S:5358 E:5363 ||| NN
expression  ||| S:5363 E:5374 ||| NN
[  ||| S:5374 E:5376 ||| -LRB-
23  ||| S:5376 E:5379 ||| CD
]  ||| S:5379 E:5381 ||| -RRB-
.  ||| S:5381 E:5391 ||| .
Aside  ||| S:5391 E:5397 ||| RB
from  ||| S:5397 E:5402 ||| IN
induction  ||| S:5402 E:5412 ||| NN
of  ||| S:5412 E:5415 ||| IN
ICER ||| S:5415 E:5419 ||| NNP
,  ||| S:5419 E:5421 ||| ,
Tat  ||| S:5421 E:5425 ||| NNP
is  ||| S:5425 E:5428 ||| VBZ
capable  ||| S:5428 E:5436 ||| JJ
of  ||| S:5436 E:5439 ||| IN
forming  ||| S:5439 E:5455 ||| VBG
complex  ||| S:5455 E:5463 ||| JJ
( ||| S:5463 E:5464 ||| -LRB-
es ||| S:5464 E:5466 ||| LS
)  ||| S:5466 E:5468 ||| -RRB-
with  ||| S:5468 E:5473 ||| IN
a  ||| S:5473 E:5475 ||| DT
component  ||| S:5475 E:5485 ||| NN
of  ||| S:5485 E:5488 ||| IN
TFIID ||| S:5488 E:5493 ||| NNP
,  ||| S:5493 E:5495 ||| ,
TAF  ||| S:5495 E:5508 ||| NNP
II  ||| S:5508 E:5511 ||| NNP
250  ||| S:5511 E:5515 ||| CD
[  ||| S:5515 E:5517 ||| -LRB-
24  ||| S:5517 E:5520 ||| CD
]  ||| S:5520 E:5522 ||| -RRB-
and  ||| S:5522 E:5526 ||| CC
Tip60  ||| S:5526 E:5532 ||| NNP
[  ||| S:5532 E:5534 ||| -LRB-
25  ||| S:5534 E:5537 ||| CD
]  ||| S:5537 E:5539 ||| -RRB-
both  ||| S:5539 E:5544 ||| CC
of  ||| S:5544 E:5555 ||| IN
which  ||| S:5555 E:5561 ||| WDT
contain  ||| S:5561 E:5569 ||| VBP
histone  ||| S:5569 E:5577 ||| JJ
acetyltransferase  ||| S:5577 E:5595 ||| NNS
( ||| S:5595 E:5596 ||| -LRB-
HAT ||| S:5596 E:5599 ||| NNP
)  ||| S:5599 E:5601 ||| -RRB-
activity ||| S:5601 E:5609 ||| NN
.  ||| S:5609 E:5611 ||| .
In  ||| S:5611 E:5622 ||| IN
these  ||| S:5622 E:5628 ||| DT
cases ||| S:5628 E:5633 ||| NNS
,  ||| S:5633 E:5635 ||| ,
Tat-TAF  ||| S:5635 E:5652 ||| NNP
II  ||| S:5652 E:5655 ||| NNP
250  ||| S:5655 E:5659 ||| CD
and  ||| S:5659 E:5663 ||| CC
Tat-Tip60  ||| S:5663 E:5673 ||| NNP
do  ||| S:5673 E:5676 ||| VBP
not  ||| S:5676 E:5680 ||| RB
affect  ||| S:5680 E:5687 ||| VB
the  ||| S:5687 E:5699 ||| DT
transcription  ||| S:5699 E:5713 ||| NN
from  ||| S:5713 E:5718 ||| IN
the  ||| S:5718 E:5722 ||| DT
HIV-1  ||| S:5722 E:5728 ||| NNP
LTR ||| S:5728 E:5731 ||| NNP
,  ||| S:5731 E:5733 ||| ,
but  ||| S:5733 E:5737 ||| CC
interfere  ||| S:5737 E:5747 ||| VB
with  ||| S:5747 E:5752 ||| IN
the  ||| S:5752 E:5764 ||| DT
transcription  ||| S:5764 E:5778 ||| JJ
activity  ||| S:5778 E:5787 ||| NN
of  ||| S:5787 E:5790 ||| IN
cellular  ||| S:5790 E:5799 ||| JJ
genes ||| S:5799 E:5804 ||| NNS
.  ||| S:5804 E:5806 ||| .
It  ||| S:5806 E:5809 ||| PRP
is  ||| S:5809 E:5812 ||| VBZ
postulated  ||| S:5812 E:5831 ||| VBN
that  ||| S:5831 E:5836 ||| IN
different  ||| S:5836 E:5846 ||| JJ
targets  ||| S:5846 E:5854 ||| NNS
of  ||| S:5854 E:5857 ||| IN
HATs  ||| S:5857 E:5862 ||| JJ
by  ||| S:5862 E:5865 ||| IN
Tat  ||| S:5865 E:5869 ||| NNP
have  ||| S:5869 E:5874 ||| VBP
different  ||| S:5874 E:5892 ||| JJ
consequences ||| S:5892 E:5904 ||| NNS
.  ||| S:5904 E:5906 ||| .
The  ||| S:5906 E:5910 ||| DT
interaction  ||| S:5910 E:5922 ||| NN
of  ||| S:5922 E:5925 ||| IN
Tat  ||| S:5925 E:5929 ||| NNP
with  ||| S:5929 E:5934 ||| IN
p300 ||| S:5934 E:5938 ||| NNP
/ ||| S:5938 E:5939 ||| NNP
CBP  ||| S:5939 E:5943 ||| NNP
and  ||| S:5943 E:5955 ||| CC
P ||| S:5955 E:5956 ||| NNP
/ ||| S:5956 E:5957 ||| NNP
CAF  ||| S:5957 E:5961 ||| NNP
stimulates  ||| S:5961 E:5972 ||| VBD
its  ||| S:5972 E:5976 ||| PRP$
ability  ||| S:5976 E:5984 ||| NN
to  ||| S:5984 E:5987 ||| TO
transactivate  ||| S:5987 E:6001 ||| VB
LTR-dependent  ||| S:6001 E:6023 ||| JJ
transcription ||| S:6023 E:6036 ||| NN
,  ||| S:6036 E:6038 ||| ,
while  ||| S:6038 E:6044 ||| IN
Tat-TAF  ||| S:6044 E:6061 ||| NNP
II  ||| S:6061 E:6064 ||| NNP
250  ||| S:6064 E:6068 ||| CD
or  ||| S:6068 E:6071 ||| CC
Tat-Tip60  ||| S:6071 E:6081 ||| CD
interactions  ||| S:6081 E:6094 ||| NNS
control  ||| S:6094 E:6110 ||| VBP
the  ||| S:6110 E:6114 ||| DT
transcription  ||| S:6114 E:6128 ||| NN
of  ||| S:6128 E:6131 ||| IN
cellular  ||| S:6131 E:6140 ||| JJ
genes ||| S:6140 E:6145 ||| NNS
.  ||| S:6145 E:6155 ||| .
Here  ||| S:6155 E:6160 ||| RB
to  ||| S:6160 E:6163 ||| TO
better  ||| S:6163 E:6170 ||| RB
understand  ||| S:6170 E:6181 ||| VB
the  ||| S:6181 E:6185 ||| DT
host  ||| S:6185 E:6190 ||| NN
response  ||| S:6190 E:6199 ||| NN
to  ||| S:6199 E:6202 ||| TO
Tat ||| S:6202 E:6205 ||| NNP
,  ||| S:6205 E:6207 ||| ,
we  ||| S:6207 E:6218 ||| PRP
have  ||| S:6218 E:6223 ||| VBP
performed  ||| S:6223 E:6233 ||| VBN
microarray  ||| S:6233 E:6244 ||| JJ
experiments  ||| S:6244 E:6256 ||| NNS
on  ||| S:6256 E:6259 ||| IN
HIV-1  ||| S:6259 E:6265 ||| NNP
infected  ||| S:6265 E:6282 ||| JJ
cells  ||| S:6282 E:6288 ||| NNS
expressing  ||| S:6288 E:6299 ||| VBG
the  ||| S:6299 E:6303 ||| DT
Tat  ||| S:6303 E:6307 ||| JJ
protein ||| S:6307 E:6314 ||| NN
.  ||| S:6314 E:6316 ||| .
To  ||| S:6316 E:6319 ||| TO
our  ||| S:6319 E:6323 ||| PRP$
surprise  ||| S:6323 E:6332 ||| NN
many  ||| S:6332 E:6337 ||| JJ
host  ||| S:6337 E:6350 ||| NN
cellular  ||| S:6350 E:6359 ||| JJ
genes  ||| S:6359 E:6365 ||| NNS
were  ||| S:6365 E:6370 ||| VBD
down-regulated  ||| S:6370 E:6385 ||| JJ
when  ||| S:6385 E:6390 ||| WRB
comparing  ||| S:6390 E:6400 ||| VBG
HIV-1  ||| S:6400 E:6414 ||| NNP
infected  ||| S:6414 E:6423 ||| VBD
latent  ||| S:6423 E:6430 ||| JJ
cells  ||| S:6430 E:6436 ||| NNS
to  ||| S:6436 E:6439 ||| TO
uninfected  ||| S:6439 E:6450 ||| VB
parental  ||| S:6450 E:6459 ||| JJ
cells ||| S:6459 E:6464 ||| NNS
.  ||| S:6464 E:6466 ||| .
Because  ||| S:6466 E:6482 ||| IN
most ||| S:6482 E:6486 ||| JJS
,  ||| S:6486 E:6488 ||| ,
if  ||| S:6488 E:6491 ||| IN
not  ||| S:6491 E:6495 ||| RB
all ||| S:6495 E:6498 ||| RB
,  ||| S:6498 E:6500 ||| ,
latent  ||| S:6500 E:6507 ||| JJ
infected  ||| S:6507 E:6516 ||| JJ
cells  ||| S:6516 E:6522 ||| NNS
available  ||| S:6522 E:6532 ||| JJ
to  ||| S:6532 E:6535 ||| TO
date  ||| S:6535 E:6548 ||| VB
( ||| S:6548 E:6549 ||| -LRB-
e.g. ||| S:6549 E:6553 ||| NNP
,  ||| S:6553 E:6555 ||| ,
ACH2 ||| S:6555 E:6559 ||| NNP
,  ||| S:6559 E:6561 ||| ,
U1 ||| S:6561 E:6563 ||| NNP
,  ||| S:6563 E:6565 ||| ,
J1.1 ||| S:6565 E:6569 ||| NNP
,  ||| S:6569 E:6571 ||| ,
OM.10 ||| S:6571 E:6576 ||| CD
)  ||| S:6576 E:6578 ||| -RRB-
have  ||| S:6578 E:6583 ||| VBP
various  ||| S:6583 E:6591 ||| JJ
expression  ||| S:6591 E:6610 ||| NN
levels  ||| S:6610 E:6617 ||| NNS
of  ||| S:6617 E:6620 ||| IN
doubly  ||| S:6620 E:6627 ||| FW
spliced  ||| S:6627 E:6635 ||| FW
viral  ||| S:6635 E:6641 ||| FW
mRNAs ||| S:6641 E:6646 ||| FW
,  ||| S:6646 E:6648 ||| ,
including  ||| S:6648 E:6658 ||| VBG
Tat ||| S:6658 E:6661 ||| NNP
,  ||| S:6661 E:6663 ||| ,
Rev ||| S:6663 E:6666 ||| NNP
,  ||| S:6666 E:6676 ||| ,
Nef ||| S:6676 E:6679 ||| NNP
,  ||| S:6679 E:6681 ||| ,
Vpr ||| S:6681 E:6684 ||| NNP
,  ||| S:6684 E:6686 ||| ,
and  ||| S:6686 E:6690 ||| CC
other  ||| S:6690 E:6696 ||| JJ
accessory  ||| S:6696 E:6706 ||| JJ
proteins ||| S:6706 E:6714 ||| NNS
,  ||| S:6714 E:6716 ||| ,
we  ||| S:6716 E:6719 ||| PRP
decided  ||| S:6719 E:6727 ||| VBD
to  ||| S:6727 E:6738 ||| TO
perform  ||| S:6738 E:6746 ||| VB
the  ||| S:6746 E:6750 ||| DT
microarray  ||| S:6750 E:6761 ||| NN
in  ||| S:6761 E:6764 ||| IN
a  ||| S:6764 E:6766 ||| DT
system  ||| S:6766 E:6773 ||| NN
where  ||| S:6773 E:6779 ||| WRB
Tat  ||| S:6779 E:6783 ||| NNP
was  ||| S:6783 E:6795 ||| VBD
constitutively  ||| S:6795 E:6810 ||| VBN
expressed ||| S:6810 E:6819 ||| VBN
;  ||| S:6819 E:6821 ||| :
asking  ||| S:6821 E:6828 ||| VBG
whether  ||| S:6828 E:6836 ||| IN
Tat  ||| S:6836 E:6840 ||| NNP
by  ||| S:6840 E:6843 ||| IN
itself ||| S:6843 E:6849 ||| PRP
,  ||| S:6849 E:6851 ||| ,
or  ||| S:6851 E:6862 ||| CC
in  ||| S:6862 E:6865 ||| IN
the  ||| S:6865 E:6869 ||| DT
absence  ||| S:6869 E:6877 ||| NN
of  ||| S:6877 E:6880 ||| IN
other  ||| S:6880 E:6886 ||| JJ
accessory  ||| S:6886 E:6896 ||| JJ
proteins ||| S:6896 E:6904 ||| NNS
,  ||| S:6904 E:6906 ||| ,
could  ||| S:6906 E:6912 ||| MD
still  ||| S:6912 E:6926 ||| RB
down-regulate  ||| S:6926 E:6940 ||| JJ
host  ||| S:6940 E:6945 ||| NN
cellular  ||| S:6945 E:6954 ||| JJ
genes ||| S:6954 E:6959 ||| NNS
.  ||| S:6959 E:6961 ||| .
Consistent  ||| S:6961 E:6972 ||| JJ
with  ||| S:6972 E:6977 ||| IN
latently  ||| S:6977 E:6994 ||| JJ
infected  ||| S:6994 E:7003 ||| JJ
cells ||| S:7003 E:7008 ||| NNS
,  ||| S:7008 E:7010 ||| ,
we  ||| S:7010 E:7013 ||| PRP
found  ||| S:7013 E:7019 ||| VBD
many  ||| S:7019 E:7024 ||| JJ
cellular  ||| S:7024 E:7033 ||| JJ
genes  ||| S:7033 E:7039 ||| NNS
to  ||| S:7039 E:7042 ||| TO
be  ||| S:7042 E:7053 ||| VB
down-regulated  ||| S:7053 E:7068 ||| JJ
in  ||| S:7068 E:7071 ||| IN
Tat  ||| S:7071 E:7075 ||| NNP
expressing  ||| S:7075 E:7086 ||| FW
lymphocytes ||| S:7086 E:7097 ||| FW
.  ||| S:7097 E:7099 ||| .
The  ||| S:7099 E:7111 ||| DT
down-regulation  ||| S:7111 E:7127 ||| NN
is  ||| S:7127 E:7130 ||| VBZ
most  ||| S:7130 E:7135 ||| RBS
apparent  ||| S:7135 E:7144 ||| JJ
on  ||| S:7144 E:7147 ||| IN
cellular  ||| S:7147 E:7156 ||| JJ
receptors  ||| S:7156 E:7166 ||| NNS
that  ||| S:7166 E:7179 ||| WDT
have  ||| S:7179 E:7184 ||| VBP
intrinsic  ||| S:7184 E:7194 ||| FW
receptor  ||| S:7194 E:7203 ||| FW
tyrosine  ||| S:7203 E:7212 ||| FW
kinase  ||| S:7212 E:7219 ||| FW
( ||| S:7219 E:7220 ||| -LRB-
RTK ||| S:7220 E:7223 ||| NNP
)  ||| S:7223 E:7225 ||| -RRB-
activity  ||| S:7225 E:7234 ||| NN
and  ||| S:7234 E:7246 ||| CC
signal  ||| S:7246 E:7253 ||| VB
transduction  ||| S:7253 E:7266 ||| JJ
members  ||| S:7266 E:7274 ||| NNS
that  ||| S:7274 E:7279 ||| IN
mediate  ||| S:7279 E:7287 ||| JJ
RTK  ||| S:7287 E:7291 ||| NNP
function ||| S:7291 E:7299 ||| NN
;  ||| S:7299 E:7309 ||| :
including  ||| S:7309 E:7319 ||| VBG
the  ||| S:7319 E:7323 ||| DT
Ras-Raf-MEK  ||| S:7323 E:7335 ||| JJ
pathway ||| S:7335 E:7342 ||| NN
,  ||| S:7342 E:7344 ||| ,
and  ||| S:7344 E:7348 ||| CC
co-activators  ||| S:7348 E:7362 ||| JJ
such  ||| S:7362 E:7375 ||| JJ
as  ||| S:7375 E:7378 ||| IN
p300 ||| S:7378 E:7382 ||| NNP
/ ||| S:7382 E:7383 ||| NNP
CBP  ||| S:7383 E:7387 ||| NNP
and  ||| S:7387 E:7391 ||| CC
SRC-1 ||| S:7391 E:7396 ||| NNP
,  ||| S:7396 E:7398 ||| ,
which  ||| S:7398 E:7404 ||| WDT
mediate  ||| S:7404 E:7412 ||| JJ
gene  ||| S:7412 E:7417 ||| NN
expression  ||| S:7417 E:7436 ||| NN
related  ||| S:7436 E:7444 ||| VBN
to  ||| S:7444 E:7447 ||| TO
hormone  ||| S:7447 E:7455 ||| VB
receptor  ||| S:7455 E:7464 ||| JJ
genes ||| S:7464 E:7469 ||| NNS
.  ||| S:7469 E:7471 ||| .
Interestingly ||| S:7471 E:7484 ||| RB
,  ||| S:7484 E:7486 ||| ,
we  ||| S:7486 E:7489 ||| PRP
also  ||| S:7489 E:7502 ||| RB
observed  ||| S:7502 E:7511 ||| VBD
up-regulation  ||| S:7511 E:7525 ||| JJ
of  ||| S:7525 E:7528 ||| IN
S-phase  ||| S:7528 E:7536 ||| JJ
genes ||| S:7536 E:7541 ||| NNS
,  ||| S:7541 E:7543 ||| ,
as  ||| S:7543 E:7546 ||| RB
well  ||| S:7546 E:7551 ||| RB
as  ||| S:7551 E:7562 ||| IN
ribosomal  ||| S:7562 E:7572 ||| JJ
genes  ||| S:7572 E:7578 ||| NNS
involved  ||| S:7578 E:7587 ||| VBN
in  ||| S:7587 E:7590 ||| IN
translation ||| S:7590 E:7601 ||| NN
.  ||| S:7601 E:7603 ||| .
Functionally ||| S:7603 E:7615 ||| NNP
,  ||| S:7615 E:7625 ||| ,
down-regulation  ||| S:7625 E:7641 ||| JJ
of  ||| S:7641 E:7644 ||| IN
receptors  ||| S:7644 E:7654 ||| NNS
may  ||| S:7654 E:7658 ||| MD
allow  ||| S:7658 E:7664 ||| VB
latent  ||| S:7664 E:7671 ||| CD
HIV-1  ||| S:7671 E:7685 ||| CD
infected  ||| S:7685 E:7694 ||| JJ
cells  ||| S:7694 E:7700 ||| NNS
to  ||| S:7700 E:7703 ||| TO
either  ||| S:7703 E:7710 ||| RB
hide  ||| S:7710 E:7715 ||| VB
from  ||| S:7715 E:7720 ||| IN
the  ||| S:7720 E:7724 ||| DT
immune  ||| S:7724 E:7731 ||| JJ
system  ||| S:7731 E:7738 ||| NN
or  ||| S:7738 E:7749 ||| CC
avoid  ||| S:7749 E:7755 ||| VB
extracellular  ||| S:7755 E:7769 ||| JJ
differentiation  ||| S:7769 E:7785 ||| NN
signals  ||| S:7785 E:7793 ||| VBZ
normally  ||| S:7793 E:7810 ||| RB
regulated  ||| S:7810 E:7820 ||| VBN
by  ||| S:7820 E:7823 ||| IN
receptors ||| S:7823 E:7832 ||| NNS
.  ||| S:7832 E:7834 ||| .
Up-regulation  ||| S:7834 E:7848 ||| JJ
of  ||| S:7848 E:7851 ||| IN
S-phase  ||| S:7851 E:7859 ||| JJ
and  ||| S:7859 E:7871 ||| CC
translation  ||| S:7871 E:7883 ||| NN
genes  ||| S:7883 E:7889 ||| NNS
may  ||| S:7889 E:7893 ||| MD
allow  ||| S:7893 E:7899 ||| VB
speeding  ||| S:7899 E:7908 ||| VBG
of  ||| S:7908 E:7911 ||| IN
cells  ||| S:7911 E:7917 ||| NNS
through  ||| S:7917 E:7925 ||| IN
the  ||| S:7925 E:7937 ||| DT
S-phase  ||| S:7937 E:7945 ||| JJ
and  ||| S:7945 E:7949 ||| CC
subsequent  ||| S:7949 E:7960 ||| JJ
accumulation  ||| S:7960 E:7973 ||| NN
at  ||| S:7973 E:7976 ||| IN
the  ||| S:7976 E:7980 ||| DT
G2  ||| S:7980 E:7983 ||| JJ
phase ||| S:7983 E:7988 ||| NN
,  ||| S:7988 E:7990 ||| ,
where  ||| S:7990 E:8004 ||| WRB
most  ||| S:8004 E:8009 ||| JJS
of  ||| S:8009 E:8012 ||| IN
the  ||| S:8012 E:8016 ||| DT
cellular  ||| S:8016 E:8025 ||| JJ
and  ||| S:8025 E:8029 ||| CC
viral  ||| S:8029 E:8035 ||| JJ
translation  ||| S:8035 E:8047 ||| NN
may  ||| S:8047 E:8051 ||| MD
take  ||| S:8051 E:8056 ||| VB
place ||| S:8056 E:8061 ||| NN
.  ||| S:8061 E:8071 ||| .
Therefore ||| S:8071 E:8080 ||| RB
,  ||| S:8080 E:8082 ||| ,
the  ||| S:8082 E:8086 ||| DT
presence  ||| S:8086 E:8095 ||| NN
of  ||| S:8095 E:8098 ||| IN
Tat  ||| S:8098 E:8102 ||| NNP
may  ||| S:8102 E:8106 ||| MD
not  ||| S:8106 E:8110 ||| RB
only  ||| S:8110 E:8115 ||| RB
control  ||| S:8115 E:8131 ||| VB
activated  ||| S:8131 E:8141 ||| VBN
transcription  ||| S:8141 E:8155 ||| VBN
on  ||| S:8155 E:8158 ||| IN
HIV-1  ||| S:8158 E:8164 ||| NNP
LTR ||| S:8164 E:8167 ||| NNP
,  ||| S:8167 E:8169 ||| ,
but  ||| S:8169 E:8173 ||| CC
also  ||| S:8173 E:8178 ||| RB
aid  ||| S:8178 E:8182 ||| VB
in  ||| S:8182 E:8185 ||| IN
the  ||| S:8185 E:8197 ||| DT
subsequent  ||| S:8197 E:8208 ||| JJ
translation  ||| S:8208 E:8220 ||| NN
of  ||| S:8220 E:8223 ||| IN
viral  ||| S:8223 E:8229 ||| JJ
mRNA  ||| S:8229 E:8234 ||| NN
in  ||| S:8234 E:8237 ||| IN
the  ||| S:8237 E:8241 ||| DT
cytoplasm ||| S:8241 E:8250 ||| NN
.  ||| S:8250 E:8274 ||| .
Results  ||| S:8274 E:8282 ||| NNS
and  ||| S:8282 E:8286 ||| CC
discussion  ||| S:8286 E:8316 ||| NN
Receptor  ||| S:8316 E:8325 ||| NNP
family  ||| S:8325 E:8332 ||| NN
members  ||| S:8332 E:8350 ||| NNS
It  ||| S:8350 E:8353 ||| PRP
has  ||| S:8353 E:8357 ||| VBZ
long  ||| S:8357 E:8362 ||| RB
been  ||| S:8362 E:8367 ||| VBN
known  ||| S:8367 E:8373 ||| VBN
that  ||| S:8373 E:8378 ||| IN
infection  ||| S:8378 E:8388 ||| NN
by  ||| S:8388 E:8391 ||| IN
HIV-1  ||| S:8391 E:8407 ||| NNP
commonly  ||| S:8407 E:8416 ||| RB
leads  ||| S:8416 E:8422 ||| VBZ
to  ||| S:8422 E:8425 ||| TO
the  ||| S:8425 E:8429 ||| DT
down-regulation  ||| S:8429 E:8445 ||| JJ
and  ||| S:8445 E:8449 ||| CC
the  ||| S:8449 E:8463 ||| DT
disappearance  ||| S:8463 E:8477 ||| NN
of  ||| S:8477 E:8480 ||| IN
CD4  ||| S:8480 E:8484 ||| CD
receptors  ||| S:8484 E:8494 ||| NNS
from  ||| S:8494 E:8499 ||| IN
the  ||| S:8499 E:8503 ||| DT
plasma  ||| S:8503 E:8510 ||| JJ
membrane ||| S:8510 E:8518 ||| NN
,  ||| S:8518 E:8530 ||| ,
a  ||| S:8530 E:8532 ||| DT
phenomenon  ||| S:8532 E:8543 ||| NN
referred  ||| S:8543 E:8552 ||| VBD
to  ||| S:8552 E:8555 ||| TO
as  ||| S:8555 E:8558 ||| RB
receptor  ||| S:8558 E:8567 ||| JJ
down-modulation ||| S:8567 E:8582 ||| NN
.  ||| S:8582 E:8594 ||| .
This ||| S:8594 E:8598 ||| DT
,  ||| S:8598 E:8600 ||| ,
in  ||| S:8600 E:8603 ||| IN
turn ||| S:8603 E:8607 ||| NN
,  ||| S:8607 E:8609 ||| ,
renders  ||| S:8609 E:8617 ||| JJ
cells  ||| S:8617 E:8623 ||| NNS
refractory  ||| S:8623 E:8634 ||| VBP
to  ||| S:8634 E:8637 ||| TO
subsequent  ||| S:8637 E:8658 ||| JJ
infection  ||| S:8658 E:8668 ||| NN
by  ||| S:8668 E:8671 ||| IN
the  ||| S:8671 E:8675 ||| DT
same  ||| S:8675 E:8680 ||| JJ
or  ||| S:8680 E:8683 ||| CC
other  ||| S:8683 E:8689 ||| JJ
viruses  ||| S:8689 E:8697 ||| NN
that  ||| S:8697 E:8702 ||| WDT
use  ||| S:8702 E:8706 ||| VBP
the  ||| S:8706 E:8710 ||| DT
CD4  ||| S:8710 E:8724 ||| JJ
receptor  ||| S:8724 E:8733 ||| NN
for  ||| S:8733 E:8737 ||| IN
entry ||| S:8737 E:8742 ||| NN
;  ||| S:8742 E:8744 ||| :
thus  ||| S:8744 E:8749 ||| RB
creating  ||| S:8749 E:8758 ||| VBG
a  ||| S:8758 E:8760 ||| DT
state  ||| S:8760 E:8766 ||| NN
of  ||| S:8766 E:8779 ||| IN
super-infection  ||| S:8779 E:8795 ||| JJ
immunity ||| S:8795 E:8803 ||| NN
.  ||| S:8803 E:8805 ||| .
Results  ||| S:8805 E:8813 ||| NNS
in  ||| S:8813 E:8816 ||| IN
Table  ||| S:8816 E:8822 ||| NNP
1indicate  ||| S:8822 E:8832 ||| NNP
that  ||| S:8832 E:8847 ||| IN
although  ||| S:8847 E:8856 ||| IN
few  ||| S:8856 E:8860 ||| JJ
receptor  ||| S:8860 E:8869 ||| NN
genes  ||| S:8869 E:8875 ||| NNS
were  ||| S:8875 E:8880 ||| VBD
up-regulated ||| S:8880 E:8892 ||| JJ
,  ||| S:8892 E:8894 ||| ,
most  ||| S:8894 E:8899 ||| JJS
of  ||| S:8899 E:8912 ||| IN
the  ||| S:8912 E:8916 ||| DT
cellular  ||| S:8916 E:8925 ||| JJ
receptors  ||| S:8925 E:8935 ||| NNS
in  ||| S:8935 E:8938 ||| IN
general ||| S:8938 E:8945 ||| JJ
,  ||| S:8945 E:8947 ||| ,
were  ||| S:8947 E:8952 ||| VBD
down-regulated  ||| S:8952 E:8967 ||| JJ
in  ||| S:8967 E:8980 ||| IN
the  ||| S:8980 E:8984 ||| DT
presence  ||| S:8984 E:8993 ||| NN
of  ||| S:8993 E:8996 ||| IN
the  ||| S:8996 E:9000 ||| DT
Tat  ||| S:9000 E:9004 ||| JJ
protein ||| S:9004 E:9011 ||| NN
.  ||| S:9011 E:9013 ||| .
Most  ||| S:9013 E:9018 ||| JJS
of  ||| S:9018 E:9021 ||| IN
these  ||| S:9021 E:9027 ||| DT
receptors  ||| S:9027 E:9047 ||| NN
or  ||| S:9047 E:9050 ||| CC
membranous  ||| S:9050 E:9061 ||| JJ
proteins  ||| S:9061 E:9070 ||| NNS
were  ||| S:9070 E:9075 ||| VBD
initially  ||| S:9075 E:9085 ||| RB
discovered  ||| S:9085 E:9096 ||| VBN
from  ||| S:9096 E:9111 ||| IN
immune  ||| S:9111 E:9118 ||| JJ
or  ||| S:9118 E:9121 ||| CC
neuronal  ||| S:9121 E:9130 ||| JJ
cells ||| S:9130 E:9135 ||| NNS
,  ||| S:9135 E:9137 ||| ,
hence  ||| S:9137 E:9143 ||| RB
they  ||| S:9143 E:9148 ||| PRP
were  ||| S:9148 E:9153 ||| VBD
given  ||| S:9153 E:9159 ||| VBN
names  ||| S:9159 E:9175 ||| NNS
related  ||| S:9175 E:9183 ||| VBN
to  ||| S:9183 E:9186 ||| TO
the  ||| S:9186 E:9190 ||| DT
immune  ||| S:9190 E:9197 ||| JJ
or  ||| S:9197 E:9200 ||| CC
nervous  ||| S:9200 E:9208 ||| JJ
system ||| S:9208 E:9214 ||| NN
.  ||| S:9214 E:9216 ||| .
For  ||| S:9216 E:9220 ||| IN
instance ||| S:9220 E:9228 ||| NN
,  ||| S:9228 E:9240 ||| ,
mRNA  ||| S:9240 E:9245 ||| JJ
for  ||| S:9245 E:9249 ||| IN
the  ||| S:9249 E:9253 ||| DT
neuropeptide  ||| S:9253 E:9266 ||| JJ
Y-like  ||| S:9266 E:9273 ||| JJ
receptor  ||| S:9273 E:9282 ||| NN
( ||| S:9282 E:9283 ||| -LRB-
Acc ||| S:9283 E:9286 ||| UH
#  ||| S:9286 E:9288 ||| #
X71635 ||| S:9288 E:9294 ||| CD
) ||| S:9294 E:9295 ||| -RRB-
,  ||| S:9295 E:9307 ||| ,
which  ||| S:9307 E:9313 ||| WDT
was  ||| S:9313 E:9317 ||| VBD
up-regulated  ||| S:9317 E:9330 ||| JJ
in  ||| S:9330 E:9333 ||| IN
Tat  ||| S:9333 E:9337 ||| NNP
expressing  ||| S:9337 E:9348 ||| VBG
cells ||| S:9348 E:9353 ||| NNS
,  ||| S:9353 E:9355 ||| ,
was  ||| S:9355 E:9369 ||| VBD
initially  ||| S:9369 E:9379 ||| RB
discovered  ||| S:9379 E:9390 ||| VBN
as  ||| S:9390 E:9393 ||| IN
a  ||| S:9393 E:9395 ||| DT
G-protein  ||| S:9395 E:9405 ||| JJ
coupled  ||| S:9405 E:9413 ||| JJ
neuropeptide  ||| S:9413 E:9436 ||| JJ
Y  ||| S:9436 E:9438 ||| NN
receptor ||| S:9438 E:9446 ||| NN
,  ||| S:9446 E:9448 ||| ,
and  ||| S:9448 E:9452 ||| CC
later  ||| S:9452 E:9458 ||| RB
found  ||| S:9458 E:9464 ||| VBN
to  ||| S:9464 E:9467 ||| TO
be  ||| S:9467 E:9470 ||| VB
homologous  ||| S:9470 E:9481 ||| VBN
to  ||| S:9481 E:9484 ||| TO
the  ||| S:9484 E:9498 ||| DT
co-receptor  ||| S:9498 E:9510 ||| JJ
CCR5  ||| S:9510 E:9515 ||| NN
needed  ||| S:9515 E:9522 ||| VBN
for  ||| S:9522 E:9526 ||| IN
HIV-1  ||| S:9526 E:9532 ||| NNP
infection  ||| S:9532 E:9542 ||| NN
of  ||| S:9542 E:9555 ||| IN
monocyte ||| S:9555 E:9563 ||| CD
/ ||| S:9563 E:9564 ||| CD
macrophage  ||| S:9564 E:9575 ||| CD
cells ||| S:9575 E:9580 ||| NNS
.  ||| S:9580 E:9582 ||| .
Therefore ||| S:9582 E:9591 ||| RB
,  ||| S:9591 E:9593 ||| ,
most  ||| S:9593 E:9598 ||| JJS
of  ||| S:9598 E:9601 ||| IN
the  ||| S:9601 E:9615 ||| DT
receptors  ||| S:9615 E:9625 ||| NN
listed  ||| S:9625 E:9632 ||| VBN
in  ||| S:9632 E:9635 ||| IN
Table  ||| S:9635 E:9641 ||| NNP
1may  ||| S:9641 E:9646 ||| NNP
in  ||| S:9646 E:9649 ||| IN
fact  ||| S:9649 E:9654 ||| NN
be  ||| S:9654 E:9657 ||| VB
expressed  ||| S:9657 E:9667 ||| VBN
in  ||| S:9667 E:9680 ||| IN
various  ||| S:9680 E:9688 ||| JJ
tissues  ||| S:9688 E:9696 ||| NNS
and  ||| S:9696 E:9700 ||| CC
have  ||| S:9700 E:9705 ||| VBP
multiple  ||| S:9705 E:9714 ||| JJ
functions ||| S:9714 E:9723 ||| NNS
.  ||| S:9723 E:9735 ||| .
Consistent  ||| S:9735 E:9746 ||| JJ
with  ||| S:9746 E:9751 ||| IN
our  ||| S:9751 E:9755 ||| PRP$
microarray  ||| S:9755 E:9766 ||| JJ
results  ||| S:9766 E:9774 ||| NNS
on  ||| S:9774 E:9777 ||| IN
CCR5  ||| S:9777 E:9792 ||| NNP
up-regulation ||| S:9792 E:9805 ||| NNP
,  ||| S:9805 E:9807 ||| ,
experiments  ||| S:9807 E:9819 ||| NNS
performed  ||| S:9819 E:9829 ||| VBN
in  ||| S:9829 E:9832 ||| IN
peripheral  ||| S:9832 E:9843 ||| JJ
blood  ||| S:9843 E:9859 ||| NN
mononuclear  ||| S:9859 E:9871 ||| NN
cells  ||| S:9871 E:9877 ||| NNS
( ||| S:9877 E:9878 ||| -LRB-
PBMCs ||| S:9878 E:9883 ||| NNP
)  ||| S:9883 E:9885 ||| -RRB-
with  ||| S:9885 E:9890 ||| IN
soluble  ||| S:9890 E:9898 ||| JJ
Tat  ||| S:9898 E:9902 ||| NNP
has  ||| S:9902 E:9906 ||| VBZ
shown  ||| S:9906 E:9922 ||| VBN
selective  ||| S:9922 E:9932 ||| JJ
entry  ||| S:9932 E:9938 ||| NN
and  ||| S:9938 E:9942 ||| CC
replication  ||| S:9942 E:9954 ||| NN
of  ||| S:9954 E:9957 ||| IN
CCR5  ||| S:9957 E:9962 ||| CD
virus  ||| S:9962 E:9968 ||| NN
into  ||| S:9968 E:9973 ||| IN
cells  ||| S:9973 E:9989 ||| NNS
[  ||| S:9989 E:9991 ||| -LRB-
27  ||| S:9991 E:9994 ||| CD
28  ||| S:9994 E:9997 ||| CD
]  ||| S:9997 E:9999 ||| -RRB-
.  ||| S:9999 E:10001 ||| .
Up-regulation  ||| S:10001 E:10015 ||| JJ
of  ||| S:10015 E:10018 ||| IN
HIV-1  ||| S:10018 E:10024 ||| NNP
coreceptor  ||| S:10024 E:10035 ||| NN
by  ||| S:10035 E:10038 ||| IN
Tat  ||| S:10038 E:10042 ||| NNP
has  ||| S:10042 E:10056 ||| VBZ
also  ||| S:10056 E:10061 ||| RB
been  ||| S:10061 E:10066 ||| VBN
reported ||| S:10066 E:10074 ||| VBN
,  ||| S:10074 E:10076 ||| ,
where  ||| S:10076 E:10082 ||| WRB
a  ||| S:10082 E:10084 ||| DT
synthetic  ||| S:10084 E:10094 ||| JJ
Tat  ||| S:10094 E:10098 ||| JJ
protein  ||| S:10098 E:10106 ||| NN
that  ||| S:10106 E:10121 ||| WDT
was  ||| S:10121 E:10125 ||| VBD
immobilized  ||| S:10125 E:10137 ||| VBN
on  ||| S:10137 E:10140 ||| IN
a  ||| S:10140 E:10142 ||| DT
solid  ||| S:10142 E:10148 ||| JJ
substrate ||| S:10148 E:10157 ||| NN
,  ||| S:10157 E:10159 ||| ,
up-regulated  ||| S:10159 E:10172 ||| JJ
the  ||| S:10172 E:10186 ||| DT
surface  ||| S:10186 E:10194 ||| NN
expression  ||| S:10194 E:10205 ||| NN
of  ||| S:10205 E:10208 ||| IN
the  ||| S:10208 E:10212 ||| DT
chemokine  ||| S:10212 E:10222 ||| JJ
receptors  ||| S:10222 E:10232 ||| NNS
in  ||| S:10232 E:10235 ||| IN
purified  ||| S:10235 E:10254 ||| JJ
populations  ||| S:10254 E:10266 ||| NNS
of  ||| S:10266 E:10269 ||| IN
primary  ||| S:10269 E:10277 ||| JJ
resting  ||| S:10277 E:10285 ||| NN
CD4+  ||| S:10285 E:10290 ||| CD
T  ||| S:10290 E:10292 ||| NN
cells ||| S:10292 E:10297 ||| NNS
.  ||| S:10297 E:10299 ||| .
Also ||| S:10299 E:10303 ||| RB
,  ||| S:10303 E:10305 ||| ,
a  ||| S:10305 E:10317 ||| DT
similar  ||| S:10317 E:10325 ||| JJ
result  ||| S:10325 E:10332 ||| NN
was  ||| S:10332 E:10336 ||| VBD
seen  ||| S:10336 E:10341 ||| VBN
from  ||| S:10341 E:10346 ||| IN
Tat  ||| S:10346 E:10350 ||| NNP
protein  ||| S:10350 E:10358 ||| NN
actively  ||| S:10358 E:10377 ||| RB
released  ||| S:10377 E:10386 ||| VBN
by  ||| S:10386 E:10389 ||| IN
HIV-1  ||| S:10389 E:10395 ||| NNP
infected  ||| S:10395 E:10404 ||| JJ
cells ||| S:10404 E:10409 ||| NNS
,  ||| S:10409 E:10411 ||| ,
implying  ||| S:10411 E:10420 ||| VBG
a  ||| S:10420 E:10422 ||| DT
potentially  ||| S:10422 E:10444 ||| RB
important  ||| S:10444 E:10454 ||| JJ
role  ||| S:10454 E:10459 ||| NN
for  ||| S:10459 E:10463 ||| IN
extracellular  ||| S:10463 E:10477 ||| JJ
Tat  ||| S:10477 E:10481 ||| NNS
in  ||| S:10481 E:10484 ||| IN
rendering  ||| S:10484 E:10494 ||| VBG
the  ||| S:10494 E:10508 ||| DT
bystander  ||| S:10508 E:10518 ||| JJ
CD4+  ||| S:10518 E:10523 ||| CD
T  ||| S:10523 E:10525 ||| NN
cells  ||| S:10525 E:10531 ||| NNS
more  ||| S:10531 E:10536 ||| RBR
susceptible  ||| S:10536 E:10548 ||| JJ
to  ||| S:10548 E:10551 ||| TO
infection  ||| S:10551 E:10561 ||| VB
[  ||| S:10561 E:10563 ||| -LRB-
28  ||| S:10563 E:10576 ||| CD
]  ||| S:10576 E:10578 ||| -RRB-
.  ||| S:10578 E:10590 ||| .
We  ||| S:10590 E:10593 ||| PRP
therefore  ||| S:10593 E:10603 ||| RB
tested  ||| S:10603 E:10610 ||| VBN
whether  ||| S:10610 E:10618 ||| IN
H9 ||| S:10618 E:10620 ||| NNP
/ ||| S:10620 E:10621 ||| NNP
Tat  ||| S:10621 E:10625 ||| NNP
cells ||| S:10625 E:10630 ||| NNS
,  ||| S:10630 E:10632 ||| ,
which  ||| S:10632 E:10638 ||| WDT
showed  ||| S:10638 E:10655 ||| VBD
an  ||| S:10655 E:10658 ||| DT
increase  ||| S:10658 E:10667 ||| NN
in  ||| S:10667 E:10670 ||| IN
CCR5  ||| S:10670 E:10675 ||| CD
expression ||| S:10675 E:10685 ||| NN
,  ||| S:10685 E:10687 ||| ,
could  ||| S:10687 E:10693 ||| MD
in  ||| S:10693 E:10696 ||| IN
fact  ||| S:10696 E:10701 ||| NN
allow  ||| S:10701 E:10717 ||| VB
better  ||| S:10717 E:10724 ||| JJR
entry  ||| S:10724 E:10730 ||| NN
and  ||| S:10730 E:10734 ||| CC
infection  ||| S:10734 E:10744 ||| NN
of  ||| S:10744 E:10747 ||| IN
the  ||| S:10747 E:10751 ||| DT
CCR5  ||| S:10751 E:10756 ||| NNP
( ||| S:10756 E:10757 ||| -LRB-
R5 ||| S:10757 E:10759 ||| NNP
)  ||| S:10759 E:10761 ||| -RRB-
virus  ||| S:10761 E:10767 ||| NN
into  ||| S:10767 E:10782 ||| IN
cells ||| S:10782 E:10787 ||| NNS
.  ||| S:10787 E:10789 ||| .
Figure  ||| S:10789 E:10796 ||| NN
3Ashows  ||| S:10796 E:10804 ||| VBZ
the  ||| S:10804 E:10808 ||| DT
result  ||| S:10808 E:10815 ||| NN
of  ||| S:10815 E:10818 ||| IN
such  ||| S:10818 E:10823 ||| PDT
an  ||| S:10823 E:10826 ||| DT
experiment ||| S:10826 E:10836 ||| NN
,  ||| S:10836 E:10848 ||| ,
where  ||| S:10848 E:10854 ||| WRB
H9 ||| S:10854 E:10856 ||| NNP
/ ||| S:10856 E:10857 ||| NNP
Tat  ||| S:10857 E:10861 ||| NNP
cells  ||| S:10861 E:10867 ||| NNS
allowed  ||| S:10867 E:10875 ||| VBD
a  ||| S:10875 E:10877 ||| DT
better  ||| S:10877 E:10884 ||| RBR
replication  ||| S:10884 E:10896 ||| JJ
profile  ||| S:10896 E:10914 ||| NN
of  ||| S:10914 E:10917 ||| IN
the  ||| S:10917 E:10921 ||| DT
R5  ||| S:10921 E:10924 ||| NN
than  ||| S:10924 E:10929 ||| IN
the  ||| S:10929 E:10933 ||| DT
CXCR4  ||| S:10933 E:10939 ||| NNP
( ||| S:10939 E:10940 ||| -LRB-
X4 ||| S:10940 E:10942 ||| NNP
)  ||| S:10942 E:10944 ||| -RRB-
virus ||| S:10944 E:10949 ||| NN
.  ||| S:10949 E:10951 ||| .
The  ||| S:10951 E:10955 ||| DT
increase  ||| S:10955 E:10964 ||| NN
in  ||| S:10964 E:10977 ||| IN
viral  ||| S:10977 E:10983 ||| JJ
titer  ||| S:10983 E:10989 ||| NNS
peaked  ||| S:10989 E:10996 ||| VBN
after  ||| S:10996 E:11002 ||| IN
some  ||| S:11002 E:11007 ||| DT
18  ||| S:11007 E:11010 ||| CD
days  ||| S:11010 E:11015 ||| NNS
of  ||| S:11015 E:11018 ||| IN
infection  ||| S:11018 E:11028 ||| NN
with  ||| S:11028 E:11043 ||| IN
the  ||| S:11043 E:11047 ||| DT
R5  ||| S:11047 E:11050 ||| JJ
virus ||| S:11050 E:11055 ||| NN
,  ||| S:11055 E:11057 ||| ,
further  ||| S:11057 E:11065 ||| RB
implying  ||| S:11065 E:11074 ||| VBG
that  ||| S:11074 E:11079 ||| IN
the  ||| S:11079 E:11083 ||| DT
CCR5  ||| S:11083 E:11088 ||| NNP
co-receptor  ||| S:11088 E:11110 ||| NNP
allowed  ||| S:11110 E:11118 ||| VBD
a  ||| S:11118 E:11120 ||| DT
better  ||| S:11120 E:11127 ||| JJR
selection  ||| S:11127 E:11137 ||| NN
of  ||| S:11137 E:11140 ||| IN
R5  ||| S:11140 E:11143 ||| CD
virus  ||| S:11143 E:11149 ||| NN
in  ||| S:11149 E:11152 ||| IN
Tat  ||| S:11152 E:11156 ||| NNP
expressing  ||| S:11156 E:11177 ||| VBG
cells ||| S:11177 E:11182 ||| NNS
.  ||| S:11182 E:11194 ||| .
Another  ||| S:11194 E:11202 ||| DT
example  ||| S:11202 E:11210 ||| NN
of  ||| S:11210 E:11213 ||| IN
co-receptors  ||| S:11213 E:11226 ||| JJ
with  ||| S:11226 E:11231 ||| IN
multiple  ||| S:11231 E:11250 ||| JJ
functions  ||| S:11250 E:11260 ||| NNS
is  ||| S:11260 E:11263 ||| VBZ
the  ||| S:11263 E:11267 ||| DT
leukotriene  ||| S:11267 E:11279 ||| JJ
family  ||| S:11279 E:11286 ||| NN
member  ||| S:11286 E:11293 ||| NN
B4 ||| S:11293 E:11295 ||| NN
,  ||| S:11295 E:11297 ||| ,
which  ||| S:11297 E:11303 ||| WDT
was  ||| S:11303 E:11317 ||| VBD
down-regulated  ||| S:11317 E:11332 ||| JJ
in  ||| S:11332 E:11335 ||| IN
Tat  ||| S:11335 E:11339 ||| NNP
expressing  ||| S:11339 E:11350 ||| VBG
cells  ||| S:11350 E:11356 ||| NNS
( ||| S:11356 E:11357 ||| -LRB-
Acc ||| S:11357 E:11360 ||| UH
#  ||| S:11360 E:11362 ||| #
D89078 ||| S:11362 E:11368 ||| CD
,  ||| S:11368 E:11380 ||| ,
Table  ||| S:11380 E:11386 ||| NNP
1 ||| S:11386 E:11387 ||| CD
) ||| S:11387 E:11388 ||| -RRB-
.  ||| S:11388 E:11390 ||| .
The  ||| S:11390 E:11394 ||| DT
cysteinyl  ||| S:11394 E:11404 ||| JJ
leukotrienes  ||| S:11404 E:11417 ||| NNS
( ||| S:11417 E:11418 ||| -LRB-
CysLT ||| S:11418 E:11423 ||| NNP
) ||| S:11423 E:11424 ||| -RRB-
,  ||| S:11424 E:11426 ||| ,
LTC ||| S:11426 E:11429 ||| NNP
,  ||| S:11429 E:11431 ||| ,
LTD ||| S:11431 E:11434 ||| NNP
,  ||| S:11434 E:11446 ||| ,
and  ||| S:11446 E:11450 ||| CC
LTE ||| S:11450 E:11453 ||| NNP
,  ||| S:11453 E:11455 ||| ,
were  ||| S:11455 E:11460 ||| VBD
first  ||| S:11460 E:11466 ||| RB
shown  ||| S:11466 E:11472 ||| VBN
to  ||| S:11472 E:11475 ||| TO
be  ||| S:11475 E:11478 ||| VB
essential  ||| S:11478 E:11488 ||| JJ
mediators  ||| S:11488 E:11498 ||| NNS
in  ||| S:11498 E:11511 ||| IN
asthma  ||| S:11511 E:11518 ||| NN
[  ||| S:11518 E:11520 ||| -LRB-
29  ||| S:11520 E:11523 ||| CD
]  ||| S:11523 E:11525 ||| -RRB-
.  ||| S:11525 E:11527 ||| .
However ||| S:11527 E:11534 ||| RB
,  ||| S:11534 E:11536 ||| ,
when  ||| S:11536 E:11541 ||| WRB
the  ||| S:11541 E:11545 ||| DT
mouse  ||| S:11545 E:11551 ||| FW
leukotriene  ||| S:11551 E:11563 ||| FW
B4  ||| S:11563 E:11576 ||| FW
receptor  ||| S:11576 E:11585 ||| FW
( ||| S:11585 E:11586 ||| -LRB-
m-BLTR ||| S:11586 E:11592 ||| NNP
)  ||| S:11592 E:11594 ||| -RRB-
gene ||| S:11594 E:11598 ||| NN
,  ||| S:11598 E:11600 ||| ,
was  ||| S:11600 E:11604 ||| VBD
cloned  ||| S:11604 E:11611 ||| VBN
it  ||| S:11611 E:11614 ||| PRP
was  ||| S:11614 E:11618 ||| VBD
shown  ||| S:11618 E:11624 ||| VBN
to  ||| S:11624 E:11627 ||| TO
have  ||| S:11627 E:11642 ||| VB
significant  ||| S:11642 E:11654 ||| JJ
sequence  ||| S:11654 E:11663 ||| NN
homology  ||| S:11663 E:11672 ||| NN
with  ||| S:11672 E:11677 ||| IN
chemokine  ||| S:11677 E:11687 ||| JJ
receptors  ||| S:11687 E:11707 ||| NNS
( ||| S:11707 E:11708 ||| -LRB-
CCR5  ||| S:11708 E:11713 ||| NNP
and  ||| S:11713 E:11717 ||| CC
CXCR4 ||| S:11717 E:11722 ||| CD
) ||| S:11722 E:11723 ||| -RRB-
,  ||| S:11723 E:11725 ||| ,
co-receptors  ||| S:11725 E:11738 ||| JJ
for  ||| S:11738 E:11742 ||| IN
many  ||| S:11742 E:11747 ||| JJ
different  ||| S:11747 E:11757 ||| JJ
HIV-1  ||| S:11757 E:11773 ||| CD
clades  ||| S:11773 E:11780 ||| NNS
[  ||| S:11780 E:11782 ||| -LRB-
30  ||| S:11782 E:11785 ||| CD
]  ||| S:11785 E:11787 ||| -RRB-
.  ||| S:11787 E:11789 ||| .
Along  ||| S:11789 E:11795 ||| IN
the  ||| S:11795 E:11799 ||| DT
same  ||| S:11799 E:11804 ||| JJ
lines ||| S:11804 E:11809 ||| NNS
,  ||| S:11809 E:11811 ||| ,
when  ||| S:11811 E:11816 ||| WRB
cells  ||| S:11816 E:11822 ||| NNS
were  ||| S:11822 E:11837 ||| VBD
infected  ||| S:11837 E:11846 ||| VBN
with  ||| S:11846 E:11851 ||| IN
10  ||| S:11851 E:11854 ||| CD
primary  ||| S:11854 E:11862 ||| JJ
clinical  ||| S:11862 E:11871 ||| JJ
isolates  ||| S:11871 E:11880 ||| NN
of  ||| S:11880 E:11883 ||| IN
HIV-1 ||| S:11883 E:11888 ||| NNP
,  ||| S:11888 E:11900 ||| ,
leukotriene  ||| S:11900 E:11912 ||| CD
B4  ||| S:11912 E:11915 ||| CD
receptor  ||| S:11915 E:11924 ||| NN
was  ||| S:11924 E:11928 ||| VBD
primarily  ||| S:11928 E:11938 ||| RB
utilized  ||| S:11938 E:11947 ||| VBN
for  ||| S:11947 E:11961 ||| IN
efficient  ||| S:11961 E:11971 ||| JJ
entry  ||| S:11971 E:11977 ||| NN
into  ||| S:11977 E:11982 ||| IN
cells  ||| S:11982 E:11988 ||| NNS
which  ||| S:11988 E:11994 ||| WDT
were  ||| S:11994 E:11999 ||| VBD
mainly  ||| S:11999 E:12006 ||| RB
of  ||| S:12006 E:12009 ||| IN
the  ||| S:12009 E:12023 ||| DT
syncytium-inducing  ||| S:12023 E:12042 ||| JJ
phenotype  ||| S:12042 E:12052 ||| NNS
[  ||| S:12052 E:12054 ||| -LRB-
31  ||| S:12054 E:12057 ||| CD
]  ||| S:12057 E:12059 ||| -RRB-
.  ||| S:12059 E:12061 ||| .
Therefore ||| S:12061 E:12070 ||| RB
,  ||| S:12070 E:12082 ||| ,
up-regulation  ||| S:12082 E:12096 ||| JJ
of  ||| S:12096 E:12099 ||| IN
neuropeptide  ||| S:12099 E:12112 ||| JJ
Y-like  ||| S:12112 E:12119 ||| JJ
receptor  ||| S:12119 E:12128 ||| NN
and  ||| S:12128 E:12142 ||| CC
down-regulation  ||| S:12142 E:12158 ||| JJ
of  ||| S:12158 E:12161 ||| IN
leukotriene  ||| S:12161 E:12173 ||| CD
B4  ||| S:12173 E:12176 ||| CD
receptor  ||| S:12176 E:12185 ||| NN
in  ||| S:12185 E:12188 ||| IN
Tat  ||| S:12188 E:12202 ||| NNP
expressing  ||| S:12202 E:12213 ||| VBG
cells  ||| S:12213 E:12219 ||| NNS
indicates  ||| S:12219 E:12229 ||| VBZ
a  ||| S:12229 E:12231 ||| DT
selective  ||| S:12231 E:12241 ||| JJ
advantage  ||| S:12241 E:12251 ||| NN
of  ||| S:12251 E:12254 ||| IN
one  ||| S:12254 E:12268 ||| CD
class  ||| S:12268 E:12274 ||| NN
of  ||| S:12274 E:12277 ||| IN
virus  ||| S:12277 E:12283 ||| NN
( ||| S:12283 E:12284 ||| -LRB-
CCR5 ||| S:12284 E:12288 ||| NNP
)  ||| S:12288 E:12290 ||| -RRB-
over  ||| S:12290 E:12295 ||| IN
another  ||| S:12295 E:12303 ||| DT
( ||| S:12303 E:12304 ||| -LRB-
CXCR4 ||| S:12304 E:12309 ||| NNP
) ||| S:12309 E:12310 ||| -RRB-
.  ||| S:12310 E:12322 ||| .
Other  ||| S:12322 E:12328 ||| JJ
examples  ||| S:12328 E:12337 ||| NNS
of  ||| S:12337 E:12340 ||| IN
consistency  ||| S:12340 E:12352 ||| NN
between  ||| S:12352 E:12360 ||| IN
our  ||| S:12360 E:12364 ||| PRP$
microarray  ||| S:12364 E:12385 ||| JJ
results  ||| S:12385 E:12393 ||| NNS
on  ||| S:12393 E:12396 ||| IN
receptors  ||| S:12396 E:12406 ||| NNS
and  ||| S:12406 E:12410 ||| CC
the  ||| S:12410 E:12414 ||| DT
HIV-1  ||| S:12414 E:12420 ||| NNP
Tat  ||| S:12420 E:12424 ||| NNP
literature ||| S:12424 E:12434 ||| NN
,  ||| S:12434 E:12446 ||| ,
include  ||| S:12446 E:12454 ||| VBP
the  ||| S:12454 E:12458 ||| DT
down-regulation  ||| S:12458 E:12474 ||| JJ
of  ||| S:12474 E:12477 ||| IN
gene  ||| S:12477 E:12482 ||| NN
expression  ||| S:12482 E:12493 ||| NN
in  ||| S:12493 E:12496 ||| IN
uPAR  ||| S:12496 E:12511 ||| NNP
( ||| S:12511 E:12512 ||| -LRB-
Acc ||| S:12512 E:12515 ||| UH
#  ||| S:12515 E:12517 ||| #
X74039 ||| S:12517 E:12523 ||| CD
) ||| S:12523 E:12524 ||| -RRB-
,  ||| S:12524 E:12526 ||| ,
IP3  ||| S:12526 E:12530 ||| NNP
( ||| S:12530 E:12531 ||| -LRB-
Acc ||| S:12531 E:12534 ||| UH
#  ||| S:12534 E:12536 ||| #
D26070 ||| S:12536 E:12542 ||| CD
,  ||| S:12542 E:12544 ||| ,
D26351 ||| S:12544 E:12550 ||| CD
) ||| S:12550 E:12551 ||| -RRB-
,  ||| S:12551 E:12553 ||| ,
Glu  ||| S:12553 E:12557 ||| NNP
R  ||| S:12557 E:12559 ||| NNP
flop  ||| S:12559 E:12574 ||| NNS
( ||| S:12574 E:12575 ||| -LRB-
Acc ||| S:12575 E:12578 ||| UH
#  ||| S:12578 E:12580 ||| #
U10302 ||| S:12580 E:12586 ||| CD
) ||| S:12586 E:12587 ||| -RRB-
,  ||| S:12587 E:12589 ||| ,
PPAR  ||| S:12589 E:12594 ||| NNP
( ||| S:12594 E:12595 ||| -LRB-
Acc ||| S:12595 E:12598 ||| UH
#  ||| S:12598 E:12600 ||| #
L07592 ||| S:12600 E:12606 ||| CD
) ||| S:12606 E:12607 ||| -RRB-
,  ||| S:12607 E:12609 ||| ,
alpha-2  ||| S:12609 E:12617 ||| FW
macroglobulin  ||| S:12617 E:12641 ||| FW
receptor  ||| S:12641 E:12650 ||| FW
protein  ||| S:12650 E:12658 ||| FW
( ||| S:12658 E:12659 ||| -LRB-
Acc ||| S:12659 E:12662 ||| UH
#  ||| S:12662 E:12664 ||| #
M63959 ||| S:12664 E:12670 ||| CD
) ||| S:12670 E:12671 ||| -RRB-
,  ||| S:12671 E:12673 ||| ,
and  ||| S:12673 E:12677 ||| CC
receptor  ||| S:12677 E:12686 ||| FW
tyrosine  ||| S:12686 E:12705 ||| FW
kinase  ||| S:12705 E:12712 ||| FW
( ||| S:12712 E:12713 ||| -LRB-
Acc ||| S:12713 E:12716 ||| UH
#  ||| S:12716 E:12718 ||| #
L36645 ||| S:12718 E:12724 ||| CD
,  ||| S:12724 E:12726 ||| ,
U66406 ||| S:12726 E:12732 ||| CD
)  ||| S:12732 E:12734 ||| -RRB-
genes ||| S:12734 E:12739 ||| NNS
.  ||| S:12739 E:12751 ||| .
The  ||| S:12751 E:12755 ||| DT
transmembranous  ||| S:12755 E:12771 ||| FW
urokinase-type  ||| S:12771 E:12786 ||| FW
plasminogen  ||| S:12786 E:12808 ||| FW
activator  ||| S:12808 E:12818 ||| FW
receptor  ||| S:12818 E:12827 ||| FW
( ||| S:12827 E:12828 ||| -LRB-
uPAR ||| S:12828 E:12832 ||| NNP
;  ||| S:12832 E:12834 ||| :
CD87 ||| S:12834 E:12838 ||| CD
)  ||| S:12838 E:12840 ||| -RRB-
focuses  ||| S:12840 E:12848 ||| VBZ
the  ||| S:12848 E:12852 ||| DT
formation  ||| S:12852 E:12862 ||| NN
of  ||| S:12862 E:12875 ||| IN
active  ||| S:12875 E:12882 ||| JJ
plasmin  ||| S:12882 E:12890 ||| NN
at  ||| S:12890 E:12893 ||| IN
the  ||| S:12893 E:12897 ||| DT
cell  ||| S:12897 E:12902 ||| NN
surface ||| S:12902 E:12909 ||| NN
,  ||| S:12909 E:12911 ||| ,
thus  ||| S:12911 E:12916 ||| RB
enhancing  ||| S:12916 E:12936 ||| VBG
directional  ||| S:12936 E:12948 ||| JJ
extracellular  ||| S:12948 E:12962 ||| JJ
proteolysis ||| S:12962 E:12973 ||| NN
.  ||| S:12973 E:12975 ||| .
Interestingly ||| S:12975 E:12988 ||| RB
,  ||| S:12988 E:12990 ||| ,
the  ||| S:12990 E:13004 ||| DT
promoter  ||| S:13004 E:13013 ||| NN
activity  ||| S:13013 E:13022 ||| NN
of  ||| S:13022 E:13025 ||| IN
the  ||| S:13025 E:13029 ||| DT
CD87  ||| S:13029 E:13034 ||| JJ
gene  ||| S:13034 E:13039 ||| NN
was  ||| S:13039 E:13043 ||| VBD
shown  ||| S:13043 E:13049 ||| VBN
to  ||| S:13049 E:13052 ||| TO
decline  ||| S:13052 E:13070 ||| VB
after  ||| S:13070 E:13076 ||| IN
infection  ||| S:13076 E:13086 ||| NN
[  ||| S:13086 E:13088 ||| -LRB-
32  ||| S:13088 E:13091 ||| CD
]  ||| S:13091 E:13093 ||| -RRB-
,  ||| S:13093 E:13095 ||| ,
implying  ||| S:13095 E:13104 ||| VBG
that  ||| S:13104 E:13109 ||| DT
post  ||| S:13109 E:13114 ||| NN
integration  ||| S:13114 E:13136 ||| NN
of  ||| S:13136 E:13139 ||| IN
HIV-1  ||| S:13139 E:13145 ||| NNP
may  ||| S:13145 E:13149 ||| MD
in  ||| S:13149 E:13152 ||| IN
fact  ||| S:13152 E:13157 ||| NN
down-regulate  ||| S:13157 E:13171 ||| JJ
CD87  ||| S:13171 E:13176 ||| CD
gene  ||| S:13176 E:13181 ||| NN
expression ||| S:13181 E:13191 ||| NN
.  ||| S:13191 E:13203 ||| .
Similarly ||| S:13203 E:13212 ||| RB
,  ||| S:13212 E:13214 ||| ,
inositol  ||| S:13214 E:13223 ||| FW
1,4,5-trisphosphate  ||| S:13223 E:13243 ||| FW
receptors  ||| S:13243 E:13253 ||| FW
( ||| S:13253 E:13254 ||| -LRB-
IP3R ||| S:13254 E:13258 ||| NNP
)  ||| S:13258 E:13270 ||| -RRB-
are  ||| S:13270 E:13274 ||| VBP
intracellular  ||| S:13274 E:13288 ||| JJ
calcium  ||| S:13288 E:13296 ||| NN
release  ||| S:13296 E:13304 ||| NN
channels  ||| S:13304 E:13313 ||| NNS
involved  ||| S:13313 E:13322 ||| VBN
in  ||| S:13322 E:13335 ||| IN
diverse  ||| S:13335 E:13343 ||| JJ
signaling  ||| S:13343 E:13353 ||| JJ
pathways  ||| S:13353 E:13362 ||| NN
and  ||| S:13362 E:13366 ||| CC
are  ||| S:13366 E:13370 ||| VBP
required  ||| S:13370 E:13379 ||| VBN
for  ||| S:13379 E:13383 ||| IN
the  ||| S:13383 E:13397 ||| DT
activation  ||| S:13397 E:13408 ||| NN
of  ||| S:13408 E:13411 ||| IN
T  ||| S:13411 E:13413 ||| NN
lymphocytes  ||| S:13413 E:13425 ||| NNS
[  ||| S:13425 E:13427 ||| -LRB-
33  ||| S:13427 E:13430 ||| CD
]  ||| S:13430 E:13432 ||| -RRB-
.  ||| S:13432 E:13434 ||| .
Tat  ||| S:13434 E:13438 ||| NNP
( ||| S:13438 E:13439 ||| -LRB-
also  ||| S:13439 E:13444 ||| RB
implicated  ||| S:13444 E:13465 ||| VBN
as  ||| S:13465 E:13468 ||| IN
a  ||| S:13468 E:13470 ||| DT
neurotoxin ||| S:13470 E:13480 ||| NN
)  ||| S:13480 E:13482 ||| -RRB-
has  ||| S:13482 E:13486 ||| VBZ
been  ||| S:13486 E:13491 ||| VBN
shown  ||| S:13491 E:13497 ||| VBN
to  ||| S:13497 E:13500 ||| TO
release  ||| S:13500 E:13508 ||| VB
calcium  ||| S:13508 E:13516 ||| VBN
from  ||| S:13516 E:13531 ||| IN
inositol  ||| S:13531 E:13540 ||| CD
1,4 ||| S:13540 E:13543 ||| CD
,  ||| S:13543 E:13545 ||| ,
5-trisphosphate  ||| S:13545 E:13561 ||| NNP
( ||| S:13561 E:13562 ||| -LRB-
IP3 ||| S:13562 E:13565 ||| NNP
)  ||| S:13565 E:13567 ||| -RRB-
receptor-regulated  ||| S:13567 E:13596 ||| JJ
stores  ||| S:13596 E:13603 ||| NNS
in  ||| S:13603 E:13606 ||| IN
neurons  ||| S:13606 E:13614 ||| NN
and  ||| S:13614 E:13618 ||| CC
astrocytes  ||| S:13618 E:13629 ||| VBP
causing  ||| S:13629 E:13637 ||| VBG
premature  ||| S:13637 E:13657 ||| JJ
apoptosis  ||| S:13657 E:13667 ||| NNS
[  ||| S:13667 E:13669 ||| -LRB-
34  ||| S:13669 E:13672 ||| CD
]  ||| S:13672 E:13674 ||| -RRB-
.  ||| S:13674 E:13676 ||| .
Down-regulation  ||| S:13676 E:13692 ||| JJ
of  ||| S:13692 E:13695 ||| IN
IP3  ||| S:13695 E:13699 ||| NNP
may  ||| S:13699 E:13703 ||| MD
therefore  ||| S:13703 E:13723 ||| RB
contribute  ||| S:13723 E:13734 ||| VB
to  ||| S:13734 E:13737 ||| TO
viral  ||| S:13737 E:13743 ||| JJ
latency  ||| S:13743 E:13751 ||| NN
and  ||| S:13751 E:13755 ||| CC
maintenance  ||| S:13755 E:13767 ||| NN
of  ||| S:13767 E:13770 ||| IN
an  ||| S:13770 E:13783 ||| DT
anti-apoptotic  ||| S:13783 E:13798 ||| JJ
state  ||| S:13798 E:13804 ||| NN
in  ||| S:13804 E:13807 ||| IN
cells ||| S:13807 E:13812 ||| NNS
.  ||| S:13812 E:13824 ||| .
HIV-1  ||| S:13824 E:13830 ||| NNP
infection  ||| S:13830 E:13840 ||| NN
can  ||| S:13840 E:13844 ||| MD
cause  ||| S:13844 E:13850 ||| VB
extensive  ||| S:13850 E:13860 ||| JJ
neuronal  ||| S:13860 E:13869 ||| JJ
loss  ||| S:13869 E:13874 ||| NN
and  ||| S:13874 E:13888 ||| CC
clinically ||| S:13888 E:13898 ||| RB
,  ||| S:13898 E:13900 ||| ,
a  ||| S:13900 E:13902 ||| DT
severe  ||| S:13902 E:13909 ||| JJ
dementia ||| S:13909 E:13917 ||| NN
.  ||| S:13917 E:13919 ||| .
The  ||| S:13919 E:13923 ||| DT
cause  ||| S:13923 E:13929 ||| NN
of  ||| S:13929 E:13932 ||| IN
the  ||| S:13932 E:13946 ||| DT
neurotoxicity  ||| S:13946 E:13960 ||| NN
remains  ||| S:13960 E:13968 ||| VBZ
unclear  ||| S:13968 E:13976 ||| JJ
as  ||| S:13976 E:13979 ||| IN
neurons  ||| S:13979 E:13987 ||| NNS
are  ||| S:13987 E:13991 ||| VBP
not  ||| S:13991 E:14005 ||| RB
infected ||| S:14005 E:14013 ||| VBN
,  ||| S:14013 E:14015 ||| ,
but  ||| S:14015 E:14019 ||| CC
the  ||| S:14019 E:14023 ||| DT
disturbance  ||| S:14023 E:14035 ||| NN
of  ||| S:14035 E:14038 ||| IN
glutamate-linked  ||| S:14038 E:14055 ||| JJ
calcium  ||| S:14055 E:14073 ||| NN
entry  ||| S:14073 E:14079 ||| NN
has  ||| S:14079 E:14083 ||| VBZ
been  ||| S:14083 E:14088 ||| VBN
implicated ||| S:14088 E:14098 ||| VBN
.  ||| S:14098 E:14100 ||| .
It  ||| S:14100 E:14103 ||| PRP
has  ||| S:14103 E:14107 ||| VBZ
been  ||| S:14107 E:14112 ||| VBN
shown  ||| S:14112 E:14118 ||| VBN
that  ||| S:14118 E:14133 ||| IN
HIV-infected  ||| S:14133 E:14146 ||| JJ
brain  ||| S:14146 E:14152 ||| NN
has  ||| S:14152 E:14156 ||| VBZ
a  ||| S:14156 E:14158 ||| DT
decrease  ||| S:14158 E:14167 ||| NN
of  ||| S:14167 E:14170 ||| IN
mRNA  ||| S:14170 E:14175 ||| JJ
and  ||| S:14175 E:14179 ||| CC
protein  ||| S:14179 E:14187 ||| NN
of  ||| S:14187 E:14200 ||| IN
the  ||| S:14200 E:14204 ||| DT
GluR-A  ||| S:14204 E:14211 ||| JJ
flop  ||| S:14211 E:14216 ||| JJ
subtype  ||| S:14216 E:14224 ||| NN
of  ||| S:14224 E:14237 ||| IN
alpha-amino-3-hydroxy-5-methyl-4-isoxazole  ||| S:14237 E:14280 ||| CD
propionic  ||| S:14280 E:14290 ||| JJ
acid  ||| S:14290 E:14305 ||| NN
( ||| S:14305 E:14306 ||| -LRB-
AMPA ||| S:14306 E:14310 ||| NNP
)  ||| S:14310 E:14312 ||| -RRB-
glutamate  ||| S:14312 E:14322 ||| JJ
receptor  ||| S:14322 E:14331 ||| NN
in  ||| S:14331 E:14334 ||| IN
cerebellar  ||| S:14334 E:14345 ||| JJ
Purkinje  ||| S:14345 E:14354 ||| JJ
cells ||| S:14354 E:14359 ||| NNS
.  ||| S:14359 E:14371 ||| .
The  ||| S:14371 E:14375 ||| DT
observed  ||| S:14375 E:14384 ||| JJ
disturbance  ||| S:14384 E:14396 ||| NN
of  ||| S:14396 E:14399 ||| IN
AMPA  ||| S:14399 E:14404 ||| NNP
receptors  ||| S:14404 E:14414 ||| NNS
may  ||| S:14414 E:14418 ||| MD
contribute  ||| S:14418 E:14439 ||| VB
to  ||| S:14439 E:14442 ||| TO
the  ||| S:14442 E:14446 ||| DT
neurotoxic  ||| S:14446 E:14457 ||| JJ
process  ||| S:14457 E:14465 ||| NN
in  ||| S:14465 E:14468 ||| IN
other  ||| S:14468 E:14474 ||| JJ
vulnerable  ||| S:14474 E:14485 ||| JJ
brain  ||| S:14485 E:14501 ||| NN
regions  ||| S:14501 E:14509 ||| NNS
and  ||| S:14509 E:14513 ||| CC
clinically  ||| S:14513 E:14524 ||| RB
to  ||| S:14524 E:14527 ||| TO
the  ||| S:14527 E:14531 ||| DT
development  ||| S:14531 E:14543 ||| NN
of  ||| S:14543 E:14546 ||| IN
dementia  ||| S:14546 E:14555 ||| NN
[  ||| S:14555 E:14567 ||| -LRB-
35  ||| S:14567 E:14570 ||| CD
]  ||| S:14570 E:14572 ||| -RRB-
.  ||| S:14572 E:14574 ||| .
Interestingly ||| S:14574 E:14587 ||| RB
,  ||| S:14587 E:14589 ||| ,
in  ||| S:14589 E:14592 ||| IN
a  ||| S:14592 E:14594 ||| DT
mouse  ||| S:14594 E:14600 ||| NN
model  ||| S:14600 E:14606 ||| NN
AMPA  ||| S:14606 E:14611 ||| NN
receptors  ||| S:14611 E:14621 ||| NNS
in  ||| S:14621 E:14634 ||| IN
the  ||| S:14634 E:14638 ||| DT
cortex ||| S:14638 E:14644 ||| NN
,  ||| S:14644 E:14646 ||| ,
striatum ||| S:14646 E:14654 ||| NN
,  ||| S:14654 E:14656 ||| ,
hippocampus ||| S:14656 E:14667 ||| NN
,  ||| S:14667 E:14669 ||| ,
and  ||| S:14669 E:14673 ||| CC
cerebellum  ||| S:14673 E:14694 ||| NNS
declined  ||| S:14694 E:14703 ||| VBD
by  ||| S:14703 E:14706 ||| IN
29-50 ||| S:14706 E:14711 ||| CD
%  ||| S:14711 E:14713 ||| NN
as  ||| S:14713 E:14716 ||| IN
early  ||| S:14716 E:14722 ||| JJ
as  ||| S:14722 E:14725 ||| IN
8  ||| S:14725 E:14727 ||| CD
weeks  ||| S:14727 E:14733 ||| NNS
post-retroviral  ||| S:14733 E:14759 ||| JJ
inoculation ||| S:14759 E:14770 ||| NN
.  ||| S:14770 E:14772 ||| .
Thus ||| S:14772 E:14776 ||| RB
,  ||| S:14776 E:14778 ||| ,
the  ||| S:14778 E:14782 ||| DT
reduction  ||| S:14782 E:14792 ||| NN
in  ||| S:14792 E:14795 ||| IN
AMPA  ||| S:14795 E:14800 ||| NNP
receptor  ||| S:14800 E:14809 ||| NN
density  ||| S:14809 E:14827 ||| NN
may  ||| S:14827 E:14831 ||| MD
contribute  ||| S:14831 E:14842 ||| VB
to  ||| S:14842 E:14845 ||| TO
the  ||| S:14845 E:14849 ||| DT
development  ||| S:14849 E:14861 ||| NN
of  ||| S:14861 E:14864 ||| IN
the  ||| S:14864 E:14868 ||| DT
cognitive  ||| S:14868 E:14888 ||| JJ
abnormalities  ||| S:14888 E:14902 ||| NNS
associated  ||| S:14902 E:14913 ||| VBN
with  ||| S:14913 E:14918 ||| IN
HIV-1  ||| S:14918 E:14924 ||| NNP
infection  ||| S:14924 E:14934 ||| NN
[  ||| S:14934 E:14936 ||| -LRB-
36  ||| S:14936 E:14939 ||| CD
]  ||| S:14939 E:14951 ||| -RRB-
.  ||| S:14951 E:14963 ||| .
Finally ||| S:14963 E:14970 ||| RB
,  ||| S:14970 E:14972 ||| ,
patients  ||| S:14972 E:14981 ||| NNS
with  ||| S:14981 E:14986 ||| IN
AIDS  ||| S:14986 E:14991 ||| NNP
who  ||| S:14991 E:14995 ||| WP
are  ||| S:14995 E:14999 ||| VBP
receiving  ||| S:14999 E:15009 ||| VBG
therapy  ||| S:15009 E:15027 ||| NN
with  ||| S:15027 E:15032 ||| IN
HIV-1  ||| S:15032 E:15038 ||| CD
protease  ||| S:15038 E:15047 ||| CD
inhibitors  ||| S:15047 E:15058 ||| NNS
have  ||| S:15058 E:15063 ||| VBP
been  ||| S:15063 E:15068 ||| VBN
reported  ||| S:15068 E:15077 ||| VBN
to  ||| S:15077 E:15080 ||| TO
be  ||| S:15080 E:15093 ||| VB
afflicted  ||| S:15093 E:15103 ||| VBN
with  ||| S:15103 E:15108 ||| IN
a  ||| S:15108 E:15110 ||| DT
syndrome  ||| S:15110 E:15119 ||| NN
characterized  ||| S:15119 E:15133 ||| VBN
by  ||| S:15133 E:15136 ||| IN
lipodystrophy  ||| S:15136 E:15160 ||| NNS
( ||| S:15160 E:15161 ||| -LRB-
fat  ||| S:15161 E:15165 ||| JJ
redistribution  ||| S:15165 E:15180 ||| NN
favoring  ||| S:15180 E:15189 ||| VBG
the  ||| S:15189 E:15193 ||| DT
accumulation  ||| S:15193 E:15206 ||| NN
of  ||| S:15206 E:15219 ||| IN
abdominal  ||| S:15219 E:15229 ||| NN
and  ||| S:15229 E:15233 ||| CC
cervical  ||| S:15233 E:15242 ||| JJ
adipose  ||| S:15242 E:15250 ||| JJ
tissue ||| S:15250 E:15256 ||| NN
) ||| S:15256 E:15257 ||| -RRB-
,  ||| S:15257 E:15259 ||| ,
hyperlipidemia ||| S:15259 E:15273 ||| NN
,  ||| S:15273 E:15285 ||| ,
and  ||| S:15285 E:15289 ||| CC
insulin  ||| S:15289 E:15297 ||| NN
resistance ||| S:15297 E:15307 ||| NN
.  ||| S:15307 E:15309 ||| .
Potential  ||| S:15309 E:15319 ||| JJ
mechanisms  ||| S:15319 E:15330 ||| NNS
for  ||| S:15330 E:15334 ||| IN
altered  ||| S:15334 E:15352 ||| JJ
adipocyte  ||| S:15352 E:15362 ||| JJ
function  ||| S:15362 E:15371 ||| NNS
include ||| S:15371 E:15378 ||| VBP
,  ||| S:15378 E:15380 ||| ,
direct  ||| S:15380 E:15387 ||| JJ
binding  ||| S:15387 E:15395 ||| NN
to  ||| S:15395 E:15398 ||| TO
PPARgamma  ||| S:15398 E:15418 ||| JJ
or  ||| S:15418 E:15421 ||| CC
inhibition  ||| S:15421 E:15432 ||| NN
of  ||| S:15432 E:15435 ||| IN
transcription  ||| S:15435 E:15449 ||| NN
of  ||| S:15449 E:15452 ||| IN
PPARgamma  ||| S:15452 E:15462 ||| JJ
promoter  ||| S:15462 E:15471 ||| NN
[  ||| S:15471 E:15473 ||| -LRB-
37  ||| S:15473 E:15486 ||| CD
]  ||| S:15486 E:15488 ||| -RRB-
.  ||| S:15488 E:15490 ||| .
The  ||| S:15490 E:15494 ||| DT
lipodystrophy  ||| S:15494 E:15508 ||| JJ
syndrome  ||| S:15508 E:15517 ||| NN
may  ||| S:15517 E:15521 ||| MD
be  ||| S:15521 E:15524 ||| VB
a  ||| S:15524 E:15526 ||| DT
result  ||| S:15526 E:15533 ||| NN
of  ||| S:15533 E:15536 ||| IN
the  ||| S:15536 E:15550 ||| DT
inhibition  ||| S:15550 E:15561 ||| NN
of  ||| S:15561 E:15564 ||| IN
2  ||| S:15564 E:15566 ||| CD
proteins  ||| S:15566 E:15575 ||| NNS
involved  ||| S:15575 E:15584 ||| VBN
in  ||| S:15584 E:15587 ||| IN
lipid  ||| S:15587 E:15593 ||| JJ
metabolism  ||| S:15593 E:15614 ||| NN
that  ||| S:15614 E:15619 ||| WDT
have  ||| S:15619 E:15624 ||| VBP
significant  ||| S:15624 E:15636 ||| JJ
homology  ||| S:15636 E:15645 ||| NN
to  ||| S:15645 E:15648 ||| TO
the  ||| S:15648 E:15652 ||| DT
catalytic  ||| S:15652 E:15662 ||| JJ
site  ||| S:15662 E:15667 ||| NN
of  ||| S:15667 E:15680 ||| IN
HIV  ||| S:15680 E:15684 ||| NNP
proteases ||| S:15684 E:15693 ||| NN
;  ||| S:15693 E:15695 ||| :
namely  ||| S:15695 E:15702 ||| FW
cytoplasmic  ||| S:15702 E:15714 ||| FW
retinoic  ||| S:15714 E:15723 ||| FW
acid  ||| S:15723 E:15728 ||| FW
binding  ||| S:15728 E:15746 ||| FW
protein  ||| S:15746 E:15754 ||| FW
type  ||| S:15754 E:15759 ||| NN
1  ||| S:15759 E:15761 ||| CD
and  ||| S:15761 E:15765 ||| CC
low  ||| S:15765 E:15769 ||| JJ
density  ||| S:15769 E:15787 ||| JJ
lipoprotein-receptor-related  ||| S:15787 E:15816 ||| JJ
protein  ||| S:15816 E:15824 ||| NN
[  ||| S:15824 E:15826 ||| -LRB-
38  ||| S:15826 E:15829 ||| CD
]  ||| S:15829 E:15831 ||| -RRB-
.  ||| S:15831 E:15833 ||| .
An  ||| S:15833 E:15846 ||| DT
additional  ||| S:15846 E:15857 ||| JJ
mechanism  ||| S:15857 E:15867 ||| NN
of  ||| S:15867 E:15870 ||| IN
PPAR  ||| S:15870 E:15875 ||| NNP
down-regulation  ||| S:15875 E:15891 ||| NNP
may  ||| S:15891 E:15895 ||| MD
be  ||| S:15895 E:15908 ||| VB
related  ||| S:15908 E:15916 ||| VBN
to  ||| S:15916 E:15919 ||| TO
Tat  ||| S:15919 E:15923 ||| NNP
expression  ||| S:15923 E:15934 ||| NN
in  ||| S:15934 E:15937 ||| IN
latent  ||| S:15937 E:15944 ||| JJ
cells ||| S:15944 E:15949 ||| NNS
.  ||| S:15949 E:15979 ||| .
Translation  ||| S:15979 E:15991 ||| NN
associated  ||| S:15991 E:16002 ||| VBN
factors  ||| S:16002 E:16020 ||| NNS
Viruses  ||| S:16020 E:16028 ||| NNS
have  ||| S:16028 E:16033 ||| VBP
evolved  ||| S:16033 E:16041 ||| VBN
a  ||| S:16041 E:16043 ||| DT
remarkable  ||| S:16043 E:16054 ||| JJ
variety  ||| S:16054 E:16062 ||| NN
of  ||| S:16062 E:16075 ||| IN
strategies  ||| S:16075 E:16086 ||| NNS
to  ||| S:16086 E:16089 ||| TO
modulate  ||| S:16089 E:16098 ||| VB
the  ||| S:16098 E:16102 ||| DT
host  ||| S:16102 E:16107 ||| NN
cell  ||| S:16107 E:16112 ||| NN
translation  ||| S:16112 E:16134 ||| NN
apparatus  ||| S:16134 E:16144 ||| NN
with  ||| S:16144 E:16149 ||| IN
the  ||| S:16149 E:16153 ||| DT
aim  ||| S:16153 E:16157 ||| NN
of  ||| S:16157 E:16160 ||| IN
optimizing  ||| S:16160 E:16171 ||| JJ
viral  ||| S:16171 E:16177 ||| JJ
mRNA  ||| S:16177 E:16192 ||| JJ
translation  ||| S:16192 E:16204 ||| NN
and  ||| S:16204 E:16208 ||| CC
replication ||| S:16208 E:16219 ||| NN
.  ||| S:16219 E:16221 ||| .
For  ||| S:16221 E:16225 ||| IN
instance ||| S:16225 E:16233 ||| NN
,  ||| S:16233 E:16235 ||| ,
viruses  ||| S:16235 E:16253 ||| VBZ
including  ||| S:16253 E:16263 ||| VBG
Herpes  ||| S:16263 E:16270 ||| JJ
simplex  ||| S:16270 E:16278 ||| JJ
virus  ||| S:16278 E:16284 ||| NN
type  ||| S:16284 E:16289 ||| NN
1  ||| S:16289 E:16291 ||| CD
( ||| S:16291 E:16292 ||| -LRB-
HSV-1 ||| S:16292 E:16297 ||| NNP
)  ||| S:16297 E:16299 ||| -RRB-
have  ||| S:16299 E:16304 ||| VBP
been  ||| S:16304 E:16319 ||| VBN
known  ||| S:16319 E:16325 ||| VBN
to  ||| S:16325 E:16328 ||| TO
induce  ||| S:16328 E:16335 ||| VB
severe  ||| S:16335 E:16342 ||| JJ
alterations  ||| S:16342 E:16354 ||| NN
of  ||| S:16354 E:16357 ||| IN
the  ||| S:16357 E:16361 ||| DT
host  ||| S:16361 E:16376 ||| NN
translational  ||| S:16376 E:16390 ||| NN
apparatus ||| S:16390 E:16399 ||| NN
,  ||| S:16399 E:16401 ||| ,
including  ||| S:16401 E:16411 ||| VBG
the  ||| S:16411 E:16415 ||| DT
up-regulation  ||| S:16415 E:16429 ||| JJ
of  ||| S:16429 E:16442 ||| IN
ribosomal  ||| S:16442 E:16452 ||| JJ
proteins  ||| S:16452 E:16461 ||| NNS
and  ||| S:16461 E:16465 ||| CC
the  ||| S:16465 E:16469 ||| DT
progressive  ||| S:16469 E:16481 ||| JJ
association  ||| S:16481 E:16493 ||| NN
of  ||| S:16493 E:16506 ||| IN
several  ||| S:16506 E:16514 ||| JJ
nonribosomal  ||| S:16514 E:16527 ||| JJ
proteins ||| S:16527 E:16535 ||| NNS
,  ||| S:16535 E:16537 ||| ,
such  ||| S:16537 E:16542 ||| JJ
as  ||| S:16542 E:16545 ||| IN
VP19C ||| S:16545 E:16550 ||| NNP
,  ||| S:16550 E:16552 ||| ,
VP26 ||| S:16552 E:16556 ||| NNP
,  ||| S:16556 E:16558 ||| ,
and  ||| S:16558 E:16572 ||| CC
the  ||| S:16572 E:16576 ||| DT
poly ||| S:16576 E:16580 ||| NN
( ||| S:16580 E:16581 ||| -LRB-
A ||| S:16581 E:16582 ||| NNP
) ||| S:16582 E:16583 ||| -RRB-
-binding  ||| S:16583 E:16592 ||| JJ
protein  ||| S:16592 E:16600 ||| NN
1  ||| S:16600 E:16602 ||| CD
( ||| S:16602 E:16603 ||| -LRB-
PAB1P ||| S:16603 E:16608 ||| NNP
)  ||| S:16608 E:16610 ||| -RRB-
to  ||| S:16610 E:16613 ||| TO
ribosomes  ||| S:16613 E:16623 ||| VB
[  ||| S:16623 E:16625 ||| -LRB-
39  ||| S:16625 E:16628 ||| CD
]  ||| S:16628 E:16640 ||| -RRB-
.  ||| S:16640 E:16642 ||| .
In  ||| S:16642 E:16645 ||| IN
the  ||| S:16645 E:16649 ||| DT
case  ||| S:16649 E:16654 ||| NN
of  ||| S:16654 E:16657 ||| IN
HIV-1 ||| S:16657 E:16662 ||| NNP
,  ||| S:16662 E:16664 ||| ,
approximately  ||| S:16664 E:16678 ||| RB
one  ||| S:16678 E:16682 ||| CD
infectious  ||| S:16682 E:16703 ||| CD
HIV-1  ||| S:16703 E:16709 ||| CD
genome  ||| S:16709 E:16716 ||| NN
in  ||| S:16716 E:16719 ||| IN
an  ||| S:16719 E:16722 ||| DT
infected  ||| S:16722 E:16731 ||| JJ
cell  ||| S:16731 E:16736 ||| NN
could  ||| S:16736 E:16742 ||| MD
be  ||| S:16742 E:16745 ||| VB
transcribed  ||| S:16745 E:16757 ||| NNS
and  ||| S:16757 E:16771 ||| CC
translated  ||| S:16771 E:16782 ||| VBN
into  ||| S:16782 E:16787 ||| IN
50,000  ||| S:16787 E:16794 ||| CD
to  ||| S:16794 E:16797 ||| TO
100,000  ||| S:16797 E:16805 ||| CD
physical  ||| S:16805 E:16814 ||| JJ
particles  ||| S:16814 E:16824 ||| NNS
[  ||| S:16824 E:16826 ||| -LRB-
40  ||| S:16826 E:16839 ||| CD
]  ||| S:16839 E:16841 ||| -RRB-
.  ||| S:16841 E:16843 ||| .
This  ||| S:16843 E:16848 ||| DT
poses  ||| S:16848 E:16854 ||| VBZ
an  ||| S:16854 E:16857 ||| DT
immense  ||| S:16857 E:16865 ||| JJ
challenge  ||| S:16865 E:16875 ||| NN
for  ||| S:16875 E:16879 ||| IN
the  ||| S:16879 E:16883 ||| DT
virus  ||| S:16883 E:16889 ||| NN
to  ||| S:16889 E:16892 ||| TO
be  ||| S:16892 E:16905 ||| VB
able  ||| S:16905 E:16910 ||| JJ
to  ||| S:16910 E:16913 ||| TO
transcribe ||| S:16913 E:16923 ||| VB
,  ||| S:16923 E:16925 ||| ,
splice ||| S:16925 E:16931 ||| NN
,  ||| S:16931 E:16933 ||| ,
transport ||| S:16933 E:16942 ||| NN
,  ||| S:16942 E:16944 ||| ,
and  ||| S:16944 E:16948 ||| CC
translate  ||| S:16948 E:16958 ||| VB
its  ||| S:16958 E:16972 ||| PRP$
RNA  ||| S:16972 E:16976 ||| NNP
into  ||| S:16976 E:16981 ||| IN
fully  ||| S:16981 E:16987 ||| RB
packaged  ||| S:16987 E:16996 ||| VBN
virions  ||| S:16996 E:17004 ||| VBN
in  ||| S:17004 E:17007 ||| IN
a  ||| S:17007 E:17009 ||| DT
timely  ||| S:17009 E:17016 ||| JJ
fashion ||| S:17016 E:17023 ||| NN
.  ||| S:17023 E:17035 ||| .
Therefore ||| S:17035 E:17044 ||| RB
,  ||| S:17044 E:17046 ||| ,
it  ||| S:17046 E:17049 ||| PRP
would  ||| S:17049 E:17055 ||| MD
be  ||| S:17055 E:17058 ||| VB
advantageous  ||| S:17058 E:17071 ||| VBN
for  ||| S:17071 E:17075 ||| IN
the  ||| S:17075 E:17079 ||| DT
virus  ||| S:17079 E:17085 ||| NN
to  ||| S:17085 E:17088 ||| TO
set  ||| S:17088 E:17102 ||| VB
the  ||| S:17102 E:17106 ||| DT
stage  ||| S:17106 E:17112 ||| NN
for  ||| S:17112 E:17116 ||| IN
each  ||| S:17116 E:17121 ||| DT
successive  ||| S:17121 E:17132 ||| JJ
step  ||| S:17132 E:17137 ||| NN
necessary  ||| S:17137 E:17147 ||| JJ
for  ||| S:17147 E:17151 ||| IN
viral  ||| S:17151 E:17167 ||| JJ
progeny  ||| S:17167 E:17175 ||| JJ
formation ||| S:17175 E:17184 ||| NN
.  ||| S:17184 E:17186 ||| .
One  ||| S:17186 E:17190 ||| CD
such  ||| S:17190 E:17195 ||| JJ
event  ||| S:17195 E:17201 ||| NN
is  ||| S:17201 E:17204 ||| VBZ
Tat ||| S:17204 E:17207 ||| NNP
's  ||| S:17207 E:17210 ||| POS
ability  ||| S:17210 E:17218 ||| NN
to  ||| S:17218 E:17231 ||| TO
control  ||| S:17231 E:17239 ||| VB
genes  ||| S:17239 E:17245 ||| NNS
that  ||| S:17245 E:17250 ||| IN
aid  ||| S:17250 E:17254 ||| NN
in  ||| S:17254 E:17257 ||| IN
translational  ||| S:17257 E:17271 ||| JJ
machinery ||| S:17271 E:17280 ||| NN
.  ||| S:17280 E:17282 ||| .
As  ||| S:17282 E:17295 ||| RB
seen  ||| S:17295 E:17300 ||| VBN
in  ||| S:17300 E:17303 ||| IN
Table  ||| S:17303 E:17309 ||| NNP
2 ||| S:17309 E:17310 ||| CD
,  ||| S:17310 E:17312 ||| ,
many  ||| S:17312 E:17317 ||| JJ
of  ||| S:17317 E:17320 ||| IN
the  ||| S:17320 E:17324 ||| DT
critical  ||| S:17324 E:17333 ||| JJ
components  ||| S:17333 E:17344 ||| NNS
of  ||| S:17344 E:17347 ||| IN
a  ||| S:17347 E:17359 ||| DT
functional  ||| S:17359 E:17370 ||| JJ
ribosome ||| S:17370 E:17378 ||| NN
,  ||| S:17378 E:17380 ||| ,
including  ||| S:17380 E:17390 ||| VBG
large  ||| S:17390 E:17396 ||| JJ
subunits  ||| S:17396 E:17405 ||| JJ
L  ||| S:17405 E:17407 ||| NNP
3 ||| S:17407 E:17408 ||| CD
,  ||| S:17408 E:17410 ||| ,
6 ||| S:17410 E:17411 ||| CD
,  ||| S:17411 E:17413 ||| ,
26 ||| S:17413 E:17415 ||| CD
,  ||| S:17415 E:17427 ||| ,
31 ||| S:17427 E:17429 ||| CD
,  ||| S:17429 E:17431 ||| ,
38 ||| S:17431 E:17433 ||| CD
,  ||| S:17433 E:17435 ||| ,
and  ||| S:17435 E:17439 ||| CC
41 ||| S:17439 E:17441 ||| CD
,  ||| S:17441 E:17443 ||| ,
as  ||| S:17443 E:17446 ||| RB
well  ||| S:17446 E:17451 ||| RB
as  ||| S:17451 E:17454 ||| IN
S  ||| S:17454 E:17456 ||| NNP
6 ||| S:17456 E:17457 ||| CD
,  ||| S:17457 E:17459 ||| ,
12 ||| S:17459 E:17461 ||| CD
,  ||| S:17461 E:17463 ||| ,
20 ||| S:17463 E:17465 ||| CD
,  ||| S:17465 E:17467 ||| ,
and  ||| S:17467 E:17471 ||| CC
24 ||| S:17471 E:17473 ||| CD
,  ||| S:17473 E:17475 ||| ,
and  ||| S:17475 E:17479 ||| CC
many  ||| S:17479 E:17494 ||| JJ
of  ||| S:17494 E:17497 ||| IN
the  ||| S:17497 E:17501 ||| DT
translation  ||| S:17501 E:17513 ||| NN
initiation  ||| S:17513 E:17524 ||| NN
factors  ||| S:17524 E:17532 ||| NNS
are  ||| S:17532 E:17536 ||| VBP
up-regulated  ||| S:17536 E:17549 ||| JJ
by  ||| S:17549 E:17562 ||| IN
Tat ||| S:17562 E:17565 ||| NNP
.  ||| S:17565 E:17567 ||| .
This  ||| S:17567 E:17572 ||| DT
would  ||| S:17572 E:17578 ||| MD
imply  ||| S:17578 E:17584 ||| VB
that  ||| S:17584 E:17589 ||| IN
Tat  ||| S:17589 E:17593 ||| NNP
up-regulates  ||| S:17593 E:17606 ||| JJ
many  ||| S:17606 E:17621 ||| JJ
ribosomal  ||| S:17621 E:17631 ||| JJ
genes  ||| S:17631 E:17637 ||| NNS
that  ||| S:17637 E:17642 ||| WDT
may  ||| S:17642 E:17646 ||| MD
be  ||| S:17646 E:17649 ||| VB
necessary  ||| S:17649 E:17659 ||| JJ
to  ||| S:17659 E:17662 ||| TO
produce  ||| S:17662 E:17680 ||| VB
functional  ||| S:17680 E:17691 ||| JJ
ribosomes  ||| S:17691 E:17701 ||| NNS
needed  ||| S:17701 E:17708 ||| VBN
for  ||| S:17708 E:17712 ||| IN
viral  ||| S:17712 E:17718 ||| JJ
mRNA  ||| S:17718 E:17723 ||| JJ
translation ||| S:17723 E:17734 ||| NN
.  ||| S:17734 E:17746 ||| .
Therefore ||| S:17746 E:17755 ||| RB
,  ||| S:17755 E:17757 ||| ,
interfering  ||| S:17757 E:17769 ||| VBG
with  ||| S:17769 E:17774 ||| IN
translation  ||| S:17774 E:17786 ||| NN
could  ||| S:17786 E:17792 ||| MD
provide  ||| S:17792 E:17800 ||| VB
a  ||| S:17800 E:17812 ||| DT
new  ||| S:17812 E:17816 ||| JJ
strategy  ||| S:17816 E:17825 ||| NN
for  ||| S:17825 E:17829 ||| IN
anti-HIV  ||| S:17829 E:17838 ||| JJ
treatment ||| S:17838 E:17847 ||| NN
.  ||| S:17847 E:17849 ||| .
Along  ||| S:17849 E:17855 ||| IN
these  ||| S:17855 E:17861 ||| DT
lines ||| S:17861 E:17866 ||| NNS
,  ||| S:17866 E:17878 ||| ,
when  ||| S:17878 E:17883 ||| WRB
the  ||| S:17883 E:17887 ||| DT
aminogylcosides  ||| S:17887 E:17903 ||| NN
( ||| S:17903 E:17904 ||| -LRB-
kanamycin ||| S:17904 E:17913 ||| UH
,  ||| S:17913 E:17915 ||| ,
hygromycin  ||| S:17915 E:17926 ||| VBG
B ||| S:17926 E:17927 ||| NNP
,  ||| S:17927 E:17939 ||| ,
paromycin  ||| S:17939 E:17949 ||| NN
and  ||| S:17949 E:17953 ||| CC
neomycin ||| S:17953 E:17961 ||| CD
)  ||| S:17961 E:17963 ||| -RRB-
due  ||| S:17963 E:17967 ||| JJ
to  ||| S:17967 E:17970 ||| TO
their  ||| S:17970 E:17976 ||| PRP$
ability  ||| S:17976 E:17984 ||| NN
to  ||| S:17984 E:17987 ||| TO
inhibit  ||| S:17987 E:18005 ||| VB
protein  ||| S:18005 E:18013 ||| NN
synthesis  ||| S:18013 E:18023 ||| NN
by  ||| S:18023 E:18026 ||| IN
affecting  ||| S:18026 E:18036 ||| VBG
ribosomal  ||| S:18036 E:18046 ||| JJ
fidelity ||| S:18046 E:18054 ||| NN
,  ||| S:18054 E:18056 ||| ,
or  ||| S:18056 E:18069 ||| CC
puromycin  ||| S:18069 E:18079 ||| NN
because  ||| S:18079 E:18087 ||| IN
of  ||| S:18087 E:18090 ||| IN
its  ||| S:18090 E:18094 ||| PRP$
competing  ||| S:18094 E:18104 ||| JJ
ability  ||| S:18104 E:18112 ||| NN
with  ||| S:18112 E:18117 ||| IN
tRNAs  ||| S:18117 E:18123 ||| JJ
for  ||| S:18123 E:18137 ||| IN
binding  ||| S:18137 E:18145 ||| VBG
on  ||| S:18145 E:18148 ||| IN
the  ||| S:18148 E:18152 ||| DT
large  ||| S:18152 E:18158 ||| JJ
ribosomal  ||| S:18158 E:18168 ||| JJ
subunit ||| S:18168 E:18175 ||| NN
,  ||| S:18175 E:18177 ||| ,
or  ||| S:18177 E:18180 ||| CC
cycloheximide  ||| S:18180 E:18204 ||| NNS
which  ||| S:18204 E:18210 ||| WDT
inhibit  ||| S:18210 E:18218 ||| VBP
the  ||| S:18218 E:18222 ||| DT
large  ||| S:18222 E:18228 ||| JJ
ribosomal  ||| S:18228 E:18238 ||| JJ
subunit  ||| S:18238 E:18246 ||| NN
by  ||| S:18246 E:18249 ||| IN
preventing  ||| S:18249 E:18270 ||| VBG
ribosomal  ||| S:18270 E:18280 ||| JJ
movement  ||| S:18280 E:18289 ||| NN
along  ||| S:18289 E:18295 ||| IN
the  ||| S:18295 E:18299 ||| DT
mRNA ||| S:18299 E:18303 ||| JJ
,  ||| S:18303 E:18305 ||| ,
were  ||| S:18305 E:18310 ||| VBD
used  ||| S:18310 E:18315 ||| VBN
in  ||| S:18315 E:18318 ||| IN
active  ||| S:18318 E:18335 ||| JJ
HIV-1  ||| S:18335 E:18341 ||| NNP
infection ||| S:18341 E:18350 ||| NN
,  ||| S:18350 E:18352 ||| ,
it  ||| S:18352 E:18355 ||| PRP
was  ||| S:18355 E:18359 ||| VBD
found  ||| S:18359 E:18365 ||| VBN
that  ||| S:18365 E:18370 ||| IN
both  ||| S:18370 E:18375 ||| DT
cycloheximide  ||| S:18375 E:18389 ||| NN
and  ||| S:18389 E:18403 ||| CC
puromycin  ||| S:18403 E:18413 ||| NNS
produced  ||| S:18413 E:18422 ||| VBD
the  ||| S:18422 E:18426 ||| DT
greatest  ||| S:18426 E:18435 ||| JJS
decrease  ||| S:18435 E:18444 ||| NN
in  ||| S:18444 E:18447 ||| IN
HIV-1  ||| S:18447 E:18463 ||| NNP
inhibition ||| S:18463 E:18473 ||| NN
,  ||| S:18473 E:18475 ||| ,
presumably  ||| S:18475 E:18486 ||| RB
by  ||| S:18486 E:18489 ||| IN
inhibiting  ||| S:18489 E:18500 ||| VBG
the  ||| S:18500 E:18504 ||| DT
large  ||| S:18504 E:18510 ||| JJ
subunit  ||| S:18510 E:18518 ||| NN
of  ||| S:18518 E:18531 ||| IN
the  ||| S:18531 E:18535 ||| DT
ribosome  ||| S:18535 E:18544 ||| NN
[  ||| S:18544 E:18546 ||| -LRB-
41  ||| S:18546 E:18549 ||| CD
]  ||| S:18549 E:18551 ||| -RRB-
.  ||| S:18551 E:18563 ||| .
Translation  ||| S:18563 E:18575 ||| NN
of  ||| S:18575 E:18578 ||| IN
HIV-1  ||| S:18578 E:18584 ||| NNP
RNAs  ||| S:18584 E:18589 ||| NNP
pose  ||| S:18589 E:18594 ||| VBD
a  ||| S:18594 E:18596 ||| DT
challenge  ||| S:18596 E:18606 ||| NN
since  ||| S:18606 E:18612 ||| IN
they  ||| S:18612 E:18627 ||| PRP
all  ||| S:18627 E:18631 ||| RB
contain  ||| S:18631 E:18639 ||| VB
a  ||| S:18639 E:18641 ||| DT
TAR  ||| S:18641 E:18645 ||| NNP
sequence  ||| S:18645 E:18654 ||| NN
at  ||| S:18654 E:18657 ||| IN
their  ||| S:18657 E:18663 ||| PRP$
5 ||| S:18663 E:18664 ||| CD
'  ||| S:18664 E:18666 ||| POS
end ||| S:18666 E:18669 ||| NN
.  ||| S:18669 E:18671 ||| .
The  ||| S:18671 E:18685 ||| DT
Tat-responsive  ||| S:18685 E:18700 ||| JJ
region  ||| S:18700 E:18707 ||| NN
( ||| S:18707 E:18708 ||| -LRB-
TAR ||| S:18708 E:18711 ||| NNP
)  ||| S:18711 E:18713 ||| -RRB-
of  ||| S:18713 E:18716 ||| IN
HIV-1  ||| S:18716 E:18722 ||| NNP
exhibits  ||| S:18722 E:18731 ||| VBZ
a  ||| S:18731 E:18743 ||| DT
trans-inhibitory  ||| S:18743 E:18760 ||| JJ
effect  ||| S:18760 E:18767 ||| NN
on  ||| S:18767 E:18770 ||| IN
translation  ||| S:18770 E:18782 ||| NN
by  ||| S:18782 E:18785 ||| IN
activating  ||| S:18785 E:18796 ||| VBG
the  ||| S:18796 E:18810 ||| DT
interferon-induced  ||| S:18810 E:18829 ||| JJ
68-kilodalton  ||| S:18829 E:18843 ||| CD
protein  ||| S:18843 E:18851 ||| NN
kinase ||| S:18851 E:18857 ||| NN
.  ||| S:18857 E:18869 ||| .
Productive  ||| S:18869 E:18880 ||| JJ
infection  ||| S:18880 E:18890 ||| NN
by  ||| S:18890 E:18893 ||| IN
HIV-1  ||| S:18893 E:18899 ||| NNP
has  ||| S:18899 E:18903 ||| VBZ
been  ||| S:18903 E:18908 ||| VBN
shown  ||| S:18908 E:18914 ||| VBN
to  ||| S:18914 E:18917 ||| TO
result  ||| S:18917 E:18924 ||| VB
in  ||| S:18924 E:18937 ||| IN
a  ||| S:18937 E:18939 ||| DT
significant  ||| S:18939 E:18951 ||| JJ
decrease  ||| S:18951 E:18960 ||| NN
in  ||| S:18960 E:18963 ||| IN
the  ||| S:18963 E:18967 ||| DT
amount  ||| S:18967 E:18974 ||| NN
of  ||| S:18974 E:18977 ||| IN
cellular  ||| S:18977 E:18986 ||| JJ
p68  ||| S:18986 E:19000 ||| CD
kinase ||| S:19000 E:19006 ||| NNS
.  ||| S:19006 E:19008 ||| .
The  ||| S:19008 E:19012 ||| DT
steady-state  ||| S:19012 E:19025 ||| JJ
amount  ||| S:19025 E:19032 ||| NN
of  ||| S:19032 E:19035 ||| IN
p68  ||| S:19035 E:19039 ||| CD
kinase  ||| S:19039 E:19046 ||| NNS
was  ||| S:19046 E:19050 ||| VBD
found  ||| S:19050 E:19066 ||| VBN
to  ||| S:19066 E:19069 ||| TO
be  ||| S:19069 E:19072 ||| VB
reduced  ||| S:19072 E:19080 ||| VBN
in  ||| S:19080 E:19083 ||| IN
cells  ||| S:19083 E:19089 ||| NNS
stably  ||| S:19089 E:19096 ||| VBP
expressing  ||| S:19096 E:19107 ||| VBG
Tat ||| S:19107 E:19110 ||| NNP
.  ||| S:19110 E:19112 ||| .
Thus ||| S:19112 E:19116 ||| RB
,  ||| S:19116 E:19118 ||| ,
the  ||| S:19118 E:19132 ||| DT
potential  ||| S:19132 E:19142 ||| JJ
translational  ||| S:19142 E:19156 ||| JJ
inhibitory  ||| S:19156 E:19167 ||| JJ
effects  ||| S:19167 E:19175 ||| NNS
of  ||| S:19175 E:19178 ||| IN
the  ||| S:19178 E:19182 ||| DT
TAR  ||| S:19182 E:19186 ||| NNP
RNA  ||| S:19186 E:19200 ||| NNP
region ||| S:19200 E:19206 ||| NN
,  ||| S:19206 E:19208 ||| ,
mediated  ||| S:19208 E:19217 ||| VBG
by  ||| S:19217 E:19220 ||| IN
activation  ||| S:19220 E:19231 ||| NN
of  ||| S:19231 E:19234 ||| IN
p68  ||| S:19234 E:19238 ||| CD
kinase ||| S:19238 E:19244 ||| NN
,  ||| S:19244 E:19246 ||| ,
may  ||| S:19246 E:19250 ||| MD
be  ||| S:19250 E:19263 ||| VB
down-regulated  ||| S:19263 E:19278 ||| JJ
by  ||| S:19278 E:19281 ||| IN
Tat  ||| S:19281 E:19285 ||| NNP
during  ||| S:19285 E:19292 ||| IN
activation  ||| S:19292 E:19303 ||| NN
of  ||| S:19303 E:19306 ||| IN
the  ||| S:19306 E:19310 ||| DT
latent  ||| S:19310 E:19327 ||| JJ
virus  ||| S:19327 E:19333 ||| NN
[  ||| S:19333 E:19335 ||| -LRB-
22  ||| S:19335 E:19338 ||| CD
]  ||| S:19338 E:19340 ||| -RRB-
.  ||| S:19340 E:19342 ||| .
Along  ||| S:19342 E:19348 ||| IN
these  ||| S:19348 E:19354 ||| DT
lines ||| S:19354 E:19359 ||| NNS
,  ||| S:19359 E:19361 ||| ,
a  ||| S:19361 E:19363 ||| DT
Tat  ||| S:19363 E:19367 ||| JJ
peptide  ||| S:19367 E:19385 ||| JJ
antagonist ||| S:19385 E:19395 ||| NN
,  ||| S:19395 E:19397 ||| ,
which  ||| S:19397 E:19403 ||| WDT
bound  ||| S:19403 E:19409 ||| VBP
specifically  ||| S:19409 E:19422 ||| RB
to  ||| S:19422 E:19425 ||| TO
TAR  ||| S:19425 E:19429 ||| NNP
RNA  ||| S:19429 E:19433 ||| NNP
and  ||| S:19433 E:19447 ||| CC
competed  ||| S:19447 E:19456 ||| VBN
with  ||| S:19456 E:19461 ||| IN
Tat  ||| S:19461 E:19465 ||| NNP
for  ||| S:19465 E:19469 ||| IN
binding ||| S:19469 E:19476 ||| JJ
,  ||| S:19476 E:19478 ||| ,
reduced  ||| S:19478 E:19486 ||| VBD
Tat-dependent  ||| S:19486 E:19510 ||| JJ
translation  ||| S:19510 E:19522 ||| NN
[  ||| S:19522 E:19524 ||| -LRB-
42  ||| S:19524 E:19527 ||| CD
]  ||| S:19527 E:19529 ||| -RRB-
.  ||| S:19529 E:19541 ||| .
Finally ||| S:19541 E:19548 ||| RB
,  ||| S:19548 E:19550 ||| ,
upregulation  ||| S:19550 E:19563 ||| VBG
of  ||| S:19563 E:19566 ||| IN
translation  ||| S:19566 E:19578 ||| NN
genes  ||| S:19578 E:19584 ||| NNS
in  ||| S:19584 E:19587 ||| IN
Tat  ||| S:19587 E:19601 ||| NNP
expressing  ||| S:19601 E:19612 ||| VBG
cells  ||| S:19612 E:19618 ||| NNS
is  ||| S:19618 E:19621 ||| VBZ
specially  ||| S:19621 E:19631 ||| RB
intriguing  ||| S:19631 E:19642 ||| JJ
in  ||| S:19642 E:19645 ||| IN
light  ||| S:19645 E:19651 ||| NN
of  ||| S:19651 E:19654 ||| IN
the  ||| S:19654 E:19668 ||| DT
recent  ||| S:19668 E:19675 ||| JJ
discovery  ||| S:19675 E:19685 ||| NN
of  ||| S:19685 E:19688 ||| IN
internal  ||| S:19688 E:19697 ||| JJ
ribosome  ||| S:19697 E:19706 ||| JJ
entry  ||| S:19706 E:19712 ||| NN
sites  ||| S:19712 E:19718 ||| NNS
( ||| S:19718 E:19719 ||| -LRB-
IRESs ||| S:19719 E:19724 ||| NNP
)  ||| S:19724 E:19736 ||| -RRB-
in  ||| S:19736 E:19739 ||| IN
HIV-1  ||| S:19739 E:19745 ||| NNP
gag  ||| S:19745 E:19749 ||| FW
ORF  ||| S:19749 E:19753 ||| FW
[  ||| S:19753 E:19755 ||| -LRB-
43  ||| S:19755 E:19758 ||| CD
]  ||| S:19758 E:19760 ||| -RRB-
.  ||| S:19760 E:19762 ||| .
IRESs  ||| S:19762 E:19768 ||| NNS
are  ||| S:19768 E:19772 ||| VBP
thought  ||| S:19772 E:19780 ||| VBN
to  ||| S:19780 E:19783 ||| TO
promote  ||| S:19783 E:19801 ||| VB
initiation  ||| S:19801 E:19812 ||| VBN
of  ||| S:19812 E:19815 ||| IN
translation  ||| S:19815 E:19827 ||| NN
by  ||| S:19827 E:19830 ||| IN
directly  ||| S:19830 E:19839 ||| RB
binding  ||| S:19839 E:19847 ||| VBG
to  ||| S:19847 E:19860 ||| TO
ribosomes ||| S:19860 E:19869 ||| VB
,  ||| S:19869 E:19871 ||| ,
in  ||| S:19871 E:19874 ||| IN
a  ||| S:19874 E:19876 ||| DT
manner  ||| S:19876 E:19883 ||| NN
independent  ||| S:19883 E:19895 ||| JJ
of  ||| S:19895 E:19898 ||| IN
the  ||| S:19898 E:19902 ||| DT
mRNA  ||| S:19902 E:19907 ||| JJ
cap  ||| S:19907 E:19911 ||| NN
or  ||| S:19911 E:19914 ||| CC
of  ||| S:19914 E:19927 ||| IN
scanning  ||| S:19927 E:19936 ||| VBG
through  ||| S:19936 E:19944 ||| IN
upstream  ||| S:19944 E:19953 ||| JJ
sequences ||| S:19953 E:19962 ||| NN
.  ||| S:19962 E:19964 ||| .
Since ||| S:19964 E:19969 ||| IN
,  ||| S:19969 E:19971 ||| ,
the  ||| S:19971 E:19975 ||| DT
TAR  ||| S:19975 E:19979 ||| NNP
is  ||| S:19979 E:19992 ||| VBZ
located  ||| S:19992 E:20000 ||| VBN
at  ||| S:20000 E:20003 ||| IN
the  ||| S:20003 E:20007 ||| DT
5 ||| S:20007 E:20008 ||| CD
'  ||| S:20008 E:20010 ||| POS
end  ||| S:20010 E:20014 ||| NN
of  ||| S:20014 E:20017 ||| IN
all  ||| S:20017 E:20021 ||| DT
HIV-1  ||| S:20021 E:20027 ||| NNP
RNA  ||| S:20027 E:20031 ||| NNP
transcripts  ||| S:20031 E:20043 ||| NNS
and  ||| S:20043 E:20057 ||| CC
the  ||| S:20057 E:20061 ||| DT
presence  ||| S:20061 E:20070 ||| NN
of  ||| S:20070 E:20073 ||| IN
secondary  ||| S:20073 E:20083 ||| JJ
structure  ||| S:20083 E:20093 ||| NN
at  ||| S:20093 E:20096 ||| IN
or  ||| S:20096 E:20099 ||| CC
near  ||| S:20099 E:20104 ||| IN
the  ||| S:20104 E:20108 ||| DT
5 ||| S:20108 E:20109 ||| CD
'  ||| S:20109 E:20111 ||| POS
end  ||| S:20111 E:20125 ||| NN
of  ||| S:20125 E:20128 ||| IN
RNAs  ||| S:20128 E:20133 ||| NNP
reduces  ||| S:20133 E:20141 ||| VBZ
the  ||| S:20141 E:20145 ||| DT
accessibility  ||| S:20145 E:20159 ||| NN
of  ||| S:20159 E:20162 ||| IN
the  ||| S:20162 E:20166 ||| DT
5 ||| S:20166 E:20167 ||| CD
'  ||| S:20167 E:20169 ||| POS
cap  ||| S:20169 E:20173 ||| NN
to  ||| S:20173 E:20176 ||| TO
eIF4F ||| S:20176 E:20181 ||| CD
,  ||| S:20181 E:20193 ||| ,
it  ||| S:20193 E:20196 ||| PRP
is  ||| S:20196 E:20199 ||| VBZ
thought  ||| S:20199 E:20207 ||| VBN
that  ||| S:20207 E:20212 ||| IN
this  ||| S:20212 E:20217 ||| DT
feature  ||| S:20217 E:20225 ||| NN
of  ||| S:20225 E:20228 ||| IN
HIV-1  ||| S:20228 E:20234 ||| NNP
mRNAs  ||| S:20234 E:20240 ||| NNP
can  ||| S:20240 E:20254 ||| MD
inhibit  ||| S:20254 E:20262 ||| VB
their  ||| S:20262 E:20268 ||| PRP$
cap-dependent  ||| S:20268 E:20282 ||| JJ
translation  ||| S:20282 E:20294 ||| NN
[  ||| S:20294 E:20296 ||| -LRB-
44  ||| S:20296 E:20299 ||| CD
45  ||| S:20299 E:20302 ||| CD
46  ||| S:20302 E:20305 ||| CD
]  ||| S:20305 E:20307 ||| -RRB-
.  ||| S:20307 E:20319 ||| .
Therefore ||| S:20319 E:20328 ||| RB
,  ||| S:20328 E:20330 ||| ,
a  ||| S:20330 E:20332 ||| DT
possible  ||| S:20332 E:20341 ||| JJ
function  ||| S:20341 E:20350 ||| NN
of  ||| S:20350 E:20353 ||| IN
the  ||| S:20353 E:20357 ||| DT
HIV-1  ||| S:20357 E:20363 ||| NNP
gag  ||| S:20363 E:20367 ||| VBD
IRES  ||| S:20367 E:20382 ||| NNP
might  ||| S:20382 E:20388 ||| MD
be  ||| S:20388 E:20391 ||| VB
to  ||| S:20391 E:20394 ||| TO
serve  ||| S:20394 E:20400 ||| VB
as  ||| S:20400 E:20403 ||| IN
a  ||| S:20403 E:20405 ||| DT
mechanism  ||| S:20405 E:20415 ||| NN
to  ||| S:20415 E:20418 ||| TO
bypass  ||| S:20418 E:20425 ||| VB
the  ||| S:20425 E:20429 ||| DT
structural  ||| S:20429 E:20450 ||| JJ
barriers  ||| S:20450 E:20459 ||| NNS
to  ||| S:20459 E:20462 ||| TO
cap-dependent  ||| S:20462 E:20476 ||| JJ
translation  ||| S:20476 E:20488 ||| NN
by  ||| S:20488 E:20491 ||| IN
recruiting  ||| S:20491 E:20512 ||| VBG
ribosomes  ||| S:20512 E:20522 ||| NNS
easily  ||| S:20522 E:20529 ||| RB
and  ||| S:20529 E:20533 ||| CC
directly  ||| S:20533 E:20542 ||| RB
to  ||| S:20542 E:20545 ||| TO
the  ||| S:20545 E:20549 ||| DT
gag  ||| S:20549 E:20553 ||| JJ
ORFs ||| S:20553 E:20557 ||| NN
.  ||| S:20557 E:20559 ||| .
IRES  ||| S:20559 E:20574 ||| NNP
entirely  ||| S:20574 E:20583 ||| RB
contained  ||| S:20583 E:20593 ||| VBN
within  ||| S:20593 E:20600 ||| IN
a  ||| S:20600 E:20602 ||| DT
translated  ||| S:20602 E:20613 ||| VBN
ORF  ||| S:20613 E:20617 ||| NNP
has  ||| S:20617 E:20621 ||| VBZ
been  ||| S:20621 E:20626 ||| VBN
shown  ||| S:20626 E:20642 ||| VBN
in  ||| S:20642 E:20645 ||| IN
the  ||| S:20645 E:20649 ||| DT
MMLV  ||| S:20649 E:20654 ||| NNP
gag  ||| S:20654 E:20658 ||| NNS
[  ||| S:20658 E:20660 ||| -LRB-
47  ||| S:20660 E:20663 ||| CD
]  ||| S:20663 E:20665 ||| -RRB-
,  ||| S:20665 E:20667 ||| ,
and  ||| S:20667 E:20671 ||| CC
host  ||| S:20671 E:20676 ||| NN
mRNA  ||| S:20676 E:20681 ||| FW
encoding  ||| S:20681 E:20690 ||| FW
p110  ||| S:20690 E:20705 ||| FW
PITSLREand  ||| S:20705 E:20716 ||| FW
p58  ||| S:20716 E:20720 ||| FW
PITSLRE  ||| S:20720 E:20728 ||| FW
[  ||| S:20728 E:20730 ||| -LRB-
48  ||| S:20730 E:20733 ||| CD
]  ||| S:20733 E:20735 ||| -RRB-
.  ||| S:20735 E:20737 ||| .
Along  ||| S:20737 E:20743 ||| IN
these  ||| S:20743 E:20749 ||| DT
lines ||| S:20749 E:20754 ||| NNS
,  ||| S:20754 E:20766 ||| ,
cap-dependent  ||| S:20766 E:20780 ||| JJ
translation  ||| S:20780 E:20792 ||| NN
may  ||| S:20792 E:20796 ||| MD
be  ||| S:20796 E:20799 ||| VB
cell  ||| S:20799 E:20804 ||| NN
cycle  ||| S:20804 E:20810 ||| NN
regulated ||| S:20810 E:20819 ||| VBN
,  ||| S:20819 E:20831 ||| ,
especially  ||| S:20831 E:20842 ||| RB
when  ||| S:20842 E:20847 ||| WRB
cells  ||| S:20847 E:20853 ||| NNS
are  ||| S:20853 E:20857 ||| VBP
arrested  ||| S:20857 E:20866 ||| VBN
at  ||| S:20866 E:20869 ||| IN
the  ||| S:20869 E:20873 ||| DT
G2  ||| S:20873 E:20876 ||| JJ
phase  ||| S:20876 E:20882 ||| NN
of  ||| S:20882 E:20885 ||| IN
the  ||| S:20885 E:20899 ||| DT
cell  ||| S:20899 E:20904 ||| NN
cycle ||| S:20904 E:20909 ||| NN
,  ||| S:20909 E:20911 ||| ,
where  ||| S:20911 E:20917 ||| WRB
the  ||| S:20917 E:20921 ||| DT
cap-dependent  ||| S:20921 E:20935 ||| JJ
translation  ||| S:20935 E:20947 ||| NN
of  ||| S:20947 E:20950 ||| IN
most  ||| S:20950 E:20965 ||| RBS
cellular  ||| S:20965 E:20974 ||| JJ
host  ||| S:20974 E:20979 ||| NN
cell  ||| S:20979 E:20984 ||| NN
mRNAs  ||| S:20984 E:20990 ||| NN
is  ||| S:20990 E:20993 ||| VBZ
inhibited  ||| S:20993 E:21003 ||| JJ
[  ||| S:21003 E:21005 ||| -LRB-
49  ||| S:21005 E:21008 ||| CD
50  ||| S:21008 E:21011 ||| CD
51  ||| S:21011 E:21014 ||| CD
]  ||| S:21014 E:21016 ||| -RRB-
.  ||| S:21016 E:21046 ||| .
Modulation  ||| S:21046 E:21057 ||| NNP
of  ||| S:21057 E:21060 ||| IN
signal  ||| S:21060 E:21067 ||| NN
transduction  ||| S:21067 E:21080 ||| VBZ
pathway  ||| S:21080 E:21098 ||| JJ
Results  ||| S:21098 E:21106 ||| NNS
in  ||| S:21106 E:21109 ||| IN
Table  ||| S:21109 E:21115 ||| NNP
3indicate  ||| S:21115 E:21125 ||| NNP
that  ||| S:21125 E:21130 ||| IN
many  ||| S:21130 E:21135 ||| JJ
seemingly  ||| S:21135 E:21155 ||| RB
different  ||| S:21155 E:21165 ||| JJ
pathways  ||| S:21165 E:21174 ||| NNS
are  ||| S:21174 E:21178 ||| VBP
being  ||| S:21178 E:21184 ||| VBG
regulated  ||| S:21184 E:21194 ||| VBN
by  ||| S:21194 E:21197 ||| IN
Tat ||| S:21197 E:21200 ||| NNP
.  ||| S:21200 E:21202 ||| .
However ||| S:21202 E:21209 ||| RB
,  ||| S:21209 E:21221 ||| ,
the  ||| S:21221 E:21225 ||| DT
signal  ||| S:21225 E:21232 ||| NN
transduction  ||| S:21232 E:21245 ||| NN
pathway ||| S:21245 E:21252 ||| NN
,  ||| S:21252 E:21254 ||| ,
MAPK ||| S:21254 E:21258 ||| NNP
,  ||| S:21258 E:21260 ||| ,
has  ||| S:21260 E:21264 ||| VBZ
been  ||| S:21264 E:21269 ||| VBN
shown  ||| S:21269 E:21275 ||| VBN
to  ||| S:21275 E:21288 ||| TO
control  ||| S:21288 E:21296 ||| VB
and  ||| S:21296 E:21300 ||| CC
be  ||| S:21300 E:21303 ||| VB
upstream  ||| S:21303 E:21312 ||| RB
of  ||| S:21312 E:21315 ||| IN
DNA-replication ||| S:21315 E:21330 ||| NNP
,  ||| S:21330 E:21342 ||| ,
transcription ||| S:21342 E:21355 ||| NN
,  ||| S:21355 E:21357 ||| ,
and  ||| S:21357 E:21361 ||| CC
cell  ||| S:21361 E:21366 ||| NN
cycle  ||| S:21366 E:21372 ||| NN
pathways  ||| S:21372 E:21381 ||| NNS
[  ||| S:21381 E:21383 ||| -LRB-
52  ||| S:21383 E:21386 ||| CD
53  ||| S:21386 E:21389 ||| CD
54  ||| S:21389 E:21392 ||| CD
]  ||| S:21392 E:21394 ||| -RRB-
.  ||| S:21394 E:21396 ||| .
The  ||| S:21396 E:21410 ||| DT
mitogen-activated  ||| S:21410 E:21428 ||| JJ
protein  ||| S:21428 E:21436 ||| NN
kinase  ||| S:21436 E:21443 ||| NNS
( ||| S:21443 E:21444 ||| -LRB-
MAPK ||| S:21444 E:21448 ||| NNP
)  ||| S:21448 E:21450 ||| -RRB-
pathway ||| S:21450 E:21457 ||| NN
,  ||| S:21457 E:21469 ||| ,
consisting  ||| S:21469 E:21480 ||| VBG
of  ||| S:21480 E:21483 ||| IN
the  ||| S:21483 E:21487 ||| DT
MAP  ||| S:21487 E:21491 ||| FW
kinase  ||| S:21491 E:21498 ||| FW
kinases  ||| S:21498 E:21506 ||| FW
( ||| S:21506 E:21507 ||| -LRB-
MKKs ||| S:21507 E:21511 ||| NNP
)  ||| S:21511 E:21513 ||| -RRB-
1  ||| S:21513 E:21515 ||| CD
and  ||| S:21515 E:21519 ||| CC
2 ||| S:21519 E:21520 ||| CD
,  ||| S:21520 E:21522 ||| ,
and  ||| S:21522 E:21536 ||| CC
extracellular  ||| S:21536 E:21550 ||| JJ
signal-regulated  ||| S:21550 E:21567 ||| JJ
kinases  ||| S:21567 E:21575 ||| NNS
( ||| S:21575 E:21576 ||| -LRB-
ERKs ||| S:21576 E:21580 ||| NNP
)  ||| S:21580 E:21582 ||| -RRB-
1  ||| S:21582 E:21584 ||| CD
and  ||| S:21584 E:21588 ||| CC
2 ||| S:21588 E:21589 ||| CD
,  ||| S:21589 E:21601 ||| ,
which  ||| S:21601 E:21607 ||| WDT
have  ||| S:21607 E:21612 ||| VBP
been  ||| S:21612 E:21617 ||| VBN
implicated  ||| S:21617 E:21628 ||| VBN
in  ||| S:21628 E:21631 ||| IN
diverse  ||| S:21631 E:21639 ||| JJ
cellular  ||| S:21639 E:21648 ||| JJ
processes  ||| S:21648 E:21668 ||| NNS
including  ||| S:21668 E:21678 ||| VBG
proliferation ||| S:21678 E:21691 ||| NN
,  ||| S:21691 E:21693 ||| ,
transformation ||| S:21693 E:21707 ||| NN
,  ||| S:21707 E:21709 ||| ,
and  ||| S:21709 E:21713 ||| CC
cell  ||| S:21713 E:21728 ||| NN
differentiation  ||| S:21728 E:21744 ||| NNS
[  ||| S:21744 E:21746 ||| -LRB-
53  ||| S:21746 E:21749 ||| CD
]  ||| S:21749 E:21751 ||| -RRB-
.  ||| S:21751 E:21753 ||| .
The  ||| S:21753 E:21757 ||| DT
MAP  ||| S:21757 E:21761 ||| NNP
kinase  ||| S:21761 E:21768 ||| NNS
( ||| S:21768 E:21769 ||| -LRB-
MAPK ||| S:21769 E:21773 ||| NNP
)  ||| S:21773 E:21775 ||| -RRB-
pathway  ||| S:21775 E:21793 ||| NN
has  ||| S:21793 E:21797 ||| VBZ
emerged  ||| S:21797 E:21805 ||| VBN
as  ||| S:21805 E:21808 ||| IN
a  ||| S:21808 E:21810 ||| DT
crucial  ||| S:21810 E:21818 ||| JJ
route  ||| S:21818 E:21824 ||| NN
between  ||| S:21824 E:21832 ||| IN
membrane-bound  ||| S:21832 E:21847 ||| NNP
Ras  ||| S:21847 E:21861 ||| NNP
and  ||| S:21861 E:21865 ||| CC
the  ||| S:21865 E:21869 ||| DT
nucleus ||| S:21869 E:21876 ||| NN
.  ||| S:21876 E:21878 ||| .
This  ||| S:21878 E:21883 ||| DT
MAPK  ||| S:21883 E:21888 ||| NNP
pathway  ||| S:21888 E:21896 ||| VBZ
encompasses  ||| S:21896 E:21908 ||| VBG
a  ||| S:21908 E:21910 ||| DT
cascade  ||| S:21910 E:21928 ||| NN
of  ||| S:21928 E:21931 ||| IN
phosphorylation  ||| S:21931 E:21947 ||| JJ
events  ||| S:21947 E:21954 ||| NNS
involving  ||| S:21954 E:21964 ||| VBG
three  ||| S:21964 E:21970 ||| CD
key  ||| S:21970 E:21974 ||| JJ
kinases ||| S:21974 E:21981 ||| NN
,  ||| S:21981 E:21993 ||| ,
namely  ||| S:21993 E:22000 ||| RB
Raf ||| S:22000 E:22003 ||| NNP
,  ||| S:22003 E:22005 ||| ,
MEK  ||| S:22005 E:22009 ||| NNP
( ||| S:22009 E:22010 ||| -LRB-
MAP  ||| S:22010 E:22014 ||| FW
kinase  ||| S:22014 E:22021 ||| FW
kinase ||| S:22021 E:22027 ||| FW
)  ||| S:22027 E:22029 ||| -RRB-
and  ||| S:22029 E:22033 ||| CC
ERK  ||| S:22033 E:22037 ||| NNP
( ||| S:22037 E:22038 ||| -LRB-
MAP  ||| S:22038 E:22042 ||| UH
kinase ||| S:22042 E:22048 ||| UH
) ||| S:22048 E:22049 ||| -RRB-
.  ||| S:22049 E:22061 ||| .
The  ||| S:22061 E:22065 ||| DT
MAPK  ||| S:22065 E:22070 ||| NNP
pathway  ||| S:22070 E:22078 ||| NN
controls  ||| S:22078 E:22087 ||| VBZ
ERKs  ||| S:22087 E:22092 ||| JJ
1  ||| S:22092 E:22094 ||| CD
and  ||| S:22094 E:22098 ||| CC
2 ||| S:22098 E:22099 ||| CD
,  ||| S:22099 E:22101 ||| ,
c-Jun  ||| S:22101 E:22107 ||| JJ
N-terminal  ||| S:22107 E:22128 ||| JJ
kinase  ||| S:22128 E:22135 ||| NNS
( ||| S:22135 E:22136 ||| -LRB-
JNK ||| S:22136 E:22139 ||| NNP
) ||| S:22139 E:22140 ||| -RRB-
,  ||| S:22140 E:22142 ||| ,
and  ||| S:22142 E:22146 ||| CC
p38 ||| S:22146 E:22149 ||| NNP
.  ||| S:22149 E:22151 ||| .
These  ||| S:22151 E:22157 ||| DT
signaling  ||| S:22157 E:22167 ||| JJ
pathways  ||| S:22167 E:22176 ||| NN
in  ||| S:22176 E:22179 ||| IN
turn ||| S:22179 E:22183 ||| NN
,  ||| S:22183 E:22195 ||| ,
activate  ||| S:22195 E:22204 ||| VBG
a  ||| S:22204 E:22206 ||| DT
variety  ||| S:22206 E:22214 ||| NN
of  ||| S:22214 E:22217 ||| IN
transcription  ||| S:22217 E:22231 ||| JJ
factors  ||| S:22231 E:22239 ||| NNS
including  ||| S:22239 E:22259 ||| VBG
NF-kappaB  ||| S:22259 E:22269 ||| JJ
( ||| S:22269 E:22270 ||| -LRB-
p50 ||| S:22270 E:22273 ||| CD
/ ||| S:22273 E:22274 ||| CD
p65 ||| S:22274 E:22277 ||| CD
) ||| S:22277 E:22278 ||| -RRB-
,  ||| S:22278 E:22280 ||| ,
AP-1  ||| S:22280 E:22285 ||| NNP
( ||| S:22285 E:22286 ||| -LRB-
c-Fos ||| S:22286 E:22291 ||| NNP
/ ||| S:22291 E:22292 ||| NNP
c-Jun ||| S:22292 E:22297 ||| NNP
) ||| S:22297 E:22298 ||| -RRB-
,  ||| S:22298 E:22300 ||| ,
and  ||| S:22300 E:22304 ||| CC
CREB  ||| S:22304 E:22319 ||| NNP
phosphorylation ||| S:22319 E:22334 ||| NN
,  ||| S:22334 E:22336 ||| ,
which  ||| S:22336 E:22342 ||| WDT
in  ||| S:22342 E:22345 ||| RB
turn  ||| S:22345 E:22350 ||| VB
coordinate  ||| S:22350 E:22361 ||| VB
the  ||| S:22361 E:22365 ||| DT
induction  ||| S:22365 E:22385 ||| NN
of  ||| S:22385 E:22388 ||| IN
many  ||| S:22388 E:22393 ||| JJ
genes  ||| S:22393 E:22399 ||| NNS
encoding  ||| S:22399 E:22408 ||| VBP
inflammatory  ||| S:22408 E:22421 ||| JJ
mediators ||| S:22421 E:22430 ||| NNS
.  ||| S:22430 E:22442 ||| .
Cytokine  ||| S:22442 E:22451 ||| JJ
receptors  ||| S:22451 E:22461 ||| JJ
such  ||| S:22461 E:22466 ||| JJ
as  ||| S:22466 E:22469 ||| IN
IL-3 ||| S:22469 E:22473 ||| NNP
,  ||| S:22473 E:22475 ||| ,
GM-CSF ||| S:22475 E:22481 ||| NNP
,  ||| S:22481 E:22483 ||| ,
and  ||| S:22483 E:22487 ||| CC
the  ||| S:22487 E:22501 ||| DT
interferons  ||| S:22501 E:22513 ||| NN
transmit  ||| S:22513 E:22522 ||| VBD
their  ||| S:22522 E:22528 ||| PRP$
regulatory  ||| S:22528 E:22539 ||| JJ
signals  ||| S:22539 E:22547 ||| NNS
primarily  ||| S:22547 E:22567 ||| RB
by  ||| S:22567 E:22570 ||| IN
the  ||| S:22570 E:22574 ||| DT
receptor-associated  ||| S:22574 E:22594 ||| JJ
Jak  ||| S:22594 E:22598 ||| JJ
family  ||| S:22598 E:22605 ||| NN
of  ||| S:22605 E:22608 ||| IN
tyrosine  ||| S:22608 E:22627 ||| JJ
kinases ||| S:22627 E:22634 ||| NN
,  ||| S:22634 E:22636 ||| ,
and  ||| S:22636 E:22640 ||| CC
activate  ||| S:22640 E:22649 ||| JJ
STAT  ||| S:22649 E:22654 ||| NNP
transcription  ||| S:22654 E:22668 ||| NN
factors ||| S:22668 E:22675 ||| NNS
.  ||| S:22675 E:22687 ||| .
Activated  ||| S:22687 E:22697 ||| NNP
STAT5  ||| S:22697 E:22703 ||| NNP
proteins  ||| S:22703 E:22712 ||| NNS
are  ||| S:22712 E:22716 ||| VBP
detected  ||| S:22716 E:22725 ||| VBN
in  ||| S:22725 E:22728 ||| IN
reduced  ||| S:22728 E:22736 ||| JJ
levels  ||| S:22736 E:22753 ||| NNS
in  ||| S:22753 E:22756 ||| IN
lymphocytes  ||| S:22756 E:22768 ||| NN
recovered  ||| S:22768 E:22778 ||| VBD
from  ||| S:22778 E:22783 ||| IN
HIV-infected  ||| S:22783 E:22796 ||| JJ
patients  ||| S:22796 E:22805 ||| NNS
and  ||| S:22805 E:22819 ||| CC
immunocompromised  ||| S:22819 E:22837 ||| JJ
mice ||| S:22837 E:22841 ||| NNS
.  ||| S:22841 E:22843 ||| .
Both  ||| S:22843 E:22848 ||| DT
of  ||| S:22848 E:22851 ||| IN
these  ||| S:22851 E:22857 ||| DT
types  ||| S:22857 E:22863 ||| NNS
of  ||| S:22863 E:22866 ||| IN
receptor  ||| S:22866 E:22885 ||| NN
signaling  ||| S:22885 E:22895 ||| VBG
pathways  ||| S:22895 E:22904 ||| NNS
have  ||| S:22904 E:22909 ||| VBP
recently  ||| S:22909 E:22918 ||| RB
been  ||| S:22918 E:22923 ||| VBN
shown  ||| S:22923 E:22929 ||| VBN
to  ||| S:22929 E:22932 ||| TO
interact  ||| S:22932 E:22951 ||| VB
with  ||| S:22951 E:22956 ||| IN
serine ||| S:22956 E:22962 ||| FW
/ ||| S:22962 E:22963 ||| FW
threonine  ||| S:22963 E:22973 ||| FW
kinases  ||| S:22973 E:22981 ||| FW
such  ||| S:22981 E:22986 ||| JJ
as  ||| S:22986 E:22989 ||| IN
MAP  ||| S:22989 E:22993 ||| NNP
kinases ||| S:22993 E:23000 ||| NN
.  ||| S:23000 E:23002 ||| .
A  ||| S:23002 E:23014 ||| DT
common  ||| S:23014 E:23021 ||| JJ
intermediate  ||| S:23021 E:23034 ||| JJ
pathway  ||| S:23034 E:23042 ||| JJ
initiating  ||| S:23042 E:23053 ||| NN
from  ||| S:23053 E:23058 ||| IN
receptors  ||| S:23058 E:23068 ||| NNS
to  ||| S:23068 E:23081 ||| TO
the  ||| S:23081 E:23085 ||| DT
nucleus  ||| S:23085 E:23093 ||| NN
is  ||| S:23093 E:23096 ||| VBZ
the  ||| S:23096 E:23100 ||| DT
Ras ||| S:23100 E:23103 ||| NNP
/ ||| S:23103 E:23104 ||| NNP
Raf ||| S:23104 E:23107 ||| NNP
/ ||| S:23107 E:23108 ||| NNP
MEK ||| S:23108 E:23111 ||| NNP
/ ||| S:23111 E:23112 ||| NNP
ERK  ||| S:23112 E:23116 ||| NNP
( ||| S:23116 E:23117 ||| -LRB-
MAPK ||| S:23117 E:23121 ||| NNP
)  ||| S:23121 E:23123 ||| -RRB-
cascade ||| S:23123 E:23130 ||| NN
,  ||| S:23130 E:23132 ||| ,
which  ||| S:23132 E:23148 ||| WDT
can  ||| S:23148 E:23152 ||| MD
result  ||| S:23152 E:23159 ||| VB
in  ||| S:23159 E:23162 ||| IN
the  ||| S:23162 E:23166 ||| DT
phosphorylation  ||| S:23166 E:23182 ||| NN
and  ||| S:23182 E:23186 ||| CC
activation  ||| S:23186 E:23197 ||| NN
of  ||| S:23197 E:23210 ||| IN
additional  ||| S:23210 E:23221 ||| JJ
downstream  ||| S:23221 E:23232 ||| JJ
kinases  ||| S:23232 E:23240 ||| NN
and  ||| S:23240 E:23244 ||| CC
transcription  ||| S:23244 E:23258 ||| JJ
factors  ||| S:23258 E:23276 ||| NNS
such  ||| S:23276 E:23281 ||| JJ
as  ||| S:23281 E:23284 ||| IN
p90Rsk ||| S:23284 E:23290 ||| NNP
,  ||| S:23290 E:23292 ||| ,
CREB ||| S:23292 E:23296 ||| NNP
,  ||| S:23296 E:23298 ||| ,
Elk ||| S:23298 E:23301 ||| NNP
,  ||| S:23301 E:23303 ||| ,
and  ||| S:23303 E:23307 ||| CC
Egr-1  ||| S:23307 E:23313 ||| NNP
[  ||| S:23313 E:23315 ||| -LRB-
55  ||| S:23315 E:23318 ||| CD
56  ||| S:23318 E:23321 ||| CD
]  ||| S:23321 E:23323 ||| -RRB-
.  ||| S:23323 E:23335 ||| .
Therefore ||| S:23335 E:23344 ||| RB
,  ||| S:23344 E:23346 ||| ,
it  ||| S:23346 E:23349 ||| PRP
is  ||| S:23349 E:23352 ||| VBZ
intriguing  ||| S:23352 E:23363 ||| VBN
that  ||| S:23363 E:23368 ||| IN
Tat  ||| S:23368 E:23372 ||| NNP
expressing  ||| S:23372 E:23383 ||| VBG
cells  ||| S:23383 E:23399 ||| NNS
show  ||| S:23399 E:23404 ||| VBP
down-regulation  ||| S:23404 E:23420 ||| JJ
of  ||| S:23420 E:23423 ||| IN
MAPK  ||| S:23423 E:23428 ||| NNP
components  ||| S:23428 E:23439 ||| NNS
( ||| S:23439 E:23440 ||| -LRB-
Table  ||| S:23440 E:23446 ||| NNP
3 ||| S:23446 E:23447 ||| CD
,  ||| S:23447 E:23449 ||| ,
Figure  ||| S:23449 E:23466 ||| NNP
3Band  ||| S:23466 E:23472 ||| NNP
3C ||| S:23472 E:23474 ||| NNP
) ||| S:23474 E:23475 ||| -RRB-
,  ||| S:23475 E:23477 ||| ,
essential  ||| S:23477 E:23487 ||| JJ
mediators  ||| S:23487 E:23497 ||| NNS
between  ||| S:23497 E:23505 ||| IN
receptors  ||| S:23505 E:23515 ||| NNS
and  ||| S:23515 E:23529 ||| CC
nuclear  ||| S:23529 E:23537 ||| JJ
transcription  ||| S:23537 E:23551 ||| JJ
factors ||| S:23551 E:23558 ||| NNS
.  ||| S:23558 E:23560 ||| .
This  ||| S:23560 E:23565 ||| DT
would  ||| S:23565 E:23571 ||| MD
imply  ||| S:23571 E:23577 ||| VB
that  ||| S:23577 E:23592 ||| DT
latently  ||| S:23592 E:23601 ||| JJ
infected  ||| S:23601 E:23610 ||| JJ
cells  ||| S:23610 E:23616 ||| NNS
that  ||| S:23616 E:23621 ||| WDT
express  ||| S:23621 E:23629 ||| VBP
Tat  ||| S:23629 E:23633 ||| NNP
( ||| S:23633 E:23634 ||| -LRB-
doubly  ||| S:23634 E:23641 ||| FW
spliced  ||| S:23641 E:23659 ||| FW
RNA ||| S:23659 E:23662 ||| NNP
)  ||| S:23662 E:23664 ||| -RRB-
and  ||| S:23664 E:23668 ||| CC
not  ||| S:23668 E:23672 ||| RB
the  ||| S:23672 E:23676 ||| DT
whole  ||| S:23676 E:23682 ||| JJ
virus  ||| S:23682 E:23688 ||| NN
( ||| S:23688 E:23689 ||| -LRB-
all  ||| S:23689 E:23693 ||| DT
three  ||| S:23693 E:23699 ||| CD
classes  ||| S:23699 E:23707 ||| NNS
of  ||| S:23707 E:23710 ||| IN
the  ||| S:23710 E:23724 ||| DT
RNA ||| S:23724 E:23727 ||| NNP
) ||| S:23727 E:23728 ||| -RRB-
,  ||| S:23728 E:23730 ||| ,
can  ||| S:23730 E:23734 ||| MD
control  ||| S:23734 E:23742 ||| VB
signal  ||| S:23742 E:23749 ||| NN
transduction  ||| S:23749 E:23762 ||| VBZ
related  ||| S:23762 E:23770 ||| VBN
to  ||| S:23770 E:23773 ||| TO
membrane  ||| S:23773 E:23792 ||| VB
and  ||| S:23792 E:23796 ||| CC
transcriptional  ||| S:23796 E:23812 ||| JJ
signaling  ||| S:23812 E:23822 ||| NNS
( ||| S:23822 E:23823 ||| -LRB-
Figure  ||| S:23823 E:23830 ||| NNP
6 ||| S:23830 E:23831 ||| CD
) ||| S:23831 E:23832 ||| -RRB-
.  ||| S:23832 E:23844 ||| .
Interestingly ||| S:23844 E:23857 ||| RB
,  ||| S:23857 E:23859 ||| ,
Tat ||| S:23859 E:23862 ||| NNP
,  ||| S:23862 E:23864 ||| ,
through  ||| S:23864 E:23872 ||| IN
the  ||| S:23872 E:23876 ||| DT
RGD  ||| S:23876 E:23880 ||| NNP
motif ||| S:23880 E:23885 ||| NN
,  ||| S:23885 E:23887 ||| ,
which  ||| S:23887 E:23903 ||| WDT
controls  ||| S:23903 E:23912 ||| VBZ
integrin-based  ||| S:23912 E:23927 ||| JJ
cell  ||| S:23927 E:23932 ||| NN
signaling ||| S:23932 E:23941 ||| NN
,  ||| S:23941 E:23943 ||| ,
has  ||| S:23943 E:23947 ||| VBZ
been  ||| S:23947 E:23952 ||| VBN
reported  ||| S:23952 E:23971 ||| VBN
to  ||| S:23971 E:23974 ||| TO
mediate  ||| S:23974 E:23982 ||| VB
the  ||| S:23982 E:23986 ||| DT
activity  ||| S:23986 E:23995 ||| NN
of  ||| S:23995 E:23998 ||| IN
phosphotyrosine  ||| S:23998 E:24024 ||| JJ
phosphatase ||| S:24024 E:24035 ||| NNS
( ||| S:24035 E:24036 ||| -LRB-
s ||| S:24036 E:24037 ||| LS
) ||| S:24037 E:24038 ||| -RRB-
.  ||| S:24038 E:24040 ||| .
This  ||| S:24040 E:24045 ||| DT
in  ||| S:24045 E:24048 ||| IN
turn  ||| S:24048 E:24053 ||| NN
which  ||| S:24053 E:24059 ||| WDT
would  ||| S:24059 E:24065 ||| MD
lead  ||| S:24065 E:24070 ||| VB
to  ||| S:24070 E:24073 ||| TO
a  ||| S:24073 E:24085 ||| DT
decrease  ||| S:24085 E:24094 ||| NN
in  ||| S:24094 E:24097 ||| IN
the  ||| S:24097 E:24101 ||| DT
levels  ||| S:24101 E:24108 ||| NNS
of  ||| S:24108 E:24111 ||| IN
phosphotyrosine-containing  ||| S:24111 E:24148 ||| JJ
proteins  ||| S:24148 E:24157 ||| NNS
such  ||| S:24157 E:24162 ||| JJ
as  ||| S:24162 E:24165 ||| IN
ERK-2 ||| S:24165 E:24170 ||| CD
/ ||| S:24170 E:24171 ||| CD
p42MAPK  ||| S:24171 E:24179 ||| CD
kinases  ||| S:24179 E:24187 ||| NNS
[  ||| S:24187 E:24189 ||| -LRB-
57  ||| S:24189 E:24192 ||| CD
]  ||| S:24192 E:24194 ||| -RRB-
.  ||| S:24194 E:24206 ||| .
Cysteine-rich  ||| S:24206 E:24220 ||| NNP
and  ||| S:24220 E:24224 ||| CC
basic  ||| S:24224 E:24230 ||| JJ
Tat  ||| S:24230 E:24234 ||| JJ
peptides  ||| S:24234 E:24243 ||| NNS
have  ||| S:24243 E:24248 ||| VBP
been  ||| S:24248 E:24253 ||| VBN
shown  ||| S:24253 E:24259 ||| VBN
to  ||| S:24259 E:24272 ||| TO
inhibit  ||| S:24272 E:24280 ||| VB
VEGF-induced  ||| S:24280 E:24293 ||| JJ
ERK  ||| S:24293 E:24297 ||| NNP
activation  ||| S:24297 E:24308 ||| NN
and  ||| S:24308 E:24312 ||| CC
mitogenesis ||| S:24312 E:24323 ||| NN
.  ||| S:24323 E:24335 ||| .
These  ||| S:24335 E:24341 ||| DT
peptides  ||| S:24341 E:24350 ||| NN
also  ||| S:24350 E:24355 ||| RB
inhibited  ||| S:24355 E:24365 ||| JJ
proliferation ||| S:24365 E:24378 ||| NN
,  ||| S:24378 E:24390 ||| ,
angiogenesis ||| S:24390 E:24402 ||| NN
,  ||| S:24402 E:24404 ||| ,
and  ||| S:24404 E:24408 ||| CC
ERK  ||| S:24408 E:24412 ||| NNP
activation  ||| S:24412 E:24423 ||| VBD
induced  ||| S:24423 E:24431 ||| VBN
by  ||| S:24431 E:24434 ||| IN
basic  ||| S:24434 E:24450 ||| JJ
fibroblast  ||| S:24450 E:24461 ||| JJ
growth  ||| S:24461 E:24468 ||| NN
factor  ||| S:24468 E:24475 ||| NN
with  ||| S:24475 E:24480 ||| IN
similar  ||| S:24480 E:24488 ||| JJ
potency  ||| S:24488 E:24496 ||| NN
and  ||| S:24496 E:24510 ||| CC
efficacy  ||| S:24510 E:24519 ||| NNS
[  ||| S:24519 E:24521 ||| -LRB-
58  ||| S:24521 E:24524 ||| CD
]  ||| S:24524 E:24526 ||| -RRB-
.  ||| S:24526 E:24528 ||| .
Consistent  ||| S:24528 E:24539 ||| JJ
with  ||| S:24539 E:24544 ||| IN
this  ||| S:24544 E:24549 ||| DT
model ||| S:24549 E:24554 ||| NN
,  ||| S:24554 E:24556 ||| ,
it  ||| S:24556 E:24559 ||| PRP
has  ||| S:24559 E:24563 ||| VBZ
been  ||| S:24563 E:24578 ||| VBN
shown  ||| S:24578 E:24584 ||| VBN
that  ||| S:24584 E:24589 ||| IN
treatment  ||| S:24589 E:24599 ||| NN
of  ||| S:24599 E:24602 ||| IN
neural  ||| S:24602 E:24609 ||| JJ
cells  ||| S:24609 E:24615 ||| NNS
with  ||| S:24615 E:24620 ||| IN
culture  ||| S:24620 E:24638 ||| NN
supernatants  ||| S:24638 E:24651 ||| NN
from  ||| S:24651 E:24656 ||| IN
HAART-treated  ||| S:24656 E:24670 ||| JJ
subjects ||| S:24670 E:24678 ||| NNS
,  ||| S:24678 E:24680 ||| ,
which  ||| S:24680 E:24696 ||| WDT
presumably  ||| S:24696 E:24707 ||| RB
contain  ||| S:24707 E:24715 ||| VB
extracellular  ||| S:24715 E:24729 ||| JJ
Tat ||| S:24729 E:24732 ||| NNP
,  ||| S:24732 E:24734 ||| ,
resulted  ||| S:24734 E:24743 ||| VBD
in  ||| S:24743 E:24756 ||| IN
down-regulation  ||| S:24756 E:24772 ||| JJ
of  ||| S:24772 E:24775 ||| IN
the  ||| S:24775 E:24779 ||| DT
JNK ||| S:24779 E:24782 ||| NNP
,  ||| S:24782 E:24784 ||| ,
AKT ||| S:24784 E:24787 ||| NNP
,  ||| S:24787 E:24789 ||| ,
and  ||| S:24789 E:24793 ||| CC
ERK  ||| S:24793 E:24797 ||| NNP
kinases  ||| S:24797 E:24805 ||| NNS
[  ||| S:24805 E:24807 ||| -LRB-
59  ||| S:24807 E:24810 ||| CD
]  ||| S:24810 E:24822 ||| -RRB-
.  ||| S:24822 E:24834 ||| .
Finally ||| S:24834 E:24841 ||| RB
,  ||| S:24841 E:24843 ||| ,
activation  ||| S:24843 E:24854 ||| VBG
of  ||| S:24854 E:24857 ||| IN
MAPKs  ||| S:24857 E:24863 ||| NNP
has  ||| S:24863 E:24867 ||| VBZ
been  ||| S:24867 E:24872 ||| VBN
shown  ||| S:24872 E:24878 ||| VBN
to  ||| S:24878 E:24891 ||| TO
activate  ||| S:24891 E:24900 ||| VB
the  ||| S:24900 E:24904 ||| DT
singly  ||| S:24904 E:24911 ||| JJ
spliced  ||| S:24911 E:24919 ||| NN
and  ||| S:24919 E:24923 ||| CC
unspliced  ||| S:24923 E:24933 ||| NNS
( ||| S:24933 E:24934 ||| -LRB-
genomic ||| S:24934 E:24941 ||| LS
)  ||| S:24941 E:24953 ||| -RRB-
latent  ||| S:24953 E:24960 ||| VBD
HIV-1  ||| S:24960 E:24966 ||| CD
virus ||| S:24966 E:24971 ||| NN
.  ||| S:24971 E:24973 ||| .
For  ||| S:24973 E:24977 ||| IN
instance ||| S:24977 E:24985 ||| NN
,  ||| S:24985 E:24987 ||| ,
the  ||| S:24987 E:24991 ||| DT
signal  ||| S:24991 E:24998 ||| NN
transduction  ||| S:24998 E:25021 ||| NN
pathways  ||| S:25021 E:25030 ||| NNS
that  ||| S:25030 E:25035 ||| WDT
regulate  ||| S:25035 E:25044 ||| VBZ
the  ||| S:25044 E:25048 ||| DT
switch  ||| S:25048 E:25055 ||| NN
from  ||| S:25055 E:25060 ||| IN
latent  ||| S:25060 E:25067 ||| VBG
to  ||| S:25067 E:25080 ||| TO
productive  ||| S:25080 E:25091 ||| JJ
infection  ||| S:25091 E:25101 ||| NNS
have  ||| S:25101 E:25106 ||| VBP
been  ||| S:25106 E:25111 ||| VBN
linked  ||| S:25111 E:25118 ||| VBN
to  ||| S:25118 E:25121 ||| TO
MAPK ||| S:25121 E:25125 ||| NNP
.  ||| S:25125 E:25127 ||| .
The  ||| S:25127 E:25141 ||| DT
induction  ||| S:25141 E:25151 ||| NN
of  ||| S:25151 E:25154 ||| IN
latent  ||| S:25154 E:25161 ||| CD
HIV-1  ||| S:25161 E:25167 ||| CD
expression  ||| S:25167 E:25178 ||| NN
has  ||| S:25178 E:25182 ||| VBZ
been  ||| S:25182 E:25187 ||| VBN
shown  ||| S:25187 E:25193 ||| VBN
to  ||| S:25193 E:25196 ||| TO
be  ||| S:25196 E:25209 ||| VB
inhibited  ||| S:25209 E:25219 ||| VBN
by  ||| S:25219 E:25222 ||| IN
PD98059  ||| S:25222 E:25230 ||| NNP
and  ||| S:25230 E:25234 ||| CC
U0126 ||| S:25234 E:25239 ||| NNP
,  ||| S:25239 E:25241 ||| ,
specific  ||| S:25241 E:25250 ||| JJ
inhibitors  ||| S:25250 E:25261 ||| NN
of  ||| S:25261 E:25274 ||| IN
MAPK  ||| S:25274 E:25279 ||| NNP
activation ||| S:25279 E:25289 ||| NN
.  ||| S:25289 E:25291 ||| .
The  ||| S:25291 E:25295 ||| DT
MAPK  ||| S:25295 E:25300 ||| NNP
acts  ||| S:25300 E:25305 ||| VBZ
by  ||| S:25305 E:25308 ||| IN
stimulating  ||| S:25308 E:25320 ||| VBG
AP-1  ||| S:25320 E:25325 ||| NNP
and  ||| S:25325 E:25329 ||| CC
a  ||| S:25329 E:25341 ||| DT
subsequent  ||| S:25341 E:25352 ||| JJ
physical  ||| S:25352 E:25361 ||| JJ
and  ||| S:25361 E:25365 ||| CC
functional  ||| S:25365 E:25376 ||| JJ
interaction  ||| S:25376 E:25388 ||| NN
of  ||| S:25388 E:25391 ||| IN
AP-1  ||| S:25391 E:25406 ||| CD
with  ||| S:25406 E:25411 ||| IN
NF-κB ||| S:25411 E:25416 ||| NNP
,  ||| S:25416 E:25418 ||| ,
resulting  ||| S:25418 E:25428 ||| VBG
in  ||| S:25428 E:25431 ||| IN
a  ||| S:25431 E:25433 ||| DT
complex  ||| S:25433 E:25441 ||| NN
that  ||| S:25441 E:25446 ||| WDT
synergistically  ||| S:25446 E:25472 ||| VBP
transactivates  ||| S:25472 E:25487 ||| VBG
the  ||| S:25487 E:25491 ||| DT
HIV-1  ||| S:25491 E:25497 ||| NNP
[  ||| S:25497 E:25499 ||| -LRB-
60  ||| S:25499 E:25502 ||| CD
]  ||| S:25502 E:25504 ||| -RRB-
.  ||| S:25504 E:25506 ||| .
At  ||| S:25506 E:25509 ||| IN
the  ||| S:25509 E:25513 ||| DT
level  ||| S:25513 E:25519 ||| NN
of  ||| S:25519 E:25532 ||| IN
infection  ||| S:25532 E:25542 ||| NN
and  ||| S:25542 E:25546 ||| CC
entry ||| S:25546 E:25551 ||| NN
,  ||| S:25551 E:25553 ||| ,
the  ||| S:25553 E:25557 ||| DT
activation  ||| S:25557 E:25568 ||| NN
of  ||| S:25568 E:25571 ||| IN
MAPK  ||| S:25571 E:25576 ||| NNP
through  ||| S:25576 E:25584 ||| IN
the  ||| S:25584 E:25598 ||| DT
Ras ||| S:25598 E:25601 ||| NNP
/ ||| S:25601 E:25602 ||| NNP
Raf ||| S:25602 E:25605 ||| NNP
/ ||| S:25605 E:25606 ||| NNP
MEK  ||| S:25606 E:25610 ||| NNP
( ||| S:25610 E:25611 ||| -LRB-
MAPK  ||| S:25611 E:25616 ||| UH
kinase ||| S:25616 E:25622 ||| UH
)  ||| S:25622 E:25624 ||| -RRB-
signaling  ||| S:25624 E:25634 ||| VBG
pathway  ||| S:25634 E:25642 ||| NN
enhances  ||| S:25642 E:25651 ||| VBZ
the  ||| S:25651 E:25665 ||| DT
infectivity  ||| S:25665 E:25677 ||| NN
of  ||| S:25677 E:25680 ||| IN
HIV-1  ||| S:25680 E:25686 ||| NNP
virions ||| S:25686 E:25693 ||| NN
.  ||| S:25693 E:25695 ||| .
Virus  ||| S:25695 E:25701 ||| NN
infectivity  ||| S:25701 E:25713 ||| NNS
can  ||| S:25713 E:25717 ||| MD
be  ||| S:25717 E:25730 ||| VB
enhanced  ||| S:25730 E:25739 ||| VBN
by  ||| S:25739 E:25742 ||| IN
treatment  ||| S:25742 E:25752 ||| NN
of  ||| S:25752 E:25755 ||| IN
cells  ||| S:25755 E:25761 ||| NNS
with  ||| S:25761 E:25766 ||| IN
MAPK  ||| S:25766 E:25771 ||| NNP
stimulators ||| S:25771 E:25782 ||| NNS
,  ||| S:25782 E:25794 ||| ,
such  ||| S:25794 E:25799 ||| JJ
as  ||| S:25799 E:25802 ||| IN
serum  ||| S:25802 E:25808 ||| NN
and  ||| S:25808 E:25812 ||| CC
phorbol  ||| S:25812 E:25820 ||| JJ
myristate  ||| S:25820 E:25830 ||| JJ
acetate ||| S:25830 E:25837 ||| NN
,  ||| S:25837 E:25839 ||| ,
as  ||| S:25839 E:25842 ||| RB
well  ||| S:25842 E:25847 ||| RB
as  ||| S:25847 E:25860 ||| RB
by  ||| S:25860 E:25863 ||| IN
coexpression  ||| S:25863 E:25876 ||| NN
of  ||| S:25876 E:25879 ||| IN
constitutively  ||| S:25879 E:25894 ||| JJ
activated  ||| S:25894 E:25904 ||| JJ
Ras ||| S:25904 E:25907 ||| NNP
,  ||| S:25907 E:25909 ||| ,
Raf ||| S:25909 E:25912 ||| NNP
,  ||| S:25912 E:25914 ||| ,
or  ||| S:25914 E:25927 ||| CC
MEK  ||| S:25927 E:25931 ||| NNP
in  ||| S:25931 E:25934 ||| IN
the  ||| S:25934 E:25938 ||| DT
absence  ||| S:25938 E:25946 ||| NN
of  ||| S:25946 E:25949 ||| IN
extracellular  ||| S:25949 E:25963 ||| JJ
stimulation  ||| S:25963 E:25975 ||| NN
[  ||| S:25975 E:25977 ||| -LRB-
61  ||| S:25977 E:25980 ||| CD
]  ||| S:25980 E:25982 ||| -RRB-
.  ||| S:25982 E:25994 ||| .
Also ||| S:25994 E:25998 ||| RB
,  ||| S:25998 E:26000 ||| ,
following  ||| S:26000 E:26010 ||| VBG
infection ||| S:26010 E:26019 ||| NN
,  ||| S:26019 E:26021 ||| ,
efficient  ||| S:26021 E:26031 ||| JJ
disengagement  ||| S:26031 E:26045 ||| NN
of  ||| S:26045 E:26048 ||| IN
the  ||| S:26048 E:26062 ||| DT
reverse  ||| S:26062 E:26070 ||| JJ
transcription  ||| S:26070 E:26084 ||| JJ
complex  ||| S:26084 E:26092 ||| NN
from  ||| S:26092 E:26097 ||| IN
the  ||| S:26097 E:26101 ||| DT
cell  ||| S:26101 E:26106 ||| NN
membrane  ||| S:26106 E:26115 ||| NNS
and  ||| S:26115 E:26129 ||| CC
subsequent  ||| S:26129 E:26140 ||| JJ
nuclear  ||| S:26140 E:26148 ||| JJ
translocation ||| S:26148 E:26161 ||| NN
,  ||| S:26161 E:26163 ||| ,
requires  ||| S:26163 E:26182 ||| VBZ
phosphorylation  ||| S:26182 E:26198 ||| VBN
of  ||| S:26198 E:26201 ||| IN
the  ||| S:26201 E:26205 ||| DT
reverse  ||| S:26205 E:26213 ||| JJ
transcription  ||| S:26213 E:26227 ||| JJ
complex  ||| S:26227 E:26245 ||| JJ
components  ||| S:26245 E:26256 ||| NNS
by  ||| S:26256 E:26259 ||| IN
ERK ||| S:26259 E:26262 ||| NNP
/ ||| S:26262 E:26263 ||| NNP
MAPK ||| S:26263 E:26267 ||| NNP
;  ||| S:26267 E:26269 ||| :
demonstrating  ||| S:26269 E:26283 ||| VBG
a  ||| S:26283 E:26285 ||| DT
critical  ||| S:26285 E:26304 ||| JJ
regulation  ||| S:26304 E:26315 ||| NN
of  ||| S:26315 E:26318 ||| IN
an  ||| S:26318 E:26321 ||| DT
early  ||| S:26321 E:26327 ||| JJ
step  ||| S:26327 E:26332 ||| NN
in  ||| S:26332 E:26335 ||| IN
HIV-1  ||| S:26335 E:26341 ||| NNP
infection  ||| S:26341 E:26351 ||| NN
by  ||| S:26351 E:26354 ||| IN
the  ||| S:26354 E:26368 ||| DT
host  ||| S:26368 E:26373 ||| NN
cell  ||| S:26373 E:26378 ||| NN
MAPK  ||| S:26378 E:26383 ||| FW
signal  ||| S:26383 E:26390 ||| FW
transduction  ||| S:26390 E:26403 ||| FW
pathway  ||| S:26403 E:26411 ||| FW
[  ||| S:26411 E:26413 ||| -LRB-
62  ||| S:26413 E:26416 ||| CD
]  ||| S:26416 E:26418 ||| -RRB-
.  ||| S:26418 E:26430 ||| .
Therefore ||| S:26430 E:26439 ||| RB
,  ||| S:26439 E:26441 ||| ,
Tat  ||| S:26441 E:26445 ||| NNP
down-regulation  ||| S:26445 E:26461 ||| NNP
of  ||| S:26461 E:26464 ||| IN
the  ||| S:26464 E:26468 ||| DT
MAPK  ||| S:26468 E:26473 ||| NNP
pathway  ||| S:26473 E:26481 ||| NN
in  ||| S:26481 E:26494 ||| IN
latent  ||| S:26494 E:26501 ||| JJ
cells  ||| S:26501 E:26507 ||| NNS
implies  ||| S:26507 E:26515 ||| VBZ
that  ||| S:26515 E:26520 ||| DT
much  ||| S:26520 E:26525 ||| JJ
of  ||| S:26525 E:26528 ||| IN
the  ||| S:26528 E:26532 ||| DT
host  ||| S:26532 E:26537 ||| NN
signal  ||| S:26537 E:26554 ||| NN
transductions  ||| S:26554 E:26568 ||| VBZ
connected  ||| S:26568 E:26578 ||| VBN
to  ||| S:26578 E:26581 ||| TO
activation  ||| S:26581 E:26592 ||| NNS
are  ||| S:26592 E:26596 ||| VBP
down-regulated ||| S:26596 E:26610 ||| JJ
,  ||| S:26610 E:26622 ||| ,
and  ||| S:26622 E:26626 ||| CC
at  ||| S:26626 E:26629 ||| IN
the  ||| S:26629 E:26633 ||| DT
same  ||| S:26633 E:26638 ||| JJ
time ||| S:26638 E:26642 ||| NN
,  ||| S:26642 E:26644 ||| ,
these  ||| S:26644 E:26650 ||| DT
cells  ||| S:26650 E:26656 ||| NNS
may  ||| S:26656 E:26660 ||| MD
be  ||| S:26660 E:26663 ||| VB
refractory  ||| S:26663 E:26674 ||| VBN
to  ||| S:26674 E:26687 ||| TO
subsequent  ||| S:26687 E:26698 ||| JJ
infection  ||| S:26698 E:26708 ||| NN
by  ||| S:26708 E:26711 ||| IN
other  ||| S:26711 E:26717 ||| JJ
viruses ||| S:26717 E:26724 ||| NN
.  ||| S:26724 E:26754 ||| .
Thymosin  ||| S:26754 E:26763 ||| JJ
family  ||| S:26763 E:26770 ||| NN
members ||| S:26770 E:26777 ||| NNS
,  ||| S:26777 E:26779 ||| ,
and  ||| S:26779 E:26783 ||| CC
cell  ||| S:26783 E:26788 ||| NN
cycle  ||| S:26788 E:26804 ||| NN
Prothymosin  ||| S:26804 E:26816 ||| FW
α  ||| S:26816 E:26818 ||| FW
( ||| S:26818 E:26819 ||| -LRB-
ProTα ||| S:26819 E:26824 ||| NNP
)  ||| S:26824 E:26826 ||| -RRB-
belongs  ||| S:26826 E:26834 ||| VBZ
to  ||| S:26834 E:26837 ||| TO
the  ||| S:26837 E:26841 ||| DT
α-Thymosin  ||| S:26841 E:26852 ||| JJ
family  ||| S:26852 E:26869 ||| NN
which  ||| S:26869 E:26875 ||| WDT
comprises  ||| S:26875 E:26885 ||| VBZ
different  ||| S:26885 E:26895 ||| JJ
polypeptides  ||| S:26895 E:26908 ||| NNS
widely  ||| S:26908 E:26915 ||| RB
distributed  ||| S:26915 E:26937 ||| VBN
within  ||| S:26937 E:26944 ||| IN
animal  ||| S:26944 E:26951 ||| JJ
tissues ||| S:26951 E:26958 ||| NNS
.  ||| S:26958 E:26960 ||| .
Although  ||| S:26960 E:26969 ||| IN
its  ||| S:26969 E:26973 ||| PRP$
role  ||| S:26973 E:26978 ||| NN
has  ||| S:26978 E:26982 ||| VBZ
remained  ||| S:26982 E:27001 ||| VBN
controversial ||| S:27001 E:27014 ||| JJ
,  ||| S:27014 E:27016 ||| ,
it  ||| S:27016 E:27019 ||| PRP
is  ||| S:27019 E:27022 ||| VBZ
involved  ||| S:27022 E:27031 ||| VBN
in  ||| S:27031 E:27034 ||| IN
the  ||| S:27034 E:27038 ||| DT
increase  ||| S:27038 E:27047 ||| NN
of  ||| S:27047 E:27060 ||| IN
immediate  ||| S:27060 E:27070 ||| JJ
early  ||| S:27070 E:27076 ||| JJ
genes  ||| S:27076 E:27082 ||| NNS
such  ||| S:27082 E:27087 ||| JJ
as  ||| S:27087 E:27090 ||| IN
c-myc  ||| S:27090 E:27096 ||| NNP
[  ||| S:27096 E:27098 ||| -LRB-
63  ||| S:27098 E:27101 ||| CD
]  ||| S:27101 E:27103 ||| -RRB-
,  ||| S:27103 E:27105 ||| ,
which  ||| S:27105 E:27111 ||| WDT
is  ||| S:27111 E:27124 ||| VBZ
upstream  ||| S:27124 E:27133 ||| RB
of  ||| S:27133 E:27136 ||| IN
cyclin  ||| S:27136 E:27143 ||| JJ
D  ||| S:27143 E:27145 ||| NNP
synthesis  ||| S:27145 E:27155 ||| NN
and  ||| S:27155 E:27159 ||| CC
necessary  ||| S:27159 E:27169 ||| JJ
for  ||| S:27169 E:27173 ||| IN
cell  ||| S:27173 E:27188 ||| NN
division  ||| S:27188 E:27197 ||| NN
[  ||| S:27197 E:27199 ||| -LRB-
64  ||| S:27199 E:27202 ||| CD
]  ||| S:27202 E:27204 ||| -RRB-
.  ||| S:27204 E:27206 ||| .
In  ||| S:27206 E:27209 ||| IN
humans ||| S:27209 E:27215 ||| NNS
,  ||| S:27215 E:27217 ||| ,
ProTα  ||| S:27217 E:27223 ||| NNP
is  ||| S:27223 E:27226 ||| VBZ
coded  ||| S:27226 E:27232 ||| VBN
by  ||| S:27232 E:27235 ||| IN
a  ||| S:27235 E:27237 ||| DT
gene  ||| S:27237 E:27252 ||| NN
family  ||| S:27252 E:27259 ||| NN
of  ||| S:27259 E:27262 ||| IN
six  ||| S:27262 E:27266 ||| CD
members ||| S:27266 E:27273 ||| NNS
.  ||| S:27273 E:27275 ||| .
One  ||| S:27275 E:27279 ||| CD
of  ||| S:27279 E:27282 ||| IN
them  ||| S:27282 E:27287 ||| PRP
contains  ||| S:27287 E:27296 ||| VBZ
introns ||| S:27296 E:27303 ||| VBN
,  ||| S:27303 E:27315 ||| ,
exons  ||| S:27315 E:27321 ||| NN
and  ||| S:27321 E:27325 ||| CC
classic  ||| S:27325 E:27333 ||| JJ
regulatory  ||| S:27333 E:27344 ||| JJ
signals ||| S:27344 E:27351 ||| NNS
,  ||| S:27351 E:27353 ||| ,
while  ||| S:27353 E:27359 ||| IN
the  ||| S:27359 E:27363 ||| DT
remaining  ||| S:27363 E:27383 ||| JJ
five  ||| S:27383 E:27388 ||| CD
are  ||| S:27388 E:27392 ||| VBP
intronless  ||| S:27392 E:27403 ||| JJ
genes  ||| S:27403 E:27409 ||| NNS
[  ||| S:27409 E:27411 ||| -LRB-
59  ||| S:27411 E:27414 ||| CD
]  ||| S:27414 E:27416 ||| -RRB-
located  ||| S:27416 E:27424 ||| VBN
on  ||| S:27424 E:27427 ||| IN
chromosome  ||| S:27427 E:27438 ||| CD
2  ||| S:27438 E:27450 ||| CD
[  ||| S:27450 E:27452 ||| -LRB-
66  ||| S:27452 E:27455 ||| CD
]  ||| S:27455 E:27457 ||| -RRB-
.  ||| S:27457 E:27459 ||| .
There  ||| S:27459 E:27465 ||| EX
are  ||| S:27465 E:27469 ||| VBP
two  ||| S:27469 E:27473 ||| CD
mRNA  ||| S:27473 E:27478 ||| JJ
transcripts ||| S:27478 E:27489 ||| NNS
,  ||| S:27489 E:27491 ||| ,
which  ||| S:27491 E:27497 ||| WDT
arise  ||| S:27497 E:27503 ||| VBP
in  ||| S:27503 E:27506 ||| IN
a  ||| S:27506 E:27518 ||| DT
ratio  ||| S:27518 E:27524 ||| NN
of  ||| S:27524 E:27527 ||| IN
9 ||| S:27527 E:27528 ||| CD
: ||| S:27528 E:27529 ||| :
1  ||| S:27529 E:27531 ||| CD
( ||| S:27531 E:27532 ||| -LRB-
shorter ||| S:27532 E:27539 ||| CD
/ ||| S:27539 E:27540 ||| CD
longer  ||| S:27540 E:27547 ||| JJR
form ||| S:27547 E:27551 ||| NN
) ||| S:27551 E:27552 ||| -RRB-
,  ||| S:27552 E:27554 ||| ,
where  ||| S:27554 E:27560 ||| WRB
only  ||| S:27560 E:27565 ||| RB
the  ||| S:27565 E:27569 ||| DT
long  ||| S:27569 E:27584 ||| JJ
transcript  ||| S:27584 E:27595 ||| NN
is  ||| S:27595 E:27598 ||| VBZ
regulated  ||| S:27598 E:27608 ||| VBN
by  ||| S:27608 E:27611 ||| IN
extracellular  ||| S:27611 E:27625 ||| JJ
signals ||| S:27625 E:27632 ||| NNS
.  ||| S:27632 E:27644 ||| .
It  ||| S:27644 E:27647 ||| PRP
has  ||| S:27647 E:27651 ||| VBZ
been  ||| S:27651 E:27656 ||| VBN
demonstrated  ||| S:27656 E:27669 ||| VBN
that  ||| S:27669 E:27674 ||| IN
malignant  ||| S:27674 E:27684 ||| JJ
tissues  ||| S:27684 E:27692 ||| NNS
with  ||| S:27692 E:27707 ||| IN
accelerated  ||| S:27707 E:27719 ||| JJ
cell  ||| S:27719 E:27724 ||| NN
cycle  ||| S:27724 E:27730 ||| NN
show  ||| S:27730 E:27735 ||| VBP
higher  ||| S:27735 E:27742 ||| JJR
levels  ||| S:27742 E:27749 ||| NNS
of  ||| S:27749 E:27752 ||| IN
ProTα  ||| S:27752 E:27768 ||| JJ
expression  ||| S:27768 E:27779 ||| NN
than  ||| S:27779 E:27784 ||| IN
normal  ||| S:27784 E:27791 ||| JJ
or  ||| S:27791 E:27794 ||| CC
surrounding  ||| S:27794 E:27806 ||| VBG
healthy  ||| S:27806 E:27814 ||| JJ
tissues  ||| S:27814 E:27822 ||| NNS
[  ||| S:27822 E:27834 ||| -LRB-
67  ||| S:27834 E:27837 ||| CD
]  ||| S:27837 E:27839 ||| -RRB-
.  ||| S:27839 E:27841 ||| .
ProTα  ||| S:27841 E:27847 ||| NNP
was  ||| S:27847 E:27851 ||| VBD
shown  ||| S:27851 E:27857 ||| VBN
as  ||| S:27857 E:27860 ||| IN
a  ||| S:27860 E:27862 ||| DT
marker  ||| S:27862 E:27869 ||| NN
for  ||| S:27869 E:27873 ||| IN
breast  ||| S:27873 E:27880 ||| JJ
cancer  ||| S:27880 E:27887 ||| NN
[  ||| S:27887 E:27889 ||| -LRB-
68  ||| S:27889 E:27902 ||| CD
]  ||| S:27902 E:27904 ||| -RRB-
,  ||| S:27904 E:27906 ||| ,
hepatocarcinoma  ||| S:27906 E:27922 ||| NNS
[  ||| S:27922 E:27924 ||| -LRB-
69  ||| S:27924 E:27927 ||| CD
]  ||| S:27927 E:27929 ||| -RRB-
,  ||| S:27929 E:27931 ||| ,
and  ||| S:27931 E:27935 ||| CC
plasma  ||| S:27935 E:27942 ||| JJ
levels  ||| S:27942 E:27949 ||| NNS
of  ||| S:27949 E:27952 ||| IN
its  ||| S:27952 E:27966 ||| PRP$
derivative  ||| S:27966 E:27977 ||| JJ
Tα  ||| S:27977 E:27991 ||| NNP
1  ||| S:27991 E:27993 ||| CD
been  ||| S:27993 E:27998 ||| VBN
proposed  ||| S:27998 E:28007 ||| VBN
as  ||| S:28007 E:28010 ||| IN
a  ||| S:28010 E:28012 ||| DT
marker  ||| S:28012 E:28019 ||| NN
for  ||| S:28019 E:28023 ||| IN
the  ||| S:28023 E:28037 ||| DT
prognosis  ||| S:28037 E:28047 ||| NN
of  ||| S:28047 E:28050 ||| IN
lung  ||| S:28050 E:28055 ||| NN
cancer  ||| S:28055 E:28062 ||| NN
[  ||| S:28062 E:28064 ||| -LRB-
70  ||| S:28064 E:28067 ||| CD
]  ||| S:28067 E:28069 ||| -RRB-
.  ||| S:28069 E:28071 ||| .
In  ||| S:28071 E:28074 ||| IN
ligand  ||| S:28074 E:28081 ||| JJ
blotting  ||| S:28081 E:28100 ||| JJ
assays ||| S:28100 E:28106 ||| NN
,  ||| S:28106 E:28108 ||| ,
ProTα  ||| S:28108 E:28114 ||| JJ
bound  ||| S:28114 E:28120 ||| NNS
only  ||| S:28120 E:28125 ||| RB
to  ||| S:28125 E:28128 ||| TO
chromatin  ||| S:28128 E:28138 ||| VB
pools  ||| S:28138 E:28144 ||| NNS
and  ||| S:28144 E:28148 ||| CC
nuclear  ||| S:28148 E:28166 ||| JJ
fractions  ||| S:28166 E:28176 ||| NNS
where  ||| S:28176 E:28182 ||| WRB
histone  ||| S:28182 E:28190 ||| JJ
H1  ||| S:28190 E:28193 ||| NN
was  ||| S:28193 E:28197 ||| VBD
present  ||| S:28197 E:28205 ||| JJ
[  ||| S:28205 E:28207 ||| -LRB-
71  ||| S:28207 E:28210 ||| CD
72  ||| S:28210 E:28213 ||| CD
]  ||| S:28213 E:28215 ||| -RRB-
.  ||| S:28215 E:28217 ||| .
The  ||| S:28217 E:28231 ||| DT
analysis  ||| S:28231 E:28240 ||| NN
of  ||| S:28240 E:28243 ||| IN
the  ||| S:28243 E:28247 ||| DT
interaction  ||| S:28247 E:28259 ||| NN
of  ||| S:28259 E:28262 ||| IN
ProTα  ||| S:28262 E:28268 ||| JJ
with  ||| S:28268 E:28273 ||| IN
H1-containing  ||| S:28273 E:28297 ||| CD
chromatin  ||| S:28297 E:28307 ||| NN
suggests  ||| S:28307 E:28316 ||| VBZ
a  ||| S:28316 E:28318 ||| DT
putative  ||| S:28318 E:28327 ||| JJ
role  ||| S:28327 E:28332 ||| NN
for  ||| S:28332 E:28336 ||| IN
ProTα  ||| S:28336 E:28342 ||| JJ
in  ||| S:28342 E:28345 ||| IN
the  ||| S:28345 E:28359 ||| DT
fine-tuning  ||| S:28359 E:28371 ||| NN
of  ||| S:28371 E:28374 ||| IN
the  ||| S:28374 E:28378 ||| DT
stoichiometry  ||| S:28378 E:28392 ||| NN
and ||| S:28392 E:28395 ||| CC
/ ||| S:28395 E:28396 ||| NNP
or  ||| S:28396 E:28399 ||| CC
mode  ||| S:28399 E:28404 ||| NN
of  ||| S:28404 E:28417 ||| IN
interaction  ||| S:28417 E:28429 ||| NN
of  ||| S:28429 E:28432 ||| IN
H1  ||| S:28432 E:28435 ||| CD
with  ||| S:28435 E:28440 ||| IN
chromatin  ||| S:28440 E:28450 ||| NNS
[  ||| S:28450 E:28452 ||| -LRB-
73  ||| S:28452 E:28455 ||| CD
]  ||| S:28455 E:28457 ||| -RRB-
.  ||| S:28457 E:28459 ||| .
Interestingly ||| S:28459 E:28472 ||| RB
,  ||| S:28472 E:28484 ||| ,
HL-60  ||| S:28484 E:28490 ||| CD
cells  ||| S:28490 E:28496 ||| NNS
overexpressing  ||| S:28496 E:28511 ||| VBP
ProTα  ||| S:28511 E:28517 ||| JJ
show  ||| S:28517 E:28522 ||| NN
an  ||| S:28522 E:28525 ||| DT
enhancement  ||| S:28525 E:28537 ||| NN
of  ||| S:28537 E:28550 ||| IN
accessibility  ||| S:28550 E:28564 ||| NN
of  ||| S:28564 E:28567 ||| IN
micrococcal  ||| S:28567 E:28579 ||| JJ
nuclease  ||| S:28579 E:28588 ||| NN
to  ||| S:28588 E:28591 ||| TO
chromatin ||| S:28591 E:28600 ||| VB
,  ||| S:28600 E:28612 ||| ,
implying  ||| S:28612 E:28621 ||| VBG
relaxed  ||| S:28621 E:28629 ||| JJ
chromatin  ||| S:28629 E:28639 ||| JJ
structure  ||| S:28639 E:28649 ||| NN
for  ||| S:28649 E:28653 ||| IN
enhanced  ||| S:28653 E:28662 ||| JJ
cell  ||| S:28662 E:28677 ||| NN
cycle  ||| S:28677 E:28683 ||| NN
gene  ||| S:28683 E:28688 ||| NN
expression  ||| S:28688 E:28699 ||| NN
[  ||| S:28699 E:28701 ||| -LRB-
74  ||| S:28701 E:28704 ||| CD
]  ||| S:28704 E:28706 ||| -RRB-
.  ||| S:28706 E:28718 ||| .
A  ||| S:28718 E:28720 ||| DT
broad  ||| S:28720 E:28726 ||| JJ
study  ||| S:28726 E:28732 ||| NN
using  ||| S:28732 E:28738 ||| VBG
several  ||| S:28738 E:28746 ||| JJ
mononuclear  ||| S:28746 E:28758 ||| NN
and  ||| S:28758 E:28772 ||| CC
fibroblastic  ||| S:28772 E:28785 ||| JJ
cell  ||| S:28785 E:28790 ||| NN
lines  ||| S:28790 E:28796 ||| NNS
has  ||| S:28796 E:28800 ||| VBZ
shown  ||| S:28800 E:28806 ||| VBN
that  ||| S:28806 E:28811 ||| IN
ProTα  ||| S:28811 E:28817 ||| JJ
mRNA  ||| S:28817 E:28832 ||| JJ
accumulation  ||| S:28832 E:28845 ||| NN
is  ||| S:28845 E:28848 ||| VBZ
cell  ||| S:28848 E:28853 ||| NN
cycle  ||| S:28853 E:28859 ||| NN
phase-dependent ||| S:28859 E:28874 ||| NN
.  ||| S:28874 E:28876 ||| .
In  ||| S:28876 E:28879 ||| IN
the  ||| S:28879 E:28883 ||| DT
U937  ||| S:28883 E:28898 ||| JJ
monocytic  ||| S:28898 E:28908 ||| JJ
cell  ||| S:28908 E:28913 ||| NN
line ||| S:28913 E:28917 ||| NN
,  ||| S:28917 E:28919 ||| ,
ProTα  ||| S:28919 E:28925 ||| JJ
mRNA  ||| S:28925 E:28930 ||| JJ
peaked  ||| S:28930 E:28937 ||| NN
at  ||| S:28937 E:28940 ||| IN
the  ||| S:28940 E:28944 ||| DT
end  ||| S:28944 E:28948 ||| NN
of  ||| S:28948 E:28951 ||| IN
S ||| S:28951 E:28952 ||| NNP
/ ||| S:28952 E:28953 ||| NNP
G2  ||| S:28953 E:28966 ||| NNP
phase  ||| S:28966 E:28972 ||| NN
and  ||| S:28972 E:28976 ||| CC
fell  ||| S:28976 E:28981 ||| VBD
towards  ||| S:28981 E:28989 ||| IN
the  ||| S:28989 E:28993 ||| DT
entry  ||| S:28993 E:28999 ||| NN
into  ||| S:28999 E:29004 ||| IN
the  ||| S:29004 E:29008 ||| DT
new  ||| S:29008 E:29012 ||| JJ
G1  ||| S:29012 E:29015 ||| CD
phase ||| S:29015 E:29020 ||| NN
.  ||| S:29020 E:29032 ||| .
More  ||| S:29032 E:29037 ||| RBR
prominent  ||| S:29037 E:29047 ||| JJ
mRNA  ||| S:29047 E:29052 ||| JJ
regulation  ||| S:29052 E:29063 ||| NN
was  ||| S:29063 E:29067 ||| VBD
found  ||| S:29067 E:29073 ||| VBN
in  ||| S:29073 E:29076 ||| IN
the  ||| S:29076 E:29090 ||| DT
fibroblastic  ||| S:29090 E:29103 ||| JJ
cell  ||| S:29103 E:29108 ||| NN
lines  ||| S:29108 E:29114 ||| NNS
CV1  ||| S:29114 E:29118 ||| NNP
and  ||| S:29118 E:29122 ||| CC
NIH3T3 ||| S:29122 E:29128 ||| NNP
,  ||| S:29128 E:29130 ||| ,
with  ||| S:29130 E:29135 ||| IN
peak  ||| S:29135 E:29140 ||| JJ
mRNA  ||| S:29140 E:29155 ||| JJ
levels  ||| S:29155 E:29162 ||| NNS
at  ||| S:29162 E:29165 ||| IN
the  ||| S:29165 E:29169 ||| DT
end  ||| S:29169 E:29173 ||| NN
of  ||| S:29173 E:29176 ||| IN
S-phase ||| S:29176 E:29183 ||| JJ
.  ||| S:29183 E:29185 ||| .
In  ||| S:29185 E:29188 ||| IN
all  ||| S:29188 E:29192 ||| DT
cases  ||| S:29192 E:29198 ||| NNS
the  ||| S:29198 E:29202 ||| DT
expression  ||| S:29202 E:29223 ||| NN
pattern  ||| S:29223 E:29231 ||| NN
coincided  ||| S:29231 E:29241 ||| NN
with  ||| S:29241 E:29246 ||| IN
that  ||| S:29246 E:29251 ||| DT
of  ||| S:29251 E:29254 ||| IN
cyclin  ||| S:29254 E:29261 ||| JJ
B  ||| S:29261 E:29263 ||| NNP
and  ||| S:29263 E:29267 ||| CC
Cdc2 ||| S:29267 E:29271 ||| CD
/ ||| S:29271 E:29272 ||| CD
cyclin  ||| S:29272 E:29279 ||| JJ
B  ||| S:29279 E:29291 ||| NN
activation  ||| S:29291 E:29302 ||| NNS
[  ||| S:29302 E:29304 ||| -LRB-
75  ||| S:29304 E:29307 ||| CD
]  ||| S:29307 E:29309 ||| -RRB-
.  ||| S:29309 E:29321 ||| .
It  ||| S:29321 E:29324 ||| PRP
is  ||| S:29324 E:29327 ||| VBZ
interesting  ||| S:29327 E:29339 ||| JJ
to  ||| S:29339 E:29342 ||| TO
note  ||| S:29342 E:29347 ||| VB
that  ||| S:29347 E:29352 ||| IN
Cdc2  ||| S:29352 E:29357 ||| NNP
( ||| S:29357 E:29358 ||| -LRB-
Acc ||| S:29358 E:29361 ||| UH
#  ||| S:29361 E:29363 ||| #
X05360 ||| S:29363 E:29369 ||| CD
) ||| S:29369 E:29370 ||| -RRB-
,  ||| S:29370 E:29382 ||| ,
Cdc10  ||| S:29382 E:29388 ||| CD
homolog  ||| S:29388 E:29396 ||| NNS
( ||| S:29396 E:29397 ||| -LRB-
Acc ||| S:29397 E:29400 ||| UH
#  ||| S:29400 E:29402 ||| #
S72008 ||| S:29402 E:29408 ||| CD
) ||| S:29408 E:29409 ||| -RRB-
,  ||| S:29409 E:29411 ||| ,
and  ||| S:29411 E:29415 ||| CC
Cdc37  ||| S:29415 E:29421 ||| NNP
( ||| S:29421 E:29422 ||| -LRB-
Acc ||| S:29422 E:29425 ||| UH
#  ||| S:29425 E:29427 ||| #
U43077 ||| S:29427 E:29433 ||| CD
)  ||| S:29433 E:29435 ||| -RRB-
were  ||| S:29435 E:29450 ||| VBD
all  ||| S:29450 E:29454 ||| DT
up-regulated  ||| S:29454 E:29467 ||| JJ
in  ||| S:29467 E:29470 ||| IN
Tat  ||| S:29470 E:29474 ||| NNP
expressing  ||| S:29474 E:29485 ||| VBG
cells ||| S:29485 E:29490 ||| NNS
.  ||| S:29490 E:29492 ||| .
Cdc2 ||| S:29492 E:29496 ||| NNP
,  ||| S:29496 E:29498 ||| ,
a  ||| S:29498 E:29510 ||| DT
catalytic  ||| S:29510 E:29520 ||| JJ
subunit  ||| S:29520 E:29528 ||| NN
of  ||| S:29528 E:29531 ||| IN
cyclin-dependent  ||| S:29531 E:29548 ||| JJ
kinases ||| S:29548 E:29555 ||| NN
,  ||| S:29555 E:29557 ||| ,
is  ||| S:29557 E:29570 ||| VBZ
required  ||| S:29570 E:29579 ||| VBN
for  ||| S:29579 E:29583 ||| IN
both  ||| S:29583 E:29588 ||| PDT
the  ||| S:29588 E:29592 ||| DT
G1-to-S  ||| S:29592 E:29600 ||| NNP
and  ||| S:29600 E:29604 ||| CC
G2-to-M  ||| S:29604 E:29612 ||| CD
transitions ||| S:29612 E:29623 ||| NNS
.  ||| S:29623 E:29625 ||| .
In  ||| S:29625 E:29638 ||| IN
the  ||| S:29638 E:29642 ||| DT
fission  ||| S:29642 E:29650 ||| FW
yeast  ||| S:29650 E:29656 ||| FW
Schizosaccharomyces  ||| S:29656 E:29676 ||| FW
pombe ||| S:29676 E:29681 ||| FW
,  ||| S:29681 E:29683 ||| ,
the  ||| S:29683 E:29697 ||| DT
execution  ||| S:29697 E:29707 ||| NN
of  ||| S:29707 E:29710 ||| IN
Start  ||| S:29710 E:29716 ||| NNP
requires  ||| S:29716 E:29725 ||| VBZ
the  ||| S:29725 E:29729 ||| DT
activity  ||| S:29729 E:29738 ||| NN
of  ||| S:29738 E:29741 ||| IN
the  ||| S:29741 E:29745 ||| DT
Cdc2  ||| S:29745 E:29760 ||| JJ
protein  ||| S:29760 E:29768 ||| NN
kinase  ||| S:29768 E:29775 ||| NNS
and  ||| S:29775 E:29779 ||| CC
the  ||| S:29779 E:29783 ||| DT
Cdc10 ||| S:29783 E:29788 ||| CD
/ ||| S:29788 E:29789 ||| CD
Sct1  ||| S:29789 E:29794 ||| CD
transcription  ||| S:29794 E:29808 ||| JJ
complex ||| S:29808 E:29815 ||| NN
.  ||| S:29815 E:29827 ||| .
The  ||| S:29827 E:29831 ||| DT
loss  ||| S:29831 E:29836 ||| NN
of  ||| S:29836 E:29839 ||| IN
any  ||| S:29839 E:29843 ||| DT
of  ||| S:29843 E:29846 ||| IN
these  ||| S:29846 E:29852 ||| DT
genes  ||| S:29852 E:29858 ||| NNS
leads  ||| S:29858 E:29864 ||| VBZ
to  ||| S:29864 E:29867 ||| TO
G1  ||| S:29867 E:29870 ||| CD
arrest  ||| S:29870 E:29877 ||| NN
[  ||| S:29877 E:29879 ||| -LRB-
69  ||| S:29879 E:29882 ||| CD
]  ||| S:29882 E:29894 ||| -RRB-
.  ||| S:29894 E:29906 ||| .
Cdc37  ||| S:29906 E:29912 ||| NNP
encodes  ||| S:29912 E:29920 ||| VBD
a  ||| S:29920 E:29922 ||| DT
50-kDa  ||| S:29922 E:29929 ||| JJ
protein  ||| S:29929 E:29937 ||| NN
that  ||| S:29937 E:29942 ||| IN
targets  ||| S:29942 E:29960 ||| NNS
intrinsically  ||| S:29960 E:29974 ||| VBP
unstable  ||| S:29974 E:29983 ||| JJ
oncoprotein  ||| S:29983 E:29995 ||| NNS
kinases  ||| S:29995 E:30003 ||| VBP
including  ||| S:30003 E:30023 ||| VBG
Cdk4 ||| S:30023 E:30027 ||| NNP
,  ||| S:30027 E:30029 ||| ,
Raf-1 ||| S:30029 E:30034 ||| NNP
,  ||| S:30034 E:30036 ||| ,
and  ||| S:30036 E:30040 ||| CC
v-src  ||| S:30040 E:30046 ||| JJ
to  ||| S:30046 E:30049 ||| TO
the  ||| S:30049 E:30053 ||| DT
molecular  ||| S:30053 E:30063 ||| JJ
chaperone  ||| S:30063 E:30073 ||| JJ
Hsp90 ||| S:30073 E:30078 ||| NN
,  ||| S:30078 E:30090 ||| ,
an  ||| S:30090 E:30093 ||| DT
interaction  ||| S:30093 E:30105 ||| NN
that  ||| S:30105 E:30110 ||| WDT
is  ||| S:30110 E:30113 ||| VBZ
thought  ||| S:30113 E:30121 ||| VBN
to  ||| S:30121 E:30124 ||| TO
be  ||| S:30124 E:30127 ||| VB
important  ||| S:30127 E:30137 ||| JJ
for  ||| S:30137 E:30141 ||| IN
the  ||| S:30141 E:30155 ||| DT
establishment  ||| S:30155 E:30169 ||| NN
of  ||| S:30169 E:30172 ||| IN
signaling  ||| S:30172 E:30182 ||| VBG
pathways ||| S:30182 E:30190 ||| NNS
.  ||| S:30190 E:30192 ||| .
Cdc37  ||| S:30192 E:30198 ||| NNP
expression  ||| S:30198 E:30209 ||| NN
may  ||| S:30209 E:30223 ||| MD
not  ||| S:30223 E:30227 ||| RB
only  ||| S:30227 E:30232 ||| RB
be  ||| S:30232 E:30235 ||| VB
required  ||| S:30235 E:30244 ||| VBN
to  ||| S:30244 E:30247 ||| TO
support  ||| S:30247 E:30255 ||| VB
proliferation  ||| S:30255 E:30269 ||| NN
in  ||| S:30269 E:30272 ||| IN
cells  ||| S:30272 E:30288 ||| NNS
that  ||| S:30288 E:30293 ||| WDT
are  ||| S:30293 E:30297 ||| VBP
developmentally  ||| S:30297 E:30313 ||| VBN
programmed  ||| S:30313 E:30324 ||| VBN
to  ||| S:30324 E:30327 ||| TO
proliferate ||| S:30327 E:30338 ||| VB
,  ||| S:30338 E:30340 ||| ,
but  ||| S:30340 E:30354 ||| CC
may  ||| S:30354 E:30358 ||| MD
also  ||| S:30358 E:30363 ||| RB
be  ||| S:30363 E:30366 ||| VB
required  ||| S:30366 E:30375 ||| VBN
in  ||| S:30375 E:30378 ||| IN
cells  ||| S:30378 E:30384 ||| NNS
that  ||| S:30384 E:30389 ||| WDT
are  ||| S:30389 E:30393 ||| VBP
inappropriately  ||| S:30393 E:30419 ||| RB
induced  ||| S:30419 E:30427 ||| VBN
to  ||| S:30427 E:30430 ||| TO
initiate  ||| S:30430 E:30439 ||| VB
proliferation  ||| S:30439 E:30453 ||| NN
by  ||| S:30453 E:30456 ||| IN
oncogenes ||| S:30456 E:30465 ||| NNS
.  ||| S:30465 E:30467 ||| .
For  ||| S:30467 E:30481 ||| IN
instance ||| S:30481 E:30489 ||| NN
,  ||| S:30489 E:30491 ||| ,
MMTV-Cdc37  ||| S:30491 E:30502 ||| FW
transgenic  ||| S:30502 E:30513 ||| FW
mice  ||| S:30513 E:30518 ||| FW
develop  ||| S:30518 E:30526 ||| FW
mammary  ||| S:30526 E:30544 ||| FW
gland  ||| S:30544 E:30550 ||| FW
tumors  ||| S:30550 E:30557 ||| FW
at  ||| S:30557 E:30560 ||| IN
a  ||| S:30560 E:30562 ||| DT
rate  ||| S:30562 E:30567 ||| NN
comparable  ||| S:30567 E:30578 ||| JJ
to  ||| S:30578 E:30581 ||| TO
that  ||| S:30581 E:30586 ||| WDT
observed  ||| S:30586 E:30605 ||| VBD
previously  ||| S:30605 E:30616 ||| RB
in  ||| S:30616 E:30619 ||| IN
MMTV-cyclin  ||| S:30619 E:30631 ||| JJ
D1  ||| S:30631 E:30634 ||| CD
mice ||| S:30634 E:30638 ||| NNS
,  ||| S:30638 E:30640 ||| ,
indicating  ||| S:30640 E:30651 ||| VBG
that  ||| S:30651 E:30656 ||| IN
Cdc37  ||| S:30656 E:30672 ||| NNP
can  ||| S:30672 E:30676 ||| MD
function  ||| S:30676 E:30685 ||| VB
as  ||| S:30685 E:30688 ||| IN
an  ||| S:30688 E:30691 ||| DT
oncogene  ||| S:30691 E:30700 ||| NN
in  ||| S:30700 E:30703 ||| IN
mice  ||| S:30703 E:30708 ||| NNS
and  ||| S:30708 E:30712 ||| CC
suggests  ||| S:30712 E:30721 ||| VBZ
that  ||| S:30721 E:30726 ||| IN
the  ||| S:30726 E:30740 ||| DT
establishment  ||| S:30740 E:30754 ||| NN
of  ||| S:30754 E:30757 ||| IN
protein  ||| S:30757 E:30765 ||| NN
kinase  ||| S:30765 E:30772 ||| NNS
pathways  ||| S:30772 E:30781 ||| VBP
mediated  ||| S:30781 E:30790 ||| VBN
by  ||| S:30790 E:30803 ||| IN
Cdc37-Hsp90  ||| S:30803 E:30815 ||| NNP
can  ||| S:30815 E:30819 ||| MD
be  ||| S:30819 E:30822 ||| VB
a  ||| S:30822 E:30824 ||| DT
rate-limiting  ||| S:30824 E:30838 ||| JJ
event  ||| S:30838 E:30844 ||| NN
in  ||| S:30844 E:30857 ||| IN
transformation  ||| S:30857 E:30872 ||| NN
[  ||| S:30872 E:30874 ||| -LRB-
76  ||| S:30874 E:30877 ||| CD
]  ||| S:30877 E:30879 ||| -RRB-
.  ||| S:30879 E:30881 ||| .
Also ||| S:30881 E:30885 ||| RB
,  ||| S:30885 E:30887 ||| ,
analysis  ||| S:30887 E:30896 ||| NN
of  ||| S:30896 E:30899 ||| IN
proteins  ||| S:30899 E:30908 ||| NNS
that  ||| S:30908 E:30923 ||| IN
co-immunoprecipitated  ||| S:30923 E:30945 ||| JJ
with  ||| S:30945 E:30950 ||| IN
Cdk6  ||| S:30950 E:30955 ||| NNP
and  ||| S:30955 E:30959 ||| CC
Cdk4  ||| S:30959 E:30964 ||| NNP
has  ||| S:30964 E:30968 ||| VBZ
shown  ||| S:30968 E:30984 ||| VBN
complexes  ||| S:30984 E:30994 ||| NNS
containing  ||| S:30994 E:31005 ||| VBG
both  ||| S:31005 E:31010 ||| DT
Hsp90  ||| S:31010 E:31016 ||| NNP
and  ||| S:31016 E:31020 ||| CC
Cdc37  ||| S:31020 E:31026 ||| NNP
[  ||| S:31026 E:31028 ||| -LRB-
77  ||| S:31028 E:31031 ||| CD
78  ||| S:31031 E:31034 ||| CD
79  ||| S:31034 E:31037 ||| CD
]  ||| S:31037 E:31049 ||| -RRB-
.  ||| S:31049 E:31061 ||| .
Cdc37  ||| S:31061 E:31067 ||| NNP
also  ||| S:31067 E:31072 ||| RB
promotes  ||| S:31072 E:31081 ||| VBZ
the  ||| S:31081 E:31085 ||| DT
production  ||| S:31085 E:31096 ||| NN
of  ||| S:31096 E:31099 ||| IN
Cak1 ||| S:31099 E:31103 ||| CD
.  ||| S:31103 E:31105 ||| .
Cak1  ||| S:31105 E:31110 ||| NNP
in  ||| S:31110 E:31123 ||| IN
yeast  ||| S:31123 E:31129 ||| NN
is  ||| S:31129 E:31132 ||| VBZ
the  ||| S:31132 E:31136 ||| DT
human  ||| S:31136 E:31142 ||| JJ
homolog  ||| S:31142 E:31150 ||| NN
of  ||| S:31150 E:31153 ||| IN
CAK  ||| S:31153 E:31157 ||| NNP
trimeric  ||| S:31157 E:31166 ||| FW
enzyme  ||| S:31166 E:31183 ||| FW
containing  ||| S:31183 E:31194 ||| FW
CDK7 ||| S:31194 E:31198 ||| FW
,  ||| S:31198 E:31200 ||| ,
cyclin  ||| S:31200 E:31207 ||| VBG
H ||| S:31207 E:31208 ||| NNP
,  ||| S:31208 E:31210 ||| ,
and  ||| S:31210 E:31214 ||| CC
MAT1 ||| S:31214 E:31218 ||| NNP
.  ||| S:31218 E:31220 ||| .
Both  ||| S:31220 E:31225 ||| DT
human  ||| S:31225 E:31231 ||| JJ
and  ||| S:31231 E:31235 ||| CC
yeast  ||| S:31235 E:31251 ||| JJ
Caks  ||| S:31251 E:31256 ||| JJ
function  ||| S:31256 E:31265 ||| NN
as  ||| S:31265 E:31268 ||| IN
RNA  ||| S:31268 E:31272 ||| NNP
polymerase  ||| S:31272 E:31283 ||| VBD
II  ||| S:31283 E:31286 ||| NNP
CTD  ||| S:31286 E:31290 ||| NNP
kinase ||| S:31290 E:31296 ||| NN
,  ||| S:31296 E:31298 ||| ,
Cdk  ||| S:31298 E:31312 ||| FW
activating  ||| S:31312 E:31323 ||| FW
kinase ||| S:31323 E:31329 ||| FW
,  ||| S:31329 E:31331 ||| ,
and  ||| S:31331 E:31335 ||| CC
DNA  ||| S:31335 E:31339 ||| NNP
damage ||| S:31339 E:31345 ||| NN
/ ||| S:31345 E:31346 ||| CD
repair  ||| S:31346 E:31353 ||| NN
enzymes ||| S:31353 E:31360 ||| NN
.  ||| S:31360 E:31362 ||| .
Cdc37 ||| S:31362 E:31367 ||| NNP
,  ||| S:31367 E:31379 ||| ,
like  ||| S:31379 E:31384 ||| IN
its  ||| S:31384 E:31388 ||| PRP$
higher  ||| S:31388 E:31395 ||| JJR
eukaryotic  ||| S:31395 E:31406 ||| JJ
homologs ||| S:31406 E:31414 ||| NN
,  ||| S:31414 E:31416 ||| ,
promotes  ||| S:31416 E:31425 ||| VBZ
the  ||| S:31425 E:31439 ||| DT
physical  ||| S:31439 E:31448 ||| JJ
integrity  ||| S:31448 E:31458 ||| NN
of  ||| S:31458 E:31461 ||| IN
multiple  ||| S:31461 E:31470 ||| JJ
protein  ||| S:31470 E:31478 ||| NN
kinases ||| S:31478 E:31485 ||| NN
,  ||| S:31485 E:31487 ||| ,
perhaps  ||| S:31487 E:31505 ||| RB
by  ||| S:31505 E:31508 ||| IN
virtue  ||| S:31508 E:31515 ||| NN
of  ||| S:31515 E:31518 ||| IN
a  ||| S:31518 E:31520 ||| DT
cotranslational  ||| S:31520 E:31536 ||| JJ
role  ||| S:31536 E:31541 ||| NN
in  ||| S:31541 E:31544 ||| IN
protein  ||| S:31544 E:31552 ||| NN
folding  ||| S:31552 E:31560 ||| NNS
[  ||| S:31560 E:31572 ||| -LRB-
80  ||| S:31572 E:31575 ||| CD
]  ||| S:31575 E:31577 ||| -RRB-
.  ||| S:31577 E:31579 ||| .
Finally ||| S:31579 E:31586 ||| RB
,  ||| S:31586 E:31588 ||| ,
Hsp90 ||| S:31588 E:31593 ||| NNP
/ ||| S:31593 E:31594 ||| NNP
Cdc37  ||| S:31594 E:31600 ||| NNP
has  ||| S:31600 E:31604 ||| VBZ
recently  ||| S:31604 E:31613 ||| RB
been  ||| S:31613 E:31618 ||| VBN
shown  ||| S:31618 E:31624 ||| VBN
in  ||| S:31624 E:31637 ||| IN
the  ||| S:31637 E:31641 ||| DT
stabilization ||| S:31641 E:31654 ||| JJ
/ ||| S:31654 E:31655 ||| CD
folding  ||| S:31655 E:31663 ||| NN
of  ||| S:31663 E:31666 ||| IN
Cdk9  ||| S:31666 E:31671 ||| CD
as  ||| S:31671 E:31674 ||| IN
well  ||| S:31674 E:31679 ||| RB
as  ||| S:31679 E:31682 ||| IN
the  ||| S:31682 E:31686 ||| DT
assembly  ||| S:31686 E:31705 ||| NN
of  ||| S:31705 E:31708 ||| IN
an  ||| S:31708 E:31711 ||| DT
active  ||| S:31711 E:31718 ||| JJ
Cdk9 ||| S:31718 E:31722 ||| CD
/ ||| S:31722 E:31723 ||| CD
cyclin  ||| S:31723 E:31730 ||| CD
T1  ||| S:31730 E:31733 ||| CD
complex  ||| S:31733 E:31741 ||| JJ
responsible  ||| S:31741 E:31753 ||| JJ
for  ||| S:31753 E:31767 ||| IN
P-TEFb-mediated  ||| S:31767 E:31783 ||| NNP
Tat  ||| S:31783 E:31787 ||| NNP
transactivation  ||| S:31787 E:31803 ||| NNS
[  ||| S:31803 E:31805 ||| -LRB-
81  ||| S:31805 E:31808 ||| CD
]  ||| S:31808 E:31810 ||| -RRB-
.  ||| S:31810 E:31840 ||| .
Transcription  ||| S:31840 E:31854 ||| NNP
and  ||| S:31854 E:31858 ||| CC
chromatin  ||| S:31858 E:31868 ||| JJ
remodeling  ||| S:31868 E:31889 ||| NN
factors  ||| S:31889 E:31907 ||| NNS
A  ||| S:31907 E:31909 ||| DT
highly  ||| S:31909 E:31916 ||| RB
ordered  ||| S:31916 E:31924 ||| VBN
chromatin  ||| S:31924 E:31934 ||| JJ
structure  ||| S:31934 E:31944 ||| NN
presents  ||| S:31944 E:31953 ||| VBZ
a  ||| S:31953 E:31965 ||| DT
physical  ||| S:31965 E:31974 ||| JJ
obstacle  ||| S:31974 E:31983 ||| NN
for  ||| S:31983 E:31987 ||| IN
gene  ||| S:31987 E:31992 ||| NN
transcription ||| S:31992 E:32005 ||| NNS
;  ||| S:32005 E:32007 ||| :
presumably  ||| S:32007 E:32018 ||| RB
by  ||| S:32018 E:32031 ||| IN
limiting  ||| S:32031 E:32040 ||| VBG
the  ||| S:32040 E:32044 ||| DT
access  ||| S:32044 E:32051 ||| NN
of  ||| S:32051 E:32054 ||| IN
transcription  ||| S:32054 E:32068 ||| JJ
factors  ||| S:32068 E:32076 ||| NNS
and  ||| S:32076 E:32080 ||| CC
RNA  ||| S:32080 E:32094 ||| NNP
polymerase  ||| S:32094 E:32105 ||| VBD
II  ||| S:32105 E:32108 ||| NNP
core  ||| S:32108 E:32113 ||| NN
machinery  ||| S:32113 E:32123 ||| NN
to  ||| S:32123 E:32126 ||| TO
target  ||| S:32126 E:32133 ||| VB
DNA  ||| S:32133 E:32137 ||| NNP
[  ||| S:32137 E:32139 ||| -LRB-
82  ||| S:32139 E:32142 ||| CD
83  ||| S:32142 E:32145 ||| CD
]  ||| S:32145 E:32147 ||| -RRB-
.  ||| S:32147 E:32149 ||| .
In  ||| S:32149 E:32162 ||| IN
concert  ||| S:32162 E:32170 ||| NN
with  ||| S:32170 E:32175 ||| IN
the  ||| S:32175 E:32179 ||| DT
observation  ||| S:32179 E:32191 ||| NN
that  ||| S:32191 E:32196 ||| IN
corepressors  ||| S:32196 E:32209 ||| NNS
are  ||| S:32209 E:32223 ||| VBP
associated  ||| S:32223 E:32234 ||| VBN
with  ||| S:32234 E:32239 ||| IN
HDAC  ||| S:32239 E:32244 ||| NNP
activities  ||| S:32244 E:32255 ||| NNS
[  ||| S:32255 E:32257 ||| -LRB-
84  ||| S:32257 E:32260 ||| CD
85  ||| S:32260 E:32263 ||| CD
]  ||| S:32263 E:32265 ||| -RRB-
,  ||| S:32265 E:32267 ||| ,
it  ||| S:32267 E:32270 ||| PRP
appears  ||| S:32270 E:32288 ||| VBZ
that  ||| S:32288 E:32293 ||| IN
the  ||| S:32293 E:32297 ||| DT
transcriptional  ||| S:32297 E:32313 ||| JJ
outcome  ||| S:32313 E:32321 ||| NN
of  ||| S:32321 E:32324 ||| IN
nuclear  ||| S:32324 E:32332 ||| JJ
receptors  ||| S:32332 E:32342 ||| NN
is  ||| S:32342 E:32355 ||| VBZ
determined  ||| S:32355 E:32366 ||| VBN
by  ||| S:32366 E:32369 ||| IN
the  ||| S:32369 E:32373 ||| DT
balance  ||| S:32373 E:32381 ||| NN
of  ||| S:32381 E:32384 ||| IN
histone  ||| S:32384 E:32392 ||| JJ
acetylation  ||| S:32392 E:32404 ||| NN
and  ||| S:32404 E:32418 ||| CC
deacetylation  ||| S:32418 E:32432 ||| JJ
activities ||| S:32432 E:32442 ||| NNS
,  ||| S:32442 E:32444 ||| ,
and  ||| S:32444 E:32448 ||| CC
that  ||| S:32448 E:32453 ||| IN
ligands  ||| S:32453 E:32461 ||| NNS
serve  ||| S:32461 E:32467 ||| VBP
as  ||| S:32467 E:32470 ||| IN
a  ||| S:32470 E:32482 ||| DT
switch  ||| S:32482 E:32489 ||| NN
to  ||| S:32489 E:32492 ||| TO
recruit  ||| S:32492 E:32500 ||| VB
HATs  ||| S:32500 E:32505 ||| JJ
with  ||| S:32505 E:32510 ||| IN
the  ||| S:32510 E:32514 ||| DT
concomitant  ||| S:32514 E:32526 ||| JJ
dismissal  ||| S:32526 E:32536 ||| NN
of  ||| S:32536 E:32549 ||| IN
HDACs ||| S:32549 E:32554 ||| JJ
.  ||| S:32554 E:32556 ||| .
Signal  ||| S:32556 E:32563 ||| NNP
transduction  ||| S:32563 E:32576 ||| VBD
pathways  ||| S:32576 E:32585 ||| RB
add  ||| S:32585 E:32589 ||| VB
another  ||| S:32589 E:32597 ||| DT
layer  ||| S:32597 E:32603 ||| NN
of  ||| S:32603 E:32616 ||| IN
regulation  ||| S:32616 E:32627 ||| NN
to  ||| S:32627 E:32630 ||| TO
the  ||| S:32630 E:32634 ||| DT
functions  ||| S:32634 E:32644 ||| NNS
of  ||| S:32644 E:32647 ||| IN
CBP ||| S:32647 E:32650 ||| NNP
/ ||| S:32650 E:32651 ||| NNP
p300 ||| S:32651 E:32655 ||| NNP
.  ||| S:32655 E:32657 ||| .
In  ||| S:32657 E:32660 ||| IN
the  ||| S:32660 E:32664 ||| DT
case  ||| S:32664 E:32669 ||| NN
of  ||| S:32669 E:32682 ||| IN
the  ||| S:32682 E:32686 ||| DT
POU  ||| S:32686 E:32690 ||| NNP
homeodomain  ||| S:32690 E:32702 ||| JJ
factor  ||| S:32702 E:32709 ||| NN
Pit-1 ||| S:32709 E:32714 ||| NN
,  ||| S:32714 E:32716 ||| ,
transcriptional  ||| S:32716 E:32742 ||| JJ
activity  ||| S:32742 E:32751 ||| NN
is  ||| S:32751 E:32754 ||| VBZ
potentiated  ||| S:32754 E:32766 ||| VBN
by  ||| S:32766 E:32769 ||| IN
MAPK  ||| S:32769 E:32774 ||| NNP
pathways  ||| S:32774 E:32783 ||| NNS
[  ||| S:32783 E:32785 ||| -LRB-
86  ||| S:32785 E:32788 ||| CD
]  ||| S:32788 E:32790 ||| -RRB-
.  ||| S:32790 E:32802 ||| .
Therefore ||| S:32802 E:32811 ||| RB
,  ||| S:32811 E:32813 ||| ,
down-regulation  ||| S:32813 E:32829 ||| JJ
of  ||| S:32829 E:32832 ||| IN
MAPK  ||| S:32832 E:32837 ||| NNP
pathway  ||| S:32837 E:32845 ||| NN
members  ||| S:32845 E:32853 ||| NNS
in  ||| S:32853 E:32856 ||| IN
Tat  ||| S:32856 E:32870 ||| NNP
expressing  ||| S:32870 E:32881 ||| VBG
cells ||| S:32881 E:32886 ||| NNS
,  ||| S:32886 E:32888 ||| ,
as  ||| S:32888 E:32891 ||| RB
seen  ||| S:32891 E:32896 ||| VBN
in  ||| S:32896 E:32899 ||| IN
Table  ||| S:32899 E:32905 ||| NNP
3 ||| S:32905 E:32906 ||| CD
,  ||| S:32906 E:32908 ||| ,
is  ||| S:32908 E:32911 ||| VBZ
consistent  ||| S:32911 E:32922 ||| JJ
with  ||| S:32922 E:32937 ||| IN
decreased  ||| S:32937 E:32947 ||| JJ
phosphorylation  ||| S:32947 E:32963 ||| NN
of  ||| S:32963 E:32966 ||| IN
DNA  ||| S:32966 E:32970 ||| NNP
binding  ||| S:32970 E:32978 ||| JJ
factors  ||| S:32978 E:32986 ||| NNS
such  ||| S:32986 E:32991 ||| JJ
as  ||| S:32991 E:33004 ||| IN
Pit-1 ||| S:33004 E:33009 ||| NNP
,  ||| S:33009 E:33011 ||| ,
and  ||| S:33011 E:33015 ||| CC
overall  ||| S:33015 E:33023 ||| JJ
lower  ||| S:33023 E:33029 ||| JJR
DNA  ||| S:33029 E:33033 ||| NN
binding  ||| S:33033 E:33041 ||| JJ
activity ||| S:33041 E:33049 ||| NN
.  ||| S:33049 E:33051 ||| .
Here ||| S:33051 E:33055 ||| RB
,  ||| S:33055 E:33057 ||| ,
we  ||| S:33057 E:33070 ||| PRP
describe  ||| S:33070 E:33079 ||| VBP
the  ||| S:33079 E:33083 ||| DT
effect  ||| S:33083 E:33090 ||| NN
of  ||| S:33090 E:33093 ||| IN
coactivator  ||| S:33093 E:33105 ||| FW
proteins  ||| S:33105 E:33114 ||| FW
SRC-1  ||| S:33114 E:33120 ||| FW
( ||| S:33120 E:33121 ||| -LRB-
Acc ||| S:33121 E:33124 ||| UH
#  ||| S:33124 E:33136 ||| #
AJ000882 ||| S:33136 E:33144 ||| CD
,  ||| S:33144 E:33146 ||| ,
U90661 ||| S:33146 E:33152 ||| NNP
,  ||| S:33152 E:33154 ||| ,
Table  ||| S:33154 E:33160 ||| NNP
1 ||| S:33160 E:33161 ||| CD
)  ||| S:33161 E:33163 ||| -RRB-
and  ||| S:33163 E:33167 ||| CC
p300  ||| S:33167 E:33172 ||| NNP
( ||| S:33172 E:33173 ||| -LRB-
Acc ||| S:33173 E:33176 ||| UH
#  ||| S:33176 E:33178 ||| #
U01877 ||| S:33178 E:33184 ||| CD
,  ||| S:33184 E:33186 ||| ,
Table  ||| S:33186 E:33202 ||| NNP
3 ||| S:33202 E:33203 ||| CD
) ||| S:33203 E:33204 ||| -RRB-
,  ||| S:33204 E:33206 ||| ,
and  ||| S:33206 E:33210 ||| CC
their  ||| S:33210 E:33216 ||| PRP$
relation  ||| S:33216 E:33225 ||| NN
to  ||| S:33225 E:33228 ||| TO
differentiation  ||| S:33228 E:33244 ||| VB
genes  ||| S:33244 E:33250 ||| NNS
such  ||| S:33250 E:33255 ||| JJ
as  ||| S:33255 E:33268 ||| IN
retinoic  ||| S:33268 E:33277 ||| JJ
acid  ||| S:33277 E:33282 ||| NN
receptor  ||| S:33282 E:33291 ||| NN
( ||| S:33291 E:33292 ||| -LRB-
RAR ||| S:33292 E:33295 ||| NNP
/ ||| S:33295 E:33296 ||| NNP
PML ||| S:33296 E:33299 ||| NNP
,  ||| S:33299 E:33301 ||| ,
Acc ||| S:33301 E:33304 ||| NNP
# ||| S:33304 E:33305 ||| NNP
:  ||| S:33305 E:33307 ||| :
X06614 ||| S:33307 E:33313 ||| CD
,  ||| S:33313 E:33315 ||| ,
Table  ||| S:33315 E:33321 ||| NNP
1 ||| S:33321 E:33322 ||| CD
) ||| S:33322 E:33323 ||| -RRB-
,  ||| S:33323 E:33335 ||| ,
and  ||| S:33335 E:33339 ||| CC
Leptin  ||| S:33339 E:33346 ||| NNP
receptor  ||| S:33346 E:33355 ||| FW
variant  ||| S:33355 E:33363 ||| FW
( ||| S:33363 E:33364 ||| -LRB-
Acc ||| S:33364 E:33367 ||| NNP
# ||| S:33367 E:33368 ||| NNP
:  ||| S:33368 E:33370 ||| :
U66496 ||| S:33370 E:33376 ||| CD
,  ||| S:33376 E:33378 ||| ,
Table  ||| S:33378 E:33384 ||| NNP
1 ||| S:33384 E:33385 ||| CD
) ||| S:33385 E:33386 ||| -RRB-
;  ||| S:33386 E:33388 ||| :
all  ||| S:33388 E:33402 ||| DT
of  ||| S:33402 E:33405 ||| IN
which  ||| S:33405 E:33411 ||| WDT
are  ||| S:33411 E:33415 ||| VBP
down-regulated  ||| S:33415 E:33430 ||| JJ
in  ||| S:33430 E:33433 ||| IN
Tat  ||| S:33433 E:33437 ||| NNP
expressing  ||| S:33437 E:33448 ||| VBG
cells  ||| S:33448 E:33464 ||| NNS
( ||| S:33464 E:33465 ||| -LRB-
Figure  ||| S:33465 E:33472 ||| NNP
5 ||| S:33472 E:33473 ||| CD
) ||| S:33473 E:33474 ||| -RRB-
.  ||| S:33474 E:33486 ||| .
Over  ||| S:33486 E:33491 ||| IN
the  ||| S:33491 E:33495 ||| DT
past  ||| S:33495 E:33500 ||| JJ
three  ||| S:33500 E:33506 ||| CD
decades  ||| S:33506 E:33514 ||| NNS
a  ||| S:33514 E:33516 ||| DT
great  ||| S:33516 E:33522 ||| JJ
deal  ||| S:33522 E:33527 ||| NN
of  ||| S:33527 E:33530 ||| IN
evidence  ||| S:33530 E:33549 ||| NN
has  ||| S:33549 E:33553 ||| VBZ
accumulated  ||| S:33553 E:33565 ||| VBN
in  ||| S:33565 E:33568 ||| IN
favor  ||| S:33568 E:33574 ||| NN
of  ||| S:33574 E:33577 ||| IN
the  ||| S:33577 E:33581 ||| DT
hypothesis  ||| S:33581 E:33592 ||| NN
that  ||| S:33592 E:33597 ||| IN
steroid  ||| S:33597 E:33615 ||| JJ
receptor  ||| S:33615 E:33624 ||| NN
hormones  ||| S:33624 E:33633 ||| NN
act  ||| S:33633 E:33637 ||| NN
via  ||| S:33637 E:33641 ||| IN
regulation  ||| S:33641 E:33652 ||| NN
of  ||| S:33652 E:33655 ||| IN
gene  ||| S:33655 E:33660 ||| NN
expression ||| S:33660 E:33670 ||| NN
.  ||| S:33670 E:33682 ||| .
The  ||| S:33682 E:33686 ||| DT
action  ||| S:33686 E:33693 ||| NN
is  ||| S:33693 E:33696 ||| VBZ
mediated  ||| S:33696 E:33705 ||| VBN
by  ||| S:33705 E:33708 ||| IN
specific  ||| S:33708 E:33717 ||| JJ
nuclear  ||| S:33717 E:33725 ||| JJ
receptor  ||| S:33725 E:33744 ||| NN
proteins ||| S:33744 E:33752 ||| NNS
,  ||| S:33752 E:33754 ||| ,
which  ||| S:33754 E:33760 ||| WDT
belong  ||| S:33760 E:33767 ||| VBP
to  ||| S:33767 E:33770 ||| TO
a  ||| S:33770 E:33772 ||| DT
superfamily  ||| S:33772 E:33784 ||| NN
of  ||| S:33784 E:33797 ||| IN
ligand-modulated  ||| S:33797 E:33814 ||| JJ
transcription  ||| S:33814 E:33828 ||| JJ
factors  ||| S:33828 E:33836 ||| NNS
that  ||| S:33836 E:33841 ||| IN
regulate  ||| S:33841 E:33860 ||| JJ
homeostasis ||| S:33860 E:33871 ||| NN
,  ||| S:33871 E:33873 ||| ,
reproduction ||| S:33873 E:33885 ||| NN
,  ||| S:33885 E:33887 ||| ,
development ||| S:33887 E:33898 ||| NN
,  ||| S:33898 E:33900 ||| ,
and  ||| S:33900 E:33914 ||| CC
differentiation  ||| S:33914 E:33930 ||| NNS
[  ||| S:33930 E:33932 ||| -LRB-
87  ||| S:33932 E:33935 ||| CD
]  ||| S:33935 E:33937 ||| -RRB-
.  ||| S:33937 E:33939 ||| .
This  ||| S:33939 E:33944 ||| DT
family  ||| S:33944 E:33951 ||| NN
includes  ||| S:33951 E:33960 ||| VBZ
receptors  ||| S:33960 E:33980 ||| VBN
for  ||| S:33980 E:33984 ||| IN
steroid  ||| S:33984 E:33992 ||| JJ
hormones ||| S:33992 E:34000 ||| NNS
,  ||| S:34000 E:34002 ||| ,
thyroid  ||| S:34002 E:34010 ||| JJ
hormones ||| S:34010 E:34018 ||| NNS
,  ||| S:34018 E:34020 ||| ,
hormonal  ||| S:34020 E:34029 ||| JJ
forms  ||| S:34029 E:34035 ||| NNS
of  ||| S:34035 E:34048 ||| IN
vitamin  ||| S:34048 E:34056 ||| JJ
A  ||| S:34056 E:34058 ||| NN
and  ||| S:34058 E:34062 ||| CC
D ||| S:34062 E:34063 ||| NNP
,  ||| S:34063 E:34065 ||| ,
peroxisomal  ||| S:34065 E:34077 ||| JJ
activators ||| S:34077 E:34087 ||| NN
,  ||| S:34087 E:34089 ||| ,
and  ||| S:34089 E:34093 ||| CC
ecdysone  ||| S:34093 E:34102 ||| NNS
[  ||| S:34102 E:34114 ||| -LRB-
88  ||| S:34114 E:34117 ||| CD
]  ||| S:34117 E:34119 ||| -RRB-
.  ||| S:34119 E:34121 ||| .
Nuclear  ||| S:34121 E:34129 ||| JJ
hormone  ||| S:34129 E:34137 ||| NN
receptors  ||| S:34137 E:34147 ||| NNS
are  ||| S:34147 E:34151 ||| VBP
ligand-dependent  ||| S:34151 E:34178 ||| JJ
transcription  ||| S:34178 E:34192 ||| JJ
factors  ||| S:34192 E:34200 ||| NNS
that  ||| S:34200 E:34205 ||| IN
regulate  ||| S:34205 E:34214 ||| JJ
genes  ||| S:34214 E:34220 ||| NNS
critical  ||| S:34220 E:34229 ||| JJ
to  ||| S:34229 E:34242 ||| TO
such  ||| S:34242 E:34247 ||| JJ
biological  ||| S:34247 E:34258 ||| JJ
processes  ||| S:34258 E:34268 ||| NNS
as  ||| S:34268 E:34271 ||| IN
development ||| S:34271 E:34282 ||| NN
,  ||| S:34282 E:34284 ||| ,
reproduction ||| S:34284 E:34296 ||| NN
,  ||| S:34296 E:34308 ||| ,
and  ||| S:34308 E:34312 ||| CC
homeostasis ||| S:34312 E:34323 ||| NN
.  ||| S:34323 E:34325 ||| .
Interestingly ||| S:34325 E:34338 ||| RB
,  ||| S:34338 E:34340 ||| ,
these  ||| S:34340 E:34346 ||| DT
receptors  ||| S:34346 E:34356 ||| NN
can  ||| S:34356 E:34370 ||| MD
function  ||| S:34370 E:34379 ||| VB
as  ||| S:34379 E:34382 ||| IN
molecular  ||| S:34382 E:34392 ||| JJ
switches ||| S:34392 E:34400 ||| NNS
,  ||| S:34400 E:34402 ||| ,
alternating  ||| S:34402 E:34414 ||| VBG
between  ||| S:34414 E:34432 ||| IN
states  ||| S:34432 E:34439 ||| NNS
of  ||| S:34439 E:34442 ||| IN
transcriptional  ||| S:34442 E:34458 ||| JJ
repression  ||| S:34458 E:34469 ||| NN
and  ||| S:34469 E:34473 ||| CC
activation ||| S:34473 E:34483 ||| NN
,  ||| S:34483 E:34495 ||| ,
depending  ||| S:34495 E:34505 ||| VBG
on  ||| S:34505 E:34508 ||| IN
the  ||| S:34508 E:34512 ||| DT
absence  ||| S:34512 E:34520 ||| NN
or  ||| S:34520 E:34523 ||| CC
presence  ||| S:34523 E:34532 ||| NN
of  ||| S:34532 E:34535 ||| IN
a  ||| S:34535 E:34537 ||| DT
cognate  ||| S:34537 E:34555 ||| JJ
hormone ||| S:34555 E:34562 ||| NN
,  ||| S:34562 E:34564 ||| ,
respectively ||| S:34564 E:34576 ||| RB
.  ||| S:34576 E:34578 ||| .
In  ||| S:34578 E:34581 ||| IN
the  ||| S:34581 E:34585 ||| DT
absence  ||| S:34585 E:34593 ||| NN
of  ||| S:34593 E:34596 ||| IN
cognate  ||| S:34596 E:34604 ||| JJ
hormone ||| S:34604 E:34611 ||| NN
,  ||| S:34611 E:34623 ||| ,
several  ||| S:34623 E:34631 ||| JJ
nuclear  ||| S:34631 E:34639 ||| JJ
receptors  ||| S:34639 E:34649 ||| NNS
actively  ||| S:34649 E:34658 ||| RB
repress  ||| S:34658 E:34666 ||| JJ
transcription  ||| S:34666 E:34690 ||| NN
of  ||| S:34690 E:34693 ||| IN
target  ||| S:34693 E:34700 ||| NN
genes  ||| S:34700 E:34706 ||| NNS
via  ||| S:34706 E:34710 ||| IN
interactions  ||| S:34710 E:34723 ||| NNS
with  ||| S:34723 E:34728 ||| IN
the  ||| S:34728 E:34732 ||| DT
nuclear  ||| S:34732 E:34750 ||| JJ
receptor  ||| S:34750 E:34759 ||| NN
corepressors  ||| S:34759 E:34772 ||| VBD
SMRT  ||| S:34772 E:34777 ||| NNP
and  ||| S:34777 E:34781 ||| CC
NCoR ||| S:34781 E:34785 ||| JJ
.  ||| S:34785 E:34787 ||| .
Upon  ||| S:34787 E:34792 ||| IN
binding  ||| S:34792 E:34800 ||| VBG
of  ||| S:34800 E:34803 ||| IN
the  ||| S:34803 E:34817 ||| DT
hormone ||| S:34817 E:34824 ||| NN
,  ||| S:34824 E:34826 ||| ,
these  ||| S:34826 E:34832 ||| DT
corepressors  ||| S:34832 E:34845 ||| JJ
dissociate  ||| S:34845 E:34856 ||| NN
from  ||| S:34856 E:34861 ||| IN
the  ||| S:34861 E:34865 ||| DT
DNA-bound  ||| S:34865 E:34885 ||| JJ
receptor ||| S:34885 E:34893 ||| NN
,  ||| S:34893 E:34895 ||| ,
which  ||| S:34895 E:34901 ||| WDT
subsequently  ||| S:34901 E:34914 ||| RB
recruits  ||| S:34914 E:34923 ||| VBZ
a  ||| S:34923 E:34925 ||| DT
nuclear  ||| S:34925 E:34933 ||| JJ
receptor  ||| S:34933 E:34952 ||| NN
coactivator  ||| S:34952 E:34964 ||| NNS
( ||| S:34964 E:34965 ||| -LRB-
NCoA ||| S:34965 E:34969 ||| NNP
)  ||| S:34969 E:34971 ||| -RRB-
complex ||| S:34971 E:34978 ||| NN
.  ||| S:34978 E:34980 ||| .
Prominent  ||| S:34980 E:34990 ||| JJ
among  ||| S:34990 E:34996 ||| IN
these  ||| S:34996 E:35012 ||| DT
coactivators  ||| S:35012 E:35025 ||| NN
is  ||| S:35025 E:35028 ||| VBZ
the  ||| S:35028 E:35032 ||| DT
SRC  ||| S:35032 E:35036 ||| NNP
( ||| S:35036 E:35037 ||| -LRB-
steroid  ||| S:35037 E:35045 ||| FW
receptor  ||| S:35045 E:35054 ||| FW
coactivator ||| S:35054 E:35065 ||| FW
)  ||| S:35065 E:35077 ||| -RRB-
family ||| S:35077 E:35083 ||| NN
,  ||| S:35083 E:35085 ||| ,
which  ||| S:35085 E:35091 ||| WDT
consists  ||| S:35091 E:35100 ||| VBZ
of  ||| S:35100 E:35103 ||| IN
SRC-1 ||| S:35103 E:35108 ||| NNP
,  ||| S:35108 E:35110 ||| ,
TIF2 ||| S:35110 E:35114 ||| NNP
/ ||| S:35114 E:35115 ||| NNP
GRIP1 ||| S:35115 E:35120 ||| NNP
,  ||| S:35120 E:35122 ||| ,
and  ||| S:35122 E:35136 ||| CC
RAC3 ||| S:35136 E:35140 ||| NNP
/ ||| S:35140 E:35141 ||| NNP
ACTR ||| S:35141 E:35145 ||| NNP
/ ||| S:35145 E:35146 ||| NNP
pCIP ||| S:35146 E:35150 ||| NNP
/ ||| S:35150 E:35151 ||| NNP
AIB-1 ||| S:35151 E:35156 ||| NNP
.  ||| S:35156 E:35158 ||| .
These  ||| S:35158 E:35164 ||| DT
cofactors  ||| S:35164 E:35174 ||| JJ
interact  ||| S:35174 E:35183 ||| NN
with  ||| S:35183 E:35198 ||| IN
nuclear  ||| S:35198 E:35206 ||| JJ
receptors  ||| S:35206 E:35216 ||| NNS
in  ||| S:35216 E:35219 ||| IN
a  ||| S:35219 E:35221 ||| DT
ligand-dependent  ||| S:35221 E:35238 ||| JJ
manner  ||| S:35238 E:35245 ||| NN
and  ||| S:35245 E:35259 ||| CC
enhance  ||| S:35259 E:35267 ||| VB
transcriptional  ||| S:35267 E:35283 ||| JJ
activation  ||| S:35283 E:35294 ||| NN
via  ||| S:35294 E:35298 ||| IN
histone  ||| S:35298 E:35316 ||| FW
acetylation ||| S:35316 E:35327 ||| FW
/ ||| S:35327 E:35328 ||| FW
methylation  ||| S:35328 E:35340 ||| FW
and  ||| S:35340 E:35344 ||| CC
recruitment  ||| S:35344 E:35356 ||| NN
of  ||| S:35356 E:35359 ||| IN
additional  ||| S:35359 E:35380 ||| JJ
cofactors  ||| S:35380 E:35390 ||| JJ
such  ||| S:35390 E:35395 ||| JJ
as  ||| S:35395 E:35398 ||| IN
CBP ||| S:35398 E:35401 ||| NNP
/ ||| S:35401 E:35402 ||| NNP
p300  ||| S:35402 E:35407 ||| NNP
[  ||| S:35407 E:35409 ||| -LRB-
89  ||| S:35409 E:35412 ||| CD
]  ||| S:35412 E:35414 ||| -RRB-
.  ||| S:35414 E:35416 ||| .
CBP ||| S:35416 E:35419 ||| NNP
/ ||| S:35419 E:35420 ||| NNP
p300  ||| S:35420 E:35425 ||| NNP
has  ||| S:35425 E:35429 ||| VBZ
been  ||| S:35429 E:35444 ||| VBN
implicated  ||| S:35444 E:35455 ||| VBN
in  ||| S:35455 E:35458 ||| IN
the  ||| S:35458 E:35462 ||| DT
functions  ||| S:35462 E:35472 ||| NNS
of  ||| S:35472 E:35475 ||| IN
a  ||| S:35475 E:35477 ||| DT
large  ||| S:35477 E:35483 ||| JJ
number  ||| S:35483 E:35490 ||| NN
of  ||| S:35490 E:35503 ||| IN
regulated  ||| S:35503 E:35513 ||| JJ
transcription  ||| S:35513 E:35527 ||| JJ
factors  ||| S:35527 E:35535 ||| NNS
based  ||| S:35535 E:35541 ||| VBN
primarily  ||| S:35541 E:35551 ||| RB
on  ||| S:35551 E:35564 ||| IN
physical  ||| S:35564 E:35573 ||| JJ
interaction  ||| S:35573 E:35585 ||| NN
and  ||| S:35585 E:35589 ||| CC
the  ||| S:35589 E:35593 ||| DT
ability  ||| S:35593 E:35601 ||| NN
to  ||| S:35601 E:35604 ||| TO
potentiate  ||| S:35604 E:35625 ||| VB
transcription  ||| S:35625 E:35639 ||| VBN
when  ||| S:35639 E:35644 ||| WRB
overexpressed  ||| S:35644 E:35658 ||| NNS
[  ||| S:35658 E:35660 ||| -LRB-
90  ||| S:35660 E:35663 ||| CD
]  ||| S:35663 E:35665 ||| -RRB-
.  ||| S:35665 E:35667 ||| .
In  ||| S:35667 E:35670 ||| IN
the  ||| S:35670 E:35674 ||| DT
case  ||| S:35674 E:35679 ||| NN
of  ||| S:35679 E:35692 ||| IN
nuclear  ||| S:35692 E:35700 ||| JJ
receptors ||| S:35700 E:35709 ||| NNS
,  ||| S:35709 E:35711 ||| ,
the  ||| S:35711 E:35715 ||| DT
interaction  ||| S:35715 E:35727 ||| NN
with  ||| S:35727 E:35732 ||| IN
CBP ||| S:35732 E:35735 ||| NNP
/ ||| S:35735 E:35736 ||| NNP
p300  ||| S:35736 E:35741 ||| NNP
is  ||| S:35741 E:35754 ||| VBZ
ligand-dependent  ||| S:35754 E:35771 ||| JJ
and  ||| S:35771 E:35775 ||| CC
relies  ||| S:35775 E:35782 ||| VBZ
on  ||| S:35782 E:35785 ||| IN
the  ||| S:35785 E:35789 ||| DT
conserved  ||| S:35789 E:35799 ||| JJ
nuclear  ||| S:35799 E:35817 ||| JJ
receptor  ||| S:35817 E:35826 ||| NN
functional  ||| S:35826 E:35837 ||| NN
domain ||| S:35837 E:35843 ||| NN
,  ||| S:35843 E:35845 ||| ,
AF-2  ||| S:35845 E:35850 ||| NNP
( ||| S:35850 E:35851 ||| -LRB-
activation  ||| S:35851 E:35862 ||| JJ
function  ||| S:35862 E:35871 ||| NN
2 ||| S:35871 E:35872 ||| CD
) ||| S:35872 E:35873 ||| -RRB-
.  ||| S:35873 E:35896 ||| .
In  ||| S:35896 E:35899 ||| IN
vivo  ||| S:35899 E:35904 ||| JJ
studies  ||| S:35904 E:35912 ||| NNS
have  ||| S:35912 E:35917 ||| VBP
supported  ||| S:35917 E:35927 ||| VBN
the  ||| S:35927 E:35941 ||| DT
conclusion  ||| S:35941 E:35952 ||| NN
that  ||| S:35952 E:35957 ||| IN
CBP ||| S:35957 E:35960 ||| NNP
/ ||| S:35960 E:35961 ||| NNP
p300  ||| S:35961 E:35966 ||| NNP
are  ||| S:35966 E:35970 ||| VBP
components  ||| S:35970 E:35981 ||| NNS
of  ||| S:35981 E:35984 ||| IN
the  ||| S:35984 E:35998 ||| DT
hormonal-regulation  ||| S:35998 E:36018 ||| JJ
of  ||| S:36018 E:36021 ||| IN
transcription  ||| S:36021 E:36035 ||| NN
in  ||| S:36035 E:36038 ||| IN
fibroblasts  ||| S:36038 E:36060 ||| VBG
isolated  ||| S:36060 E:36069 ||| VBN
from  ||| S:36069 E:36074 ||| IN
a  ||| S:36074 E:36076 ||| DT
p300- ||| S:36076 E:36081 ||| NNP
/ ||| S:36081 E:36082 ||| NNP
-  ||| S:36082 E:36084 ||| :
mouse ||| S:36084 E:36089 ||| NN
;  ||| S:36089 E:36091 ||| :
and  ||| S:36091 E:36095 ||| CC
loss  ||| S:36095 E:36100 ||| NN
of  ||| S:36100 E:36103 ||| IN
the  ||| S:36103 E:36107 ||| DT
p300  ||| S:36107 E:36112 ||| JJ
gene  ||| S:36112 E:36127 ||| NN
severely  ||| S:36127 E:36136 ||| RB
affects  ||| S:36136 E:36144 ||| VBZ
retinoic  ||| S:36144 E:36153 ||| JJ
acid  ||| S:36153 E:36158 ||| NN
( ||| S:36158 E:36159 ||| -LRB-
RA ||| S:36159 E:36161 ||| NNP
) ||| S:36161 E:36162 ||| -RRB-
-dependent  ||| S:36162 E:36183 ||| JJ
transcription  ||| S:36183 E:36197 ||| NNS
[  ||| S:36197 E:36199 ||| -LRB-
91  ||| S:36199 E:36202 ||| CD
]  ||| S:36202 E:36204 ||| -RRB-
.  ||| S:36204 E:36206 ||| .
In  ||| S:36206 E:36209 ||| IN
a  ||| S:36209 E:36211 ||| DT
separate  ||| S:36211 E:36220 ||| JJ
study  ||| S:36220 E:36226 ||| NN
using  ||| S:36226 E:36242 ||| VBG
hammerhead  ||| S:36242 E:36253 ||| JJ
ribozymes  ||| S:36253 E:36263 ||| NN
that  ||| S:36263 E:36268 ||| WDT
specifically  ||| S:36268 E:36281 ||| RB
cleave  ||| S:36281 E:36288 ||| JJ
CBP  ||| S:36288 E:36292 ||| NNP
or  ||| S:36292 E:36295 ||| CC
p300  ||| S:36295 E:36310 ||| NNP
mRNA ||| S:36310 E:36314 ||| NNP
,  ||| S:36314 E:36316 ||| ,
Kawasaki  ||| S:36316 E:36325 ||| NNP
et  ||| S:36325 E:36328 ||| FW
al  ||| S:36328 E:36331 ||| FW
[  ||| S:36331 E:36333 ||| -LRB-
92  ||| S:36333 E:36336 ||| CD
]  ||| S:36336 E:36338 ||| -RRB-
reported  ||| S:36338 E:36347 ||| VBD
that  ||| S:36347 E:36352 ||| DT
reduced  ||| S:36352 E:36370 ||| JJ
cellular  ||| S:36370 E:36379 ||| JJ
CBP  ||| S:36379 E:36383 ||| NNP
or  ||| S:36383 E:36386 ||| CC
p300  ||| S:36386 E:36391 ||| CD
levels  ||| S:36391 E:36398 ||| NNS
resulted  ||| S:36398 E:36407 ||| VBD
in  ||| S:36407 E:36410 ||| IN
compromised  ||| S:36410 E:36432 ||| JJ
expression  ||| S:36432 E:36443 ||| NN
of  ||| S:36443 E:36446 ||| IN
endogenous  ||| S:36446 E:36457 ||| JJ
RA-inducible  ||| S:36457 E:36470 ||| JJ
genes  ||| S:36470 E:36476 ||| NNS
such  ||| S:36476 E:36481 ||| JJ
as  ||| S:36481 E:36494 ||| IN
p21 ||| S:36494 E:36497 ||| NNP
/ ||| S:36497 E:36498 ||| NNP
Waf1  ||| S:36498 E:36503 ||| NNP
and  ||| S:36503 E:36507 ||| CC
p27  ||| S:36507 E:36511 ||| CD
cdk  ||| S:36511 E:36515 ||| CD
inhibitors ||| S:36515 E:36525 ||| NNS
.  ||| S:36525 E:36527 ||| .
Along  ||| S:36527 E:36533 ||| IN
this  ||| S:36533 E:36538 ||| DT
line ||| S:36538 E:36542 ||| NN
,  ||| S:36542 E:36544 ||| ,
Tat  ||| S:36544 E:36558 ||| NNP
expressing  ||| S:36558 E:36569 ||| VBG
cells  ||| S:36569 E:36575 ||| NNS
have  ||| S:36575 E:36580 ||| VBP
lower  ||| S:36580 E:36586 ||| JJR
levels  ||| S:36586 E:36593 ||| NNS
of  ||| S:36593 E:36596 ||| IN
p21 ||| S:36596 E:36599 ||| CD
/ ||| S:36599 E:36600 ||| CD
Waf1  ||| S:36600 E:36605 ||| CD
presumably  ||| S:36605 E:36626 ||| RB
due  ||| S:36626 E:36630 ||| JJ
to  ||| S:36630 E:36633 ||| TO
inactivation  ||| S:36633 E:36646 ||| VB
of  ||| S:36646 E:36649 ||| IN
p53  ||| S:36649 E:36653 ||| NN
and  ||| S:36653 E:36657 ||| CC
a  ||| S:36657 E:36659 ||| DT
lack  ||| S:36659 E:36664 ||| NN
of  ||| S:36664 E:36667 ||| IN
p300 ||| S:36667 E:36671 ||| CD
/ ||| S:36671 E:36672 ||| CD
RA-  ||| S:36672 E:36676 ||| JJ
induced  ||| S:36676 E:36694 ||| JJ
gene  ||| S:36694 E:36699 ||| NN
expression ||| S:36699 E:36709 ||| NN
.  ||| S:36709 E:36711 ||| .
Consistent  ||| S:36711 E:36722 ||| JJ
with  ||| S:36722 E:36727 ||| IN
this  ||| S:36727 E:36732 ||| DT
interpretation ||| S:36732 E:36746 ||| NN
,  ||| S:36746 E:36748 ||| ,
CBP  ||| S:36748 E:36762 ||| NNP
and  ||| S:36762 E:36766 ||| CC
p300  ||| S:36766 E:36771 ||| CD
harbor  ||| S:36771 E:36778 ||| NN
transcriptional  ||| S:36778 E:36794 ||| NN
activation  ||| S:36794 E:36805 ||| NN
of  ||| S:36805 E:36818 ||| IN
ligand-induced  ||| S:36818 E:36833 ||| NNP
RA  ||| S:36833 E:36836 ||| NNP
or  ||| S:36836 E:36839 ||| CC
ER  ||| S:36839 E:36842 ||| NNP
function  ||| S:36842 E:36851 ||| NN
on  ||| S:36851 E:36854 ||| IN
a  ||| S:36854 E:36856 ||| DT
chromatinized  ||| S:36856 E:36880 ||| JJ
template  ||| S:36880 E:36889 ||| NNS
[  ||| S:36889 E:36891 ||| -LRB-
93  ||| S:36891 E:36894 ||| CD
]  ||| S:36894 E:36896 ||| -RRB-
.  ||| S:36896 E:36908 ||| .
The  ||| S:36908 E:36912 ||| DT
NcoA  ||| S:36912 E:36917 ||| JJ
family  ||| S:36917 E:36924 ||| NN
members  ||| S:36924 E:36932 ||| NNS
constitute  ||| S:36932 E:36943 ||| VBP
SRC-1 ||| S:36943 E:36948 ||| CD
/ ||| S:36948 E:36949 ||| CD
NcoA-1  ||| S:36949 E:36956 ||| CD
[  ||| S:36956 E:36958 ||| -LRB-
89  ||| S:36958 E:36961 ||| CD
]  ||| S:36961 E:36973 ||| -RRB-
,  ||| S:36973 E:36975 ||| ,
TIF2 ||| S:36975 E:36979 ||| CD
/ ||| S:36979 E:36980 ||| CD
GRIP1 ||| S:36980 E:36985 ||| CD
/ ||| S:36985 E:36986 ||| CD
NcoA-2 ||| S:36986 E:36992 ||| CD
,  ||| S:36992 E:36994 ||| ,
[  ||| S:36994 E:36996 ||| -LRB-
94  ||| S:36996 E:36999 ||| CD
95  ||| S:36999 E:37002 ||| CD
]  ||| S:37002 E:37004 ||| -RRB-
and  ||| S:37004 E:37008 ||| CC
pCIP ||| S:37008 E:37012 ||| NNP
/ ||| S:37012 E:37013 ||| NNP
ACTR ||| S:37013 E:37017 ||| NNP
/ ||| S:37017 E:37018 ||| NNP
AIB1  ||| S:37018 E:37023 ||| NNP
[  ||| S:37023 E:37025 ||| -LRB-
96  ||| S:37025 E:37028 ||| CD
97  ||| S:37028 E:37041 ||| CD
98  ||| S:37041 E:37044 ||| CD
]  ||| S:37044 E:37046 ||| -RRB-
proteins ||| S:37046 E:37054 ||| NNS
,  ||| S:37054 E:37056 ||| ,
which  ||| S:37056 E:37062 ||| WDT
interact  ||| S:37062 E:37071 ||| VBZ
with  ||| S:37071 E:37076 ||| IN
liganded  ||| S:37076 E:37085 ||| JJ
RA  ||| S:37085 E:37088 ||| NNP
receptor  ||| S:37088 E:37107 ||| NN
( ||| S:37107 E:37108 ||| -LRB-
RAR ||| S:37108 E:37111 ||| NNP
) ||| S:37111 E:37112 ||| -RRB-
,  ||| S:37112 E:37114 ||| ,
and  ||| S:37114 E:37118 ||| CC
CBP ||| S:37118 E:37121 ||| NNP
/ ||| S:37121 E:37122 ||| NNP
p300 ||| S:37122 E:37126 ||| NNP
.  ||| S:37126 E:37128 ||| .
Overexpression  ||| S:37128 E:37143 ||| NNP
of  ||| S:37143 E:37146 ||| IN
these  ||| S:37146 E:37152 ||| DT
NCoA  ||| S:37152 E:37157 ||| JJ
factors  ||| S:37157 E:37175 ||| NNS
enhances  ||| S:37175 E:37184 ||| VBZ
ligand-induced  ||| S:37184 E:37199 ||| JJ
transactivation  ||| S:37199 E:37215 ||| NN
of  ||| S:37215 E:37218 ||| IN
several  ||| S:37218 E:37236 ||| JJ
nuclear  ||| S:37236 E:37244 ||| JJ
receptors  ||| S:37244 E:37254 ||| NNS
[  ||| S:37254 E:37256 ||| -LRB-
99  ||| S:37256 E:37259 ||| CD
]  ||| S:37259 E:37261 ||| -RRB-
.  ||| S:37261 E:37263 ||| .
A  ||| S:37263 E:37265 ||| DT
weak  ||| S:37265 E:37270 ||| JJ
intrinsic  ||| S:37270 E:37280 ||| JJ
HAT  ||| S:37280 E:37284 ||| NNP
activity  ||| S:37284 E:37303 ||| NN
has  ||| S:37303 E:37307 ||| VBZ
been  ||| S:37307 E:37312 ||| VBN
reported  ||| S:37312 E:37321 ||| VBN
in  ||| S:37321 E:37324 ||| IN
SRC-1 ||| S:37324 E:37329 ||| NNP
/ ||| S:37329 E:37330 ||| NNP
NCoA-1  ||| S:37330 E:37337 ||| NNP
and  ||| S:37337 E:37341 ||| CC
pCIP ||| S:37341 E:37345 ||| NNP
/ ||| S:37345 E:37346 ||| NNP
ACTR ||| S:37346 E:37350 ||| NNP
/ ||| S:37350 E:37351 ||| NNP
AIB1 ||| S:37351 E:37355 ||| NNP
,  ||| S:37355 E:37367 ||| ,
suggesting  ||| S:37367 E:37378 ||| VBG
that  ||| S:37378 E:37383 ||| IN
chromatin  ||| S:37383 E:37393 ||| JJ
remodeling  ||| S:37393 E:37404 ||| NN
may  ||| S:37404 E:37408 ||| MD
also  ||| S:37408 E:37413 ||| RB
be  ||| S:37413 E:37416 ||| VB
a  ||| S:37416 E:37428 ||| DT
function  ||| S:37428 E:37437 ||| NN
of  ||| S:37437 E:37440 ||| IN
these  ||| S:37440 E:37446 ||| DT
NCoA  ||| S:37446 E:37451 ||| JJ
factors  ||| S:37451 E:37459 ||| NNS
[  ||| S:37459 E:37461 ||| -LRB-
99  ||| S:37461 E:37464 ||| CD
100  ||| S:37464 E:37468 ||| CD
]  ||| S:37468 E:37470 ||| -RRB-
;  ||| S:37470 E:37472 ||| :
although  ||| S:37472 E:37481 ||| IN
they  ||| S:37481 E:37496 ||| PRP
do  ||| S:37496 E:37499 ||| VBP
not  ||| S:37499 E:37503 ||| RB
appear  ||| S:37503 E:37510 ||| VB
to  ||| S:37510 E:37513 ||| TO
contain  ||| S:37513 E:37521 ||| VB
regions  ||| S:37521 E:37529 ||| NNS
homologous  ||| S:37529 E:37540 ||| VBP
to  ||| S:37540 E:37543 ||| TO
the  ||| S:37543 E:37547 ||| DT
HAT  ||| S:37547 E:37561 ||| NNP
domains  ||| S:37561 E:37569 ||| NN
of  ||| S:37569 E:37572 ||| IN
CBP ||| S:37572 E:37575 ||| NNP
/ ||| S:37575 E:37576 ||| NNP
p300  ||| S:37576 E:37581 ||| NNP
or  ||| S:37581 E:37584 ||| CC
p ||| S:37584 E:37585 ||| JJ
/ ||| S:37585 E:37586 ||| NNP
CAF ||| S:37586 E:37589 ||| NNP
.  ||| S:37589 E:37591 ||| .
Structure-function  ||| S:37591 E:37610 ||| JJ
analysis  ||| S:37610 E:37629 ||| NN
of  ||| S:37629 E:37632 ||| IN
the  ||| S:37632 E:37636 ||| DT
NCoAs  ||| S:37636 E:37642 ||| NNS
have  ||| S:37642 E:37647 ||| VBP
revealed  ||| S:37647 E:37656 ||| VBN
multiple  ||| S:37656 E:37665 ||| JJ
copies  ||| S:37665 E:37672 ||| NNS
of  ||| S:37672 E:37675 ||| IN
a  ||| S:37675 E:37677 ||| DT
signature  ||| S:37677 E:37697 ||| NN
motif ||| S:37697 E:37702 ||| NN
,  ||| S:37702 E:37704 ||| ,
LXXLL ||| S:37704 E:37709 ||| NNP
,  ||| S:37709 E:37711 ||| ,
with  ||| S:37711 E:37716 ||| IN
conserved  ||| S:37716 E:37726 ||| JJ
spacing  ||| S:37726 E:37734 ||| NN
that  ||| S:37734 E:37739 ||| WDT
is  ||| S:37739 E:37742 ||| VBZ
required  ||| S:37742 E:37751 ||| VBN
for  ||| S:37751 E:37765 ||| IN
interaction  ||| S:37765 E:37777 ||| NN
with  ||| S:37777 E:37782 ||| IN
nuclear  ||| S:37782 E:37790 ||| JJ
receptors  ||| S:37790 E:37800 ||| NNS
and  ||| S:37800 E:37804 ||| CC
CBP ||| S:37804 E:37807 ||| NNP
/ ||| S:37807 E:37808 ||| NNP
p300  ||| S:37808 E:37813 ||| NNP
[  ||| S:37813 E:37815 ||| -LRB-
99  ||| S:37815 E:37818 ||| CD
101  ||| S:37818 E:37832 ||| CD
]  ||| S:37832 E:37834 ||| -RRB-
.  ||| S:37834 E:37836 ||| .
Intriguingly ||| S:37836 E:37848 ||| NNP
,  ||| S:37848 E:37850 ||| ,
different  ||| S:37850 E:37860 ||| JJ
LXXLL  ||| S:37860 E:37866 ||| NN
motifs  ||| S:37866 E:37873 ||| NNS
are  ||| S:37873 E:37877 ||| VBP
required  ||| S:37877 E:37886 ||| VBN
for  ||| S:37886 E:37900 ||| IN
PPARγ  ||| S:37900 E:37906 ||| NNP
( ||| S:37906 E:37907 ||| -LRB-
Peroxisome  ||| S:37907 E:37918 ||| FW
Proliferator  ||| S:37918 E:37931 ||| FW
activated  ||| S:37931 E:37941 ||| FW
receptor  ||| S:37941 E:37950 ||| FW
γ ||| S:37950 E:37951 ||| FW
,  ||| S:37951 E:37953 ||| ,
a  ||| S:37953 E:37965 ||| DT
gene  ||| S:37965 E:37970 ||| NN
down-regulated  ||| S:37970 E:37985 ||| NN
in  ||| S:37985 E:37988 ||| IN
Tat  ||| S:37988 E:37992 ||| NNP
expressing  ||| S:37992 E:38003 ||| VBG
cells ||| S:38003 E:38008 ||| NNS
;  ||| S:38008 E:38010 ||| :
Acc ||| S:38010 E:38013 ||| RB
#  ||| S:38013 E:38015 ||| #
L07592 ||| S:38015 E:38021 ||| CD
,  ||| S:38021 E:38033 ||| ,
Table  ||| S:38033 E:38039 ||| NNP
1 ||| S:38039 E:38040 ||| CD
)  ||| S:38040 E:38042 ||| -RRB-
function  ||| S:38042 E:38051 ||| NN
in  ||| S:38051 E:38054 ||| IN
response  ||| S:38054 E:38063 ||| NN
to  ||| S:38063 E:38066 ||| TO
different  ||| S:38066 E:38076 ||| JJ
classes  ||| S:38076 E:38084 ||| NNS
of  ||| S:38084 E:38097 ||| IN
ligands ||| S:38097 E:38104 ||| NN
,  ||| S:38104 E:38106 ||| ,
suggesting  ||| S:38106 E:38117 ||| VBG
distinct  ||| S:38117 E:38126 ||| JJ
configuration  ||| S:38126 E:38140 ||| NN
of  ||| S:38140 E:38143 ||| IN
assembled  ||| S:38143 E:38163 ||| JJ
complexes ||| S:38163 E:38172 ||| NNS
.  ||| S:38172 E:38184 ||| .
Taken  ||| S:38184 E:38190 ||| VBN
together ||| S:38190 E:38198 ||| RB
,  ||| S:38198 E:38200 ||| ,
through  ||| S:38200 E:38208 ||| IN
the  ||| S:38208 E:38212 ||| DT
use  ||| S:38212 E:38216 ||| NN
of  ||| S:38216 E:38219 ||| IN
microarray  ||| S:38219 E:38240 ||| JJ
technology ||| S:38240 E:38250 ||| NN
,  ||| S:38250 E:38252 ||| ,
we  ||| S:38252 E:38255 ||| PRP
have  ||| S:38255 E:38260 ||| VBP
described  ||| S:38260 E:38270 ||| VBN
one  ||| S:38270 E:38274 ||| CD
of  ||| S:38274 E:38277 ||| IN
the  ||| S:38277 E:38281 ||| DT
first  ||| S:38281 E:38297 ||| JJ
observations  ||| S:38297 E:38310 ||| NNS
about  ||| S:38310 E:38316 ||| IN
how  ||| S:38316 E:38320 ||| WRB
Tat  ||| S:38320 E:38324 ||| NNP
is  ||| S:38324 E:38327 ||| VBZ
able  ||| S:38327 E:38332 ||| JJ
to  ||| S:38332 E:38335 ||| TO
control  ||| S:38335 E:38343 ||| VB
various  ||| S:38343 E:38361 ||| JJ
host  ||| S:38361 E:38366 ||| NN
cellular  ||| S:38366 E:38375 ||| JJ
machineries ||| S:38375 E:38386 ||| NN
.  ||| S:38386 E:38388 ||| .
Although  ||| S:38388 E:38397 ||| IN
our  ||| S:38397 E:38401 ||| PRP$
data  ||| S:38401 E:38406 ||| NN
is  ||| S:38406 E:38419 ||| VBZ
consistent  ||| S:38419 E:38430 ||| JJ
with  ||| S:38430 E:38435 ||| IN
most  ||| S:38435 E:38440 ||| JJS
of  ||| S:38440 E:38443 ||| IN
the  ||| S:38443 E:38447 ||| DT
cited  ||| S:38447 E:38453 ||| JJ
literature  ||| S:38453 E:38464 ||| NN
on  ||| S:38464 E:38467 ||| IN
the  ||| S:38467 E:38481 ||| DT
effects  ||| S:38481 E:38489 ||| NNS
of  ||| S:38489 E:38492 ||| IN
Tat  ||| S:38492 E:38496 ||| NNP
in  ||| S:38496 E:38499 ||| IN
infected  ||| S:38499 E:38508 ||| JJ
host  ||| S:38508 E:38513 ||| NN
and  ||| S:38513 E:38517 ||| CC
uninfected  ||| S:38517 E:38528 ||| JJ
bystander  ||| S:38528 E:38548 ||| JJ
cells ||| S:38548 E:38553 ||| NNS
,  ||| S:38553 E:38555 ||| ,
we  ||| S:38555 E:38558 ||| PRP
caution  ||| S:38558 E:38566 ||| VBP
that  ||| S:38566 E:38571 ||| IN
the  ||| S:38571 E:38575 ||| DT
transcriptional  ||| S:38575 E:38591 ||| JJ
profiling  ||| S:38591 E:38601 ||| NN
in  ||| S:38601 E:38614 ||| IN
chronically  ||| S:38614 E:38626 ||| RB
infected  ||| S:38626 E:38635 ||| JJ
cells  ||| S:38635 E:38641 ||| NNS
such  ||| S:38641 E:38646 ||| JJ
as  ||| S:38646 E:38649 ||| IN
ACH2  ||| S:38649 E:38654 ||| NNP
or  ||| S:38654 E:38657 ||| CC
H9 ||| S:38657 E:38659 ||| NNP
/ ||| S:38659 E:38660 ||| NNP
Tat  ||| S:38660 E:38664 ||| NNP
cells  ||| S:38664 E:38680 ||| NNS
may  ||| S:38680 E:38684 ||| MD
not  ||| S:38684 E:38688 ||| RB
necessarily  ||| S:38688 E:38700 ||| RB
be  ||| S:38700 E:38703 ||| VB
representative  ||| S:38703 E:38718 ||| NN
of  ||| S:38718 E:38721 ||| IN
the  ||| S:38721 E:38725 ||| DT
pattern  ||| S:38725 E:38733 ||| NN
of  ||| S:38733 E:38746 ||| IN
expression  ||| S:38746 E:38757 ||| NN
observed  ||| S:38757 E:38766 ||| VBD
in  ||| S:38766 E:38769 ||| IN
most  ||| S:38769 E:38774 ||| JJS
cells  ||| S:38774 E:38780 ||| NNS
infected  ||| S:38780 E:38789 ||| VBN
by  ||| S:38789 E:38792 ||| IN
other  ||| S:38792 E:38798 ||| JJ
group  ||| S:38798 E:38814 ||| NN
M ||| S:38814 E:38815 ||| NNP
,  ||| S:38815 E:38817 ||| ,
N ||| S:38817 E:38818 ||| NNP
,  ||| S:38818 E:38820 ||| ,
or  ||| S:38820 E:38823 ||| CC
O  ||| S:38823 E:38825 ||| NNP
HIV-1  ||| S:38825 E:38831 ||| NNP
isolates ||| S:38831 E:38839 ||| VBZ
.  ||| S:38839 E:38851 ||| .
We  ||| S:38851 E:38854 ||| PRP
recently  ||| S:38854 E:38863 ||| RB
extended  ||| S:38863 E:38872 ||| VBN
our  ||| S:38872 E:38876 ||| PRP$
observations  ||| S:38876 E:38889 ||| NNS
by  ||| S:38889 E:38892 ||| IN
utilizing  ||| S:38892 E:38912 ||| JJ
other  ||| S:38912 E:38918 ||| JJ
HIV-1  ||| S:38918 E:38924 ||| NNP
infected  ||| S:38924 E:38933 ||| JJ
cells  ||| S:38933 E:38939 ||| NNS
which  ||| S:38939 E:38945 ||| WDT
normally  ||| S:38945 E:38954 ||| RB
express  ||| S:38954 E:38962 ||| VB
Tat  ||| S:38962 E:38976 ||| NNP
( ||| S:38976 E:38977 ||| -LRB-
U1 ||| S:38977 E:38979 ||| NNP
) ||| S:38979 E:38980 ||| -RRB-
,  ||| S:38980 E:38982 ||| ,
and  ||| S:38982 E:38986 ||| CC
addition  ||| S:38986 E:38995 ||| NN
of  ||| S:38995 E:38998 ||| IN
exogenous  ||| S:38998 E:39008 ||| FW
purified  ||| S:39008 E:39017 ||| FW
Tat  ||| S:39017 E:39021 ||| FW
to  ||| S:39021 E:39034 ||| TO
uninfected  ||| S:39034 E:39045 ||| VB
PBMCs ||| S:39045 E:39050 ||| JJ
.  ||| S:39050 E:39052 ||| .
Preliminary  ||| S:39052 E:39064 ||| JJ
results  ||| S:39064 E:39072 ||| NNS
using  ||| S:39072 E:39078 ||| VBG
western  ||| S:39078 E:39086 ||| JJ
blots  ||| S:39086 E:39102 ||| NN
supports  ||| S:39102 E:39111 ||| VBZ
the  ||| S:39111 E:39115 ||| DT
idea  ||| S:39115 E:39120 ||| NN
that  ||| S:39120 E:39125 ||| IN
genes  ||| S:39125 E:39131 ||| NNS
which  ||| S:39131 E:39137 ||| WDT
were  ||| S:39137 E:39142 ||| VBD
altered  ||| S:39142 E:39150 ||| VBN
in  ||| S:39150 E:39153 ||| IN
H9 ||| S:39153 E:39155 ||| NNP
/ ||| S:39155 E:39156 ||| NNP
Tat  ||| S:39156 E:39170 ||| NNP
system  ||| S:39170 E:39177 ||| NN
also  ||| S:39177 E:39182 ||| RB
showed  ||| S:39182 E:39189 ||| VBD
a  ||| S:39189 E:39191 ||| DT
similar  ||| S:39191 E:39199 ||| JJ
level  ||| S:39199 E:39205 ||| NN
of  ||| S:39205 E:39208 ||| IN
change  ||| S:39208 E:39215 ||| NN
in  ||| S:39215 E:39218 ||| IN
few  ||| S:39218 E:39222 ||| JJ
of  ||| S:39222 E:39235 ||| IN
the  ||| S:39235 E:39239 ||| DT
tested  ||| S:39239 E:39246 ||| JJ
genes  ||| S:39246 E:39252 ||| NNS
( ||| S:39252 E:39253 ||| -LRB-
Figure  ||| S:39253 E:39260 ||| NNP
3C ||| S:39260 E:39262 ||| NNP
) ||| S:39262 E:39263 ||| -RRB-
.  ||| S:39263 E:39265 ||| .
This  ||| S:39265 E:39270 ||| DT
notion  ||| S:39270 E:39277 ||| NN
of  ||| S:39277 E:39280 ||| IN
consistency  ||| S:39280 E:39302 ||| NN
was  ||| S:39302 E:39306 ||| VBD
further  ||| S:39306 E:39314 ||| RB
confirmed  ||| S:39314 E:39324 ||| VBD
using  ||| S:39324 E:39330 ||| VBG
the  ||| S:39330 E:39334 ||| DT
IL-8  ||| S:39334 E:39339 ||| JJ
activation  ||| S:39339 E:39350 ||| NN
by  ||| S:39350 E:39353 ||| IN
Tat ||| S:39353 E:39356 ||| NNP
.  ||| S:39356 E:39368 ||| .
Interleukin-8  ||| S:39368 E:39382 ||| NNP
( ||| S:39382 E:39383 ||| -LRB-
IL-8 ||| S:39383 E:39387 ||| NNP
)  ||| S:39387 E:39389 ||| -RRB-
belongs  ||| S:39389 E:39397 ||| VBZ
to  ||| S:39397 E:39400 ||| TO
the  ||| S:39400 E:39404 ||| DT
CXC  ||| S:39404 E:39408 ||| NNP
chemokine  ||| S:39408 E:39418 ||| JJ
family  ||| S:39418 E:39435 ||| NN
and  ||| S:39435 E:39439 ||| CC
is  ||| S:39439 E:39442 ||| VBZ
secreted  ||| S:39442 E:39451 ||| VBN
by  ||| S:39451 E:39454 ||| IN
several  ||| S:39454 E:39462 ||| JJ
different  ||| S:39462 E:39472 ||| JJ
cell  ||| S:39472 E:39477 ||| NN
types ||| S:39477 E:39482 ||| NNS
,  ||| S:39482 E:39494 ||| ,
including  ||| S:39494 E:39504 ||| VBG
monocytes ||| S:39504 E:39513 ||| NN
,  ||| S:39513 E:39515 ||| ,
neutrophils ||| S:39515 E:39526 ||| NN
,  ||| S:39526 E:39528 ||| ,
endothelial  ||| S:39528 E:39540 ||| JJ
cells ||| S:39540 E:39545 ||| NNS
,  ||| S:39545 E:39557 ||| ,
fibroblasts ||| S:39557 E:39568 ||| NN
,  ||| S:39568 E:39570 ||| ,
and  ||| S:39570 E:39574 ||| CC
T  ||| S:39574 E:39576 ||| NN
lymphocytes ||| S:39576 E:39587 ||| NN
.  ||| S:39587 E:39589 ||| .
IL-8  ||| S:39589 E:39594 ||| NNP
production  ||| S:39594 E:39605 ||| NN
( ||| S:39605 E:39606 ||| -LRB-
induced  ||| S:39606 E:39624 ||| VBN
by  ||| S:39624 E:39627 ||| IN
several  ||| S:39627 E:39635 ||| JJ
stimuli ||| S:39635 E:39642 ||| NNS
,  ||| S:39642 E:39644 ||| ,
including  ||| S:39644 E:39654 ||| VBG
IL-1 ||| S:39654 E:39658 ||| NNP
,  ||| S:39658 E:39660 ||| ,
TNF- ||| S:39660 E:39664 ||| NNP
,  ||| S:39664 E:39666 ||| ,
and  ||| S:39666 E:39670 ||| CC
phorbol  ||| S:39670 E:39688 ||| FW
myristate  ||| S:39688 E:39698 ||| FW
acetate ||| S:39698 E:39705 ||| FW
)  ||| S:39705 E:39707 ||| -RRB-
is  ||| S:39707 E:39710 ||| VBZ
primarily  ||| S:39710 E:39720 ||| RB
regulated  ||| S:39720 E:39730 ||| VBN
at  ||| S:39730 E:39733 ||| IN
the  ||| S:39733 E:39747 ||| DT
transcriptional  ||| S:39747 E:39763 ||| JJ
level ||| S:39763 E:39768 ||| NN
.  ||| S:39768 E:39770 ||| .
IL-8  ||| S:39770 E:39775 ||| NNP
is  ||| S:39775 E:39778 ||| VBZ
a  ||| S:39778 E:39780 ||| DT
potent  ||| S:39780 E:39787 ||| JJ
chemotactic  ||| S:39787 E:39809 ||| JJ
factor  ||| S:39809 E:39816 ||| NN
for  ||| S:39816 E:39820 ||| IN
granulocytes  ||| S:39820 E:39833 ||| NN
and  ||| S:39833 E:39837 ||| CC
T  ||| S:39837 E:39839 ||| NN
lymphocytes ||| S:39839 E:39850 ||| NN
,  ||| S:39850 E:39852 ||| ,
and  ||| S:39852 E:39856 ||| CC
is  ||| S:39856 E:39859 ||| VBZ
found  ||| S:39859 E:39875 ||| VBN
in  ||| S:39875 E:39878 ||| IN
HIV-infected  ||| S:39878 E:39891 ||| JJ
individuals ||| S:39891 E:39902 ||| NNS
.  ||| S:39902 E:39904 ||| .
The  ||| S:39904 E:39908 ||| DT
CXC  ||| S:39908 E:39912 ||| FW
chemokine  ||| S:39912 E:39922 ||| FW
IL-8  ||| S:39922 E:39927 ||| FW
does  ||| S:39927 E:39942 ||| VBZ
not  ||| S:39942 E:39946 ||| RB
bind  ||| S:39946 E:39951 ||| VBN
to  ||| S:39951 E:39954 ||| TO
CCR5 ||| S:39954 E:39958 ||| CD
.  ||| S:39958 E:39960 ||| .
It  ||| S:39960 E:39963 ||| PRP
has  ||| S:39963 E:39967 ||| VBZ
previously  ||| S:39967 E:39978 ||| RB
been  ||| S:39978 E:39983 ||| VBN
shown  ||| S:39983 E:39989 ||| VBN
that  ||| S:39989 E:39994 ||| IN
IL-8  ||| S:39994 E:40009 ||| CD
mRNA  ||| S:40009 E:40014 ||| JJ
induction  ||| S:40014 E:40024 ||| NN
was  ||| S:40024 E:40028 ||| VBD
seen  ||| S:40028 E:40033 ||| VBN
less  ||| S:40033 E:40038 ||| RBR
then  ||| S:40038 E:40043 ||| RB
1  ||| S:40043 E:40045 ||| CD
h  ||| S:40045 E:40047 ||| NN
after  ||| S:40047 E:40053 ||| IN
Tat  ||| S:40053 E:40057 ||| NNP
( ||| S:40057 E:40058 ||| -LRB-
72aa ||| S:40058 E:40062 ||| NNP
)  ||| S:40062 E:40074 ||| -RRB-
stimulation ||| S:40074 E:40085 ||| NN
,  ||| S:40085 E:40087 ||| ,
and  ||| S:40087 E:40091 ||| CC
levels  ||| S:40091 E:40098 ||| NNS
remained  ||| S:40098 E:40107 ||| VBD
elevated  ||| S:40107 E:40116 ||| VBN
for  ||| S:40116 E:40120 ||| IN
up  ||| S:40120 E:40123 ||| RB
to  ||| S:40123 E:40126 ||| TO
24  ||| S:40126 E:40129 ||| CD
h ||| S:40129 E:40130 ||| NN
,  ||| S:40130 E:40142 ||| ,
leading  ||| S:40142 E:40150 ||| VBG
to  ||| S:40150 E:40153 ||| TO
IL-8  ||| S:40153 E:40158 ||| CD
protein  ||| S:40158 E:40166 ||| NN
production  ||| S:40166 E:40177 ||| NN
[  ||| S:40177 E:40179 ||| -LRB-
102  ||| S:40179 E:40183 ||| CD
]  ||| S:40183 E:40185 ||| -RRB-
.  ||| S:40185 E:40187 ||| .
Along  ||| S:40187 E:40193 ||| IN
these  ||| S:40193 E:40209 ||| DT
lines ||| S:40209 E:40214 ||| NNS
,  ||| S:40214 E:40216 ||| ,
we  ||| S:40216 E:40219 ||| PRP
have  ||| S:40219 E:40224 ||| VBP
previously  ||| S:40224 E:40235 ||| RB
shown  ||| S:40235 E:40241 ||| VBN
that  ||| S:40241 E:40246 ||| IN
the  ||| S:40246 E:40250 ||| DT
IL-8  ||| S:40250 E:40255 ||| JJ
gene  ||| S:40255 E:40260 ||| NN
is  ||| S:40260 E:40273 ||| VBZ
expressed  ||| S:40273 E:40283 ||| VBN
in  ||| S:40283 E:40286 ||| IN
a  ||| S:40286 E:40288 ||| DT
cell  ||| S:40288 E:40293 ||| NN
cycle-dependent  ||| S:40293 E:40309 ||| JJ
manner  ||| S:40309 E:40316 ||| NN
in  ||| S:40316 E:40319 ||| IN
cells  ||| S:40319 E:40325 ||| NNS
that  ||| S:40325 E:40340 ||| WDT
express  ||| S:40340 E:40348 ||| VBP
the  ||| S:40348 E:40352 ||| DT
Tat  ||| S:40352 E:40356 ||| JJ
protein ||| S:40356 E:40363 ||| NN
,  ||| S:40363 E:40365 ||| ,
and  ||| S:40365 E:40369 ||| CC
the  ||| S:40369 E:40373 ||| DT
induction  ||| S:40373 E:40383 ||| NN
is  ||| S:40383 E:40386 ||| VBZ
during  ||| S:40386 E:40393 ||| IN
the  ||| S:40393 E:40407 ||| DT
S  ||| S:40407 E:40409 ||| NNP
phase  ||| S:40409 E:40415 ||| NN
of  ||| S:40415 E:40418 ||| IN
the  ||| S:40418 E:40422 ||| DT
cell  ||| S:40422 E:40427 ||| NN
cycle  ||| S:40427 E:40433 ||| NN
and  ||| S:40433 E:40437 ||| CC
regulated  ||| S:40437 E:40447 ||| VBN
by  ||| S:40447 E:40450 ||| IN
stable  ||| S:40450 E:40457 ||| JJ
NF-kB  ||| S:40457 E:40473 ||| JJ
binding  ||| S:40473 E:40481 ||| NN
to  ||| S:40481 E:40484 ||| TO
the  ||| S:40484 E:40488 ||| DT
IL-8  ||| S:40488 E:40493 ||| JJ
promoter  ||| S:40493 E:40502 ||| NN
[  ||| S:40502 E:40504 ||| -LRB-
103  ||| S:40504 E:40508 ||| CD
]  ||| S:40508 E:40510 ||| -RRB-
.  ||| S:40510 E:40512 ||| .
When  ||| S:40512 E:40517 ||| WRB
looking  ||| S:40517 E:40525 ||| VBG
for  ||| S:40525 E:40539 ||| IN
IL-8  ||| S:40539 E:40544 ||| CD
at  ||| S:40544 E:40547 ||| IN
the  ||| S:40547 E:40551 ||| DT
G1 ||| S:40551 E:40553 ||| NNP
/ ||| S:40553 E:40554 ||| NNP
S  ||| S:40554 E:40556 ||| NNP
border ||| S:40556 E:40562 ||| NN
,  ||| S:40562 E:40564 ||| ,
we  ||| S:40564 E:40567 ||| PRP
found  ||| S:40567 E:40573 ||| VBD
that  ||| S:40573 E:40578 ||| IN
all  ||| S:40578 E:40582 ||| DT
Tat  ||| S:40582 E:40586 ||| NNP
containing  ||| S:40586 E:40607 ||| VBG
cells ||| S:40607 E:40612 ||| NNS
,  ||| S:40612 E:40614 ||| ,
including  ||| S:40614 E:40624 ||| VBG
PBMCs  ||| S:40624 E:40630 ||| NN
that  ||| S:40630 E:40635 ||| WDT
were  ||| S:40635 E:40640 ||| VBD
treated  ||| S:40640 E:40648 ||| VBN
with  ||| S:40648 E:40653 ||| IN
exogenous  ||| S:40653 E:40673 ||| JJ
Tat  ||| S:40673 E:40677 ||| NNP
showed  ||| S:40677 E:40684 ||| VBD
an  ||| S:40684 E:40687 ||| DT
up-regulation  ||| S:40687 E:40701 ||| JJ
of  ||| S:40701 E:40704 ||| IN
IL-8  ||| S:40704 E:40709 ||| CD
in  ||| S:40709 E:40712 ||| IN
the  ||| S:40712 E:40716 ||| DT
supernatant  ||| S:40716 E:40738 ||| NN
( ||| S:40738 E:40739 ||| -LRB-
Figure  ||| S:40739 E:40746 ||| NNP
4 ||| S:40746 E:40747 ||| CD
) ||| S:40747 E:40748 ||| -RRB-
,  ||| S:40748 E:40750 ||| ,
further  ||| S:40750 E:40758 ||| RB
implying  ||| S:40758 E:40767 ||| VBG
that  ||| S:40767 E:40772 ||| IN
results  ||| S:40772 E:40780 ||| NNS
obtained  ||| S:40780 E:40789 ||| VBN
from  ||| S:40789 E:40804 ||| IN
the  ||| S:40804 E:40808 ||| DT
H9 ||| S:40808 E:40810 ||| NNP
/ ||| S:40810 E:40811 ||| NNP
Tat  ||| S:40811 E:40815 ||| NNP
system  ||| S:40815 E:40822 ||| NN
may  ||| S:40822 E:40826 ||| MD
infact  ||| S:40826 E:40833 ||| RB
be  ||| S:40833 E:40836 ||| VB
of  ||| S:40836 E:40839 ||| IN
general  ||| S:40839 E:40847 ||| JJ
physiological  ||| S:40847 E:40871 ||| JJ
relevance  ||| S:40871 E:40881 ||| NN
in  ||| S:40881 E:40884 ||| IN
vivo ||| S:40884 E:40888 ||| NN
.  ||| S:40888 E:40900 ||| .
Finally ||| S:40900 E:40907 ||| RB
,  ||| S:40907 E:40909 ||| ,
throughout  ||| S:40909 E:40920 ||| IN
the  ||| S:40920 E:40924 ||| DT
current  ||| S:40924 E:40932 ||| JJ
study  ||| S:40932 E:40938 ||| NN
we  ||| S:40938 E:40941 ||| PRP
came  ||| S:40941 E:40946 ||| VBD
across  ||| S:40946 E:40963 ||| IN
some  ||| S:40963 E:40968 ||| DT
technical  ||| S:40968 E:40978 ||| JJ
findings  ||| S:40978 E:40987 ||| NNS
that  ||| S:40987 E:40992 ||| WDT
were  ||| S:40992 E:40997 ||| VBD
critical  ||| S:40997 E:41006 ||| JJ
in  ||| S:41006 E:41009 ||| IN
the  ||| S:41009 E:41023 ||| DT
confirmation  ||| S:41023 E:41036 ||| NN
of  ||| S:41036 E:41039 ||| IN
most  ||| S:41039 E:41044 ||| JJS
of  ||| S:41044 E:41047 ||| IN
our  ||| S:41047 E:41051 ||| PRP$
results ||| S:41051 E:41058 ||| NNS
.  ||| S:41058 E:41060 ||| .
For  ||| S:41060 E:41064 ||| IN
instance ||| S:41064 E:41072 ||| NN
,  ||| S:41072 E:41074 ||| ,
few  ||| S:41074 E:41088 ||| JJ
genes  ||| S:41088 E:41094 ||| NNS
did  ||| S:41094 E:41098 ||| VBD
not  ||| S:41098 E:41102 ||| RB
correlate  ||| S:41102 E:41112 ||| VBN
in  ||| S:41112 E:41115 ||| IN
their  ||| S:41115 E:41121 ||| PRP$
activation  ||| S:41121 E:41132 ||| NN
or  ||| S:41132 E:41145 ||| CC
suppression  ||| S:41145 E:41157 ||| JJ
levels  ||| S:41157 E:41164 ||| NNS
when  ||| S:41164 E:41169 ||| WRB
comparing  ||| S:41169 E:41179 ||| VBG
fold  ||| S:41179 E:41184 ||| JJ
changes  ||| S:41184 E:41192 ||| NNS
between  ||| S:41192 E:41210 ||| IN
microarrays  ||| S:41210 E:41222 ||| NN
and  ||| S:41222 E:41226 ||| CC
protein  ||| S:41226 E:41234 ||| NN
levels  ||| S:41234 E:41241 ||| NNS
using  ||| S:41241 E:41247 ||| VBG
western  ||| S:41247 E:41255 ||| JJ
blot  ||| S:41255 E:41270 ||| JJ
analysis ||| S:41270 E:41278 ||| NN
.  ||| S:41278 E:41280 ||| .
We  ||| S:41280 E:41283 ||| PRP
suspect  ||| S:41283 E:41291 ||| VBP
this  ||| S:41291 E:41296 ||| DT
is  ||| S:41296 E:41299 ||| VBZ
because  ||| S:41299 E:41307 ||| IN
many  ||| S:41307 E:41312 ||| JJ
genes  ||| S:41312 E:41318 ||| NNS
that  ||| S:41318 E:41323 ||| WDT
are  ||| S:41323 E:41337 ||| VBP
transcribed  ||| S:41337 E:41349 ||| NNS
may  ||| S:41349 E:41353 ||| MD
not  ||| S:41353 E:41357 ||| RB
necessarily  ||| S:41357 E:41369 ||| RB
be  ||| S:41369 E:41372 ||| VB
translated ||| S:41372 E:41382 ||| VBN
,  ||| S:41382 E:41384 ||| ,
due  ||| S:41384 E:41388 ||| JJ
to  ||| S:41388 E:41401 ||| TO
their  ||| S:41401 E:41407 ||| PRP$
cell  ||| S:41407 E:41412 ||| NN
cycle  ||| S:41412 E:41418 ||| NN
stage ||| S:41418 E:41423 ||| NN
,  ||| S:41423 E:41425 ||| ,
5 ||| S:41425 E:41426 ||| CD
'  ||| S:41426 E:41428 ||| POS
stem  ||| S:41428 E:41433 ||| NN
and  ||| S:41433 E:41437 ||| CC
loop  ||| S:41437 E:41442 ||| JJ
RNA  ||| S:41442 E:41446 ||| NNP
structures ||| S:41446 E:41456 ||| NNS
,  ||| S:41456 E:41468 ||| ,
varying  ||| S:41468 E:41476 ||| VBG
half-lives  ||| S:41476 E:41487 ||| JJ
of  ||| S:41487 E:41490 ||| IN
proteins  ||| S:41490 E:41499 ||| NNS
and  ||| S:41499 E:41503 ||| CC
mRNAs ||| S:41503 E:41508 ||| JJ
,  ||| S:41508 E:41510 ||| ,
and  ||| S:41510 E:41514 ||| CC
a  ||| S:41514 E:41516 ||| DT
host  ||| S:41516 E:41521 ||| NN
of  ||| S:41521 E:41534 ||| IN
other  ||| S:41534 E:41540 ||| JJ
unknown  ||| S:41540 E:41548 ||| JJ
variables ||| S:41548 E:41557 ||| NNS
.  ||| S:41557 E:41559 ||| .
Also ||| S:41559 E:41563 ||| RB
,  ||| S:41563 E:41565 ||| ,
specific  ||| S:41565 E:41574 ||| JJ
changes  ||| S:41574 E:41582 ||| NNS
that  ||| S:41582 E:41597 ||| WDT
occur  ||| S:41597 E:41603 ||| VBP
in  ||| S:41603 E:41606 ||| IN
a  ||| S:41606 E:41608 ||| DT
cell  ||| S:41608 E:41613 ||| NN
may  ||| S:41613 E:41617 ||| MD
not  ||| S:41617 E:41621 ||| RB
be  ||| S:41621 E:41624 ||| VB
required  ||| S:41624 E:41633 ||| VBN
in  ||| S:41633 E:41636 ||| IN
redundant  ||| S:41636 E:41646 ||| JJ
pathways  ||| S:41646 E:41665 ||| NN
that  ||| S:41665 E:41670 ||| IN
score  ||| S:41670 E:41676 ||| NN
for  ||| S:41676 E:41680 ||| IN
a  ||| S:41680 E:41682 ||| DT
specific  ||| S:41682 E:41691 ||| JJ
function ||| S:41691 E:41699 ||| NN
.  ||| S:41699 E:41701 ||| .
This  ||| S:41701 E:41706 ||| DT
is  ||| S:41706 E:41709 ||| VBZ
commonly  ||| S:41709 E:41718 ||| RB
seen  ||| S:41718 E:41733 ||| VBN
in  ||| S:41733 E:41736 ||| IN
the  ||| S:41736 E:41740 ||| DT
differences  ||| S:41740 E:41752 ||| NNS
between  ||| S:41752 E:41760 ||| IN
HIV-1  ||| S:41760 E:41766 ||| NNP
infected  ||| S:41766 E:41775 ||| JJ
or  ||| S:41775 E:41778 ||| CC
Tat  ||| S:41778 E:41792 ||| NNP
expressing  ||| S:41792 E:41814 ||| NN
in  ||| S:41814 E:41817 ||| IN
vitro  ||| S:41817 E:41823 ||| JJ
cell  ||| S:41823 E:41828 ||| NN
lines  ||| S:41828 E:41834 ||| NNS
and  ||| S:41834 E:41838 ||| CC
AIDS  ||| S:41838 E:41853 ||| NNP
patients  ||| S:41853 E:41862 ||| NNS
PBMC  ||| S:41862 E:41867 ||| JJ
samples ||| S:41867 E:41874 ||| NNS
.  ||| S:41874 E:41876 ||| .
Therefore ||| S:41876 E:41885 ||| RB
,  ||| S:41885 E:41887 ||| ,
other  ||| S:41887 E:41893 ||| JJ
microarrays  ||| S:41893 E:41905 ||| NN
would  ||| S:41905 E:41921 ||| MD
have  ||| S:41921 E:41926 ||| VB
to  ||| S:41926 E:41929 ||| TO
be  ||| S:41929 E:41932 ||| VB
performed  ||| S:41932 E:41942 ||| VBN
on  ||| S:41942 E:41945 ||| IN
purified  ||| S:41945 E:41954 ||| JJ
infected  ||| S:41954 E:41963 ||| JJ
PBMCs  ||| S:41963 E:41969 ||| JJ
to  ||| S:41969 E:41982 ||| TO
confirm  ||| S:41982 E:41990 ||| VB
most  ||| S:41990 E:41995 ||| JJS
of  ||| S:41995 E:41998 ||| IN
the  ||| S:41998 E:42002 ||| DT
changes  ||| S:42002 E:42010 ||| NNS
observed  ||| S:42010 E:42019 ||| VBD
in  ||| S:42019 E:42022 ||| IN
Tables  ||| S:42022 E:42029 ||| NNP
1 ||| S:42029 E:42030 ||| CD
,  ||| S:42030 E:42032 ||| ,
2 ||| S:42032 E:42033 ||| CD
,  ||| S:42033 E:42035 ||| ,
and  ||| S:42035 E:42049 ||| CC
3 ||| S:42049 E:42050 ||| CD
.  ||| S:42050 E:42052 ||| .
Unfortunately ||| S:42052 E:42065 ||| RB
,  ||| S:42065 E:42067 ||| ,
to  ||| S:42067 E:42070 ||| TO
date  ||| S:42070 E:42075 ||| VB
this  ||| S:42075 E:42080 ||| DT
particular  ||| S:42080 E:42091 ||| JJ
issue  ||| S:42091 E:42097 ||| NN
is  ||| S:42097 E:42100 ||| VBZ
not  ||| S:42100 E:42114 ||| RB
feasibly  ||| S:42114 E:42123 ||| JJ
addressable ||| S:42123 E:42134 ||| NN
,  ||| S:42134 E:42136 ||| ,
since  ||| S:42136 E:42142 ||| IN
it  ||| S:42142 E:42145 ||| PRP
is  ||| S:42145 E:42148 ||| VBZ
not  ||| S:42148 E:42152 ||| RB
possible  ||| S:42152 E:42161 ||| JJ
to  ||| S:42161 E:42164 ||| TO
isolate  ||| S:42164 E:42182 ||| VB
a  ||| S:42182 E:42184 ||| DT
homogenous  ||| S:42184 E:42195 ||| JJ
population  ||| S:42195 E:42206 ||| NN
of  ||| S:42206 E:42209 ||| IN
infected  ||| S:42209 E:42218 ||| JJ
T-  ||| S:42218 E:42221 ||| JJ
or  ||| S:42221 E:42224 ||| CC
Monocytic  ||| S:42224 E:42234 ||| NNP
cells  ||| S:42234 E:42250 ||| NNS
from  ||| S:42250 E:42255 ||| IN
AIDS  ||| S:42255 E:42260 ||| NNP
patients ||| S:42260 E:42268 ||| NNS
.  ||| S:42268 E:42270 ||| .
Also ||| S:42270 E:42274 ||| RB
,  ||| S:42274 E:42276 ||| ,
confirmatory  ||| S:42276 E:42289 ||| JJ
tests  ||| S:42289 E:42295 ||| NNS
for  ||| S:42295 E:42299 ||| IN
protein  ||| S:42299 E:42317 ||| NN
expression  ||| S:42317 E:42328 ||| NN
would  ||| S:42328 E:42334 ||| MD
have  ||| S:42334 E:42339 ||| VB
to  ||| S:42339 E:42342 ||| TO
be  ||| S:42342 E:42345 ||| VB
done  ||| S:42345 E:42350 ||| VBN
with  ||| S:42350 E:42355 ||| IN
both  ||| S:42355 E:42360 ||| DT
hydrophilic  ||| S:42360 E:42382 ||| NN
and  ||| S:42382 E:42386 ||| CC
hydrophobic  ||| S:42386 E:42398 ||| JJ
extraction  ||| S:42398 E:42409 ||| JJ
buffers ||| S:42409 E:42416 ||| NN
.  ||| S:42416 E:42418 ||| .
For  ||| S:42418 E:42422 ||| IN
instance ||| S:42422 E:42430 ||| NN
,  ||| S:42430 E:42432 ||| ,
we  ||| S:42432 E:42435 ||| PRP
have  ||| S:42435 E:42450 ||| VBP
observed  ||| S:42450 E:42459 ||| VBN
that  ||| S:42459 E:42464 ||| IN
PCNA  ||| S:42464 E:42469 ||| NNP
protein ||| S:42469 E:42476 ||| NN
,  ||| S:42476 E:42478 ||| ,
which  ||| S:42478 E:42484 ||| WDT
is  ||| S:42484 E:42487 ||| VBZ
up-regulated  ||| S:42487 E:42500 ||| JJ
in  ||| S:42500 E:42503 ||| IN
Tat  ||| S:42503 E:42517 ||| NNP
expressing  ||| S:42517 E:42528 ||| VBG
cells ||| S:42528 E:42533 ||| NNS
,  ||| S:42533 E:42535 ||| ,
extract  ||| S:42535 E:42543 ||| VB
best  ||| S:42543 E:42548 ||| JJS
with  ||| S:42548 E:42553 ||| IN
hydrophobic  ||| S:42553 E:42565 ||| JJ
buffers  ||| S:42565 E:42583 ||| NN
from  ||| S:42583 E:42588 ||| IN
the  ||| S:42588 E:42592 ||| DT
nucleus ||| S:42592 E:42599 ||| NN
,  ||| S:42599 E:42601 ||| ,
presumably  ||| S:42601 E:42612 ||| RB
due  ||| S:42612 E:42616 ||| JJ
to  ||| S:42616 E:42619 ||| TO
its  ||| S:42619 E:42623 ||| PRP$
binding  ||| S:42623 E:42631 ||| JJ
to  ||| S:42631 E:42634 ||| TO
DNA  ||| S:42634 E:42648 ||| NNP
replication  ||| S:42648 E:42660 ||| JJ
machinery  ||| S:42660 E:42670 ||| NN
( ||| S:42670 E:42671 ||| -LRB-
data  ||| S:42671 E:42676 ||| NNS
not  ||| S:42676 E:42680 ||| RB
shown ||| S:42680 E:42685 ||| VBN
) ||| S:42685 E:42686 ||| -RRB-
.  ||| S:42686 E:42688 ||| .
Future  ||| S:42688 E:42705 ||| JJ
experiments  ||| S:42705 E:42717 ||| NNS
will  ||| S:42717 E:42722 ||| MD
address  ||| S:42722 E:42730 ||| VB
issues  ||| S:42730 E:42737 ||| NNS
related  ||| S:42737 E:42745 ||| VBN
to  ||| S:42745 E:42748 ||| TO
differences  ||| S:42748 E:42770 ||| NNS
between  ||| S:42770 E:42778 ||| IN
various  ||| S:42778 E:42786 ||| JJ
HIV-1  ||| S:42786 E:42792 ||| NNP
Tat  ||| S:42792 E:42796 ||| NNP
clades ||| S:42796 E:42802 ||| NN
,  ||| S:42802 E:42804 ||| ,
host  ||| S:42804 E:42809 ||| NN
expression  ||| S:42809 E:42820 ||| NN
levels  ||| S:42820 E:42837 ||| NNS
between  ||| S:42837 E:42845 ||| IN
T-  ||| S:42845 E:42848 ||| JJ
and  ||| S:42848 E:42852 ||| CC
Monocytic  ||| S:42852 E:42862 ||| NNP
cells ||| S:42862 E:42867 ||| NNS
,  ||| S:42867 E:42869 ||| ,
and  ||| S:42869 E:42873 ||| CC
its  ||| S:42873 E:42877 ||| PRP$
effect  ||| S:42877 E:42884 ||| NN
at  ||| S:42884 E:42887 ||| IN
various  ||| S:42887 E:42905 ||| JJ
stages  ||| S:42905 E:42912 ||| NNS
of  ||| S:42912 E:42915 ||| IN
the  ||| S:42915 E:42919 ||| DT
cell  ||| S:42919 E:42924 ||| NN
cycle ||| S:42924 E:42929 ||| NN
.  ||| S:42929 E:42962 ||| .
Conclusions  ||| S:42962 E:42982 ||| NNP
Expression  ||| S:42982 E:42993 ||| NNP
profiling  ||| S:42993 E:43003 ||| NN
from  ||| S:43003 E:43008 ||| IN
HIV-1  ||| S:43008 E:43014 ||| NNP
or  ||| S:43014 E:43017 ||| CC
Tat  ||| S:43017 E:43021 ||| NNP
expressing  ||| S:43021 E:43032 ||| VBG
cells  ||| S:43032 E:43046 ||| NNS
holds  ||| S:43046 E:43052 ||| VBZ
great  ||| S:43052 E:43058 ||| JJ
promise  ||| S:43058 E:43066 ||| NN
for  ||| S:43066 E:43070 ||| IN
rapid  ||| S:43070 E:43076 ||| JJ
functional  ||| S:43076 E:43087 ||| JJ
analysis ||| S:43087 E:43095 ||| NN
.  ||| S:43095 E:43097 ||| .
Here ||| S:43097 E:43101 ||| RB
,  ||| S:43101 E:43103 ||| ,
we  ||| S:43103 E:43114 ||| PRP
have  ||| S:43114 E:43119 ||| VBP
described  ||| S:43119 E:43129 ||| VBN
the  ||| S:43129 E:43133 ||| DT
effect  ||| S:43133 E:43140 ||| NN
of  ||| S:43140 E:43143 ||| IN
Tat  ||| S:43143 E:43147 ||| NNP
and  ||| S:43147 E:43151 ||| CC
its  ||| S:43151 E:43155 ||| PRP$
alterations  ||| S:43155 E:43167 ||| NN
with  ||| S:43167 E:43180 ||| IN
the  ||| S:43180 E:43184 ||| DT
host  ||| S:43184 E:43189 ||| NN
cellular  ||| S:43189 E:43198 ||| JJ
gene  ||| S:43198 E:43203 ||| NN
expression ||| S:43203 E:43213 ||| NN
.  ||| S:43213 E:43215 ||| .
We  ||| S:43215 E:43218 ||| PRP
observed  ||| S:43218 E:43227 ||| VBD
that  ||| S:43227 E:43232 ||| IN
more  ||| S:43232 E:43245 ||| JJR
than  ||| S:43245 E:43250 ||| IN
2 ||| S:43250 E:43251 ||| CD
/ ||| S:43251 E:43252 ||| CD
3  ||| S:43252 E:43254 ||| CD
of  ||| S:43254 E:43257 ||| IN
the  ||| S:43257 E:43261 ||| DT
cellular  ||| S:43261 E:43270 ||| JJ
genes  ||| S:43270 E:43276 ||| NNS
tested  ||| S:43276 E:43283 ||| VBD
were  ||| S:43283 E:43288 ||| VBD
down-regulated  ||| S:43288 E:43311 ||| JJ
by  ||| S:43311 E:43314 ||| IN
Tat ||| S:43314 E:43317 ||| NNP
.  ||| S:43317 E:43319 ||| .
These  ||| S:43319 E:43325 ||| DT
genes  ||| S:43325 E:43331 ||| NNS
belong  ||| S:43331 E:43338 ||| VBP
to  ||| S:43338 E:43341 ||| TO
receptor ||| S:43341 E:43349 ||| NN
,  ||| S:43349 E:43351 ||| ,
co-receptor ||| S:43351 E:43362 ||| NNP
,  ||| S:43362 E:43364 ||| ,
and  ||| S:43364 E:43376 ||| CC
co-activator  ||| S:43376 E:43389 ||| JJ
pathways  ||| S:43389 E:43398 ||| NN
that  ||| S:43398 E:43403 ||| WDT
are  ||| S:43403 E:43407 ||| VBP
part  ||| S:43407 E:43412 ||| NN
of  ||| S:43412 E:43415 ||| IN
serine ||| S:43415 E:43421 ||| FW
/ ||| S:43421 E:43422 ||| FW
threonine  ||| S:43422 E:43440 ||| FW
receptor  ||| S:43440 E:43449 ||| FW
tyrosine  ||| S:43449 E:43458 ||| FW
kinase ||| S:43458 E:43464 ||| FW
,  ||| S:43464 E:43466 ||| ,
Ras ||| S:43466 E:43469 ||| NNP
/ ||| S:43469 E:43470 ||| NNP
Raf ||| S:43470 E:43473 ||| NNP
/ ||| S:43473 E:43474 ||| NNP
MEK ||| S:43474 E:43477 ||| NNP
/ ||| S:43477 E:43478 ||| NNP
ERK  ||| S:43478 E:43482 ||| NNP
( ||| S:43482 E:43483 ||| -LRB-
MAPK ||| S:43483 E:43487 ||| NNP
)  ||| S:43487 E:43489 ||| -RRB-
cascade ||| S:43489 E:43496 ||| NN
,  ||| S:43496 E:43506 ||| ,
which  ||| S:43506 E:43512 ||| WDT
control  ||| S:43512 E:43520 ||| VBP
proliferative  ||| S:43520 E:43534 ||| VBN
and ||| S:43534 E:43537 ||| CC
/ ||| S:43537 E:43538 ||| NNP
or  ||| S:43538 E:43541 ||| CC
differentiation  ||| S:43541 E:43557 ||| JJ
signals ||| S:43557 E:43564 ||| NNS
.  ||| S:43564 E:43574 ||| .
We  ||| S:43574 E:43577 ||| PRP
also  ||| S:43577 E:43582 ||| RB
observed  ||| S:43582 E:43591 ||| VBD
a  ||| S:43591 E:43593 ||| DT
great  ||| S:43593 E:43599 ||| JJ
deal  ||| S:43599 E:43604 ||| NN
of  ||| S:43604 E:43607 ||| IN
increase  ||| S:43607 E:43616 ||| NN
in  ||| S:43616 E:43619 ||| IN
the  ||| S:43619 E:43623 ||| DT
host  ||| S:43623 E:43628 ||| NN
cell  ||| S:43628 E:43641 ||| NN
translation  ||| S:43641 E:43653 ||| NN
apparatus  ||| S:43653 E:43663 ||| NN
with  ||| S:43663 E:43668 ||| IN
the  ||| S:43668 E:43672 ||| DT
possible  ||| S:43672 E:43681 ||| JJ
aim  ||| S:43681 E:43685 ||| NN
of  ||| S:43685 E:43688 ||| IN
optimizing  ||| S:43688 E:43707 ||| JJ
viral  ||| S:43707 E:43713 ||| JJ
mRNA  ||| S:43713 E:43718 ||| JJ
translation  ||| S:43718 E:43730 ||| NN
prior  ||| S:43730 E:43736 ||| RB
to  ||| S:43736 E:43739 ||| TO
viral  ||| S:43739 E:43745 ||| JJ
maturation  ||| S:43745 E:43756 ||| NN
and  ||| S:43756 E:43768 ||| CC
release ||| S:43768 E:43775 ||| NN
.  ||| S:43775 E:43777 ||| .
Therefore ||| S:43777 E:43786 ||| RB
,  ||| S:43786 E:43788 ||| ,
HIV-1  ||| S:43788 E:43794 ||| NNP
accessory  ||| S:43794 E:43804 ||| FW
doubly  ||| S:43804 E:43811 ||| FW
spliced  ||| S:43811 E:43819 ||| FW
messages  ||| S:43819 E:43836 ||| FW
such  ||| S:43836 E:43841 ||| JJ
as  ||| S:43841 E:43844 ||| IN
Tat ||| S:43844 E:43847 ||| NNP
,  ||| S:43847 E:43849 ||| ,
may  ||| S:43849 E:43853 ||| MD
control  ||| S:43853 E:43861 ||| VB
the  ||| S:43861 E:43865 ||| DT
host  ||| S:43865 E:43870 ||| NN
gene  ||| S:43870 E:43875 ||| NN
expression  ||| S:43875 E:43886 ||| NN
in  ||| S:43886 E:43897 ||| IN
latently  ||| S:43897 E:43906 ||| JJ
infected  ||| S:43906 E:43915 ||| JJ
cells ||| S:43915 E:43920 ||| NNS
,  ||| S:43920 E:43922 ||| ,
and  ||| S:43922 E:43926 ||| CC
determine  ||| S:43926 E:43936 ||| VB
not  ||| S:43936 E:43940 ||| RB
only  ||| S:43940 E:43945 ||| RB
viral  ||| S:43945 E:43959 ||| JJ
transcription ||| S:43959 E:43972 ||| NN
,  ||| S:43972 E:43974 ||| ,
but  ||| S:43974 E:43978 ||| CC
also  ||| S:43978 E:43983 ||| RB
the  ||| S:43983 E:43987 ||| DT
fate  ||| S:43987 E:43992 ||| NN
of  ||| S:43992 E:43995 ||| IN
post-transcriptional  ||| S:43995 E:44024 ||| JJ
events ||| S:44024 E:44030 ||| NNS
.  ||| S:44030 E:44054 ||| .
Materials  ||| S:44054 E:44064 ||| NNS
and  ||| S:44064 E:44068 ||| CC
method  ||| S:44068 E:44094 ||| NN
Cell  ||| S:44094 E:44099 ||| NNP
culture  ||| S:44099 E:44117 ||| NN
ACH  ||| S:44117 E:44132 ||| NNP
2  ||| S:44132 E:44134 ||| CD
cells  ||| S:44134 E:44140 ||| NNS
are  ||| S:44140 E:44144 ||| VBP
HIV-1  ||| S:44144 E:44150 ||| NNP
infected  ||| S:44150 E:44159 ||| VBD
CD4  ||| S:44159 E:44173 ||| CD
lymphocytic  ||| S:44173 E:44185 ||| CD
cells ||| S:44185 E:44190 ||| NNS
,  ||| S:44190 E:44192 ||| ,
with  ||| S:44192 E:44197 ||| IN
an  ||| S:44197 E:44200 ||| DT
integrated  ||| S:44200 E:44211 ||| JJ
wild-type  ||| S:44211 E:44231 ||| JJ
single-copy  ||| S:44231 E:44243 ||| JJ
chromatinized  ||| S:44243 E:44257 ||| JJ
DNA ||| S:44257 E:44260 ||| NN
.  ||| S:44260 E:44262 ||| .
The  ||| S:44262 E:44266 ||| DT
CEM  ||| S:44266 E:44270 ||| NNP
T  ||| S:44270 E:44272 ||| NN
cell  ||| S:44272 E:44277 ||| NN
( ||| S:44277 E:44278 ||| -LRB-
12D7 ||| S:44278 E:44282 ||| NNP
)  ||| S:44282 E:44284 ||| -RRB-
is  ||| S:44284 E:44297 ||| VBZ
the  ||| S:44297 E:44301 ||| DT
parental  ||| S:44301 E:44310 ||| JJ
cell  ||| S:44310 E:44315 ||| NN
for  ||| S:44315 E:44319 ||| IN
ACH  ||| S:44319 E:44334 ||| NNP
2  ||| S:44334 E:44336 ||| CD
cells ||| S:44336 E:44341 ||| NNS
.  ||| S:44341 E:44343 ||| .
ACH2  ||| S:44343 E:44348 ||| NNP
cell  ||| S:44348 E:44353 ||| NN
lines  ||| S:44353 E:44359 ||| NNS
has  ||| S:44359 E:44363 ||| VBZ
a  ||| S:44363 E:44365 ||| DT
single  ||| S:44365 E:44382 ||| JJ
copy  ||| S:44382 E:44387 ||| NN
of  ||| S:44387 E:44390 ||| IN
LAI  ||| S:44390 E:44394 ||| NNP
strain  ||| S:44394 E:44401 ||| NN
proviral  ||| S:44401 E:44410 ||| NN
sequence ||| S:44410 E:44418 ||| NN
.  ||| S:44418 E:44420 ||| .
The  ||| S:44420 E:44424 ||| DT
TAR  ||| S:44424 E:44428 ||| NNP
has  ||| S:44428 E:44432 ||| VBZ
a  ||| S:44432 E:44434 ||| DT
point  ||| S:44434 E:44450 ||| NN
mutation  ||| S:44450 E:44459 ||| NN
at  ||| S:44459 E:44462 ||| IN
( ||| S:44462 E:44463 ||| -LRB-
C37  ||| S:44463 E:44467 ||| NNP
- ||| S:44467 E:44468 ||| :
>  ||| S:44468 E:44470 ||| CD
T ||| S:44470 E:44471 ||| NN
) ||| S:44471 E:44472 ||| -RRB-
,  ||| S:44472 E:44474 ||| ,
which  ||| S:44474 E:44480 ||| WDT
no  ||| S:44480 E:44483 ||| RB
longer  ||| S:44483 E:44490 ||| JJR
responds  ||| S:44490 E:44509 ||| NNS
( ||| S:44509 E:44510 ||| -LRB-
efficiently ||| S:44510 E:44521 ||| LS
)  ||| S:44521 E:44523 ||| -RRB-
to  ||| S:44523 E:44526 ||| TO
Tat ||| S:44526 E:44529 ||| NNP
.  ||| S:44529 E:44531 ||| .
However ||| S:44531 E:44538 ||| RB
,  ||| S:44538 E:44540 ||| ,
the  ||| S:44540 E:44544 ||| DT
cell  ||| S:44544 E:44549 ||| NN
line  ||| S:44549 E:44554 ||| NN
is  ||| S:44554 E:44557 ||| VBZ
fully  ||| S:44557 E:44573 ||| RB
capable  ||| S:44573 E:44581 ||| JJ
of  ||| S:44581 E:44584 ||| IN
making  ||| S:44584 E:44591 ||| VBG
infectious  ||| S:44591 E:44602 ||| JJ
virus  ||| S:44602 E:44608 ||| NN
in  ||| S:44608 E:44611 ||| IN
presence  ||| S:44611 E:44620 ||| NN
of  ||| S:44620 E:44623 ||| IN
TNF ||| S:44623 E:44626 ||| NNP
,  ||| S:44626 E:44638 ||| ,
PHA ||| S:44638 E:44641 ||| NNP
,  ||| S:44641 E:44643 ||| ,
PMA ||| S:44643 E:44646 ||| NNP
,  ||| S:44646 E:44648 ||| ,
and  ||| S:44648 E:44652 ||| CC
a  ||| S:44652 E:44654 ||| DT
host  ||| S:44654 E:44659 ||| NN
of  ||| S:44659 E:44662 ||| IN
other  ||| S:44662 E:44668 ||| JJ
stimuli ||| S:44668 E:44675 ||| NNS
.  ||| S:44675 E:44677 ||| .
H9  ||| S:44677 E:44680 ||| NNP
and  ||| S:44680 E:44684 ||| CC
H9 ||| S:44684 E:44686 ||| NNP
/ ||| S:44686 E:44687 ||| NNP
Tat  ||| S:44687 E:44701 ||| NNP
cells  ||| S:44701 E:44707 ||| NNS
are  ||| S:44707 E:44711 ||| VBP
both  ||| S:44711 E:44716 ||| DT
CD4+  ||| S:44716 E:44721 ||| NNP
Lymphocytic  ||| S:44721 E:44733 ||| NNP
cells ||| S:44733 E:44738 ||| NNS
,  ||| S:44738 E:44740 ||| ,
where  ||| S:44740 E:44746 ||| WRB
H9  ||| S:44746 E:44749 ||| JJ
cells  ||| S:44749 E:44765 ||| NNS
carry  ||| S:44765 E:44771 ||| VBP
a  ||| S:44771 E:44773 ||| DT
control  ||| S:44773 E:44781 ||| NN
integrated  ||| S:44781 E:44792 ||| JJ
vector  ||| S:44792 E:44799 ||| NN
without  ||| S:44799 E:44807 ||| IN
the  ||| S:44807 E:44811 ||| DT
Tat  ||| S:44811 E:44815 ||| JJ
open  ||| S:44815 E:44830 ||| JJ
reading  ||| S:44830 E:44838 ||| NN
frame ||| S:44838 E:44843 ||| NN
,  ||| S:44843 E:44845 ||| ,
and  ||| S:44845 E:44849 ||| CC
H9 ||| S:44849 E:44851 ||| NNP
/ ||| S:44851 E:44852 ||| NNP
Tat  ||| S:44852 E:44856 ||| NNP
cells  ||| S:44856 E:44862 ||| NNS
carry  ||| S:44862 E:44868 ||| VBP
integrated  ||| S:44868 E:44879 ||| VBN
Tat  ||| S:44879 E:44893 ||| JJ
expression  ||| S:44893 E:44904 ||| NN
vector ||| S:44904 E:44910 ||| NN
.  ||| S:44910 E:44912 ||| .
Both  ||| S:44912 E:44917 ||| DT
cell  ||| S:44917 E:44922 ||| NN
lines  ||| S:44922 E:44928 ||| NNS
were  ||| S:44928 E:44933 ||| VBD
a  ||| S:44933 E:44935 ||| DT
generous  ||| S:44935 E:44944 ||| JJ
gift  ||| S:44944 E:44959 ||| NN
of  ||| S:44959 E:44962 ||| IN
George  ||| S:44962 E:44969 ||| NNP
Pavlakis  ||| S:44969 E:44978 ||| NNP
( ||| S:44978 E:44979 ||| -LRB-
NCI ||| S:44979 E:44982 ||| NNP
,  ||| S:44982 E:44984 ||| ,
NIH ||| S:44984 E:44987 ||| NNP
) ||| S:44987 E:44988 ||| -RRB-
.  ||| S:44988 E:44990 ||| .
U1  ||| S:44990 E:44993 ||| NNP
is  ||| S:44993 E:44996 ||| VBZ
a  ||| S:44996 E:44998 ||| DT
monocytic  ||| S:44998 E:45008 ||| JJ
clone  ||| S:45008 E:45024 ||| NN
harboring  ||| S:45024 E:45034 ||| VBD
two  ||| S:45034 E:45038 ||| CD
copies  ||| S:45038 E:45045 ||| NNS
of  ||| S:45045 E:45048 ||| IN
the  ||| S:45048 E:45052 ||| DT
viral  ||| S:45052 E:45058 ||| JJ
genome  ||| S:45058 E:45065 ||| NN
from  ||| S:45065 E:45070 ||| IN
parental  ||| S:45070 E:45089 ||| JJ
U973  ||| S:45089 E:45094 ||| CD
cells ||| S:45094 E:45099 ||| NNS
.  ||| S:45099 E:45101 ||| .
All  ||| S:45101 E:45105 ||| DT
cells  ||| S:45105 E:45111 ||| NNS
were  ||| S:45111 E:45116 ||| VBD
cultured  ||| S:45116 E:45125 ||| VBN
at  ||| S:45125 E:45128 ||| IN
37°C  ||| S:45128 E:45133 ||| NNP
up  ||| S:45133 E:45136 ||| RB
to  ||| S:45136 E:45139 ||| TO
10  ||| S:45139 E:45152 ||| CD
5cells  ||| S:45152 E:45159 ||| CD
per  ||| S:45159 E:45163 ||| IN
ml  ||| S:45163 E:45166 ||| NN
in  ||| S:45166 E:45169 ||| IN
RPMI-1640  ||| S:45169 E:45179 ||| CD
media ||| S:45179 E:45184 ||| NNS
,  ||| S:45184 E:45186 ||| ,
containing  ||| S:45186 E:45197 ||| VBG
10 ||| S:45197 E:45199 ||| CD
%  ||| S:45199 E:45201 ||| NN
Fetal  ||| S:45201 E:45217 ||| NNP
Bovine  ||| S:45217 E:45224 ||| NNP
Serum  ||| S:45224 E:45230 ||| NNP
( ||| S:45230 E:45231 ||| -LRB-
FBS ||| S:45231 E:45234 ||| NNP
)  ||| S:45234 E:45236 ||| -RRB-
treated  ||| S:45236 E:45244 ||| VBN
with  ||| S:45244 E:45249 ||| IN
a  ||| S:45249 E:45251 ||| DT
mixture  ||| S:45251 E:45259 ||| NN
of  ||| S:45259 E:45262 ||| IN
1 ||| S:45262 E:45263 ||| CD
%  ||| S:45263 E:45275 ||| NN
streptomycin  ||| S:45275 E:45288 ||| NNS
and  ||| S:45288 E:45292 ||| CC
penicillin  ||| S:45292 E:45303 ||| JJ
antibiotics ||| S:45303 E:45314 ||| NN
,  ||| S:45314 E:45316 ||| ,
and  ||| S:45316 E:45320 ||| CC
1 ||| S:45320 E:45321 ||| CD
%  ||| S:45321 E:45333 ||| NN
L-glutamine  ||| S:45333 E:45345 ||| NNS
( ||| S:45345 E:45346 ||| -LRB-
Gibco ||| S:45346 E:45351 ||| NNP
/ ||| S:45351 E:45352 ||| NNP
BRL ||| S:45352 E:45355 ||| NNP
) ||| S:45355 E:45356 ||| -RRB-
.  ||| S:45356 E:45358 ||| .
Phytohemagglutinin-activated  ||| S:45358 E:45397 ||| NNP
PBMC  ||| S:45397 E:45402 ||| NNP
were  ||| S:45402 E:45407 ||| VBD
kept  ||| S:45407 E:45412 ||| VBN
in  ||| S:45412 E:45415 ||| IN
culture  ||| S:45415 E:45423 ||| NN
for  ||| S:45423 E:45427 ||| IN
2  ||| S:45427 E:45429 ||| CD
days  ||| S:45429 E:45434 ||| NNS
prior  ||| S:45434 E:45440 ||| RB
to  ||| S:45440 E:45443 ||| TO
addition  ||| S:45443 E:45452 ||| NN
of  ||| S:45452 E:45465 ||| IN
Tat  ||| S:45465 E:45469 ||| NNP
protein ||| S:45469 E:45476 ||| NN
.  ||| S:45476 E:45478 ||| .
Isolation  ||| S:45478 E:45488 ||| NNP
and  ||| S:45488 E:45492 ||| CC
treatment  ||| S:45492 E:45502 ||| NN
of  ||| S:45502 E:45505 ||| IN
PBMC  ||| S:45505 E:45510 ||| NNP
were  ||| S:45510 E:45525 ||| VBD
performed  ||| S:45525 E:45535 ||| VBN
by  ||| S:45535 E:45538 ||| IN
following  ||| S:45538 E:45548 ||| VBG
the  ||| S:45548 E:45552 ||| DT
guidelines  ||| S:45552 E:45563 ||| NNS
of  ||| S:45563 E:45566 ||| IN
the  ||| S:45566 E:45570 ||| DT
Centers  ||| S:45570 E:45578 ||| NNPS
for  ||| S:45578 E:45592 ||| IN
Disease  ||| S:45592 E:45600 ||| NNP
Control ||| S:45600 E:45607 ||| NNP
.  ||| S:45607 E:45609 ||| .
Approximately  ||| S:45609 E:45623 ||| RB
5  ||| S:45623 E:45625 ||| CD
×  ||| S:45625 E:45627 ||| CD
10  ||| S:45627 E:45630 ||| CD
6PBMC  ||| S:45630 E:45636 ||| CD
were  ||| S:45636 E:45641 ||| VBD
used  ||| S:45641 E:45646 ||| VBN
for  ||| S:45646 E:45660 ||| IN
treatment  ||| S:45660 E:45670 ||| NN
of  ||| S:45670 E:45673 ||| IN
wild  ||| S:45673 E:45678 ||| JJ
type  ||| S:45678 E:45683 ||| NN
and  ||| S:45683 E:45687 ||| CC
K41A  ||| S:45687 E:45692 ||| NNP
Tat  ||| S:45692 E:45696 ||| NNP
mutant  ||| S:45696 E:45703 ||| NNS
( ||| S:45703 E:45704 ||| -LRB-
100  ||| S:45704 E:45708 ||| CD
ng ||| S:45708 E:45710 ||| CD
/ ||| S:45710 E:45711 ||| CD
ml ||| S:45711 E:45713 ||| CD
)  ||| S:45713 E:45725 ||| -RRB-
proteins ||| S:45725 E:45733 ||| NNS
.  ||| S:45733 E:45735 ||| .
After  ||| S:45735 E:45741 ||| IN
an  ||| S:45741 E:45744 ||| DT
initial  ||| S:45744 E:45752 ||| JJ
incubation  ||| S:45752 E:45763 ||| NN
for  ||| S:45763 E:45767 ||| IN
one  ||| S:45767 E:45771 ||| CD
hr  ||| S:45771 E:45774 ||| NN
with  ||| S:45774 E:45779 ||| IN
Tat  ||| S:45779 E:45793 ||| NNP
proteins ||| S:45793 E:45801 ||| NNS
,  ||| S:45801 E:45803 ||| ,
cells  ||| S:45803 E:45809 ||| NNS
were  ||| S:45809 E:45814 ||| VBD
washed  ||| S:45814 E:45821 ||| VBN
and  ||| S:45821 E:45825 ||| CC
cultured  ||| S:45825 E:45834 ||| NN
in  ||| S:45834 E:45837 ||| IN
complete  ||| S:45837 E:45856 ||| JJ
media  ||| S:45856 E:45862 ||| NNS
for  ||| S:45862 E:45866 ||| IN
24  ||| S:45866 E:45869 ||| CD
hrs ||| S:45869 E:45872 ||| NN
,  ||| S:45872 E:45874 ||| ,
prior  ||| S:45874 E:45880 ||| RB
to  ||| S:45880 E:45883 ||| TO
western  ||| S:45883 E:45891 ||| JJ
blots.  ||| S:45891 E:45898 ||| CD
pCEP4 ||| S:45898 E:45903 ||| CD
,  ||| S:45903 E:45905 ||| ,
eTat  ||| S:45905 E:45920 ||| JJ
cells  ||| S:45920 E:45926 ||| NNS
were  ||| S:45926 E:45931 ||| VBD
HeLa  ||| S:45931 E:45936 ||| JJ
cells  ||| S:45936 E:45942 ||| NNS
stably  ||| S:45942 E:45949 ||| VBP
transfected  ||| S:45949 E:45961 ||| VBN
with  ||| S:45961 E:45966 ||| IN
either  ||| S:45966 E:45973 ||| RB
a  ||| S:45973 E:45985 ||| DT
backbone  ||| S:45985 E:45994 ||| NN
control  ||| S:45994 E:46002 ||| NN
plasmid  ||| S:46002 E:46010 ||| NNS
( ||| S:46010 E:46011 ||| -LRB-
pCEP4 ||| S:46011 E:46016 ||| NNP
;  ||| S:46016 E:46018 ||| :
Invitrogen ||| S:46018 E:46028 ||| LS
)  ||| S:46028 E:46030 ||| -RRB-
or  ||| S:46030 E:46033 ||| CC
a  ||| S:46033 E:46035 ||| DT
plasmid  ||| S:46035 E:46053 ||| NN
expressing  ||| S:46053 E:46064 ||| VBG
Tat  ||| S:46064 E:46068 ||| NNP
( ||| S:46068 E:46069 ||| -LRB-
1-86 ||| S:46069 E:46073 ||| NNP
)  ||| S:46073 E:46075 ||| -RRB-
with  ||| S:46075 E:46080 ||| IN
a  ||| S:46080 E:46082 ||| DT
C-terminal  ||| S:46082 E:46093 ||| JJ
epitope  ||| S:46093 E:46101 ||| JJ
tag  ||| S:46101 E:46115 ||| NN
( ||| S:46115 E:46116 ||| -LRB-
eTat ||| S:46116 E:46120 ||| NNP
)  ||| S:46120 E:46122 ||| -RRB-
[  ||| S:46122 E:46124 ||| -LRB-
103  ||| S:46124 E:46128 ||| CD
]  ||| S:46128 E:46130 ||| -RRB-
.  ||| S:46130 E:46132 ||| .
HeLa  ||| S:46132 E:46137 ||| JJ
cell  ||| S:46137 E:46142 ||| NN
lines  ||| S:46142 E:46148 ||| NNS
containing  ||| S:46148 E:46159 ||| VBG
either  ||| S:46159 E:46166 ||| RB
the  ||| S:46166 E:46180 ||| DT
control  ||| S:46180 E:46188 ||| NN
or  ||| S:46188 E:46191 ||| CC
eTat  ||| S:46191 E:46196 ||| JJ
plasmid  ||| S:46196 E:46204 ||| NN
were  ||| S:46204 E:46209 ||| VBD
selected  ||| S:46209 E:46218 ||| VBN
by  ||| S:46218 E:46221 ||| IN
single-cell  ||| S:46221 E:46243 ||| JJ
dilution ||| S:46243 E:46251 ||| NN
.  ||| S:46251 E:46253 ||| .
Both  ||| S:46253 E:46258 ||| DT
cell  ||| S:46258 E:46263 ||| NN
types  ||| S:46263 E:46269 ||| NNS
were  ||| S:46269 E:46274 ||| VBD
selected  ||| S:46274 E:46283 ||| VBN
and  ||| S:46283 E:46287 ||| CC
maintained  ||| S:46287 E:46308 ||| VBN
under  ||| S:46308 E:46314 ||| IN
200  ||| S:46314 E:46318 ||| CD
μg  ||| S:46318 E:46321 ||| NN
of  ||| S:46321 E:46324 ||| IN
hygromycin  ||| S:46324 E:46335 ||| FW
per  ||| S:46335 E:46339 ||| FW
ml ||| S:46339 E:46341 ||| FW
.  ||| S:46341 E:46343 ||| .
Verification  ||| S:46343 E:46356 ||| NN
of  ||| S:46356 E:46359 ||| IN
Tat  ||| S:46359 E:46373 ||| NNP
transcriptional  ||| S:46373 E:46389 ||| JJ
activity  ||| S:46389 E:46398 ||| NN
was  ||| S:46398 E:46402 ||| VBD
achieved  ||| S:46402 E:46411 ||| VBN
by  ||| S:46411 E:46414 ||| IN
electroporation  ||| S:46414 E:46440 ||| NN
of  ||| S:46440 E:46443 ||| IN
reporter  ||| S:46443 E:46452 ||| NN
plasmids  ||| S:46452 E:46461 ||| NN
as  ||| S:46461 E:46464 ||| IN
previously  ||| S:46464 E:46475 ||| RB
described  ||| S:46475 E:46485 ||| VBN
[  ||| S:46485 E:46487 ||| -LRB-
103  ||| S:46487 E:46491 ||| CD
]  ||| S:46491 E:46503 ||| -RRB-
.  ||| S:46503 E:46533 ||| .
Cell  ||| S:46533 E:46538 ||| NN
cycle  ||| S:46538 E:46544 ||| NN
analysis  ||| S:46544 E:46563 ||| NN
Hela  ||| S:46563 E:46568 ||| NNP
cells  ||| S:46568 E:46574 ||| NNS
were  ||| S:46574 E:46579 ||| VBD
blocked  ||| S:46579 E:46587 ||| VBN
with  ||| S:46587 E:46592 ||| IN
hydroxyurea  ||| S:46592 E:46604 ||| NNS
( ||| S:46604 E:46605 ||| -LRB-
Hu ||| S:46605 E:46607 ||| NNP
)  ||| S:46607 E:46609 ||| -RRB-
( ||| S:46609 E:46610 ||| -LRB-
2  ||| S:46610 E:46612 ||| CD
mM ||| S:46612 E:46614 ||| NN
)  ||| S:46614 E:46626 ||| -RRB-
for  ||| S:46626 E:46630 ||| IN
14  ||| S:46630 E:46633 ||| CD
h ||| S:46633 E:46634 ||| NNS
.  ||| S:46634 E:46636 ||| .
Following  ||| S:46636 E:46646 ||| VBG
the  ||| S:46646 E:46650 ||| DT
block ||| S:46650 E:46655 ||| NN
,  ||| S:46655 E:46657 ||| ,
cells  ||| S:46657 E:46663 ||| NNS
were  ||| S:46663 E:46668 ||| VBD
released  ||| S:46668 E:46677 ||| VBN
by  ||| S:46677 E:46690 ||| IN
being  ||| S:46690 E:46696 ||| VBG
washed  ||| S:46696 E:46703 ||| VBN
twice  ||| S:46703 E:46709 ||| RB
with  ||| S:46709 E:46714 ||| IN
phosphate-buffered  ||| S:46714 E:46733 ||| JJ
saline  ||| S:46733 E:46740 ||| NNS
( ||| S:46740 E:46741 ||| -LRB-
PBS ||| S:46741 E:46744 ||| NNP
)  ||| S:46744 E:46756 ||| -RRB-
and  ||| S:46756 E:46760 ||| CC
by  ||| S:46760 E:46763 ||| IN
the  ||| S:46763 E:46767 ||| DT
addition  ||| S:46767 E:46776 ||| NN
of  ||| S:46776 E:46779 ||| IN
complete  ||| S:46779 E:46788 ||| JJ
medium ||| S:46788 E:46794 ||| NN
.  ||| S:46794 E:46796 ||| .
All  ||| S:46796 E:46800 ||| DT
suspension  ||| S:46800 E:46821 ||| NN
cells  ||| S:46821 E:46827 ||| NNS
were  ||| S:46827 E:46832 ||| VBD
treated  ||| S:46832 E:46840 ||| VBN
with  ||| S:46840 E:46845 ||| IN
1 ||| S:46845 E:46846 ||| CD
%  ||| S:46846 E:46848 ||| NN
serum  ||| S:46848 E:46854 ||| NN
for  ||| S:46854 E:46858 ||| IN
48  ||| S:46858 E:46861 ||| CD
hrs  ||| S:46861 E:46865 ||| NNS
prior  ||| S:46865 E:46871 ||| RB
to  ||| S:46871 E:46884 ||| TO
addition  ||| S:46884 E:46893 ||| NN
of  ||| S:46893 E:46896 ||| IN
Hu ||| S:46896 E:46898 ||| NNP
.  ||| S:46898 E:46900 ||| .
Supernatants  ||| S:46900 E:46913 ||| NNP
were  ||| S:46913 E:46918 ||| VBD
collected  ||| S:46918 E:46928 ||| VBN
and  ||| S:46928 E:46932 ||| CC
analyzed  ||| S:46932 E:46951 ||| VBD
by  ||| S:46951 E:46954 ||| IN
an  ||| S:46954 E:46957 ||| DT
IL-8  ||| S:46957 E:46962 ||| NNP
ELISA  ||| S:46962 E:46968 ||| NNP
according  ||| S:46968 E:46978 ||| VBG
to  ||| S:46978 E:46981 ||| TO
the  ||| S:46981 E:46985 ||| DT
manufacturer ||| S:46985 E:46997 ||| NN
's  ||| S:46997 E:47010 ||| POS
instructions  ||| S:47010 E:47023 ||| NNS
( ||| S:47023 E:47024 ||| -LRB-
Biosource  ||| S:47024 E:47034 ||| NNP
International ||| S:47034 E:47047 ||| NNP
) ||| S:47047 E:47048 ||| -RRB-
.  ||| S:47048 E:47050 ||| .
For  ||| S:47050 E:47054 ||| IN
controls ||| S:47054 E:47062 ||| NNS
,  ||| S:47062 E:47074 ||| ,
each  ||| S:47074 E:47079 ||| DT
sample ||| S:47079 E:47085 ||| NN
,  ||| S:47085 E:47087 ||| ,
approximately  ||| S:47087 E:47101 ||| RB
1  ||| S:47101 E:47103 ||| CD
×  ||| S:47103 E:47105 ||| CD
10  ||| S:47105 E:47108 ||| CD
6cells  ||| S:47108 E:47115 ||| CD
was  ||| S:47115 E:47119 ||| VBD
processed  ||| S:47119 E:47139 ||| VBN
for  ||| S:47139 E:47143 ||| IN
cell  ||| S:47143 E:47148 ||| NN
sorting ||| S:47148 E:47155 ||| NN
.  ||| S:47155 E:47157 ||| .
Cells  ||| S:47157 E:47163 ||| NNS
were  ||| S:47163 E:47168 ||| VBD
washed  ||| S:47168 E:47175 ||| VBN
with  ||| S:47175 E:47180 ||| IN
PBS  ||| S:47180 E:47184 ||| NNP
and  ||| S:47184 E:47188 ||| CC
fixed  ||| S:47188 E:47194 ||| VBN
by  ||| S:47194 E:47207 ||| IN
addition  ||| S:47207 E:47216 ||| NN
of  ||| S:47216 E:47219 ||| IN
500  ||| S:47219 E:47223 ||| CD
μl  ||| S:47223 E:47226 ||| NN
of  ||| S:47226 E:47229 ||| IN
70 ||| S:47229 E:47231 ||| CD
%  ||| S:47231 E:47233 ||| NN
ethanol ||| S:47233 E:47240 ||| NN
.  ||| S:47240 E:47242 ||| .
For  ||| S:47242 E:47256 ||| IN
fluorescence-activated  ||| S:47256 E:47279 ||| JJ
cell  ||| S:47279 E:47284 ||| NN
sorting  ||| S:47284 E:47292 ||| NNS
( ||| S:47292 E:47293 ||| -LRB-
FACS ||| S:47293 E:47297 ||| NNP
)  ||| S:47297 E:47299 ||| -RRB-
analysis ||| S:47299 E:47307 ||| NN
,  ||| S:47307 E:47319 ||| ,
cells  ||| S:47319 E:47325 ||| NNS
were  ||| S:47325 E:47330 ||| VBD
stained  ||| S:47330 E:47338 ||| VBN
with  ||| S:47338 E:47343 ||| IN
a  ||| S:47343 E:47345 ||| DT
cocktail  ||| S:47345 E:47354 ||| NN
of  ||| S:47354 E:47357 ||| IN
propidium  ||| S:47357 E:47367 ||| JJ
iodide  ||| S:47367 E:47384 ||| NNS
( ||| S:47384 E:47385 ||| -LRB-
PI ||| S:47385 E:47387 ||| NNP
)  ||| S:47387 E:47389 ||| -RRB-
buffer  ||| S:47389 E:47396 ||| NN
( ||| S:47396 E:47397 ||| -LRB-
PBS  ||| S:47397 E:47401 ||| NNP
with  ||| S:47401 E:47406 ||| IN
Ca2+  ||| S:47406 E:47411 ||| NNP
and  ||| S:47411 E:47415 ||| CC
Mg2+ ||| S:47415 E:47419 ||| NNP
,  ||| S:47419 E:47421 ||| ,
RNase  ||| S:47421 E:47427 ||| NNP
A  ||| S:47427 E:47429 ||| NNP
[ ||| S:47429 E:47430 ||| -LRB-
10  ||| S:47430 E:47433 ||| CD
μg ||| S:47433 E:47435 ||| CD
/ ||| S:47435 E:47436 ||| CD
ml ||| S:47436 E:47438 ||| CD
] ||| S:47438 E:47439 ||| -RRB-
,  ||| S:47439 E:47451 ||| ,
NP-40  ||| S:47451 E:47457 ||| NNP
[ ||| S:47457 E:47458 ||| -LRB-
0.1 ||| S:47458 E:47461 ||| CD
% ||| S:47461 E:47462 ||| NN
] ||| S:47462 E:47463 ||| -RRB-
,  ||| S:47463 E:47465 ||| ,
and  ||| S:47465 E:47469 ||| CC
PI  ||| S:47469 E:47472 ||| NNP
[ ||| S:47472 E:47473 ||| -LRB-
50  ||| S:47473 E:47476 ||| CD
μg ||| S:47476 E:47478 ||| CD
/ ||| S:47478 E:47479 ||| CD
ml ||| S:47479 E:47481 ||| CD
] ||| S:47481 E:47482 ||| CD
)  ||| S:47482 E:47484 ||| -RRB-
followed  ||| S:47484 E:47493 ||| VBD
by  ||| S:47493 E:47496 ||| IN
cell-sorting  ||| S:47496 E:47519 ||| JJ
analysis ||| S:47519 E:47527 ||| NN
.  ||| S:47527 E:47529 ||| .
FACS  ||| S:47529 E:47534 ||| NNP
data  ||| S:47534 E:47539 ||| NNS
acquired  ||| S:47539 E:47548 ||| VBD
were  ||| S:47548 E:47553 ||| VBD
analyzed  ||| S:47553 E:47562 ||| VBN
by  ||| S:47562 E:47565 ||| IN
ModFit  ||| S:47565 E:47572 ||| NNP
LT  ||| S:47572 E:47585 ||| NNP
software  ||| S:47585 E:47594 ||| NN
( ||| S:47594 E:47595 ||| -LRB-
Verity  ||| S:47595 E:47602 ||| NNP
Software  ||| S:47602 E:47611 ||| NNP
House ||| S:47611 E:47616 ||| NNP
,  ||| S:47616 E:47618 ||| ,
Inc. ||| S:47618 E:47622 ||| NNP
) ||| S:47622 E:47623 ||| -RRB-
.  ||| S:47623 E:47653 ||| .
Cell  ||| S:47653 E:47658 ||| NN
extract  ||| S:47658 E:47666 ||| NN
preparation  ||| S:47666 E:47678 ||| NN
and  ||| S:47678 E:47682 ||| CC
immunoblotting  ||| S:47682 E:47707 ||| VBG
All  ||| S:47707 E:47711 ||| DT
cells  ||| S:47711 E:47717 ||| NNS
were  ||| S:47717 E:47722 ||| VBD
cultured  ||| S:47722 E:47731 ||| VBN
to  ||| S:47731 E:47734 ||| TO
mid-log  ||| S:47734 E:47742 ||| JJ
phase  ||| S:47742 E:47748 ||| NN
of  ||| S:47748 E:47751 ||| IN
growth ||| S:47751 E:47757 ||| NN
,  ||| S:47757 E:47769 ||| ,
washed  ||| S:47769 E:47776 ||| VBN
with  ||| S:47776 E:47781 ||| IN
PBS  ||| S:47781 E:47785 ||| NNP
without  ||| S:47785 E:47793 ||| IN
Ca  ||| S:47793 E:47796 ||| NNP
2+and  ||| S:47796 E:47802 ||| NNP
Mg  ||| S:47802 E:47805 ||| NNP
2+ ||| S:47805 E:47807 ||| NNP
,  ||| S:47807 E:47809 ||| ,
and  ||| S:47809 E:47813 ||| CC
lysed  ||| S:47813 E:47819 ||| NN
in  ||| S:47819 E:47822 ||| IN
a  ||| S:47822 E:47834 ||| DT
buffer  ||| S:47834 E:47841 ||| NN
containing  ||| S:47841 E:47852 ||| VBG
50  ||| S:47852 E:47855 ||| CD
mM  ||| S:47855 E:47858 ||| JJ
Tris-HCl  ||| S:47858 E:47867 ||| NN
( ||| S:47867 E:47868 ||| -LRB-
pH  ||| S:47868 E:47871 ||| NNP
7.5 ||| S:47871 E:47874 ||| CD
) ||| S:47874 E:47875 ||| -RRB-
,  ||| S:47875 E:47877 ||| ,
120  ||| S:47877 E:47881 ||| CD
mM  ||| S:47881 E:47884 ||| JJ
NaCl ||| S:47884 E:47888 ||| NN
,  ||| S:47888 E:47890 ||| ,
5  ||| S:47890 E:47902 ||| CD
mM  ||| S:47902 E:47905 ||| JJ
EDTA ||| S:47905 E:47909 ||| NNP
,  ||| S:47909 E:47911 ||| ,
50  ||| S:47911 E:47914 ||| CD
mM  ||| S:47914 E:47917 ||| JJ
NaF ||| S:47917 E:47920 ||| NN
,  ||| S:47920 E:47922 ||| ,
0.2  ||| S:47922 E:47926 ||| CD
mM  ||| S:47926 E:47929 ||| JJ
Na  ||| S:47929 E:47943 ||| NNP
3  ||| S:47943 E:47945 ||| CD
VO  ||| S:47945 E:47959 ||| CD
4  ||| S:47959 E:47961 ||| CD
,  ||| S:47961 E:47963 ||| ,
1  ||| S:47963 E:47965 ||| CD
mM  ||| S:47965 E:47968 ||| JJ
DTT ||| S:47968 E:47971 ||| NNP
,  ||| S:47971 E:47973 ||| ,
0.5 ||| S:47973 E:47976 ||| CD
%  ||| S:47976 E:47978 ||| NN
NP-40  ||| S:47978 E:47984 ||| NN
and  ||| S:47984 E:47988 ||| CC
protease  ||| S:47988 E:48007 ||| JJ
inhibitors  ||| S:48007 E:48018 ||| NNS
( ||| S:48018 E:48019 ||| -LRB-
Protease  ||| S:48019 E:48028 ||| FW
inhibitor  ||| S:48028 E:48038 ||| FW
cocktail  ||| S:48038 E:48047 ||| FW
tablets ||| S:48047 E:48054 ||| FW
,  ||| S:48054 E:48066 ||| ,
Boehringer  ||| S:48066 E:48077 ||| NNP
Mannheim ||| S:48077 E:48085 ||| NNP
,  ||| S:48085 E:48087 ||| ,
one  ||| S:48087 E:48091 ||| CD
tablet  ||| S:48091 E:48098 ||| NN
per  ||| S:48098 E:48102 ||| IN
50  ||| S:48102 E:48105 ||| CD
ml ||| S:48105 E:48107 ||| CD
) ||| S:48107 E:48108 ||| -RRB-
.  ||| S:48108 E:48110 ||| .
The  ||| S:48110 E:48114 ||| DT
lysate  ||| S:48114 E:48131 ||| NN
was  ||| S:48131 E:48135 ||| VBD
incubated  ||| S:48135 E:48145 ||| VBN
on  ||| S:48145 E:48148 ||| IN
ice  ||| S:48148 E:48152 ||| NN
for  ||| S:48152 E:48156 ||| IN
15  ||| S:48156 E:48159 ||| CD
min ||| S:48159 E:48162 ||| NN
,  ||| S:48162 E:48164 ||| ,
and  ||| S:48164 E:48168 ||| CC
microcentrifuged  ||| S:48168 E:48185 ||| NN
at  ||| S:48185 E:48198 ||| IN
4°C  ||| S:48198 E:48202 ||| CD
for  ||| S:48202 E:48206 ||| IN
10  ||| S:48206 E:48209 ||| CD
min ||| S:48209 E:48212 ||| NNS
.  ||| S:48212 E:48214 ||| .
Total  ||| S:48214 E:48220 ||| JJ
cellular  ||| S:48220 E:48229 ||| JJ
protein  ||| S:48229 E:48237 ||| NN
was  ||| S:48237 E:48241 ||| VBD
separated  ||| S:48241 E:48251 ||| VBN
on  ||| S:48251 E:48264 ||| IN
4-20 ||| S:48264 E:48268 ||| CD
%  ||| S:48268 E:48270 ||| NN
Tris-glycine  ||| S:48270 E:48283 ||| JJ
gels  ||| S:48283 E:48288 ||| NNS
( ||| S:48288 E:48289 ||| -LRB-
Novex ||| S:48289 E:48294 ||| NNP
,  ||| S:48294 E:48296 ||| ,
Inc. ||| S:48296 E:48300 ||| NNP
)  ||| S:48300 E:48302 ||| -RRB-
and  ||| S:48302 E:48306 ||| CC
transferred  ||| S:48306 E:48318 ||| VBN
to  ||| S:48318 E:48331 ||| TO
a  ||| S:48331 E:48333 ||| DT
polvinylidene  ||| S:48333 E:48347 ||| JJ
difluoride  ||| S:48347 E:48358 ||| NNS
( ||| S:48358 E:48359 ||| -LRB-
PVDF ||| S:48359 E:48363 ||| NNP
)  ||| S:48363 E:48365 ||| -RRB-
membranes  ||| S:48365 E:48375 ||| NNS
( ||| S:48375 E:48376 ||| -LRB-
Immobilon-P  ||| S:48376 E:48398 ||| JJ
transfer  ||| S:48398 E:48407 ||| NN
membranes ||| S:48407 E:48416 ||| NNS
;  ||| S:48416 E:48418 ||| :
Millipore  ||| S:48418 E:48428 ||| NNP
Corp. ||| S:48428 E:48433 ||| NNP
)  ||| S:48433 E:48435 ||| -RRB-
overnight  ||| S:48435 E:48445 ||| JJ
at  ||| S:48445 E:48448 ||| IN
0.08  ||| S:48448 E:48453 ||| NNP
A.  ||| S:48453 E:48466 ||| NNP
Following  ||| S:48466 E:48476 ||| VBG
the  ||| S:48476 E:48480 ||| DT
transfer ||| S:48480 E:48488 ||| NN
,  ||| S:48488 E:48490 ||| ,
blots  ||| S:48490 E:48496 ||| NN
were  ||| S:48496 E:48501 ||| VBD
blocked  ||| S:48501 E:48509 ||| VBN
with  ||| S:48509 E:48514 ||| IN
5 ||| S:48514 E:48515 ||| CD
%  ||| S:48515 E:48527 ||| NN
non-fat  ||| S:48527 E:48535 ||| JJ
dry  ||| S:48535 E:48539 ||| JJ
milk  ||| S:48539 E:48544 ||| NN
in  ||| S:48544 E:48547 ||| IN
50  ||| S:48547 E:48550 ||| CD
ml  ||| S:48550 E:48553 ||| NN
of  ||| S:48553 E:48556 ||| IN
TNE  ||| S:48556 E:48560 ||| NNP
50  ||| S:48560 E:48563 ||| CD
( ||| S:48563 E:48564 ||| -LRB-
100  ||| S:48564 E:48568 ||| CD
mM  ||| S:48568 E:48571 ||| JJ
Tris-Cl  ||| S:48571 E:48579 ||| NN
[ ||| S:48579 E:48580 ||| -LRB-
pH  ||| S:48580 E:48593 ||| NNP
8.0 ||| S:48593 E:48596 ||| NNP
] ||| S:48596 E:48597 ||| -RRB-
,  ||| S:48597 E:48599 ||| ,
50  ||| S:48599 E:48602 ||| CD
mM  ||| S:48602 E:48605 ||| JJ
NaCl ||| S:48605 E:48609 ||| NN
,  ||| S:48609 E:48611 ||| ,
1  ||| S:48611 E:48613 ||| CD
mM  ||| S:48613 E:48616 ||| JJ
EDTA ||| S:48616 E:48620 ||| NNP
)  ||| S:48620 E:48622 ||| -RRB-
plus  ||| S:48622 E:48627 ||| CC
0.1 ||| S:48627 E:48630 ||| CD
%  ||| S:48630 E:48632 ||| NN
NP-40 ||| S:48632 E:48637 ||| NN
.  ||| S:48637 E:48639 ||| .
Membranes  ||| S:48639 E:48659 ||| NNP
were  ||| S:48659 E:48664 ||| VBD
probed  ||| S:48664 E:48671 ||| VBN
with  ||| S:48671 E:48676 ||| IN
a  ||| S:48676 E:48678 ||| DT
1 ||| S:48678 E:48679 ||| CD
: ||| S:48679 E:48680 ||| :
200-1 ||| S:48680 E:48685 ||| CD
: ||| S:48685 E:48686 ||| :
1000  ||| S:48686 E:48691 ||| CD
dilution  ||| S:48691 E:48700 ||| NN
of  ||| S:48700 E:48703 ||| IN
antibodies  ||| S:48703 E:48714 ||| NNS
at  ||| S:48714 E:48727 ||| IN
4°C  ||| S:48727 E:48731 ||| CD
overnight ||| S:48731 E:48740 ||| JJ
,  ||| S:48740 E:48742 ||| ,
followed  ||| S:48742 E:48751 ||| VBN
by  ||| S:48751 E:48754 ||| IN
three  ||| S:48754 E:48760 ||| CD
washes  ||| S:48760 E:48767 ||| NN
with  ||| S:48767 E:48772 ||| IN
TNE  ||| S:48772 E:48776 ||| NNP
50  ||| S:48776 E:48779 ||| CD
plus  ||| S:48779 E:48794 ||| CC
0.1 ||| S:48794 E:48797 ||| CD
%  ||| S:48797 E:48799 ||| NN
NP-40 ||| S:48799 E:48804 ||| NN
.  ||| S:48804 E:48806 ||| .
All  ||| S:48806 E:48810 ||| DT
antibodies  ||| S:48810 E:48821 ||| NNS
used  ||| S:48821 E:48826 ||| VBN
in  ||| S:48826 E:48829 ||| IN
this  ||| S:48829 E:48834 ||| DT
study  ||| S:48834 E:48840 ||| NN
were  ||| S:48840 E:48855 ||| VBD
purchased  ||| S:48855 E:48865 ||| VBN
from  ||| S:48865 E:48870 ||| IN
Santa  ||| S:48870 E:48876 ||| NNP
Cruz  ||| S:48876 E:48881 ||| NNP
Biotechnology ||| S:48881 E:48894 ||| NNP
.  ||| S:48894 E:48896 ||| .
The  ||| S:48896 E:48900 ||| DT
next  ||| S:48900 E:48905 ||| JJ
day ||| S:48905 E:48908 ||| NN
,  ||| S:48908 E:48920 ||| ,
blots  ||| S:48920 E:48926 ||| NN
were  ||| S:48926 E:48931 ||| VBD
incubated  ||| S:48931 E:48941 ||| VBN
with  ||| S:48941 E:48946 ||| IN
10  ||| S:48946 E:48949 ||| CD
ml  ||| S:48949 E:48952 ||| NN
of  ||| S:48952 E:48955 ||| IN
125I-protein  ||| S:48955 E:48968 ||| NNP
G  ||| S:48968 E:48980 ||| NNP
( ||| S:48980 E:48981 ||| -LRB-
Amersham ||| S:48981 E:48989 ||| NNP
,  ||| S:48989 E:48991 ||| ,
50  ||| S:48991 E:48994 ||| CD
μl ||| S:48994 E:48996 ||| CD
/ ||| S:48996 E:48997 ||| CD
10  ||| S:48997 E:49000 ||| CD
ml  ||| S:49000 E:49003 ||| JJ
solution ||| S:49003 E:49011 ||| NN
)  ||| S:49011 E:49013 ||| -RRB-
in  ||| S:49013 E:49016 ||| IN
TNE  ||| S:49016 E:49020 ||| NNP
50  ||| S:49020 E:49023 ||| CD
plus  ||| S:49023 E:49028 ||| CC
0.1 ||| S:49028 E:49031 ||| CD
%  ||| S:49031 E:49043 ||| NN
NP-40  ||| S:49043 E:49049 ||| NN
for  ||| S:49049 E:49053 ||| IN
2  ||| S:49053 E:49055 ||| CD
hrs  ||| S:49055 E:49059 ||| NN
at  ||| S:49059 E:49062 ||| IN
4°C ||| S:49062 E:49065 ||| CD
.  ||| S:49065 E:49067 ||| .
Finally ||| S:49067 E:49074 ||| RB
,  ||| S:49074 E:49076 ||| ,
blots  ||| S:49076 E:49082 ||| NN
were  ||| S:49082 E:49087 ||| VBD
washed  ||| S:49087 E:49094 ||| VBN
twice  ||| S:49094 E:49110 ||| RB
in  ||| S:49110 E:49113 ||| IN
TNE  ||| S:49113 E:49117 ||| NNP
50  ||| S:49117 E:49120 ||| CD
plus  ||| S:49120 E:49125 ||| CC
0.1 ||| S:49125 E:49128 ||| CD
%  ||| S:49128 E:49130 ||| NN
NP-40  ||| S:49130 E:49136 ||| NN
and  ||| S:49136 E:49140 ||| CC
placed  ||| S:49140 E:49147 ||| VBN
on  ||| S:49147 E:49150 ||| IN
a  ||| S:49150 E:49152 ||| DT
PhosphorImager  ||| S:49152 E:49177 ||| JJ
cassette  ||| S:49177 E:49186 ||| NN
for  ||| S:49186 E:49190 ||| IN
further  ||| S:49190 E:49198 ||| JJ
analysis ||| S:49198 E:49206 ||| NN
.  ||| S:49206 E:49236 ||| .
Total  ||| S:49236 E:49242 ||| JJ
RNA  ||| S:49242 E:49246 ||| NNP
purification  ||| S:49246 E:49269 ||| VBD
Cells  ||| S:49269 E:49275 ||| NNP
were  ||| S:49275 E:49280 ||| VBD
grown  ||| S:49280 E:49286 ||| VBN
to  ||| S:49286 E:49289 ||| TO
mid-log  ||| S:49289 E:49297 ||| JJ
phase  ||| S:49297 E:49303 ||| NN
of  ||| S:49303 E:49306 ||| IN
growth  ||| S:49306 E:49313 ||| NN
( ||| S:49313 E:49314 ||| -LRB-
5.0  ||| S:49314 E:49318 ||| CD
×  ||| S:49318 E:49320 ||| CD
10  ||| S:49320 E:49333 ||| CD
6 ||| S:49333 E:49334 ||| CD
) ||| S:49334 E:49335 ||| -RRB-
,  ||| S:49335 E:49337 ||| ,
pelleted ||| S:49337 E:49345 ||| NN
,  ||| S:49345 E:49347 ||| ,
and  ||| S:49347 E:49351 ||| CC
washed  ||| S:49351 E:49358 ||| VBD
twice  ||| S:49358 E:49364 ||| RB
with  ||| S:49364 E:49369 ||| IN
cold  ||| S:49369 E:49374 ||| JJ
D-PBS  ||| S:49374 E:49380 ||| NN
without  ||| S:49380 E:49388 ||| IN
Ca  ||| S:49388 E:49401 ||| NNP
2+ ||| S:49401 E:49403 ||| NNP
/ ||| S:49403 E:49404 ||| NNP
Mg  ||| S:49404 E:49407 ||| NNP
2+ ||| S:49407 E:49409 ||| NNP
.  ||| S:49409 E:49411 ||| .
Total  ||| S:49411 E:49417 ||| JJ
RNA  ||| S:49417 E:49421 ||| NNP
was  ||| S:49421 E:49425 ||| VBD
extracted  ||| S:49425 E:49435 ||| VBN
on  ||| S:49435 E:49438 ||| IN
ice  ||| S:49438 E:49442 ||| NN
using  ||| S:49442 E:49448 ||| VBG
Trizol  ||| S:49448 E:49465 ||| NNP
Reagent  ||| S:49465 E:49473 ||| NNP
( ||| S:49473 E:49474 ||| -LRB-
Life  ||| S:49474 E:49479 ||| NNP
Technologies ||| S:49479 E:49491 ||| NNPS
,  ||| S:49491 E:49493 ||| ,
Inc. ||| S:49493 E:49497 ||| NNP
) ||| S:49497 E:49498 ||| -RRB-
.  ||| S:49498 E:49500 ||| .
Purified  ||| S:49500 E:49509 ||| NNP
RNA  ||| S:49509 E:49513 ||| NNP
was  ||| S:49513 E:49517 ||| VBD
then  ||| S:49517 E:49532 ||| RB
analyzed  ||| S:49532 E:49541 ||| VBN
on  ||| S:49541 E:49544 ||| IN
a  ||| S:49544 E:49546 ||| DT
1 ||| S:49546 E:49547 ||| CD
%  ||| S:49547 E:49549 ||| NN
agarose  ||| S:49549 E:49557 ||| NN
gel  ||| S:49557 E:49561 ||| NN
for  ||| S:49561 E:49565 ||| IN
quality  ||| S:49565 E:49573 ||| NN
and  ||| S:49573 E:49577 ||| CC
quantity  ||| S:49577 E:49596 ||| NN
prior  ||| S:49596 E:49602 ||| RB
to  ||| S:49602 E:49605 ||| TO
each  ||| S:49605 E:49610 ||| DT
experiment ||| S:49610 E:49620 ||| NN
.  ||| S:49620 E:49650 ||| .
Glass  ||| S:49650 E:49656 ||| NNP
slide  ||| S:49656 E:49662 ||| NN
microarray  ||| S:49662 E:49683 ||| VBD
Gene  ||| S:49683 E:49688 ||| NNP
expression  ||| S:49688 E:49699 ||| NN
analysis  ||| S:49699 E:49708 ||| NN
was  ||| S:49708 E:49712 ||| VBD
performed  ||| S:49712 E:49722 ||| VBN
using  ||| S:49722 E:49738 ||| VBG
Micromax™ ||| S:49738 E:49747 ||| CD
:  ||| S:49747 E:49749 ||| :
Human  ||| S:49749 E:49755 ||| NNP
cDNA  ||| S:49755 E:49760 ||| NNP
Microarray  ||| S:49760 E:49771 ||| NNP
System  ||| S:49771 E:49778 ||| NNP
I  ||| S:49778 E:49780 ||| NNP
( ||| S:49780 E:49781 ||| -LRB-
cat ||| S:49781 E:49784 ||| JJ
#  ||| S:49784 E:49786 ||| #
MPS101 ||| S:49786 E:49792 ||| CD
,  ||| S:49792 E:49804 ||| ,
NEN  ||| S:49804 E:49808 ||| NNP
Life  ||| S:49808 E:49813 ||| NNP
Science  ||| S:49813 E:49821 ||| NNP
Products ||| S:49821 E:49829 ||| NNPS
) ||| S:49829 E:49830 ||| -RRB-
.  ||| S:49830 E:49832 ||| .
On  ||| S:49832 E:49835 ||| IN
a  ||| S:49835 E:49837 ||| DT
glass  ||| S:49837 E:49843 ||| NN
microarray  ||| S:49843 E:49854 ||| NN
slide ||| S:49854 E:49859 ||| NN
,  ||| S:49859 E:49871 ||| ,
2400  ||| S:49871 E:49876 ||| CD
know  ||| S:49876 E:49881 ||| VBP
human  ||| S:49881 E:49887 ||| JJ
genes  ||| S:49887 E:49893 ||| NNS
were  ||| S:49893 E:49898 ||| VBD
arrayed  ||| S:49898 E:49906 ||| VBN
into  ||| S:49906 E:49911 ||| IN
4  ||| S:49911 E:49913 ||| CD
separate  ||| S:49913 E:49922 ||| JJ
grids  ||| S:49922 E:49938 ||| NNS
( ||| S:49938 E:49939 ||| -LRB-
A ||| S:49939 E:49940 ||| NNP
,  ||| S:49940 E:49942 ||| ,
B ||| S:49942 E:49943 ||| NNP
,  ||| S:49943 E:49945 ||| ,
C ||| S:49945 E:49946 ||| NNP
,  ||| S:49946 E:49948 ||| ,
D ||| S:49948 E:49949 ||| NNP
) ||| S:49949 E:49950 ||| -RRB-
,  ||| S:49950 E:49952 ||| ,
containing  ||| S:49952 E:49963 ||| VBG
600  ||| S:49963 E:49967 ||| CD
genes  ||| S:49967 E:49973 ||| NNS
each  ||| S:49973 E:49978 ||| DT
( ||| S:49978 E:49979 ||| -LRB-
gene  ||| S:49979 E:49984 ||| NN
description  ||| S:49984 E:50006 ||| NN
and  ||| S:50006 E:50010 ||| CC
location  ||| S:50010 E:50019 ||| NN
on  ||| S:50019 E:50022 ||| IN
microarrays  ||| S:50022 E:50034 ||| JJ
available  ||| S:50034 E:50044 ||| JJ
at  ||| S:50044 E:50047 ||| IN
NEN  ||| S:50047 E:50051 ||| NNP
website ||| S:50051 E:50058 ||| NN
:  ||| S:50058 E:50070 ||| :
www.nenlifesci.com ||| S:50070 E:50088 ||| CD
) ||| S:50088 E:50089 ||| -RRB-
.  ||| S:50089 E:50091 ||| .
All  ||| S:50091 E:50095 ||| DT
human  ||| S:50095 E:50101 ||| JJ
genes  ||| S:50101 E:50107 ||| NNS
were  ||| S:50107 E:50112 ||| VBD
~2200  ||| S:50112 E:50118 ||| CD
bp  ||| S:50118 E:50121 ||| JJ
cDNAs ||| S:50121 E:50126 ||| NN
,  ||| S:50126 E:50138 ||| ,
and  ||| S:50138 E:50142 ||| CC
were  ||| S:50142 E:50147 ||| VBD
characterized  ||| S:50147 E:50161 ||| VBN
from  ||| S:50161 E:50166 ||| IN
50+  ||| S:50166 E:50170 ||| CD
human  ||| S:50170 E:50176 ||| JJ
cDNA  ||| S:50176 E:50181 ||| JJ
libraries  ||| S:50181 E:50201 ||| NNS
( ||| S:50201 E:50202 ||| -LRB-
AlphaGene ||| S:50202 E:50211 ||| NNP
,  ||| S:50211 E:50213 ||| ,
Inc. ||| S:50213 E:50217 ||| NNP
,  ||| S:50217 E:50219 ||| ,
Woburn ||| S:50219 E:50225 ||| NNP
,  ||| S:50225 E:50227 ||| ,
MA ||| S:50227 E:50229 ||| NNP
) ||| S:50229 E:50230 ||| -RRB-
.  ||| S:50230 E:50232 ||| .
In  ||| S:50232 E:50235 ||| IN
addition  ||| S:50235 E:50244 ||| NN
to  ||| S:50244 E:50247 ||| TO
the  ||| S:50247 E:50251 ||| DT
human  ||| S:50251 E:50267 ||| JJ
genes ||| S:50267 E:50272 ||| NNS
,  ||| S:50272 E:50274 ||| ,
three  ||| S:50274 E:50280 ||| CD
plant  ||| S:50280 E:50286 ||| NN
control  ||| S:50286 E:50294 ||| NN
genes  ||| S:50294 E:50300 ||| NNS
were  ||| S:50300 E:50305 ||| VBD
spotted  ||| S:50305 E:50313 ||| VBN
on  ||| S:50313 E:50316 ||| IN
each  ||| S:50316 E:50331 ||| DT
grid  ||| S:50331 E:50336 ||| NN
and  ||| S:50336 E:50340 ||| CC
were  ||| S:50340 E:50345 ||| VBD
utilized  ||| S:50345 E:50354 ||| VBN
to  ||| S:50354 E:50357 ||| TO
balance  ||| S:50357 E:50365 ||| VB
the  ||| S:50365 E:50369 ||| DT
Cyanine-3  ||| S:50369 E:50379 ||| NNP
( ||| S:50379 E:50380 ||| -LRB-
Cy-3 ||| S:50380 E:50384 ||| NNP
)  ||| S:50384 E:50396 ||| -RRB-
and  ||| S:50396 E:50400 ||| CC
Cyanine-5  ||| S:50400 E:50410 ||| NNP
( ||| S:50410 E:50411 ||| -LRB-
Cy-5 ||| S:50411 E:50415 ||| NNP
)  ||| S:50415 E:50417 ||| -RRB-
fluorescence  ||| S:50417 E:50430 ||| JJ
signals ||| S:50430 E:50437 ||| NNS
.  ||| S:50437 E:50449 ||| .
A  ||| S:50449 E:50451 ||| DT
total  ||| S:50451 E:50457 ||| NN
of  ||| S:50457 E:50460 ||| IN
8  ||| S:50460 E:50462 ||| CD
μg  ||| S:50462 E:50465 ||| CD
each  ||| S:50465 E:50470 ||| DT
of  ||| S:50470 E:50473 ||| IN
H9  ||| S:50473 E:50476 ||| NNP
( ||| S:50476 E:50477 ||| -LRB-
control  ||| S:50477 E:50485 ||| NN
sample ||| S:50485 E:50491 ||| NN
)  ||| S:50491 E:50493 ||| -RRB-
and  ||| S:50493 E:50497 ||| CC
H9 ||| S:50497 E:50499 ||| NNP
/ ||| S:50499 E:50500 ||| NNP
Tat  ||| S:50500 E:50514 ||| NNP
( ||| S:50514 E:50515 ||| -LRB-
test  ||| S:50515 E:50520 ||| NN
sample ||| S:50520 E:50526 ||| NN
)  ||| S:50526 E:50528 ||| -RRB-
mRNAs  ||| S:50528 E:50534 ||| NNP
were  ||| S:50534 E:50539 ||| VBD
reverse  ||| S:50539 E:50547 ||| JJ
transcribed  ||| S:50547 E:50559 ||| NN
into  ||| S:50559 E:50564 ||| IN
Biotin  ||| S:50564 E:50581 ||| NNP
and  ||| S:50581 E:50585 ||| CC
Dinitrophenyl  ||| S:50585 E:50599 ||| NNP
( ||| S:50599 E:50600 ||| -LRB-
DNP ||| S:50600 E:50603 ||| NNP
)  ||| S:50603 E:50605 ||| -RRB-
labeled  ||| S:50605 E:50613 ||| VBD
cDNA ||| S:50613 E:50617 ||| JJ
,  ||| S:50617 E:50619 ||| ,
respectively ||| S:50619 E:50631 ||| RB
.  ||| S:50631 E:50633 ||| .
After  ||| S:50633 E:50649 ||| IN
cDNA  ||| S:50649 E:50654 ||| JJ
quality  ||| S:50654 E:50662 ||| NN
and  ||| S:50662 E:50666 ||| CC
quantities  ||| S:50666 E:50677 ||| NNS
were  ||| S:50677 E:50682 ||| VBD
analyzed ||| S:50682 E:50690 ||| VBN
,  ||| S:50690 E:50692 ||| ,
both  ||| S:50692 E:50697 ||| DT
cDNAs  ||| S:50697 E:50713 ||| NN
were  ||| S:50713 E:50718 ||| VBD
then  ||| S:50718 E:50723 ||| RB
pooled  ||| S:50723 E:50730 ||| VBN
and  ||| S:50730 E:50734 ||| CC
simultaneously  ||| S:50734 E:50749 ||| RB
hybridized  ||| S:50749 E:50760 ||| JJ
overnight  ||| S:50760 E:50780 ||| JJ
at  ||| S:50780 E:50783 ||| IN
65°C  ||| S:50783 E:50788 ||| CD
onto  ||| S:50788 E:50793 ||| IN
the  ||| S:50793 E:50797 ||| DT
glass  ||| S:50797 E:50803 ||| NN
microarray ||| S:50803 E:50813 ||| NN
.  ||| S:50813 E:50815 ||| .
The  ||| S:50815 E:50819 ||| DT
next  ||| S:50819 E:50824 ||| JJ
day ||| S:50824 E:50827 ||| NN
,  ||| S:50827 E:50829 ||| ,
the  ||| S:50829 E:50843 ||| DT
microarray  ||| S:50843 E:50854 ||| JJ
slide  ||| S:50854 E:50860 ||| NN
was  ||| S:50860 E:50864 ||| VBD
serially  ||| S:50864 E:50873 ||| VBN
washed  ||| S:50873 E:50880 ||| VBN
in  ||| S:50880 E:50883 ||| IN
0.5×  ||| S:50883 E:50888 ||| NNP
SSC  ||| S:50888 E:50892 ||| NNP
( ||| S:50892 E:50893 ||| -LRB-
Sodium  ||| S:50893 E:50910 ||| NNP
Citrate-Sodium  ||| S:50910 E:50925 ||| NNP
Chloride ||| S:50925 E:50933 ||| NNP
)  ||| S:50933 E:50935 ||| -RRB-
+  ||| S:50935 E:50937 ||| CD
0.01 ||| S:50937 E:50941 ||| CD
%  ||| S:50941 E:50943 ||| NN
SDS  ||| S:50943 E:50947 ||| NNP
( ||| S:50947 E:50948 ||| -LRB-
Sodium  ||| S:50948 E:50955 ||| NNP
Dodecyl  ||| S:50955 E:50973 ||| NNP
Sulfate ||| S:50973 E:50980 ||| NNP
) ||| S:50980 E:50981 ||| -RRB-
,  ||| S:50981 E:50983 ||| ,
0.06×  ||| S:50983 E:50989 ||| NNP
SSC  ||| S:50989 E:50993 ||| NNP
+  ||| S:50993 E:50995 ||| CD
0.01 ||| S:50995 E:50999 ||| CD
%  ||| S:50999 E:51001 ||| NN
SDS ||| S:51001 E:51004 ||| NNP
,  ||| S:51004 E:51006 ||| ,
and  ||| S:51006 E:51010 ||| CC
0.06×  ||| S:51010 E:51016 ||| NNP
SSC ||| S:51016 E:51019 ||| NNP
.  ||| S:51019 E:51021 ||| .
Next ||| S:51021 E:51025 ||| JJ
,  ||| S:51025 E:51027 ||| ,
the  ||| S:51027 E:51041 ||| DT
Tyramide  ||| S:51041 E:51050 ||| NNP
Signal  ||| S:51050 E:51057 ||| NNP
Amplification  ||| S:51057 E:51071 ||| NNP
( ||| S:51071 E:51072 ||| -LRB-
TSA™ ||| S:51072 E:51076 ||| NNP
)  ||| S:51076 E:51078 ||| -RRB-
was  ||| S:51078 E:51082 ||| VBD
then  ||| S:51082 E:51087 ||| RB
used  ||| S:51087 E:51092 ||| VBN
to  ||| S:51092 E:51105 ||| TO
amplify  ||| S:51105 E:51113 ||| VB
the  ||| S:51113 E:51117 ||| DT
Cy-3  ||| S:51117 E:51122 ||| NNP
and  ||| S:51122 E:51126 ||| CC
Cy-5  ||| S:51126 E:51131 ||| NNP
signals  ||| S:51131 E:51139 ||| VBZ
using  ||| S:51139 E:51145 ||| VBG
antibody-enzyme  ||| S:51145 E:51171 ||| JJ
conjugates ||| S:51171 E:51181 ||| NN
,  ||| S:51181 E:51183 ||| ,
α-DNP-Horseradish  ||| S:51183 E:51201 ||| JJ
peroxidase  ||| S:51201 E:51212 ||| NNS
( ||| S:51212 E:51213 ||| -LRB-
HRP ||| S:51213 E:51216 ||| NNP
)  ||| S:51216 E:51218 ||| -RRB-
and  ||| S:51218 E:51232 ||| CC
α-Streptavidin-HRP  ||| S:51232 E:51251 ||| JJ
with  ||| S:51251 E:51256 ||| IN
Tyramide  ||| S:51256 E:51265 ||| NNP
linked  ||| S:51265 E:51272 ||| VBD
Cy-3  ||| S:51272 E:51277 ||| CD
and  ||| S:51277 E:51281 ||| CC
Cy-5 ||| S:51281 E:51285 ||| NNP
.  ||| S:51285 E:51297 ||| .
Screening  ||| S:51297 E:51307 ||| NNP
and  ||| S:51307 E:51311 ||| CC
data  ||| S:51311 E:51316 ||| NN
analysis  ||| S:51316 E:51325 ||| NN
was  ||| S:51325 E:51329 ||| VBD
performed  ||| S:51329 E:51339 ||| VBN
by  ||| S:51339 E:51342 ||| IN
NEN.  ||| S:51342 E:51375 ||| FW
cDNA  ||| S:51375 E:51380 ||| FW
filter  ||| S:51380 E:51387 ||| FW
hybridization  ||| S:51387 E:51411 ||| FW
Gene  ||| S:51411 E:51416 ||| NNP
expression  ||| S:51416 E:51427 ||| NN
of  ||| S:51427 E:51430 ||| IN
CEM  ||| S:51430 E:51434 ||| NNP
and  ||| S:51434 E:51438 ||| CC
ACH2  ||| S:51438 E:51443 ||| NNP
were  ||| S:51443 E:51448 ||| VBD
performed  ||| S:51448 E:51458 ||| VBN
using  ||| S:51458 E:51474 ||| VBG
Atlas  ||| S:51474 E:51480 ||| NNP
Human  ||| S:51480 E:51486 ||| NNP
cDNA  ||| S:51486 E:51491 ||| NNP
Expression  ||| S:51491 E:51502 ||| NNP
Array  ||| S:51502 E:51508 ||| NNP
( ||| S:51508 E:51509 ||| -LRB-
Clontech  ||| S:51509 E:51518 ||| NNP
Laboratories  ||| S:51518 E:51541 ||| NNPS
Inc. ||| S:51541 E:51545 ||| NNP
,  ||| S:51545 E:51547 ||| ,
Palo  ||| S:51547 E:51552 ||| NNP
Alto ||| S:51552 E:51556 ||| NNP
,  ||| S:51556 E:51558 ||| ,
CA ||| S:51558 E:51560 ||| NNP
)  ||| S:51560 E:51562 ||| -RRB-
according  ||| S:51562 E:51572 ||| VBG
to  ||| S:51572 E:51575 ||| TO
the  ||| S:51575 E:51579 ||| DT
manufacturer ||| S:51579 E:51591 ||| NN
's  ||| S:51591 E:51604 ||| POS
directions ||| S:51604 E:51614 ||| NNS
.  ||| S:51614 E:51616 ||| .
One  ||| S:51616 E:51620 ||| CD
μg  ||| S:51620 E:51623 ||| NN
of  ||| S:51623 E:51626 ||| IN
poly  ||| S:51626 E:51631 ||| VBG
A  ||| S:51631 E:51633 ||| DT
+RNA  ||| S:51633 E:51638 ||| CD
each  ||| S:51638 E:51643 ||| DT
was  ||| S:51643 E:51647 ||| VBD
DNase  ||| S:51647 E:51653 ||| JJ
I  ||| S:51653 E:51665 ||| PRP
treated ||| S:51665 E:51672 ||| VBD
,  ||| S:51672 E:51674 ||| ,
purified  ||| S:51674 E:51683 ||| VBZ
using  ||| S:51683 E:51689 ||| VBG
a  ||| S:51689 E:51691 ||| DT
CHROMA  ||| S:51691 E:51698 ||| NNP
SPIN-200  ||| S:51698 E:51707 ||| NNP
column ||| S:51707 E:51713 ||| NN
,  ||| S:51713 E:51715 ||| ,
and  ||| S:51715 E:51729 ||| CC
reverse  ||| S:51729 E:51737 ||| VB
transcribed  ||| S:51737 E:51749 ||| VBN
into  ||| S:51749 E:51754 ||| IN
32P-labeled  ||| S:51754 E:51766 ||| NNP
cDNA ||| S:51766 E:51770 ||| NNP
.  ||| S:51770 E:51772 ||| .
The  ||| S:51772 E:51776 ||| DT
CHROMA  ||| S:51776 E:51793 ||| NNP
SPIN-200  ||| S:51793 E:51802 ||| NNP
column  ||| S:51802 E:51809 ||| NN
was  ||| S:51809 E:51813 ||| VBD
used  ||| S:51813 E:51818 ||| VBN
to  ||| S:51818 E:51821 ||| TO
purify  ||| S:51821 E:51828 ||| VB
the  ||| S:51828 E:51832 ||| DT
32P-labeled  ||| S:51832 E:51844 ||| JJ
cDNA  ||| S:51844 E:51859 ||| NN
from  ||| S:51859 E:51864 ||| IN
unincorporated  ||| S:51864 E:51879 ||| JJ
32P-labeled  ||| S:51879 E:51891 ||| NNP
dNTPs  ||| S:51891 E:51897 ||| NNP
and  ||| S:51897 E:51901 ||| CC
small  ||| S:51901 E:51907 ||| JJ
(  ||| S:51907 E:51908 ||| -LRB-
< ||| S:51908 E:51909 ||| SYM
0.1  ||| S:51909 E:51923 ||| CD
kb ||| S:51923 E:51925 ||| CD
)  ||| S:51925 E:51927 ||| -RRB-
cDNA  ||| S:51927 E:51932 ||| JJ
fragments ||| S:51932 E:51941 ||| NNS
.  ||| S:51941 E:51943 ||| .
Each  ||| S:51943 E:51948 ||| DT
sample  ||| S:51948 E:51955 ||| NN
was  ||| S:51955 E:51959 ||| VBD
then  ||| S:51959 E:51964 ||| RB
hybridized  ||| S:51964 E:51975 ||| VBN
to  ||| S:51975 E:51978 ||| TO
a  ||| S:51978 E:51990 ||| DT
human  ||| S:51990 E:51996 ||| JJ
cDNA  ||| S:51996 E:52001 ||| JJ
expression  ||| S:52001 E:52012 ||| NN
array  ||| S:52012 E:52018 ||| NN
overnight  ||| S:52018 E:52028 ||| RB
with  ||| S:52028 E:52033 ||| IN
continuous  ||| S:52033 E:52054 ||| JJ
agitation  ||| S:52054 E:52064 ||| NN
at  ||| S:52064 E:52067 ||| IN
68°C ||| S:52067 E:52071 ||| CD
.  ||| S:52071 E:52073 ||| .
The  ||| S:52073 E:52077 ||| DT
next  ||| S:52077 E:52082 ||| JJ
day ||| S:52082 E:52085 ||| NN
,  ||| S:52085 E:52087 ||| ,
the  ||| S:52087 E:52091 ||| DT
array  ||| S:52091 E:52097 ||| NN
was  ||| S:52097 E:52101 ||| VBD
washed  ||| S:52101 E:52118 ||| VBN
three  ||| S:52118 E:52124 ||| CD
times  ||| S:52124 E:52130 ||| NNS
with  ||| S:52130 E:52135 ||| IN
gentle  ||| S:52135 E:52142 ||| JJ
agitation ||| S:52142 E:52151 ||| NN
,  ||| S:52151 E:52153 ||| ,
first  ||| S:52153 E:52159 ||| JJ
wash  ||| S:52159 E:52164 ||| NN
with  ||| S:52164 E:52169 ||| IN
2×  ||| S:52169 E:52172 ||| NNP
SSC  ||| S:52172 E:52186 ||| NNP
+  ||| S:52186 E:52188 ||| CD
1 ||| S:52188 E:52189 ||| CD
%  ||| S:52189 E:52191 ||| NN
SDS  ||| S:52191 E:52195 ||| NNP
and  ||| S:52195 E:52199 ||| CC
the  ||| S:52199 E:52203 ||| DT
last  ||| S:52203 E:52208 ||| JJ
two  ||| S:52208 E:52212 ||| CD
washes  ||| S:52212 E:52219 ||| NN
with  ||| S:52219 E:52224 ||| IN
0.1×  ||| S:52224 E:52229 ||| NNP
SSC  ||| S:52229 E:52233 ||| NNP
+  ||| S:52233 E:52235 ||| CD
0.5 ||| S:52235 E:52238 ||| CD
%  ||| S:52238 E:52240 ||| NN
SDS  ||| S:52240 E:52254 ||| NN
at  ||| S:52254 E:52257 ||| IN
37°C ||| S:52257 E:52261 ||| CD
.  ||| S:52261 E:52263 ||| .
Array  ||| S:52263 E:52269 ||| NN
was  ||| S:52269 E:52273 ||| VBD
exposed  ||| S:52273 E:52281 ||| VBN
to  ||| S:52281 E:52284 ||| TO
a  ||| S:52284 E:52286 ||| DT
PhosphorImager  ||| S:52286 E:52301 ||| JJ
Cassette  ||| S:52301 E:52320 ||| NNP
and  ||| S:52320 E:52324 ||| CC
analyzed  ||| S:52324 E:52333 ||| VBD
using  ||| S:52333 E:52339 ||| VBG
ImageQuant  ||| S:52339 E:52350 ||| JJ
software ||| S:52350 E:52358 ||| NN
.  ||| S:52358 E:52388 ||| .
Northern  ||| S:52388 E:52397 ||| JJ
blots  ||| S:52397 E:52413 ||| JJ
Total  ||| S:52413 E:52419 ||| JJ
cellular  ||| S:52419 E:52428 ||| JJ
RNA  ||| S:52428 E:52432 ||| NNP
was  ||| S:52432 E:52436 ||| VBD
extracted  ||| S:52436 E:52446 ||| VBN
using  ||| S:52446 E:52452 ||| VBG
the  ||| S:52452 E:52456 ||| DT
RNAzol  ||| S:52456 E:52473 ||| JJ
reagent  ||| S:52473 E:52481 ||| NNS
( ||| S:52481 E:52482 ||| -LRB-
Gibco ||| S:52482 E:52487 ||| NNP
/ ||| S:52487 E:52488 ||| NNP
BRL ||| S:52488 E:52491 ||| NNP
) ||| S:52491 E:52492 ||| -RRB-
.  ||| S:52492 E:52494 ||| .
Total  ||| S:52494 E:52500 ||| JJ
RNA  ||| S:52500 E:52504 ||| NNP
( ||| S:52504 E:52505 ||| -LRB-
20  ||| S:52505 E:52508 ||| CD
μg ||| S:52508 E:52510 ||| CD
)  ||| S:52510 E:52512 ||| -RRB-
was  ||| S:52512 E:52516 ||| VBD
isolated  ||| S:52516 E:52525 ||| VBN
from  ||| S:52525 E:52540 ||| IN
various  ||| S:52540 E:52548 ||| JJ
cells  ||| S:52548 E:52554 ||| NNS
and  ||| S:52554 E:52558 ||| CC
ran  ||| S:52558 E:52562 ||| VBD
on  ||| S:52562 E:52565 ||| IN
a  ||| S:52565 E:52567 ||| DT
1 ||| S:52567 E:52568 ||| CD
%  ||| S:52568 E:52570 ||| NN
formaldehyde-agarose  ||| S:52570 E:52591 ||| JJ
gel  ||| S:52591 E:52605 ||| JJ
overnight  ||| S:52605 E:52615 ||| JJ
at  ||| S:52615 E:52618 ||| IN
75  ||| S:52618 E:52621 ||| CD
V ||| S:52621 E:52622 ||| NNP
,  ||| S:52622 E:52624 ||| ,
transferred  ||| S:52624 E:52636 ||| VBN
onto  ||| S:52636 E:52641 ||| IN
a  ||| S:52641 E:52643 ||| DT
0.2  ||| S:52643 E:52647 ||| CD
μm  ||| S:52647 E:52660 ||| FW
nitrocellulose  ||| S:52660 E:52675 ||| FW
membrane  ||| S:52675 E:52684 ||| FW
( ||| S:52684 E:52685 ||| -LRB-
Millipore  ||| S:52685 E:52695 ||| NNP
Inc. ||| S:52695 E:52699 ||| NNP
) ||| S:52699 E:52700 ||| -RRB-
,  ||| S:52700 E:52702 ||| ,
UV  ||| S:52702 E:52715 ||| NNP
cross-linked ||| S:52715 E:52727 ||| NNP
,  ||| S:52727 E:52729 ||| ,
and  ||| S:52729 E:52733 ||| CC
hybridized  ||| S:52733 E:52744 ||| JJ
overnight  ||| S:52744 E:52754 ||| JJ
at  ||| S:52754 E:52757 ||| IN
42°C  ||| S:52757 E:52762 ||| CD
with  ||| S:52762 E:52777 ||| IN
32P-end-labeled  ||| S:52777 E:52793 ||| CD
40  ||| S:52793 E:52796 ||| CD
mer  ||| S:52796 E:52800 ||| CD
oligo  ||| S:52800 E:52806 ||| CD
probes  ||| S:52806 E:52813 ||| NNS
including  ||| S:52813 E:52823 ||| VBG
p21 ||| S:52823 E:52826 ||| CD
/ ||| S:52826 E:52827 ||| CD
Waf1 ||| S:52827 E:52831 ||| CD
,  ||| S:52831 E:52843 ||| ,
C-myc ||| S:52843 E:52848 ||| NNP
,  ||| S:52848 E:52850 ||| ,
Pro-thymosin ||| S:52850 E:52862 ||| NNP
,  ||| S:52862 E:52864 ||| ,
Actin ||| S:52864 E:52869 ||| NNP
,  ||| S:52869 E:52871 ||| ,
Tat ||| S:52871 E:52874 ||| NNP
,  ||| S:52874 E:52876 ||| ,
and  ||| S:52876 E:52880 ||| CC
Ubiquitin  ||| S:52880 E:52900 ||| NNP
( ||| S:52900 E:52901 ||| -LRB-
Loftstrand ||| S:52901 E:52911 ||| NNP
,  ||| S:52911 E:52913 ||| ,
Gaithersburg ||| S:52913 E:52925 ||| NNP
,  ||| S:52925 E:52927 ||| ,
Md. ||| S:52927 E:52930 ||| NNP
) ||| S:52930 E:52931 ||| -RRB-
.  ||| S:52931 E:52933 ||| .
Next  ||| S:52933 E:52938 ||| JJ
day ||| S:52938 E:52941 ||| NN
,  ||| S:52941 E:52943 ||| ,
membranes  ||| S:52943 E:52953 ||| NN
were  ||| S:52953 E:52968 ||| VBD
washed  ||| S:52968 E:52975 ||| VBN
two  ||| S:52975 E:52979 ||| CD
times  ||| S:52979 E:52985 ||| NNS
for  ||| S:52985 E:52989 ||| IN
15  ||| S:52989 E:52992 ||| CD
min  ||| S:52992 E:52996 ||| CD
each ||| S:52996 E:53000 ||| DT
,  ||| S:53000 E:53002 ||| ,
with  ||| S:53002 E:53007 ||| IN
10  ||| S:53007 E:53010 ||| CD
ml  ||| S:53010 E:53013 ||| NN
of  ||| S:53013 E:53016 ||| IN
0.2 ||| S:53016 E:53019 ||| CD
%  ||| S:53019 E:53031 ||| NN
SDS-2XSSC  ||| S:53031 E:53041 ||| NN
at  ||| S:53041 E:53044 ||| IN
37°C ||| S:53044 E:53048 ||| NNP
,  ||| S:53048 E:53050 ||| ,
exposed ||| S:53050 E:53057 ||| VBN
,  ||| S:53057 E:53059 ||| ,
and  ||| S:53059 E:53063 ||| CC
counted  ||| S:53063 E:53071 ||| VBN
on  ||| S:53071 E:53074 ||| IN
PhosphorImager  ||| S:53074 E:53099 ||| NNP
Cassette ||| S:53099 E:53107 ||| NNP
.  ||| S:53107 E:53137 ||| .
Viral  ||| S:53137 E:53143 ||| JJ
infection  ||| S:53143 E:53153 ||| NN
and  ||| S:53153 E:53157 ||| CC
ELISA  ||| S:53157 E:53163 ||| NNP
assay  ||| S:53163 E:53179 ||| VBD
Both  ||| S:53179 E:53184 ||| DT
H9  ||| S:53184 E:53187 ||| NNP
and  ||| S:53187 E:53191 ||| CC
H9 ||| S:53191 E:53193 ||| NNP
/ ||| S:53193 E:53194 ||| NNP
Tat  ||| S:53194 E:53198 ||| NNP
cells  ||| S:53198 E:53204 ||| NNS
were  ||| S:53204 E:53209 ||| VBD
infected  ||| S:53209 E:53218 ||| VBN
in  ||| S:53218 E:53221 ||| IN
the  ||| S:53221 E:53225 ||| DT
presence  ||| S:53225 E:53244 ||| NN
of  ||| S:53244 E:53247 ||| IN
10  ||| S:53247 E:53250 ||| CD
ug  ||| S:53250 E:53253 ||| NN
of  ||| S:53253 E:53256 ||| IN
polybrene ||| S:53256 E:53265 ||| NN
.  ||| S:53265 E:53267 ||| .
For  ||| S:53267 E:53271 ||| IN
PBMC  ||| S:53271 E:53276 ||| NNP
infections ||| S:53276 E:53286 ||| NNS
,  ||| S:53286 E:53288 ||| ,
PHA  ||| S:53288 E:53292 ||| NNP
activated  ||| S:53292 E:53312 ||| JJ
PBMCs  ||| S:53312 E:53318 ||| NN
were  ||| S:53318 E:53323 ||| VBD
kept  ||| S:53323 E:53328 ||| VBN
in  ||| S:53328 E:53331 ||| IN
culture  ||| S:53331 E:53339 ||| NN
for  ||| S:53339 E:53343 ||| IN
2  ||| S:53343 E:53345 ||| CD
days  ||| S:53345 E:53350 ||| NNS
prior  ||| S:53350 E:53356 ||| RB
to  ||| S:53356 E:53359 ||| TO
each  ||| S:53359 E:53374 ||| DT
infection ||| S:53374 E:53383 ||| NN
.  ||| S:53383 E:53385 ||| .
Isolation  ||| S:53385 E:53395 ||| NNP
and  ||| S:53395 E:53399 ||| CC
treatment  ||| S:53399 E:53409 ||| NN
of  ||| S:53409 E:53412 ||| IN
PBMCs  ||| S:53412 E:53418 ||| NNP
were  ||| S:53418 E:53433 ||| VBD
performed  ||| S:53433 E:53443 ||| VBN
by  ||| S:53443 E:53446 ||| IN
following  ||| S:53446 E:53456 ||| VBG
guidelines  ||| S:53456 E:53467 ||| NNS
from  ||| S:53467 E:53472 ||| IN
the  ||| S:53472 E:53476 ||| DT
CDC  ||| S:53476 E:53490 ||| NNP
( ||| S:53490 E:53491 ||| -LRB-
Isolation ||| S:53491 E:53500 ||| NNP
,  ||| S:53500 E:53502 ||| ,
culture ||| S:53502 E:53509 ||| NN
,  ||| S:53509 E:53511 ||| ,
and  ||| S:53511 E:53515 ||| CC
identification  ||| S:53515 E:53530 ||| NN
of  ||| S:53530 E:53533 ||| IN
HIV ||| S:53533 E:53536 ||| NNP
,  ||| S:53536 E:53548 ||| ,
Procedural  ||| S:53548 E:53559 ||| NNP
Guide ||| S:53559 E:53564 ||| NNP
,  ||| S:53564 E:53566 ||| ,
July  ||| S:53566 E:53571 ||| NNP
1991 ||| S:53571 E:53575 ||| CD
,  ||| S:53575 E:53577 ||| ,
Atlanta ||| S:53577 E:53584 ||| NNP
,  ||| S:53584 E:53586 ||| ,
GA ||| S:53586 E:53588 ||| NNP
) ||| S:53588 E:53589 ||| -RRB-
.  ||| S:53589 E:53591 ||| .
Approximately  ||| S:53591 E:53615 ||| RB
2  ||| S:53615 E:53617 ||| CD
×  ||| S:53617 E:53619 ||| CD
10  ||| S:53619 E:53622 ||| CD
6of  ||| S:53622 E:53626 ||| CD
H9  ||| S:53626 E:53629 ||| CD
or  ||| S:53629 E:53632 ||| CC
H9 ||| S:53632 E:53634 ||| NNP
/ ||| S:53634 E:53635 ||| NNP
Tat  ||| S:53635 E:53639 ||| NNP
cells ||| S:53639 E:53644 ||| NNS
,  ||| S:53644 E:53646 ||| ,
and  ||| S:53646 E:53650 ||| CC
5  ||| S:53650 E:53652 ||| CD
×  ||| S:53652 E:53654 ||| CD
10  ||| S:53654 E:53657 ||| CD
6PBMC  ||| S:53657 E:53663 ||| CD
cells  ||| S:53663 E:53679 ||| NNS
were  ||| S:53679 E:53684 ||| VBD
infected  ||| S:53684 E:53693 ||| VBN
with  ||| S:53693 E:53698 ||| IN
either  ||| S:53698 E:53705 ||| RB
an  ||| S:53705 E:53708 ||| DT
HXB-2  ||| S:53708 E:53714 ||| NNP
( ||| S:53714 E:53715 ||| -LRB-
CXCR4 ||| S:53715 E:53720 ||| NNP
,  ||| S:53720 E:53722 ||| ,
T-tropic ||| S:53722 E:53730 ||| NNP
) ||| S:53730 E:53731 ||| -RRB-
,  ||| S:53731 E:53733 ||| ,
or  ||| S:53733 E:53746 ||| CC
BaL  ||| S:53746 E:53750 ||| NNP
( ||| S:53750 E:53751 ||| -LRB-
CCR5 ||| S:53751 E:53755 ||| NNP
,  ||| S:53755 E:53757 ||| ,
Macrophage-tropic ||| S:53757 E:53774 ||| NNP
)  ||| S:53774 E:53776 ||| -RRB-
at  ||| S:53776 E:53779 ||| IN
5  ||| S:53779 E:53781 ||| CD
ng  ||| S:53781 E:53784 ||| NN
of  ||| S:53784 E:53787 ||| IN
p24  ||| S:53787 E:53791 ||| FW
gag  ||| S:53791 E:53795 ||| FW
antigen ||| S:53795 E:53802 ||| FW
/  ||| S:53802 E:53814 ||| FW
HIV-1  ||| S:53814 E:53820 ||| FW
strain ||| S:53820 E:53826 ||| FW
.  ||| S:53826 E:53828 ||| .
Both  ||| S:53828 E:53833 ||| DT
viral  ||| S:53833 E:53839 ||| JJ
isolates  ||| S:53839 E:53848 ||| NN
were  ||| S:53848 E:53853 ||| VBD
obtained  ||| S:53853 E:53862 ||| VBN
from  ||| S:53862 E:53867 ||| IN
the  ||| S:53867 E:53881 ||| DT
NIH  ||| S:53881 E:53885 ||| NNP
AIDS  ||| S:53885 E:53890 ||| NNP
research  ||| S:53890 E:53899 ||| NN
and  ||| S:53899 E:53903 ||| CC
reference  ||| S:53903 E:53913 ||| NN
reagent  ||| S:53913 E:53921 ||| NN
program ||| S:53921 E:53928 ||| NN
.  ||| S:53928 E:53930 ||| .
After  ||| S:53930 E:53936 ||| IN
8  ||| S:53936 E:53948 ||| CD
hrs  ||| S:53948 E:53952 ||| NN
of  ||| S:53952 E:53955 ||| IN
infection ||| S:53955 E:53964 ||| NN
,  ||| S:53964 E:53966 ||| ,
cells  ||| S:53966 E:53972 ||| NNS
were  ||| S:53972 E:53977 ||| VBD
washed  ||| S:53977 E:53984 ||| VBN
and  ||| S:53984 E:53988 ||| CC
fresh  ||| S:53988 E:53994 ||| JJ
media  ||| S:53994 E:54000 ||| NNS
was  ||| S:54000 E:54014 ||| VBD
added ||| S:54014 E:54019 ||| VBN
.  ||| S:54019 E:54021 ||| .
Samples  ||| S:54021 E:54029 ||| NNS
were  ||| S:54029 E:54034 ||| VBD
collected  ||| S:54034 E:54044 ||| VBN
every  ||| S:54044 E:54050 ||| DT
3  ||| S:54050 E:54052 ||| CD
rdday  ||| S:54052 E:54058 ||| NNS
and  ||| S:54058 E:54062 ||| CC
stored  ||| S:54062 E:54069 ||| VBD
at  ||| S:54069 E:54082 ||| IN
-20  ||| S:54082 E:54086 ||| NNP
C  ||| S:54086 E:54088 ||| NNP
for  ||| S:54088 E:54092 ||| IN
p24  ||| S:54092 E:54096 ||| FW
gag  ||| S:54096 E:54100 ||| FW
ELISA ||| S:54100 E:54105 ||| FW
.  ||| S:54105 E:54107 ||| .
Media  ||| S:54107 E:54113 ||| NNS
from  ||| S:54113 E:54118 ||| IN
HIV-1  ||| S:54118 E:54124 ||| NNP
infected  ||| S:54124 E:54133 ||| JJ
cells  ||| S:54133 E:54149 ||| NNS
were  ||| S:54149 E:54154 ||| VBD
centrifuged  ||| S:54154 E:54166 ||| VBN
to  ||| S:54166 E:54169 ||| TO
pellet  ||| S:54169 E:54176 ||| VB
the  ||| S:54176 E:54180 ||| DT
cells  ||| S:54180 E:54186 ||| NNS
and  ||| S:54186 E:54190 ||| CC
supernatants  ||| S:54190 E:54213 ||| NNS
were  ||| S:54213 E:54218 ||| VBD
collected ||| S:54218 E:54227 ||| VBN
,  ||| S:54227 E:54229 ||| ,
and  ||| S:54229 E:54233 ||| CC
diluted  ||| S:54233 E:54241 ||| VBN
to  ||| S:54241 E:54244 ||| TO
1 ||| S:54244 E:54245 ||| CD
: ||| S:54245 E:54246 ||| :
100  ||| S:54246 E:54250 ||| CD
to  ||| S:54250 E:54253 ||| TO
1 ||| S:54253 E:54254 ||| CD
: ||| S:54254 E:54255 ||| :
1000  ||| S:54255 E:54260 ||| CD
in  ||| S:54260 E:54263 ||| IN
RPMI  ||| S:54263 E:54278 ||| NNP
1640  ||| S:54278 E:54283 ||| CD
prior  ||| S:54283 E:54289 ||| JJ
to  ||| S:54289 E:54292 ||| TO
ELISA ||| S:54292 E:54297 ||| NNP
.  ||| S:54297 E:54299 ||| .
The  ||| S:54299 E:54303 ||| DT
p24  ||| S:54303 E:54307 ||| JJ
gag  ||| S:54307 E:54311 ||| JJ
antigen  ||| S:54311 E:54319 ||| NN
level  ||| S:54319 E:54325 ||| NN
was  ||| S:54325 E:54339 ||| VBD
analyzed  ||| S:54339 E:54348 ||| VBN
by  ||| S:54348 E:54351 ||| IN
HIVAG™-1  ||| S:54351 E:54360 ||| NNP
Monoclonal  ||| S:54360 E:54371 ||| NNP
antibody  ||| S:54371 E:54380 ||| NN
Kit  ||| S:54380 E:54384 ||| NNP
( ||| S:54384 E:54385 ||| -LRB-
Abbott  ||| S:54385 E:54402 ||| NNP
Laboratories ||| S:54402 E:54414 ||| NNPS
,  ||| S:54414 E:54416 ||| ,
Diagnostics  ||| S:54416 E:54428 ||| NNP
Division ||| S:54428 E:54436 ||| NNP
) ||| S:54436 E:54437 ||| -RRB-
.  ||| S:54437 E:54470 ||| .
Authors ||| S:54470 E:54477 ||| NNP
'  ||| S:54477 E:54479 ||| POS
Contributions  ||| S:54479 E:54501 ||| NNP
CF ||| S:54501 E:54503 ||| NNP
,  ||| S:54503 E:54505 ||| ,
and  ||| S:54505 E:54509 ||| CC
FS  ||| S:54509 E:54512 ||| NNP
carried  ||| S:54512 E:54520 ||| VBD
out  ||| S:54520 E:54524 ||| RP
the  ||| S:54524 E:54528 ||| DT
ACH2  ||| S:54528 E:54533 ||| NNP
and  ||| S:54533 E:54537 ||| CC
H9 ||| S:54537 E:54539 ||| NNP
/ ||| S:54539 E:54540 ||| NNP
Tat  ||| S:54540 E:54544 ||| NNP
microarrays ||| S:54544 E:54555 ||| NN
.  ||| S:54555 E:54565 ||| .
LD ||| S:54565 E:54567 ||| NNP
,  ||| S:54567 E:54569 ||| ,
CE ||| S:54569 E:54571 ||| NNP
,  ||| S:54571 E:54573 ||| ,
IZ ||| S:54573 E:54575 ||| NNP
,  ||| S:54575 E:54577 ||| ,
CGL ||| S:54577 E:54580 ||| NNP
,  ||| S:54580 E:54582 ||| ,
and  ||| S:54582 E:54586 ||| CC
KW  ||| S:54586 E:54589 ||| NNP
aided  ||| S:54589 E:54595 ||| VBD
in  ||| S:54595 E:54598 ||| IN
westerns ||| S:54598 E:54606 ||| NN
,  ||| S:54606 E:54608 ||| ,
northerns ||| S:54608 E:54617 ||| NN
,  ||| S:54617 E:54619 ||| ,
p24  ||| S:54619 E:54631 ||| NNP
and  ||| S:54631 E:54635 ||| CC
ELISA  ||| S:54635 E:54641 ||| NNP
assays ||| S:54641 E:54647 ||| NN
.  ||| S:54647 E:54649 ||| .
AM ||| S:54649 E:54651 ||| NNP
,  ||| S:54651 E:54653 ||| ,
KK ||| S:54653 E:54655 ||| NNP
,  ||| S:54655 E:54657 ||| ,
SB ||| S:54657 E:54659 ||| NNP
,  ||| S:54659 E:54661 ||| ,
AP ||| S:54661 E:54663 ||| NNP
,  ||| S:54663 E:54665 ||| ,
and  ||| S:54665 E:54669 ||| CC
FK  ||| S:54669 E:54672 ||| NNP
aided  ||| S:54672 E:54678 ||| VBD
in  ||| S:54678 E:54681 ||| IN
data  ||| S:54681 E:54694 ||| NN
interpretation ||| S:54694 E:54708 ||| NN
,  ||| S:54708 E:54710 ||| ,
Bioinformatics ||| S:54710 E:54724 ||| NNP
,  ||| S:54724 E:54726 ||| ,
literature  ||| S:54726 E:54737 ||| NN
searches  ||| S:54737 E:54746 ||| NNS
and  ||| S:54746 E:54758 ||| CC
writing  ||| S:54758 E:54766 ||| VBG
the  ||| S:54766 E:54770 ||| DT
manuscript ||| S:54770 E:54780 ||| NN
.  ||| S:54780 E:54797 ||| .
